<SEC-DOCUMENT>0001410578-22-002669.txt : 20220818
<SEC-HEADER>0001410578-22-002669.hdr.sgml : 20220818
<ACCEPTANCE-DATETIME>20220818162051
ACCESSION NUMBER:		0001410578-22-002669
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220818
DATE AS OF CHANGE:		20220818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		221177705

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cvac-20220630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8167.22744 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/18/2022 7:20:48 PM -->
      <!-- iXBRL Library version: 1.0.8167.22751 -->
      <!-- iXBRL Service Job ID: 02a0eed8-2dd6-4a6d-a416-96c42242c43d -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cvac="http://www.curevac.com/20220630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:href="cvac-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KhUGmIdimECoLuArSGzN7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_sTG3gTwnF06uW__PG0Jy7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CreBB5VP3EKrtTllWwe7cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_josAwYgRAUikV20Ufw6ucQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_TujPDblK1EuxI80RvU-NLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ukmwgK4pjkeQL_CmzxJNpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_hBqt_J_E8U2Ykx9xI6ZM9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_Niu8fCC5EEeSADXrcrVtmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_d2Hm2LGP_ke9M8xIEktJpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_skb-i2lgmkG-FxOxet3a0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_cvXKLI50Ok29UKYe1Lppng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Pyt_GawsiEiGAxSCTTHNSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_YkJamxu9vUOFt13D2FrYnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_PImd1JWYGUuBROPVuT6t1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_Lc0XNMKuKEqN_5NhPdFzTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_m6vvO3sZ60-XG1n4n_R1BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_kJmg11wUDk6B6oaK6o4npw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_J42m4KTLKUOHHRX1Xm1Ajg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_IZKQNmwJz0Otp2sIpw7z9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_IbyWgW8zTka7Hdyj-GqiEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_ygWZIJY7-ECXlg47u0aOrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_2xzoP9RNVk-PMBP-aAb16g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_jk-0HXYllkOyUB1FBqMB3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_Z1RDELYnhkW7Qf2dwfv-dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_SdTrfxiB0U-Z0Gmk5GUxOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_TtMaJsFnHU-GN-4kQhkccg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_94_eUZcr1k6ch6WDNbNttg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelepmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9FShId--2E63ykkNfrEmmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_w31L0BBG7UmU35R2D2Zt4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_G2czk_grS0e2UewXI2oR9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_9BE_1GHmUECsOC7edBk3kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Ke6127tPckS7cBQb7_LfxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_zpKYCdvoIkWzWr5AFwv_Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_IfolEyZFMEKGD2w2ivzW5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_z5pHV_ql802Y2Ej33MoQPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_MC60TuOPQEegv3N3oZBOrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_vdvY7bSHZkecZoTxnUfO6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-23</xbrli:startDate><xbrli:endDate>2021-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_Ucvqwtp93kihEInyQPUvNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_0AMNouAweEWk9_wb8d_Q1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_6Kj0uxl05kGcqv5cmngJhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_9XL-YVNtDkqObkYAyoA2kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_8Pr5Ggh9JEajOUbg_YKR8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_fTCAXcXeVEGq1xPWfKyuDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_z_OM4LPemU2vaJCSSgPmxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_zRxCoItDgkao45OmbONCMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_7UE4OxQYgE2K901Hl7Dixg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zKdBd8Au7EmwSNmyKFumnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_-c6P1_7DkUS3B8fykDBDmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0ytFSqcEM0C2FCZayK49MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_vsww_6W8XEuzXqcrXTgKVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6BsM7vzIFU2WSKtxlf-yDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_F5SaMz-K80GYDBc1b5afng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_bnkru9QQjkyVNYTwKq09QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_HZud9yt_LUuUPbn-LCJnCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_EJ4D4Sg-IEKFiOm7DAMDwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xukue48ZDEGBV7izRS3Mlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_MRAiZ2HMfU6clBflMMQ4Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_iUPLBTtqT0GEW_-lUGmSbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_gNxzEodT6kKGuBFaWKy0eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_GtBW4y4FQU2LNtgqNQvYqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Une6DLwLW0WGIfTxv_fmOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Dav_DW2ztk6-ETIcsBP69w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lSeomaiJs0W8Yf_-pG_B6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VUFJcmrBx0OexVdaoisNAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_YkmeTmz-k0ywp539pQH2GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_KdHhy8rMGkOPdf-0LDkcag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_tG8hTQGLX0ejbiTFxdHWvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TemporaryDifferenceMember_xwvzCyZJjUu1_z9vpwK1lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_Aoq6kdzIgEGb4JC-aygDJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_OUBDouNJ3UGASomEVEai6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_uYl7CoErZUmkaktvlFSJJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_sV-2gWepY06B0A8GEXWNAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_v6FcOJX3ZkOQL_If3V44wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_RMhcUw7iwE2lpjvCLpz2Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_D9PmNvxW2EyJO-U9VmXN0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qKO-s7r8BUa2lgRm6ekFrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_5j4KchYGIk-8GogPJ3dGGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:EquipmentPhysicallyLocatedAtCmoFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_EQdNS6liQkqj9HAUfbkJkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_smq0Fsap1kGMdfi_JvJUpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_i0uFtxo5n0yyYkb8Bj-Qmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_LesCyMz7FUK3ZxQEsZWNEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_nDNQwxmp00GQTEs0t5pDCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_fVqKtHZJh0ajtDFuaqC7Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4HZPRvJI5kWlz0cNNfXq8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2PVjDRq_NEuYUZZxVJgpqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_VcYuM-X1zEyJpdM394rd0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_v2Ngz-T8qke5OXbIqZxvLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_U6gYHkTqeUaGi_F9UXcWaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember__uQ5VVHK0UWYczs0k7a3Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_DRz3CCZAlUWbryO3lgpfCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_nVyvmSWGc0qjWc-iNGi-MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_i3Ky2o24PUOSBVz8jJnLZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_KAq3DEF70UWNcG0E7Qz2aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_YvgJJg2RWkS_B2vVJFNGhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9v7ROjz4KUq67xb-vGVl4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_SgeNIgwqzk63aou9DXpoZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_6VL2por91EyDuYch-uIbWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelepmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_npRUdd2jrEKdKNSOmQ2E7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefOperatingOfficerAndChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_mNAuTnZ79kmgMEM_evAL-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_MEfyfKoJLka_FnOTfjHVVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Qe5xZZRKBkalAhPMb0rKlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_FFHzzrCoqEGuPsRnxpT4pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember___Jw5IM-M0uiIYastW7Ohw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_bCZajafyHk2TYShK6GXT_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Dnjk8zLjh0uRxWQLYgQLtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_Z76paJTu3EqO8ZEo9vC15A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitForKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_dVCXiI28WUKjmh4pxWG7HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_37SI7EeG40qNRBNVTiXh4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_eqJNUVFrwEyBJVapO8-7UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3nipjvAshE6IJam5p-Fh3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_07cYvreliEeikUXp57lJ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_vwSDHWlV6k6kvpxM2G58Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_ZrMDEhuAEUCN6lkugW0ldw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_PD-hd6qO7kyci1VNI1JU4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_wjj_nYzRdkKzd4QyrVUUTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_sc6LsyPDbUSO09oxzVOOUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_2xPxwRpHIkSSwvWmnWr95Q"><xbrli:measure>cvac:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ"><xbrli:measure>cvac:Option</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_loan_jqkBG3F-sEycxO6evEyZWQ"><xbrli:measure>cvac:loan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CHF_x9ufSMA390KJ8aeE_m0Llg"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:16.1pt;"><a id="_4b528791_a3b5_4124_b902_16bb5a97acfc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:DocumentType" id="Narr_DZtvmPd3eUCn7s3L-Z9zuw"><b style="font-weight:bold;">6-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:18pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:14pt;">For the month of August 2022</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:14.0pt;margin-bottom:6pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:89.87%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Commission File Number: 001-39446</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:EntityRegistrantName" id="Narr_vOo4an9x-EG5_ebx_aQMWw"><b style="font-weight:bold;">CureVac N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Exact Name of Registrant as Specified in Its Charter</i>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Friedrich-Miescher-Strasse 15, 72076</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T&#xFC;bingen, Germany</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+49 7071 9883 0</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of principal executive office)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#xA0;20-F or Form 40-F:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:29.07%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Form 20-F</p></td><td style="vertical-align:top;width:14.54%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:Times New Roman;">&#x2327;</span></p></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Form 40-F</p></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#xA0;S-T&#xA0;Rule&#xA0;101(b)(1):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:Times New Roman;">&#x2327;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#xA0;S-T&#xA0;Rule&#xA0;101(b)(7):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:Times New Roman;">&#x2327;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_aa2a3aef_6962_4e58_93ff_aff9aef5e06c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the "SEC") for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac's financial results and business updates as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management's Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company&#x2019;s Registration Statement on Form F-3 (File No. 333-259613).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_47e52f61_a289_4adb_88e7_80a21eafbdc2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CUREVAC N.V.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;white-space:nowrap;width:3%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;white-space:nowrap;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#xA0;Franz-Werner&#xA0;Haas,&#xA0;LLD,&#xA0;LLM</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 18, 2022</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_847ca7d2_46b9_4d11_bc2b_6cea7a3134b9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT NO.</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;width:84.44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DESCRIPTION</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:84.44%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20220630xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:84.44%;margin:0pt;padding:5.25pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20220630xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvac-20220630xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8167.22744 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/18/2022 7:20:59 PM -->
      <!-- iXBRL Library version: 1.0.8167.22751 -->
      <!-- iXBRL Service Job ID: 02a0eed8-2dd6-4a6d-a416-96c42242c43d -->

  <html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:cvac="http://www.curevac.com/20220630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" sign="-" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_TRglPcGML0e_hUXjrMmiTQ">1.44</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" sign="-" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_FZYYIZzFzEG5z9weWkLHmw">0.39</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:DocumentType" id="Tc__0PEvMYZiEKJvl9qAGCAiQ_1_1">6-K</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:EntityRegistrantName" id="Tc_BKAvsUb9nkONpy04ND3m2g_6_1">CureVac N.V.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:DocumentPeriodEndDate" id="Tc_v8qFBEhVFECIi9HAu8pCQQ_7_1">2022-06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:CurrentFiscalYearEndDate" id="Tc_502bDbvpWUSUJ-YVwmVhEw_15_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:DocumentFiscalYearFocus" id="Tc_qkuS5_rNYkiiNATBtjyZIg_16_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:DocumentFiscalPeriodFocus" id="Tc_uSIE1RQJZkKQU4Gb7CmB-A_17_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:EntityCentralIndexKey" id="Tc_FPf0TbwlwE6JoQa9FlugTQ_18_1">0001809122</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="dei:AmendmentFlag" id="Tc_xFN4dQxQ9kes232XoWp34A_19_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" id="Hidden_paLxtlx0ME-S6iMem_-Thw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" id="Hidden_ax13MWhvAkygsY3Qa2lubQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" id="Hidden_VaaVoc4-BUS38rqyfpqYaA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" id="Hidden_QA1a_vf9GkqcKLlbclhWew">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" id="Hidden_63o3hDQhqUq352WtyGlB1Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" id="Hidden_N47nZFniJECqb2Lp26J_Lw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" id="Hidden_Lnb8kAVvp0G7sN4zz77g-w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" id="Hidden_uSbXAWSAcEOq0VSQLDDkMg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities" id="Hidden_4fCn4I71xkWAphcGg6A1Hg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities" id="Hidden_3YDIfJwocUSKswvm-giWwg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" id="Hidden_GGwjEWJr3ECslJpKAubuAw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" id="Hidden_rOAP57ONDkCcfobBYmvLlw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ" decimals="2" name="ifrs-full:ParValuePerShare" id="Hidden_G3msjGiE3kqZNUEVJNk5yA">0.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg" decimals="-6" name="cvac:NetValueOfInventoryTransferred" id="Hidden_jkLIgqZzAkOONGLtAkGXdA">98000000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvac-20220630.xsd"></link:schemaRef></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:75.74pt;"><a id="_052d75e9_be11_43dd_8d7b_e981ffd8d259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20220630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:217.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 50pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 17pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.3pt;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Unaudited Interim Condensed Consolidated Financial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">As of June 30, 2022 and for the six&#xA0;months ended</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;letter-spacing:-0.2pt;">June 30, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7ea34195_94a6_4c7b_8e70_d077ddbb06b0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Operations and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Other Comprehensive Income (Loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_da8fe3b7_3ba5_4de4_a879_147f3c3a2419"></a><a id="Tc_z_qenuD-R0OoZqM8tHdP_w_1_4"></a><a id="Tc_RogcQfMWY0us3XkHloGjHA_2_2"></a><a id="Tc_iw-0XuqYS02MR7R7lw0kFg_2_4"></a><a id="Tc_0CEFwZ1OoECcKI3OklfaDQ_2_6"></a><a id="Tc_6X3PLd-7KE6J9NAzymc35g_3_0"></a><a id="Tc_R5mPcKopM0moWCqP8QWbcg_3_4"></a><a id="Tc_ASdygsEpa0-BdvN1X2H0pw_4_0"></a><a id="Tc_wbewoCH7Wkmpfen94avwJg_4_2"></a><a id="Tc_jHFAJxyeoEqC5vkcH_clFQ_5_0"></a><a id="Tc_6cbLaMDDwkGdovgLttsseQ_5_2"></a><a id="Tc_niu50KV580-OFfUz5XaaYQ_6_0"></a><a id="Tc_NFei3TZXDEOEDsI6zrIivw_6_2"></a><a id="Tc_qg4J_rQliU2iSJqBKo3B4w_7_0"></a><a id="Tc_CxTXI1cSTkKeuKYpQmA0ng_7_2"></a><a id="Tc_nN2xUQk-dkq4qLmgxzX_Mg_8_0"></a><a id="Tc_FRRTDtgkMUaSybZ37u1-YA_8_2"></a><a id="Tc_lLnOWgMZvU6kaNgOg_OzSA_9_0"></a><a id="Tc_9gpSxhAbQEmV0wA0nrjxlw_9_2"></a><a id="Tc_6bAC6IGw50WB5ZdicAz_2A_10_0"></a><a id="Tc_jC6NOuia1UqeeLeYl93Asg_11_0"></a><a id="Tc_2s4RqTQQQU2EI6R15w2KUw_12_0"></a><a id="Tc_Jqa9hcZRTE2JfYv5JCXCjQ_13_0"></a><a id="Tc_h0TEu2zlz0iis0OMYQ-uKQ_14_0"></a><a id="Tc_febGjEk2FUO0V6S1QrC9Tg_15_0"></a><a id="Tc_TMRH3IatZEuKvV9TEzc7Zw_15_2"></a><a id="Tc_UrwBrsbIG0KJa9DdAxDiQA_16_0"></a><a id="Tc_BtI3C4m7LUGLeVK3pyaJFQ_17_0"></a><a id="Tc_hg9bg3K_QkWMVqQg21oKTg_18_0"></a><a id="Tc_O9Ax0ErMTka3hKuy6jFzOg_19_0"></a><a id="Tc_WO-UwGF7RECa2MKmXTROQw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended&#xA0;June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR, except per share amounts)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_A_zx8R3WLUSN7_enqbZ_yQ_4_4">32,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_IUtnWmHW9Emjn_Ssrhe-MA_4_6">44,519</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_An-IhNr0XkGf4PXQ9EfP1g_5_4">53,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_BUI4ZUJguUScgbUJAIdAug_5_6">79,913</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_95iIScviE02USXJHapM2Ig_6_4">1,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_Xfk8Zo_0VkKyBW95phrKxA_6_6">819</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_GKh37xONSEWBx2S0KaKt0g_7_4">236,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_TNQquZ1tBkCPdJLUmJK2sw_7_6">22,422</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_1I3mYbLWFECgDQSQTI5rBw_8_4">50,651</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_tljYrWlmD0m63VXcYQbiJQ_8_6">51,678</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_K9xZGRs3e0a87AERNp2SAw_9_4">45,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_McFdM0xFDEqQd7NLEGXAMw_9_6">35,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_hUepJmI7XEGV-FVkIrH7OQ_10_4">214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_SXGNeXN7SEqAEeKHdoaagA_10_6">461</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_FdyEwyH0aEmzSYjOfd5o7w_11_4">263,658</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_wKkO-tIiQEm3-ofrWbd3NQ_11_6">75,567</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_ABZp4V1HvUOPgowVVgqbVA_12_4">7,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_xY1wuODh9EKohem9Iz70Nw_12_6">5,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_-u9-DOdph0qRTO3tMXfrxg_13_4">8,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_RAM5MfXo5k6HgVoBDtgRuw_13_6">2,535</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_PyW48IARmUmTUFuWDEtL3Q_14_4">264,427</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_PbkfwEGoJ0ygVV-gyzub_w_14_6">72,759</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit/ (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_K930oT0IL0i-LAhtRoPQbQ_15_4">1,329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_bwGtOGqjaUib-pSrdn_7eA_15_6">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_gVMWt2Q94kuwT7qMxa3IFg_16_4">265,756</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_JCH4tynesUyzxI_p1IEqhw_16_6">72,677</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_Y4ZHfujhr0SRKu0qQ14UBg_18_4">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_rBpglPbnIECnStk0z2K9sA_18_6">212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_fX18lHmNwkGNdmtyp7sTfg_19_4">265,786</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_U4c04oiaekWUHf_z73EPYA_19_6">72,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_SklGBmgkvUSmuc7W63QlhQ_20_4">1.44</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc__FcR6fcV_U6AzgToO4r8Lw_20_6">0.39</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_871f5f52_c19b_4565_bd18_0f8f26c9703f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_6e74aabb_0b12_4803_9703_0900f19ee9c2"></a><a id="Tc__4dIHFiKYUqIa5JVRlXt8w_1_4"></a><a id="Tc_EMIo7cDvmkWToSMlSNaGHg_1_6"></a><a id="Tc_90Cj85M8HU2iLkkW1ch_pQ_2_0"></a><a id="Tc_tfA7h3yuoUGnSwjjVVK1EA_2_2"></a><a id="Tc_ywQdzno0kEetSD9xLFlJqg_2_4"></a><a id="Tc__tRzP6OZN0W3e6WG2VPO1Q_2_6"></a><a id="Tc_sz_57sRztE2Gsy9tcsvSIw_3_6"></a><a id="Tc_CnigzlcwokS-c-KBw6pJmg_4_0"></a><a id="Tc_nKlKqkWSdkC2W9bASSxBzA_5_0"></a><a id="Tc_MBQDSLfCW0OcXDjR5cF6Zw_6_0"></a><a id="Tc_6GOjQFdzs0K3MUlGX4EBZA_6_2"></a><a id="Tc_whq-UNquB0ycfSLAiJdBPw_7_0"></a><a id="Tc_93oL3V6QZ0W0NvCqoYTrsg_7_2"></a><a id="Tc_qh2b5Jdm4UyFCt10aIqV8A_8_0"></a><a id="Tc_fElw21szd0WofIipGR8UvQ_9_0"></a><a id="Tc_n-Bs3CtvnkuTqquF3Eby-A_10_0"></a><a id="Tc_Dt7xeNGfJkygo8omDShIlQ_10_2"></a><a id="Tc_vor0gjN1yE6BzCkGe6Tc-A_11_0"></a><a id="Tc_W2XULlLW4UmXhBYnCC8gNQ_12_0"></a><a id="Tc_yiARjI4h3kW1Ug3rBvmh_Q_13_0"></a><a id="Tc_2XnWxwrp3UuvModrEWXB-Q_13_2"></a><a id="Tc_kSJlhXFVJUiT11vpesWLZg_13_4"></a><a id="Tc_JFMl-0OxoEKwO5IRNIX-uQ_14_0"></a><a id="Tc_QSZRhCikkkO1RJyAPj0DVQ_14_2"></a><a id="Tc_-0PKFp6bZ0WmNI5xvLcb_Q_15_0"></a><a id="Tc_G-OXm7IWTUaW-krokeV1Rw_15_2"></a><a id="Tc_koiaYJa9_EWI6Ym1Dyzqug_16_0"></a><a id="Tc_-GTMtDdlhUaahXSBQb-7kQ_17_0"></a><a id="Tc_8OENzYkWfE-kakoNHwBOWw_17_2"></a><a id="Tc_ZA6BJq55uUKNzcLOTu3NNA_18_0"></a><a id="Tc_wuvURlKdOU24VmPDZcqt5Q_19_0"></a><a id="Tc_pIKb_OnfjkCHa0t6fWog5Q_20_0"></a><a id="Tc_3zZS_iozskG2thxyC4llqg_21_0"></a><a id="Tc_WMxPuz3hmE2r327bv1L4fg_22_0"></a><a id="Tc_f34SQ5U0MkKue9KW68T-jA_22_2"></a><a id="Tc_LU6co5AFIU2J3IvzEIsTuQ_23_0"></a><a id="Tc_NRoR2bm0oke0EPujk0OcEA_24_0"></a><a id="Tc_WzTy1KmnLUStm9vY2Rz2mg_25_0"></a><a id="Tc_nDhSJSRTXUOd8tjT-l_U3A_26_0"></a><a id="Tc_y4FWdWcTc0W9_ZQZ_Fy-xQ_27_0"></a><a id="Tc_o5BfIMVB4UKbDul4PLAQ3g_28_0"></a><a id="Tc_k5ke86zvmkG5odZCOF4pGg_29_0"></a><a id="Tc_5jVhElARmEiShsBph5u2kw_30_0"></a><a id="Tc_o96heWmMgE63Cf4dClPdOQ_31_0"></a><a id="Tc_hr_ANt4aT0COzkxNlKo-yA_31_2"></a><a id="Tc_YM0__Kae10-ynsVIkbrD2A_32_0"></a><a id="Tc_D5f2kBMLG0a5JNhRP1uxeA_33_0"></a><a id="Tc_lkTIfUaJgE-4TAG3e6RIuA_34_0"></a><a id="Tc_cQucGhSu1EyCplP36wZmDA_35_0"></a><a id="Tc_CU30-4tstU6AoR-5uXDdWw_36_0"></a><a id="Tc_BfxxX6G9xUyyf-ezn40TGw_36_2"></a><a id="Tc_9u7I2XO0DkKcGGWjR3yqrg_37_0"></a><a id="Tc_yYLWhMbDyUiD1o9J9dSxuA_37_2"></a><a id="Tc_ZMoPVSXCdUG8wnIYyb1IQA_38_0"></a><a id="Tc_Dw-hrvD-EEqax3Mz7ONyzw_38_2"></a><a id="Tc_zKt-9lhdFkSjFZVpvOmqwg_39_0"></a><a id="Tc_F3TDroRosU68DIr9eoxUsg_39_2"></a><a id="Tc_GUfVETNskEe8FM65p4za4w_40_0"></a><a id="Tc_2lAvi5JVdUObIEsFFIJhpw_41_0"></a><a id="Tc_b8R-7siaB0KJtcUNkbug0g_42_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_rIjWQpQTZkS2Ykg2k9qLJA_6_4">13,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_RU3BpphwyUOidrT71nFoDQ_6_6">12,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_8YqPmOZTaEOcA6X6hGHzUw_7_4">168,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_i9FaQUVvY0eL6zrOxBe8VQ_7_6">192,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_INtFs7-E90WCUNXmqyX0ZQ_8_4">32,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_ZRqvI8bcLkOjwtR1lo4zAQ_8_6">42,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_pAGkMBiAYEu6giVmILO5lw_9_4">1,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_xVFyURfaH0S1KY_uq9nUMg_9_6">1,663</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_pO-8rKHk5kKgYr-UC2bLxQ_10_4">2,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_djkAnyaQUE-eOkYQj1kJgw_10_6">1,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_aqaLBijzsUKeFVJOqtDi7Q_11_4">218,223</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_HmiRsZVi90utVZWP9QsWdg_11_6">250,231</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_o7zLwSw5WE6oZWvFfQQ9Vw_13_6">865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_Wff4ZkRMC0CHswddhJzIUw_14_4">56,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_Vk6YoCywkk2tCE-Jo3SP_g_14_6">13,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_jY8K8UvThUCnCG5nms8SaA_15_4">18,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_ohaeu3XZJ0ygo1HC0Qi1tQ_15_6">13,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_b9mDMHFTs0uYm2n3lgUL-g_16_4">4,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_xuzF4m2BQUCWwH2Mc6dDog_16_6">3,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_L4CNnVJ0OUGFLQxSInzZQw_17_4">49,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_g0ZwSRcj10Kf-D6DetpeYA_17_6">70,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_Cy2Pku6t0km2x1wvfnQNqA_18_4">811,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_IF09K5rV6U6j7NAFBLlrAQ_18_6">573,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_o5EAxx-ZtkGoyZZY_siDZA_19_4">940,019</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_3L_xT6PchUae9A0NvKrduw_19_6">675,589</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_eEBimCmXNUyLW7rUd8LH2w_20_4">1,158,242</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_D06llgRHska8nXEwwNgK6A_20_6">925,820</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_JeUHIT46D0WPkBOvPn9aQQ_23_4">22,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_F_Et38xYrk2mvE1OppxgYQ_23_6">22,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_gDWAvP1_o0qoGiWDjyD39g_24_4">1,728,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_nfJuijQtNEaLS83wMI7KjA_24_6">1,732,148</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_jq9KkUA8_ESaQ3giXDX4aw_25_4">5,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_VRy-wO4ZxUe41CAMfkZTAw_25_6">1,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_cm80f0UKtUGU1JWJhvDL_g_26_4">1,056,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_IHtbKmKitECNOmHpK12Lpg_26_6">1,129,462</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_h3BWMK27H02IKttCsFozIw_27_4">34</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_FcxV06KV_Uu-B6s16UVYyg_27_6">246</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_BwNV6pb1nkum3UC5-gCLGw_28_4">688,476</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_lGZjz5zMQkOfC012soT8rA_28_6">623,202</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_P4xyzjUpOk6Y_HOX3efaag_30_4">25,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_GYAP_ozfWEmZn5np2B2SQQ_30_6">35,931</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_nm5J5rHbFUGGDpgsx2DP_Q_31_4">86,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_ltkBj-YpwUuBcS_pt-ptXQ_31_6">70,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_ezHr2WVeXUWUloToqvF3Mg_32_4">264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_Vh3NiAIoqkKPIP4tXJN_Dg_32_6">264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_VogM8ginLEuRmh3fVwK__Q_33_4">112,032</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_wp7bW97txk-BA26kF9PYEA_33_6">106,985</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_Tt_fBHJfgUWu_Ql2cFHL9Q_35_4">3,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_wIc5OPOIJkCrvE0vmVkFZA_35_6">4,278</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_hYh2RTFCFku3mK0xh4XI1A_36_4">127,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_0VPe7wAk6ku600BZGwYN6Q_36_6">48,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_U2jJ-uynNkuy0yReOqIQwA_37_4">170,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_PPWr2qv4WkCJWuJ-D3Uw7g_37_6">92,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_uP0AwpglX0GJtIcuFGcseg_38_4">739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_eotOxDhs7UqXI8y4XLWl_g_38_6">613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_cV0gLGeGL0mCbWX-kllefA_39_4">55,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_ByhTykhUVEuBioRckRaEJg_39_6">49,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc__ByFqfTQTk2JsGx290c_1A_40_4">357,734</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_YGrmkzj1gky-WpIdNF-bfg_40_6">195,633</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_SVOC8zTFvUO1Mespnliy3g_41_4">469,766</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_dhx7PUCmkkW-VowwUNPqhg_41_6">302,618</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_3JQPhEuOkE6--uQI0EpkHg_42_4">1,158,242</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc__P7U9dI6B0Gtj_847EkWvA_42_6">925,820</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_5bf06358_0db5_4c20_95d4_5c1b92e0d21f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Changes in Shareholders&#x2019; Equity </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">for the six months ended June 30, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><a id="_8affb9f5_7a37_4d0e_97bd_0bd3dcd38810"></a><a id="Tc_6krvx05XCkWUhQgGbPs-eA_1_10"></a><a id="Tc_iLL2DRNdrUWIzt96Ng2BBg_2_2"></a><a id="Tc_8IrceWLkkESO32JQnpfF0w_2_4"></a><a id="Tc_H9mMtG_qEkCr_WtOMEQT5Q_2_6"></a><a id="Tc_YiVMsDqbTU2RqR38nzHpbw_2_8"></a><a id="Tc_JH4m7kkLLESA7VVUn29Z4w_2_10"></a><a id="Tc_1uJxwUNcgUuS2MUgdlHBvA_2_12"></a><a id="Tc_Ck4-GIvlSUumTV-5IMgsJA_3_0"></a><a id="Tc_BySYGcfk10uHH8i2tzni8A_3_2"></a><a id="Tc_CU-D0VJfIUanMBIS45W5GA_3_4"></a><a id="Tc_AT_vWmUKeUGcVWx1exseKQ_3_6"></a><a id="Tc_BEcfTkqo_EeSLno5Agrq7g_3_8"></a><a id="Tc_EaGzJaTQGEO4xzA-HFsiBg_3_10"></a><a id="Tc_LyKXLT5jL02llh3YXGetmw_3_12"></a><a id="Tc_WpQqXF9vVUSFEtn2u4LGOQ_4_0"></a><a id="Tc_7Xe3GRQ5L0iRZ2yh2NEY9Q_4_6"></a><a id="Tc_Kw39AbPhhku74AUgDhFLgA_5_0"></a><a id="Tc_VdcmuEtKz0ifdXEMpHefcg_5_2"></a><a id="Tc_ggPYBg5WMU6m1nzdb4Lg5Q_5_4"></a><a id="Tc_ZMsqZC8Myka99VzCDc4yTg_5_6"></a><a id="Tc_NCMVuu4aKUWOMQbKCE9c3g_5_10"></a><a id="Tc_wrdbuyujyESyM7Yu-IvnqQ_6_0"></a><a id="Tc_r1beQsE3Ekm7hhdOvZIrig_6_2"></a><a id="Tc_5YFr1x_cokWyah8IMpasKQ_6_4"></a><a id="Tc_4_R7J2GWNU-AKI9CkwLcXA_6_6"></a><a id="Tc_tiDdUwDgJEC8FcmbZlhYlw_6_8"></a><a id="Tc_d18raHnebUKkWhGEOwleFg_7_0"></a><a id="Tc_HyKdi2zjU0Wiwi0sTIFbeA_7_2"></a><a id="Tc_GygFRzr6okGy-z3BO7IiMA_7_4"></a><a id="Tc_JURxAAu1X0GPNAVJg-Zr1g_7_6"></a><a id="Tc_N_1q8YdHH0SY6sTqM9cx7g_8_0"></a><a id="Tc_DJNsidKq1k6IrBUbyy-KlA_8_2"></a><a id="Tc_1MZHOdau8Uek2Yai43JiOA_8_6"></a><a id="Tc_NtdXzpKaK0-KKoLj8MqZJw_8_8"></a><a id="Tc_6CZTvnuGsEaKf6lH5Duzzg_8_10"></a><a id="Tc_71JurOHla0KmUJWvcyUTZA_9_0"></a><a id="Tc_HvPfcvs6xEGfG3Vmq5fJcw_9_6"></a><a id="Tc_t1gY2NYNBUqeFAGNTfAGAQ_9_8"></a><a id="Tc_01lrL5rfgkCP6z5SbZ-R3g_9_10"></a><a id="Tc_sYO2LrQbCUaMIhrhOOrdJg_10_0"></a><a id="Tc_Hm_ykZn2VEG3pr-neIyHQQ_10_6"></a><a id="Tc_3-uyY-055Uuu97buw-c2QA_10_8"></a><a id="Tc_vhXXhUKjLkah-M96JJXL3g_10_10"></a><a id="Tc_IUnu_F09WUiGirKEoYj4Zg_11_0"></a><a id="Tc_EkZuT2waDUeicrtLd4xcqQ_11_2"></a><a id="Tc_HuKJ_qj4oE6pHQfWuMLZng_11_8"></a><a id="Tc_MldDC39AtkiSyqGZ2oba2Q_11_10"></a><a id="Tc_1ZAodFQllU2Un23PydTnFQ_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_0uN4IImhtk29MylD3AVWoA_4_2">21,655</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_YkmeTmz-k0ywp539pQH2GQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_dYuMMAUCJ0-2M2O0W-X_Hw_4_4">1,334,704</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lSeomaiJs0W8Yf_-pG_B6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_fasPfzi3TUupnWMoMnfB6Q_4_8">645,069</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VUFJcmrBx0OexVdaoisNAg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_CjFvRn9yL0e7JX9pUYW3uQ_4_10">57</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_3C-nmDg8f0CsNxc5-JCW6w_4_12">711,347</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_sxz0m3dYC06VxVJXcSBQ0g_5_8">265,756</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_eXfI_oLfU06BkC8n083odQ_5_12">265,756</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_sd1lq2ISAUmcqKVVIuBVJQ_6_10">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_9IINRowfIEK7ZXjW5nEZeQ_6_12">30</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_8g5gfzPUuUGPJhpELtX3RA_7_8">265,756</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_yygkdTfr60OY8xwOTzrw5A_7_10">30</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_V6g1mkDMVECIROO3cAm4Lg_7_12">265,786</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments (net of taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w" decimals="3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_QNrB8DRSBEKUVOfl4MBShw_8_4">9,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_7ReaadY0nkGdOjJxzS90zA_8_12">9,382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_zwQkKqW0zEW2hN8mxOxtHg_9_2">690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_POIRRA_pTEOuzEkJgvNBqQ_9_4">403,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_mPJ_lhK21UGum4Lg9xEAzQ_9_12">404,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_g-B5HNlAW0WFChv0tnwvHw_10_2">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_-PFKqHY4RUu4zITIbZ5EbQ_10_4">1,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_M_C0TtuXqEuXbm9aOYD_Sw_10_12">2,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Repurchase of common shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_vcOF-pVwZE-21VyHdZL4Ew_11_4">22,739</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_9XL-YVNtDkqObkYAyoA2kA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_4YXJp1wWJ0W08Iq4YpVn9Q_11_6">3,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_EyMB5Vyrc0-HTzkbaAfeSw_11_12">25,761</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of June 30, 2021 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Une6DLwLW0WGIfTxv_fmOA" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_NYtR-sO_1U2fc1-1Jlc_1A_12_2">22,425</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Dav_DW2ztk6-ETIcsBP69w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_AQ8Rks4JkUusQxmiOmnz7A_12_4">1,726,713</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_iUPLBTtqT0GEW_-lUGmSbA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_WHnfD_QdwkK-Z_hWR9a70Q_12_6">3,022</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_gNxzEodT6kKGuBFaWKy0eA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_FoDMewB2okG4eHwQWBJmjw_12_8">910,825</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_GtBW4y4FQU2LNtgqNQvYqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_LoxNtWxKjkuGCU75znMTig_12_10">27</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_QEY4ZLeuz0aIJ87W2rmo7g_12_12">835,318</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><a id="_53791026_d2a8_485c_af8f_0dafa30aee62"></a><a id="Tc_yOTz6IsTz0KOmt2w2CGTNg_1_10"></a><a id="Tc_-HZ3QVGpQUW-RWyfRnp5zg_2_2"></a><a id="Tc_esOyikpmpU2frm4993FKVg_2_4"></a><a id="Tc_0Fsm-CshsEeRH_4QMHNckQ_2_6"></a><a id="Tc_GLVhIpCC7E-lGxaTqjNEIw_2_8"></a><a id="Tc_M1rAtYUft0CBk2CMbKH7xA_2_10"></a><a id="Tc_KidGMLqTNE24Smd7uAxCxg_2_12"></a><a id="Tc_izL1E0S-iE2K-EZhgLbUeg_3_0"></a><a id="Tc_niKVt29VF0Sak4q7B1fvKQ_3_2"></a><a id="Tc_AgelRh0HEE-2at41y47SbQ_3_4"></a><a id="Tc_80HL86MceEy9IJOySqZHyA_3_6"></a><a id="Tc_69TevyGxFEiwmRQiimW7vA_3_8"></a><a id="Tc_VLuPzqZE-kK_O7cafYB91A_3_10"></a><a id="Tc_rbImXaJbEEyHsneSV0ojwQ_3_12"></a><a id="Tc_yQjoRaC6Ak24EDNBnufVSg_4_0"></a><a id="Tc_mhBoVJ_bLkqXZsSKTOzR5g_5_0"></a><a id="Tc_5PcAEapXdk-gL05xZ995Tw_5_2"></a><a id="Tc_ecEMZeXXBUW_EtdOgR2Mig_5_4"></a><a id="Tc_aTjsum8H5kytDSXw3sA3BQ_5_6"></a><a id="Tc_cWbm0OCG8k6dtju4ChSGxw_5_10"></a><a id="Tc_gtfmBnevhEOckVJ1kpUdWQ_6_0"></a><a id="Tc_M5_gbV0Ll0WUrd_8VoqcaQ_6_2"></a><a id="Tc_NxEy7kKCZE6wA7E7ihsF2g_6_4"></a><a id="Tc_dWwvdn7oQ0ST4EO5vAnujA_6_6"></a><a id="Tc_tr08RVsgVECrnjk-L5PAWg_6_8"></a><a id="Tc_64G2wDmEq0OVA64KEaLuiQ_7_0"></a><a id="Tc_RqUkSq1nyUKo6wEueS-xHg_7_2"></a><a id="Tc_wBXpZZamiEe-5lCsvSQEkg_7_4"></a><a id="Tc_R_FXA_tuZESb0PYvJULSeg_7_6"></a><a id="Tc_SNE71hC1V02MEZOjeHjKIA_8_0"></a><a id="Tc_jKuUV5TbF0eU7ss273LqYA_8_2"></a><a id="Tc_R5Fd9gOfEkelqvSslrsj6g_8_6"></a><a id="Tc_-GnzAL5TL0y-BwYv0QkLyg_8_8"></a><a id="Tc_kuH7pwL6bESyQJmfd5ghVQ_8_10"></a><a id="Tc__TehwYjgAEWSKpAoQ9ER7g_9_0"></a><a id="Tc_7TzSYV2rzEmDDfGsj1eWtA_10_0"></a><a id="Tc_mLBKJ4pYPk27HfK2YpsxAA_10_4"></a><a id="Tc_Fj50ksdWB0uCBTJZim9zAA_10_6"></a><a id="Tc_5-9Q6fIS9kapi1OsRUfmmw_10_8"></a><a id="Tc_1H7vZS65K0KThnnIM3qXDQ_10_10"></a><a id="Tc_h-BYc6jokU6UculDJVP0lg_11_0"></a><a id="Tc_W6PSc5HA9U6a_XRBkoiisg_11_2"></a><a id="Tc_gCnvn7_mv0m6gyPDDn8k5Q_11_8"></a><a id="Tc_4gZ1-MnpXUuRvSCstUUNHg_11_10"></a><a id="Tc_WqandW7goEqVXBCNsFBl0A_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xukue48ZDEGBV7izRS3Mlw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_kwm5E-s8KUK3kdiSXAoL5w_4_2">22,454</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_MRAiZ2HMfU6clBflMMQ4Iw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_vb1WYzwk0ESNeRIl8JjxCA_4_4">1,728,658</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_bnkru9QQjkyVNYTwKq09QA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_rhsBPVVcPUKB2QBC7kqvgA_4_6">5,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_HZud9yt_LUuUPbn-LCJnCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_Aa3R3HRdLUWzpPFPP3fjNQ_4_8">1,056,785</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_EJ4D4Sg-IEKFiOm7DAMDwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_roPgynPGzU2Jh4WXMBx3ew_4_10">34</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_A1Q5Lyq1SUyYjQdPhA8CgA_4_12">688,476</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_18lKrKpaakKTebeqePQcmg_5_8">72,677</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_n_Vpwmvdr06oz9T2zf8ebg_5_12">72,677</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_m7VkqCvcsk-9OTaALjvoMw_6_10">212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_7IWlBWBeekurGcaYGJ1aZw_6_12">212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_kuIfUkdCPkW8axxSnBZedg_7_8">72,677</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_slr43G4fgEWqv8r08SbPRQ_7_10">212</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_mcUsYvJb1U2ghnq5eplCcg_7_12">72,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments (net of taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_TJkOFqAW4EWggt95HRxA9g_8_4">2,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_jIvA7lmi1kScFGLNnuzAcA_8_12">2,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_GAZJFykryEaicwr0Jf75_Q_9_2">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_0whWC4jCRE-f1IzMnQyreg_9_4">4,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_8EAONjNAhUG4YC-7B2z1tg_9_12">4,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_Pbyvm-CWoEiPz-lSHz66aw_10_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_XSZX1EGjY0aYQFWfYQzk-Q_10_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_9lWr6fSWK0uuXuWJ3M_thw_11_4">3,452</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_v2Ngz-T8qke5OXbIqZxvLg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_AcxrJaCrvUW7dtGukxw6Hg_11_6">4,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_7VynHZywKk2AddlpTXQmwA_11_12">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of June 30, 2022 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6BsM7vzIFU2WSKtxlf-yDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_CU5rdBl540K0Amx8lvo1lA_12_2">22,496</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_F5SaMz-K80GYDBc1b5afng" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_TKAMdUT_DU-9xjmW0k1q6Q_12_4">1,732,148</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_-c6P1_7DkUS3B8fykDBDmw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_5hUItKl5HkCIy5Fqm1wFOg_12_6">1,734</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0ytFSqcEM0C2FCZayK49MQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_FFADtThVh0SkyzxKivIFwA_12_8">1,129,462</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_vsww_6W8XEuzXqcrXTgKVg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_tGz4_3AOckmzTdA2KqCLmQ_12_10">246</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_Lcyb7UaUQ0a8dGfRvtew-g_12_12">623,202</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_fdaf57bf_c39e_4cdf_b378_73f6c85a8b03"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_c0e2a4b1_ab2f_4c85_b08c_3a239209dafc"></a><a id="Tc_Laly7qoAp0CasSI7nLvdsQ_1_2"></a><a id="Tc_i_ws-foZ9UOnmpaWeFSunQ_2_2"></a><a id="Tc_19VtPMJqb0iuTTg8bQVVOg_2_4"></a><a id="Tc_tMMzxallJk2GudBdEk4dsg_3_0"></a><a id="Tc_FAAxdeKeNEuVo9LdRqjuGg_3_2"></a><a id="Tc_dGbfgm9gTEKjYEfI6_RXJA_4_0"></a><a id="Tc_JnMtgLnSwkajasfqeo32WA_5_0"></a><a id="Tc_oZ6jmzUodkOcj8TGtMpVfg_6_0"></a><a id="Tc_hsz1uDhFVEiS6VYe1bZ0zw_7_0"></a><a id="Tc_BoIRvzpxa0aEwUNKJOdegQ_8_0"></a><a id="Tc_-3c3dDh2N0uBIWU5Szrr6g_9_0"></a><a id="Tc_GFp_-bg2tE2e7u4-ETt52g_10_0"></a><a id="Tc__vLYzM22oUutP77TbZho9Q_10_2"></a><a id="Tc_h778w5WiU0S-7XqwhVWu2w_11_0"></a><a id="Tc_0MlOSdtknk2sHRE1e5fBPg_12_0"></a><a id="Tc_Ff4E4WQ_a0qi-Evk37NyMw_12_2"></a><a id="Tc_chPW9bB-LESyl2wevF0ZMg_14_0"></a><a id="Tc_FGdIaXhfGUeysqtG3kYEcQ_15_0"></a><a id="Tc_tUViO26nUUOk56MPg47X7A_16_0"></a><a id="Tc_NUWfkOzPekm2mXeLa40JYA_17_0"></a><a id="Tc_7Z1sEvvNYUGfteOKLOFi8w_18_0"></a><a id="Tc_XbcaO3_7ykm5oAzh8hN3oA_19_0"></a><a id="Tc_WAE_hyX8uES1tJqax_sikQ_19_4"></a><a id="Tc_Z9yHKvXiQkuEGKjP80aj4Q_20_0"></a><a id="Tc_8VPbRVoLPUqDLv7RZL4nhA_20_2"></a><a id="Tc_HpZSrHkNd0mWIDMov6vKmg_21_0"></a><a id="Tc_aIsWRUcDC0Wau6fxYr9jag_21_2"></a><a id="Tc_CVN39VoVBEWKPjp9mFZ_hA_22_0"></a><a id="Tc_gt3TuWnlKUiAzDmp8FUsWw_22_4"></a><a id="Tc_5lM5HpllZUC4mIbAYE6O7A_23_0"></a><a id="Tc_LhlYpNN1ikSx0AeepmfIkw_24_0"></a><a id="Tc_wABkNKu3jUWQOTU50vfphA_26_0"></a><a id="Tc_VZWG0Qb-XUqNz0ATDfxqdA_27_0"></a><a id="Tc_yN_wnLpNE0e3vBoQxKtsdQ_28_0"></a><a id="Tc_wWstmXaVKUGkcrChV1LNQw_30_0"></a><a id="Tc_tb_sdqfkuUqKpBEiO-QFhQ_32_0"></a><a id="Tc_KQTmhgnpw0GbR7Db9ButoQ_33_0"></a><a id="Tc_p_IfCI1mME6XGvHH1p4gmw_34_0"></a><a id="Tc_YAOD8I-TaEKveM2BJgIJpg_35_0"></a><a id="Tc_-AqyYeHwHEa7AbIDJ8GDVA_35_2"></a><a id="Tc_usHBtplEOUKmqGbWIw9Xqw_36_0"></a><a id="Tc_eQIS1MUGOUyBNV5bb8FFRQ_36_4"></a><a id="Tc_JhtsCwlrhEG9ZSpeVVpCOw_37_0"></a><a id="Tc_Er93DDJyUEeMYfjtaVD3eg_38_0"></a><a id="Tc_C3CCOBKD6Uuaxi1aq9fNEg_39_0"></a><a id="Tc_d0uLb_N7FEi6ul1sA3MJvQ_40_0"></a><a id="Tc_zN_4eysajESdN0iErRdR2g_41_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_WQjwTnI66k2vFt3ndO5eyQ_5_2">264,427</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_ze_lZmwEu0yXMFlxttTnRA_5_4">72,759</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile loss before tax to net cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_B9zrJWGkS0qSnbFtZ5-Big_7_2">7,296</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_OjA9BFA_1k6fqnfxc92Z8Q_7_4">5,343</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_U30CKO_640itGmOSv4dAlg_8_2">8,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_iEya1sMBI0iFM8-ZuEcbqQ_8_4">2,536</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and impairment of property, plant and equipment and right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_D7bLen1bS0KnXHgb3rZrWg_9_2">6,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_MwvkCaXnQUeZo7t8SIzOBQ_9_4">16,651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of inventory and prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentsOfInventoryAndPrepayments" scale="3" id="Tc_fHjmAro6TUWEtHzpaqk4Nw_10_4">25,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based payment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_5HNqpP8eHUidFXhmgIEBaQ_11_2">8,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_u8LJ02Pq_EWvikysN7jn3g_11_4">3,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash income from release of provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions" scale="3" id="Tc_55OEjohX2E6Vb0bUlz18YQ_12_4">47,242</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in trade receivables and contract assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" sign="-" scale="3" id="Tc_EnWVjENr4ke72GYZGt_T3w_15_2">3,072</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_-nzS7tB09EmCXAhsrbZ2UQ_15_4">5,164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_SESyTeb2Nk6iiTrIKuZUcA_16_2">48,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_h7E6-1kUNE2QxJXh8dxlcg_16_4">16,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" sign="-" scale="3" id="Tc_LS7d9S54fkqd9WsdIYPBZA_17_2">135,440</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" sign="-" scale="3" id="Tc_qd8SvnqQ_0eTq1tLrXDDEg_17_4">14,051</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="Tc_1G0cjunlBEueEDWMDzuOAQ_18_2">165,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_WfVvHCwsJ0SPU5vMu9a0GQ_18_4">129,038</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Decrease) / increase in other current financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" scale="3" id="Tc_buJ4oECAzEayMnpHWKP-9Q_19_2">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_tbWxlAeyqkWKsOUHFKhM9Q_20_4">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income taxes paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_Oi97-PqQp0SbiVO5JIOLYQ_21_4">126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_6MJbJANBNkmt0Y0_xjZeUQ_22_2">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_sAf_Yg8wOkuL20B7gmAFPQ_23_2">5,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_Dj_TRDK2jUijuhdbP0eVNA_23_4">2,608</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_ACgxTz7N80KUJfJcNAzsaA_24_2">274,898</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_UobZ_lafdEyiijJWm9aAsQ_24_4">201,175</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_cRvWSxc2BkanR5M0zB9LfA_27_2">69,751</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_obvvrN1W5UiOajlRu8ZFdw_27_4">43,507</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_0soS4HaTY0KWJVT9jp6DqA_28_2">3,966</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_veIbtgGMEkaT3icsEltIKQ_28_4">1,208</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_wMAecLQuCECt47qvrJCxzg_30_2">73,717</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_fy3yeQ1Uq0yHYxtKofh_eg_30_4">44,715</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments on lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_ih99Ht3GCUSTXLW6ZPk0Ag_33_2">1,531</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_FBV4jIMl8Em8RyI3TdmWzQ_33_4">1,943</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment on / Proceeds from Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrument" sign="-" scale="3" id="Tc_mgSJINGFdUeuSqdfTU2e7Q_34_2">23,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrument" scale="3" id="Tc_x_rjgLua10C02jYb_heEAw_34_4">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds on At-the-market offering program (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc__cK75nCSKk-71S89_g6Kng_35_4">4,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of shares (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_IQXubA4hLUmaWPUWVuj73w_36_2">404,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in)provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_-L56zjXS70KQwgFiUICZtA_37_2">378,845</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_jaULv35vbU-7y_qndO88Zg_37_4">3,409</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" id="Tc_hG40cl88l06DLtZDVAwDPQ_38_2">30,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_Zfg_dr7Z8060bz-vn5xYxA_38_4">242,481</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency translation gains (losses) on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_zzkTYoeQr0q4eREG1NhaTg_39_2">2,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_3BZ_Zsq4q0-BsRZLFRtfZg_39_4">4,583</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc__tu1csoefEmGRtg-CpflQw_40_2">1,322,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_tokMOYKakkWQ6VZYC810_g_40_4">811,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_lgIUHdweaUGh4rtayIYyDg_41_2">1,355,812</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_mtfpRpH_lECOUGh-aYd-XQ_41_4">573,566</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:CorporateInformationTextBlock" id="Tb_yefHbHxeEkGg_c8HRKrCoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#x201C;CureVac&#x201D; or &#x201C;CV&#x201D; or the &#x201C;Company&#x201D;) is the parent company of CureVac Group (&#x201C;Group&#x201D;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under RSIN 861149336. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 46 &#x2013; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="Tb_KmVv7-FaT0KX4EImSu_XpA" continuedAt="Tb_KmVv7-FaT0KX4EImSu_XpA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_kx3g3dpArUmi4FdkYA6okg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the six months ended June 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 18, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201C;EUR&#x201D;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="Tb_YmkVTop99UCdOunuD0ROgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the six months ended June 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="Tb_k-eHf3rkeEqSJGQubt-mGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><ix:continuation id="Tb_KmVv7-FaT0KX4EImSu_XpA_cont1"></ix:continuation><a id="Tc_LcMZJQNV5Eaaxj_qkDLCXg_1_2"></a><a id="Tc_1VmO3hiPQEyR8LaBLtg8tA_2_2"></a><a id="Tc_p-B_mQof60aqArs5RApE3w_2_4"></a><a id="Tc_1VxzjZVKPE6NVwOTXCZbVA_3_2"></a><a id="Tc_dxDekmnGuUSRhu2MISctag_3_4"></a><a id="Tc_Rvdo2trb-kq0hqlzAi9K3w_4_0"></a><a id="Tc_InL8Q9SOJUiIFr6snEGMzQ_5_0"></a><a id="Tc_DqPT8rXwAUKxMet8QCLGkg_6_0"></a><a id="Tc_qlEXEI0SAUSxO9CuKvsdVA_7_0"></a><a id="Tc_tYdE8XXvc0mYdL77-X7ccQ_7_4"></a><a id="Tc_yrNHm0Zox0S0wjQbS6i8ww_8_0"></a><a id="Tc_clIZybPxkEmfKVKn0cjcGw_9_0"></a><a id="Tc_k4mSFD08R0eJwMvtNvoZEQ_10_0"></a><a id="Tc_uw1YizBvUE6qqwL6oILSRA_11_0"></a><a id="Tc_5MtNW4ZIz0WYrAh7oEudXA_12_0"></a><a id="_e90e3f68_b522_416b_8175_63d388a14daf"></a><a id="Tc__JiN5ZC1oESFg4hD4TpNtw_1_4"></a><a id="Tc_DsofCvXWO0WVfCpUsYeQkw_1_6"></a><a id="Tc_hVWMvtnYr0yoeSE-mwXapQ_1_8"></a><a id="Tc_rknwe5TcJ02ybcz4KCAwcA_2_4"></a><a id="Tc_J2iXOUYhgEmMIEUyFMTFnA_2_6"></a><a id="Tc_lWDzjedms0Svpip5yF19JA_2_8"></a><a id="Tc_ivHAugVY8ES_-wXLyK8nCw_3_4"></a><a id="Tc_c6ETm7_g9EWX-Zqy5Ve8EQ_3_6"></a><a id="Tc_1k8fpb0xVkGZLPAbYlKvZQ_3_8"></a><a id="Tc_OzF-1h47tUWr6vyuv1_09g_4_2"></a><a id="Tc_RgLIuEt3x0qzwFhA87k93g_4_4"></a><a id="Tc_B4lM4zgPAUqLgwRizQ05Og_4_6"></a><a id="Tc_uLSAaZiI_0y7NP-hko2nHg_4_8"></a><a id="Tc_9Aw7WXapBEaEA4QKM6-8Qw_5_0"></a><a id="Tc_661TM87xVUeeGHsa-4pWGg_5_2"></a><a id="Tc_fytre62WSEeWHbZL8FwanA_5_4"></a><a id="Tc_jELl67DOdECWuYGljj_Qvg_5_6"></a><a id="Tc_yYv3RZ8sJE6joeHO73WDyg_5_8"></a><a id="Tc_k4wAOpwN-UO3C8Eh03GvIg_5_10"></a><a id="Tc_HzeraNVgrUiAlF5Nkk0TxA_6_4"></a><a id="Tc_VoRjFVU--kKHOoQ--F87kA_6_6"></a><a id="Tc_ZhGnpcbSUkSsFY-yWvN4kg_6_8"></a><a id="Tc_n-49Vzi_zku7qKryaCKJaw_7_0"></a><a id="Tc_QxXLqfO0B0-KIH_9kGGKzA_7_2"></a><a id="Tc_a5dniL6pMkecb7eFvL0sog_8_0"></a><a id="Tc_qhgLe_GVOkymSA-qEv3vBg_8_2"></a><a id="Tc_rptduoHH30Sq9nreqrpTVA_9_0"></a><a id="Tc_uuoLEtTCd0S_l3fkJ-fZ2Q_9_2"></a><a id="Tc_ciP9BUgkd02CsNWM3wftgQ_9_4"></a><a id="Tc_-_QrGRcPtEqwrfihqvsXmg_9_6"></a><a id="Tc_atGgarL4dkSaZKsBRQ3Xsg_9_10"></a><a id="Tc_ywEIf50MsEmKZQ2BUbybNg_10_0"></a><a id="Tc_MLHrh5FxIUaPLPFVRUitdA_10_2"></a><a id="Tc_SQvBMA50qkWuL5p7xVlaww_11_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="Tb_v49KF3SWJUCHMw_GLX5Wnw" continuedAt="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_wncZWgBtwUC88fUhg_pT2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_mxFKd7NtT0yW0eQjP6D4cQ_5_2">29,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_lDXiljhyZkOAr9NlDGzGCA_5_4">43,041</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_IZKQNmwJz0Otp2sIpw7z9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_30cDkBq6k02SlPoGprAtdA_7_2">2,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_IbyWgW8zTka7Hdyj-GqiEQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_N-chJcvoYkS5GZLSXVNoyw_9_2">169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_Lc0XNMKuKEqN_5NhPdFzTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_bmlrQ4jaek-V-p3wn9J6dw_9_4">586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_J42m4KTLKUOHHRX1Xm1Ajg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_i3sosvnP2kOs5zNvzGAYrQ_11_2">870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_PImd1JWYGUuBROPVuT6t1w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_xkLNAjLg90aR6WkPN8pAvQ_11_4">892</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_FN89pEk9Q0it8m4WiUjvAw_12_2">32,425</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_PEa-wbXhpE2-cC_6uL0jrg_12_4">44,519</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2022 EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_Au00DK75gUGk_Jvb_LBT4A">31,818</ix:nonFraction>k (2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_roPpiGHf9UmoLJCfWf2DTg">27,730</ix:nonFraction>k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_kJmg11wUDk6B6oaK6o4npw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_98A7MrKID0SskXxy5DlPpg">431</ix:nonFraction>k (2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_2xzoP9RNVk-PMBP-aAb16g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_qOqsRaoHmEujjcIe2uaMUg">338</ix:nonFraction>k) related to delivery of products and (iii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_m6vvO3sZ60-XG1n4n_R1BQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_IF-MlLR_n0CcpMR4fGwfwQ">12,270</ix:nonFraction>k (2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_ygWZIJY7-ECXlg47u0aOrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_Ye0WlQCu5kWwc3u0tttoQA">4,357</ix:nonFraction>k) were recognized from those research and development services considered distinct within the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the six months ended June 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_dTJNHdYX8kCCVgsPZaawyA">43,041</ix:nonFraction>k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201D;GSK I&#x201D;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201C;GSK II&#x201D;). In the first quarter of 2022, the Company reached a development milestone of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalDevelopmentMilestonePaymentsReceived" scale="3" id="Narr_CDZAEfZCm0WdvZiP5QOCUQ">10,000</ix:nonFraction>k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2022, also includes recognition of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_VEr1wMzBXEuBCEX2Gu1Trg">5,321</ix:nonFraction>k of the milestone amount. The remaining EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember___Jw5IM-M0uiIYastW7Ohw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" scale="3" id="Narr_bSQbtzFmgkOAudDcuzW6ng">4,679</ix:nonFraction>k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2021, revenue primarily consisted of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_7X6GqIb4Pk-B4oPO0h6l8g">29,335</ix:nonFraction>k recognized from the upfront payments under the collaboration with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="Tb_Yt5fmAVG70So2liGkPPdug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#xA0;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront&#xA0;payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_MMftP5xcEUaQcw9Is72raQ">205,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_LesCyMz7FUK3ZxQEsZWNEw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_xV8XRavTMEyOi97sxurzUA">10,000</ix:nonFraction>k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_fVqKtHZJh0ajtDFuaqC7Fg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_Pb0u8sig0kC_pztRaGxB_w_7_4">135,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_7KO8bRA7QEuIlbe-Nav9MA_7_6">114,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ukmwgK4pjkeQL_CmzxJNpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_yRNxI6BbeEKyvbLbO0TGAQ_7_8">24,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CreBB5VP3EKrtTllWwe7cw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_LZ0iLLiu-UG_P4kqr7ioZg_7_10">30,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr__-RIL4iyM0mjf65gtV0MUQ">3,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_0sIwgHPtnEeQxWqsrUKluA">2,524</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2PVjDRq_NEuYUZZxVJgpqg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_lWwTb_YNlUirYiii3-XTNg_8_4">1,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_unIzDyAVwE2ndWmMh5yGTA_8_6">1,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_Niu8fCC5EEeSADXrcrVtmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_GmbqFsEZAEW1j0J8OJo8lw_8_8">155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_TujPDblK1EuxI80RvU-NLQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_wztsqFy0_EGC9CZ0Rj1eKg_8_10">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_nDNQwxmp00GQTEs0t5pDCg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_6HQ_MSNcN0-sbjGak0Fw6A">30,000</ix:nonFraction>k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_d2Hm2LGP_ke9M8xIEktJpg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_Y5adTHVLUEar8FKYgciE6w_9_8">2,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_fCb9uvT8EkSbTwrtQ7P6DQ">10,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_A1K2Ub5TF0-XNcmUeZX1zA">8,937</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4HZPRvJI5kWlz0cNNfXq8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_Gz7g1kEXBkiN-chDncu85w_10_4">5,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_8YPjlUQrjk-NTrRHSzd0Yw_10_6">4,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_hBqt_J_E8U2Ykx9xI6ZM9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_6L7Dxo3C5kWEXwWwuEtYqg_10_8">894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_josAwYgRAUikV20Ufw6ucQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_K9gT0wycJk6CFZh-ohEJdQ_10_10">894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_VcYuM-X1zEyJpdM394rd0Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_1CLJozD7GkaGhLVcyJWkhA_11_4">142,095</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_AMkhj2ybDE64ZWUfPWrh9Q_11_6">120,278</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_8ohJGXs2QkyA-Bmhh7aCOA_11_8">27,731</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_gYwMT3lsI0OGZ5UEJ9dQ8g_11_10">31,818</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_RnLsGrbTOUyyE7wWtRgpYQ_1_2"></a><a id="Tc_RH771gRQ6kOAeaD5u7dhXQ_1_4"></a><a id="Tc_s1g-v67Xu02Z7MtYOh4Avw_2_2"></a><a id="Tc_T0cDrY_soUuJqU5UYy2EBw_2_4"></a><a id="Tc_NTxQVYjh_0qdUrXKbWmo_A_3_2"></a><a id="Tc_1E7qeImE4EqRkT85lGGtcw_3_4"></a><a id="Tc_uCkGGk3yyU2EHIznIMjHfA_4_0"></a><a id="Tc_ItEUgsTty0KHMflPTimv8w_5_0"></a><a id="_a57e6c2d_85a8_49ce_b083_2cd0093d1b8c"></a><a id="Tc_jdQzKq79XUacxgrzGC70xw_1_2"></a><a id="Tc_5SH3s9yxREKM_69gcvUJeg_2_2"></a><a id="Tc_GceEkXb_p0meRZoey6guxQ_2_4"></a><a id="Tc_pxEmsIEPlEKBT0sD5p_oCQ_3_2"></a><a id="Tc_WKah94bSYU-57L4btNwJ4g_3_4"></a><a id="Tc_AcwfWkjkVESabhJDYtlr4Q_4_0"></a><a id="Tc_ULPGwzmwm0OW787waSQXOg_5_0"></a><a id="Tc_urFPItPvDkuLIjIhGlfxIA_6_0"></a><a id="Tc_yxKk-HlbtkiXJIFXvfotxg_7_0"></a><a id="Tc_ZYVL91LKg06X8IdxJWpVvw_8_0"></a><a id="Tc_MqsSKMdXZUGeGc2vZZon9w_9_0"></a><a id="Tc_rYd4O_GcMESO8u0HwkP8cg_10_0"></a><a id="_b8cc9470_7330_458c_a4e5_9e6eb4e16312"></a><a id="Tc_3gJ4CoWYR0Wb8sJpMT0Nsw_1_2"></a><a id="Tc_DvBg9g_Zr06FD4k1P7fDkw_2_2"></a><a id="Tc_h-Wte-xwCEmLH2IEO4BQig_2_4"></a><a id="Tc_I29xe4Hny0-dVxU19Q7RuQ_3_2"></a><a id="Tc_-2RPqo_dNkeD6Th6eErFyw_3_4"></a><a id="Tc_66MkgI12BUGASR20LQYXnA_4_0"></a><a id="Tc_NUpWBX0lCUab_c_nEV-8ag_5_0"></a><a id="Tc_4gk1nr6MTEaFI-fmrIx8GQ_6_0"></a><a id="Tc_HLppEUfQd0-s-5727mQ4qA_7_0"></a><ix:continuation id="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont1" continuedAt="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Contract balances:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="Tb_oAtysuPHtU-6xkuXVs0mYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_25NQDVhhJkOtHGoxsX4d5A_4_2">18,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_CKFUie7fIk-EUMfUeF1HcQ_4_4">13,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_DeuaZ0ZMWkCjgG8eAzHAFw_5_2">142,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_zStEtLKBEES3hT0f4-vlHw_5_4">120,278</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="Group_N3j4INlhzUW5WtSQHuwrLA" continuedAt="Group_N3j4INlhzUW5WtSQHuwrLA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_DViOEqayy06mtNWeTRSfoQ_4_2">9,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_1WvHxFwCsECbkUkWAncOOg_4_4">13,869</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_I_B6dPSz0U6sX_WBXqm7bg_5_2">2,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_IP3wx92lgUW6y1e8u8a6QA_5_4">36,883</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_sEgqNsyFOkG6tFRAZJyXMg_6_2">31,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_XRAt8ahHG0CJkXWYpNgY0A_6_4">19,516</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_dZ4DvLySwkSk2JSIGAEGSA_7_2">2,543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_ls1Llc0AV0ypo2ugW85erA_7_4">1,150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_hqJpaKxRKE23I-6kpnOsew_8_2">1,594</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_g-IkmV8g4EiGVY8cEyobyw_8_4">8,326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_ZZaHoA7qmU-WNDExUIshLQ_9_2">5,329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_-jMAMMu-8U-YZLnUTgxiiA_9_4">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_zRGoMSvqK0iaRTOhAPZb7w_10_2">53,156</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_Zwp59rq3wUykmZr69VHt-A_10_4">79,913</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, cost of sales mainly increased compared to the same period of 2021 due to increased write-offs for raw materials amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:WriteOffOfRawMaterials" scale="3" id="Narr_W_zFcjaOyUG2-s5EzLfbmg">34,640</ix:nonFraction>k, which were procured for manufacture into products to sell to GSK are now no longer expected to be purchased. The prior year Third Party Services have been higher due to last year&#x2019;s set-up activities for production process for CVnCoV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><ix:continuation id="Group_N3j4INlhzUW5WtSQHuwrLA_2" continuedAt="Group_N3j4INlhzUW5WtSQHuwrLA_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_bqfBaGUWVEqsE_DP0CifNA_4_2">664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_rDIIccLFLEiLFc_W3p6OIA_4_4">560</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_kuUnlj4gW0Wg9fmjJItFYw_5_2">43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_wTEy7n39E0aUdL7VI_71ww_5_4">32</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_FfyaxZBI20WijbY1j0MbFQ_6_2">322</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_epHLsX8dRUurjW2sH0Ns5Q_6_4">227</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_4eGhcRMEUkaTZva7Rgz8CA_7_2">1,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_hPfKGvUtEkGXhTmfg_44sQ_7_4">819</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_yyUB2XuVYkuRz7H7EmYF1Q">499</ix:nonFraction>k (June 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_eV2R3GqAhEanLlv5FOLHlQ">543</ix:nonFraction>) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_aj0uVo6yJEqi0r754ZYRXw">61</ix:nonFraction>k (June 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_q-iOJdHU4U6vhQRLWud3iQ">121</ix:nonFraction>k).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7ed042bf_5bb6_4c25_90ed_255d0d66ff45"></a><a id="Tc_kJfAc-q0uUSMjLWQISZf7A_1_2"></a><a id="Tc__WCPpHJoMEWk9exBlEbeQQ_2_2"></a><a id="Tc_MYb7GwdY0UGnMgqP9dRwlQ_2_4"></a><a id="Tc_3CEHIsOKFE-I24ZWIA_B6g_3_2"></a><a id="Tc_n0SJWUg1E0GQT5frOz-OeQ_3_4"></a><a id="Tc_EFuPMncQzUaFUnVGe_zkjg_4_0"></a><a id="Tc_8hO_FaovGE6zGnrjSzDJAw_5_0"></a><a id="Tc_wha3WGl52UyDeWkKk4DKRg_6_0"></a><a id="Tc_61XJF8twVUyZNtFL3aHwfQ_7_0"></a><a id="Tc_vsO8HrU8-k6xe4ZZWOEOPw_8_0"></a><a id="Tc_rkNBnPf6vUmRfG1uB8R0WQ_9_0"></a><a id="Tc_3WlnxrMUzE6k_uZDVH3AtA_10_0"></a><a id="Tc_PMuQ4R58ykyXiYLYV7diBg_11_0"></a><a id="_4327f95d_500a_46c4_8df7_d7cca2e714e3"></a><a id="Tc_U46-fz9rMUCeHvnRa8PGGA_1_2"></a><a id="Tc_cjZ0JT3IpkCmaCtNQFG69w_2_2"></a><a id="Tc_WoyYV6tURUed_S7NbsrqPw_2_4"></a><a id="Tc_gbS1-dOI_kifbcY3Z8P26A_3_2"></a><a id="Tc_nOF9FlOfU0y-wgd1QEpqRA_3_4"></a><a id="Tc_39-p4rBtSEOJRJ6G3m5c-w_4_0"></a><a id="Tc_Kb3tT3Tin0-8rDKp9t8GQQ_5_0"></a><a id="Tc_jqFNTbFmo0a8oj96nbUjYA_6_0"></a><a id="Tc_1UD3Tr2fhEq9rS0ABKjnyg_7_0"></a><a id="Tc_xP_Cz6nh6kOW_dGpzUCDBQ_8_0"></a><a id="Tc_7-M4Tmxlc06gJ2n7Cx52Rg_9_0"></a><a id="Tc_DRel68i3L0qB7PSxE3tlVA_10_0"></a><ix:continuation id="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont2" continuedAt="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><ix:continuation id="Group_N3j4INlhzUW5WtSQHuwrLA_3" continuedAt="Group_N3j4INlhzUW5WtSQHuwrLA_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_bfmtKDeZSES3cofZtQeskw_4_2">5,928</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_J7ZftD09W0ikqmtQwWUCVQ_4_4">23,419</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_VAVJ7deRpEamM2DWNG5ObA_5_2">15,219</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_bMxUv210PkyleoFeR1dYqw_5_4">14,849</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_1xRLS50jckCjQdFXTGnnEw_6_2">1,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_1Tr4E8IIwUiSwNtcrPSr_w_6_4">2,119</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_R1feLbloDEOuNBzgv2-Xlg_7_2">1,413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_3hKNTUa2e0OxUyAuv9xfsQ_7_4">1,354</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_86zBd9CNSki_VH9mgUrRbw_8_2">210,590</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" sign="-" scale="3" id="Tc_caTKdrLHdkq3rHpvh78twQ_8_4">21,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_bC9jt3AuPky-g35q3jwJXA_9_2">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_uvVaTd5O8UStGy-8il7kGw_9_4">464</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_FLAkJYVXpkCYQVQT_O5zUg_10_2">1,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_HudfQsVy-0Wna8JFM8SVMw_10_4">1,270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_pgQSsPBhxEaqfVQlZKY-_A_11_2">236,267</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_FOVrNAtbKkyi4XBUl3FPig_11_4">22,422</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#xB4;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the six months ended June 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased resulting in reversal of provision for onerous contracts in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_U6gYHkTqeUaGi_F9UXcWaw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionForOnerousContracts" scale="3" id="Narr_RvHI7hvkn0u65Zzp1U-lCA">21,303</ix:nonFraction>k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, in the six months ended on June 30, 2022 the balance was impacted by further consumption of inventory. As of June 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_nhX8lFjthka1hauXzwyXaQ">14,759</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_FOhorJi0vUmNLs2-eeQawg">14,849</ix:nonFraction>k) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_uVpvkWZ7hEaBnfhl_j8sUA">90</ix:nonFraction>k (June 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_KD23XunahUS_X9uPo-cq4A">370</ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><ix:continuation id="Group_N3j4INlhzUW5WtSQHuwrLA_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_gFAPfqCZ0Ey1pSJ-8uZBdA_4_2">19,362</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_Rk_Vwjp1LUSAcvRc16cZVg_4_4">18,971</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_4CPrMvf2PEqPFJqd-ojflQ_5_2">1,230</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_q8OtamhTn0y9RlVjaSlT7g_5_4">2,704</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_4nfjBz-mZ0OvKIOUpGae7g_6_2">18,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_sYs50Hqky0iLWJmgs5La0g_6_4">12,796</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_SymS6EZkjU6K_N5xkmxRUw_7_2">3,491</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_AbRj1Ce9iEaVKPddUt2ylQ_7_4">5,320</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_iZXz4QDDGkmmnlWvfAB-Kw_8_2">3,325</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_1_VJM8GLy0i3IYnyeDAagw_8_4">6,091</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_6XS2sGmXmUegyOszebcdkQ_9_2">4,458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_J90ix0NfwEew-DcXDVsskQ_9_4">5,796</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_nFcwXiOuM0WyPmVW-8j73A_10_2">50,651</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_ez8n-TLzWkuP4B4k7Ktd_Q_10_4">51,678</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022, of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_SsxUL6MplkmfLU4fNwRsCQ">15,525</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_sWnEKll5Z0KW7zd3MbaHIA">11,642</ix:nonFraction>k) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_0-7LT1CoIUSiR3vQe8EaQQ">3,446</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_H52DU50nU02_PXMzV3-o6g">7,720</ix:nonFraction>k). During the six months ended June 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The increase in &#x201C;Other&#x201D; mainly result from additional insurance costs of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Narr_uiswK7dEFU6aP9XZrhs39g">2,769</ix:nonFraction>k, mainly related to the D&amp;O insurance (June 30, 2021: EUR  <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Narr_-cczUUwtrkiqoh9Xx6WlTw">2,343</ix:nonFraction>k).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_NAA0qDftQES-nS3RZvhr3A_1_2"></a><a id="Tc_lu6fFgSwzUaCSmFGPTbI8w_2_2"></a><a id="Tc_Dutgh3Jx6EKW-CGMuKLEjQ_2_4"></a><a id="Tc_i_mftmh7b0uDFff8yWuX_Q_3_2"></a><a id="Tc_MfVfkQ21eEaGmxCbtL0Rqg_3_4"></a><a id="Tc_dubeJKu8DEGicoCzHvuE-Q_4_0"></a><a id="Tc_69UiZwQ4FkaabzS9B4UnqA_4_2"></a><a id="Tc_XiOmJmJO5EW0RgVLhMHj-A_5_0"></a><a id="Tc_KYCHZ3piaUqCpG4IKqceBA_5_2"></a><a id="Tc_4nz6v0r5qkadaiIE_evB6Q_6_0"></a><a id="Tc_tfaNnAl0iESHOMMvgokcTg_6_2"></a><a id="Tc_m37F5JnxSUGGyUVxzdauXQ_7_0"></a><a id="Tc_inuaMazPnE6UX1LWG-wfCg_8_0"></a><a id="Tc_NIn0y6Ipvk-BA1s35bC6hw_9_0"></a><ix:continuation id="Tb_v49KF3SWJUCHMw_GLX5Wnw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_2pJ5xMgFvkKDGyTdzPAHXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_DuOqXE-WiUOkAPMLnvaNVg_4_4">33,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_b6Nknr9qHUKEUbrVJeU6hQ_5_4">610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_v6qSd-zEKkiAu_RNxyNRuA_6_4">310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_g-gr9Ze1XEuLTgnqZTZi_w_7_2">45,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_i-i7-EGMKUuqtZCTXM3-4A_7_4">104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_IMAGf8Ey0kKs6wvs3pf-5g_8_2">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_8cy8dwkm5kqh6kaD054XPQ_8_4">222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_ZiipVWgKKkaCj3TSK1IM9Q_9_2">45,234</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_X4domwyp-kqeA2GNLgn2Nw_9_4">35,207</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" scale="3" id="Narr_6gzLLnu7IU2rDjrPWfCi8g">20,500</ix:nonFraction>k) and for reimbursement of prepayments (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" scale="3" id="Narr_uoHG0__WKEmHv8S-0j413A">12,000</ix:nonFraction>k), which were recognized in other operating income in the six months ended June 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" scale="3" id="Narr_d6VMMVIgn0OTlMurMXIO0Q">25,059</ix:nonFraction>k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research (BMBF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant terminated in 2021. With regard to the grant component, during the six months ended June 30, 2021, the Group has recognized grant income in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zKdBd8Au7EmwSNmyKFumnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_RHfpSoff20OC8oFmjMj96A">44,090</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_8Pr5Ggh9JEajOUbg_YKR8Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_6fd4hUAIK0KrXsQjDyt70A">0</ix:nonFraction>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations (CEPI)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_MEfyfKoJLka_FnOTfjHVVg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_40GsJC1RVEqf56ColKmJGg">8,300</ix:nonFraction>k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_mNAuTnZ79kmgMEM_evAL-A" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_kaOsbs-0NkOCOFQkFoNLSA">15,300</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_skb-i2lgmkG-FxOxet3a0w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_2TSSSTYylkyJ76mUKSCetQ">8</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Pyt_GawsiEiGAxSCTTHNSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_EHR6QoEhiE-v6RNK5eFieg">23</ix:nonFraction>k) as &#x201C;other operating income&#x201D;. As of June 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_fTCAXcXeVEGq1xPWfKyuDQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_hHgTqFP6z063gFNnrFy_iQ">1,281</ix:nonFraction>k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_zRxCoItDgkao45OmbONCMw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_hvHFAOYAFUmTtsypvYtbIg">1,288</ix:nonFraction>k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the six months ended June 30, 2022, CureVac recognized EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_cvXKLI50Ok29UKYe1Lppng" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_65S44xsq7U60P4eH-UDY0A">96</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_YkJamxu9vUOFt13D2FrYnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_FqOBE3N5O0O4qRUzIY3S4Q">211</ix:nonFraction>k) from the amortization of the grants on a straight-line basis into other operating income. As of June 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_z_OM4LPemU2vaJCSSgPmxQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_M0-E5puvv0aHo18e_m6_5A">1,782</ix:nonFraction>k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_7UE4OxQYgE2K901Hl7Dixg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_45JhgT22BUKV-C9yrXYlQg">1,879</ix:nonFraction>k). </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="Tb_VimYx0VGG0Cym0WsGxVJQg" continuedAt="Tb_VimYx0VGG0Cym0WsGxVJQg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_yfH60iO9pkW74IGWws2yIw">386,250,000</ix:nonFraction> common shares and <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_lhCIGVrQzUKQI-sRXptCCQ">386,250,000</ix:nonFraction> preferred shares, each having a <span style="-sec-ix-hidden:Hidden_G3msjGiE3kqZNUEVJNk5yA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_iWZCtorh2EORXbkJzQ0tiw">0.12</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_2tp7xS_pzEqi19apLBfPLQ">no</ix:nonFraction> preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_C8yKhTvhjE-J5qvdk_pBmA_1_0"></a><a id="Tc_4lmb__od2E-YLh6oDJ2lXw_2_0"></a><a id="Tc_X4J4Rf2lMk-OV2XpoKyS4Q_3_0"></a><a id="Tc_DQgngx4xIkq-6sHrczXEWQ_4_0"></a><a id="Tc_ybCoqKou2kq3cJliIDsCfg_5_0"></a><a id="Tc_2ihGPa-wK0yOuNHGx4a1lw_6_0"></a><a id="Tc_RhWm16yHeEOzKzyhhvGtmQ_7_0"></a><a id="Tc_AocOzG3svkCcgkbLHCWWEQ_8_0"></a><a id="Tc_jkfuanESUUSnKKT1LGk5tw_9_0"></a><ix:continuation id="Tb_VimYx0VGG0Cym0WsGxVJQg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_sc6LsyPDbUSO09oxzVOOUw" decimals="-5" format="ixt:numdotdecimal" name="cvac:AggregateGrossProceedsReceivableFromIssuingShares" scale="6" id="Narr__9kEBf2etku8J4ljBvU6wg">600.0</ix:nonFraction> million. In June 2022, <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_6_1_2022_To_6_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_FFHzzrCoqEGuPsRnxpT4pQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_gxJtvMgTBk63fs8GehAyXA">340,015</ix:nonFraction> shares were issued under the ATM program, raising USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="Duration_6_1_2022_To_6_30_2022_SdTrfxiB0U-Z0Gmk5GUxOg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_8qidjZ2IPEmaswdq8JKaBQ">4.8</ix:nonFraction> million in net proceeds; related offering expenses were recorded against the proceeds in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="Tb_U7vNJdlrcUagsx0y6o8mlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_mOwk0-VwLUiHcmdopBJhmg_1_2">187,120,728</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="INF" format="ixt:numdotdecimal" name="cvac:ShareOptionExercises" scale="0" id="Tc_i0LEhxnufEufRoV8_895ig_2_2">78,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_qK9ga3dyOkaxFr7TbOtOVw_3_2">78,732</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_3_31_2022_PD-hd6qO7kyci1VNI1JU4g" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_fBJjFGbqAkCeXfZY_y8eWg_4_2">187,120,728</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_bXhUc4lJzUOJrDpUkFHN3g_5_2">340,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuedDuringPeriodForExercises" scale="0" id="Tc_2FA2MUmuyU2_hIQcp6GIDw_6_2">6,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA" decimals="INF" format="ixt:numdotdecimal" name="cvac:ShareOptionExercises" scale="0" id="Tc_eveALTUbs0S7UKOTZkD3Gg_7_2">39,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_yHLFTQEHx0G8_Z8w3tA-Bw_8_2">39,418</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_0ZxAkDNns0WHRejQSSjqBA_9_2">187,466,954</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_03bf7b14_b737_4a4d_8eba_4fe934d6b53f"></a><a id="Tc_mOhKDVaDNkuwGepgHwt0lQ_1_2"></a><a id="Tc_lZ_kKyRFeUa2kLmveEXbDQ_1_4"></a><a id="Tc_q1dTTG11HEeTxIetW4JFhw_2_2"></a><a id="Tc_29T8DIaMbku5JsnwvYbmPA_2_4"></a><a id="Tc__0OQJQaN402q-fSuI4nQWw_3_0"></a><a id="Tc_sAA1ehZI6E6byPxJ7lJpBQ_4_0"></a><a id="Tc_DjGEv-fnekKp18bq-CUevA_5_0"></a><a id="Tc_GrNfxLV6mk-BXRCTHo_czA_6_0"></a><a id="_3abf0353_fdeb_45f9_88e5_72c70aa14878"></a><a id="Tc_iISu7H2hckW5lAegPxNgPQ_1_0"></a><a id="Tc_cIFbjZ46OESRZ0SSpPW61A_1_2"></a><a id="Tc_WYP5E--wYkqMMkwseBprtg_1_4"></a><a id="Tc_jjSzWS4h7USiX4uCxgwFaQ_2_2"></a><a id="Tc_5z_SJhObOkion1LpWPkKvA_2_4"></a><a id="Tc_z1vQd3zDB0apvjR_m-nnEg_3_0"></a><a id="Tc_0yts9TYfO0ChdBqIzv0Iww_4_0"></a><a id="Tc_VfbsQuOBU02Xt4Ipa7QBcQ_5_0"></a><a id="Tc_ozZ8n2m4bEyG_Vxtgj7MfA_6_0"></a><a id="Tc_pcfjTXslD0ewdeMs-pyyGw_7_0"></a><a id="Tc_1H8mk4-fWE6tNZV8J9P2KQ_7_2"></a><a id="Tc_9dyvaZRwt0y7XpqKi-KDvQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_sO7UhmDUBkuKlR39AK0jhQ" continuedAt="Tb_sO7UhmDUBkuKlR39AK0jhQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_xknoQOOL50q1Ma2lAJEUCA">3,597</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_yh5kQmgJMUqSqaY207LguQ">8,212</ix:nonFraction>k, respectively, as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_7RDgTEzgj0u93xy5XFAZEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Six months period ended June 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_LRw1LY2yLEGIu8vrGKa07A_3_2">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_BpG0lfVSekaXWvfTkFepXg_3_4">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" scale="3" id="Tc_EEaVbbCq_E6jMEEHXZWgDQ_4_2">122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" scale="3" id="Tc_4g8dYHNKmkeS9Mv-1pnfLw_4_4">61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_wb6BWBH0lkW5zeyYEdVX1w_5_2">7,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_EzK6cYM9yEebsF24n9Ijjg_5_4">3,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_NBwprsDUfUWuK7iuhzO2zA_6_2">8,212</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_8JlYzLItak6DCEdE2DvSmA_6_4">3,597</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="Tb_GQ_P5_vfo0iaxBG72itZeQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Six months ended June 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3nipjvAshE6IJam5p-Fh3Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_ONsL4LDqH0GvwldHoIZG8A_3_2">7,331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_QXG7f3n3JkWLBsR13KEpQg_3_4">3,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_07cYvreliEeikUXp57lJ0A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_3lI_Dy6sJEaiAyE8UP574A_4_2">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_dVCXiI28WUKjmh4pxWG7HQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_7uAdDaW7wkeNpdTRatuXBA_4_4">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_eqJNUVFrwEyBJVapO8-7UA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_A8NEPDbfkEy21A9b9oj5sw_5_2">323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Dnjk8zLjh0uRxWQLYgQLtw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_AVixmlIkrEOQk_Tagc3LYA_5_4">82</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_37SI7EeG40qNRBNVTiXh4A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_IjJEFUJbKUCD4Ji5NxEbfw_6_2">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_bCZajafyHk2TYShK6GXT_Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_ssIlfEAtAU6JcKG9YQXXgw_6_4">17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_Z76paJTu3EqO8ZEo9vC15A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_0Dkss-FYN0OHfcaA5Dj4pg_7_4">497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_gl9UAGy-KkK8sT4hpOOotw_8_2">8,212</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_0nUAwyIxJ06YlmXKVASXTw_8_4">3,597</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_G2czk_grS0e2UewXI2oR9w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_Xq74ixliT0OZHJZmbUce2A">266,155</ix:nonFraction> options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_w31L0BBG7UmU35R2D2Zt4A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_2XQPDaUQ3k-Oxq0NZZZ_jQ">266,156</ix:nonFraction> options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. On June 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_9BE_1GHmUECsOC7edBk3kw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_BT62Irbn40OvILmzuo_4ug">6,303</ix:nonFraction> of his options in May 2022.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sO7UhmDUBkuKlR39AK0jhQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9FShId--2E63ykkNfrEmmw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_zIEoIcKyc0Ohc6jFanCtYQ">20,000</ix:nonFraction> options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_94_eUZcr1k6ch6WDNbNttg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_JnEd5BsfQk27n_IEtVbdaw">30,000</ix:nonFraction> options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9v7ROjz4KUq67xb-vGVl4g" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_FHPmuUh3dEGiBwXUey7sDw">none</ix:nonFraction> of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_6VL2por91EyDuYch-uIbWw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_UdPQCq3v40-tMVTbrSRSmg">none</ix:nonFraction> of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June all his options forfeited. All expenses recognized up to him leaving were reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_GKRrWR1rz0WI6IJqljAkdw">11,500</ix:nonFraction> options to <ix:nonFraction unitRef="Unit_Standard_employee_2xPxwRpHIkSSwvWmnWr95Q" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfKeyEmployees" scale="0" id="Narr_A8G-rTsF-ke2Af8hwEl7LQ">two</ix:nonFraction> key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_npRUdd2jrEKdKNSOmQ2E7A" decimals="0" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_KvtGP2VbVkmAfzA2GGfenw">none</ix:nonFraction> of the options granted to the COO and CDO under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_TtMaJsFnHU-GN-4kQhkccg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr__ZERAqIItEGN5JNvGjtLHQ">130,000</ix:nonFraction> options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_SgeNIgwqzk63aou9DXpoZA" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_GGUduZl79kCIVbMLqOeoKw">none</ix:nonFraction> of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP during the six months ended June 30, 2022, is in an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_vwSDHWlV6k6kvpxM2G58Vw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_avmE7Hlhaky1f8Rx3wG3cg">3,078</ix:nonFraction>k (2021; EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_ZrMDEhuAEUCN6lkugW0ldw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_OFcnnzqehU2SxH4E_mFDKw">7,331</ix:nonFraction>k) and is included in general and administrative expenses and sales and marketing expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, the group awarded <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_Ucvqwtp93kihEInyQPUvNA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_pg2x-_HFBUSrmHLlOCFFFg">10,956</ix:nonFraction> RSUs to supervisory board members and on December 23, 2021, the group awarded <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_vdvY7bSHZkecZoTxnUfO6g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_BxIt3mr4fUi-tfclgJumow">63,095</ix:nonFraction> RSUs to the executive board and various key employees. Within the first half of 2022, <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_8IiNdakVxE-w4AwwYKAZfQ">10,238</ix:nonFraction> RSU&#x2019;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_MC60TuOPQEegv3N3oZBOrA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_U3Kz-erzmECYbLbWsIOSFg">5,000</ix:nonFraction> options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, the group awarded <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_IfolEyZFMEKGD2w2ivzW5A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_sgsBzkco6EyPkcV0wolzbw">37,868</ix:nonFraction> RSUs to supervisory board members and <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_z5pHV_ql802Y2Ej33MoQPA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_9LaWtEyL30S4HdIgLf81Sg">193,340</ix:nonFraction> RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_zpKYCdvoIkWzWr5AFwv_Hg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_AwkV71TvAEarnCygpxhOtA">36,000</ix:nonFraction> options to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; <ix:nonFraction unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ" contextRef="As_Of_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Ke6127tPckS7cBQb7_LfxA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="Narr_-zN8iqC7Vk217Yj6UFcgpw">101,609</ix:nonFraction> options were exercised within the first and second quarter of 2022 at a weighted average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A" contextRef="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KhUGmIdimECoLuArSGzN7Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="6" id="Narr_To-8cLlaiE-mold3jj8xgA">19.24</ix:nonFraction>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DisclosureOfFixedAssetsExplanatory" id="Tb_BRd-JecBz0KqlsDVQaW5YQ" continuedAt="Tb_BRd-JecBz0KqlsDVQaW5YQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, the Group acquired intangible assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_-ZmiL_KXCUK6mCbAQsGsqg">1,207</ix:nonFraction>k (six months ended June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_i0uFtxo5n0yyYkb8Bj-Qmw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_3cCIZ2RmVUu7Rx_OjJRM0A">3,966</ix:nonFraction>k). The acquisitions during the six months ended June 30, 2022 and 2021 mainly related to licenses, software and prepayments made to acquire those.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_D9PmNvxW2EyJO-U9VmXN0Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_FiNaeAH0Wkq_dV4A_qJwHw">3,034</ix:nonFraction>k (June 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_smq0Fsap1kGMdfi_JvJUpw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_BJDysr29UkG1_75OP06FOg">6,302</ix:nonFraction>k) as well as additional amounts recognized as construction in progress of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qKO-s7r8BUa2lgRm6ekFrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_1v5akhmv9kSyLrXVEPmyqA">39,386</ix:nonFraction>k for Company-owned GMP IV facility (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_EQdNS6liQkqj9HAUfbkJkQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_1-m3KyMPBEu25ggym57qoQ">29,552</ix:nonFraction>k) and equipment physically located at the CMO facilities (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_5j4KchYGIk-8GogPJ3dGGg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_9SvN5QoxPkCSKSz5pd7k-g">3,657</ix:nonFraction>k) and the remaining amount mainly for Company&#x2019;s GMP facilities. The increase was partially offset by EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" scale="3" id="Narr_e-s8G1i3606dq0ZOS8MsMg">5,854</ix:nonFraction>k impairment of equipment located at a CMO facility, which was recognized in cost of sales.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BRd-JecBz0KqlsDVQaW5YQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="Tb_dgcr2wGE4UOc6YrCJV36Bg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organizations for the sale of Ultra-Low Temperature freezers for a total price of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" scale="3" id="Narr_1HoF7JNMmU-E_bV-sJyVUw">865</ix:nonFraction>k. The actual sale of the assets occurred in July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="Tb_sy4vNW_4lEGfEv8Gn4IFoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials. During the six months ended June 30, 2022, the decrease in inventory of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseInInventory" scale="3" id="Narr_jUPcs3lhnUqKpEfB3cSsXQ">42,918</ix:nonFraction>k is due primarily to transfer of inventory EUR <span style="-sec-ix-hidden:Hidden_jkLIgqZzAkOONGLtAkGXdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9,8</span></span> million (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Narr_-cn-5Zqckk29YBft4DbMbA">34,640</ix:nonFraction>k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="Tb_Uqe74iPIhE6YumZM8UVaSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of June 30, 2022 amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_4-rTojgVZkWQ0jzII0CzvQ">70,968</ix:nonFraction>k (December 31, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_8Qxzc0d9hE2Aj5HK5U8x4g">49,244</ix:nonFraction>k) and mainly include receivables for the GSK compensation of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_aIxGBGj0WkSXGOxLLCc1hA">45,801</ix:nonFraction>k (December 31, 2021; EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_ep_o1p0mAEin2Osqr2UUpA">0</ix:nonFraction>k). For more details we refer to note 3.6. In addition, other assets include further prepayments for material in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_L4bdJ1cEw0izL8wj0BDBzA">4,653</ix:nonFraction>k (December 31, 2021:EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_x6KOnLhIpUm3xk1_LkVUZw">5,724</ix:nonFraction>k) and tax claims against the tax authorities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_jPOoHYXHn0K7SKJADJJ14Q">15,160</ix:nonFraction>k (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_sw192lM6Y0SLGb-Hs2DahQ">35,234</ix:nonFraction>k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc"></a><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc_2"></a><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc_3"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348_2"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348_3"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644_2"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644_3"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0_2"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0_3"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626_2"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626_3"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101_2"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101_3"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="Tb_MkBA8QIe3EKE0tb4PzFi0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_Cu0gox-LKU2qnRmqgBgivQ"><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_DJ7Vp8AVfEiwCAIPuk089w">no</ix:nonFraction></ix:nonFraction> transfers between Level 1 and Level 2 fair value measurements and <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_JKKQ8MjqX0ebgJKFEU-BsA"><ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_6Az2mQZsKEmq4gwsQYLheA">no</ix:nonFraction></ix:nonFraction> transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2022 and 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="Tb_63kCQ2zkd0mc3EJcz7Mnzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the six months ended June 30, 2022, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInTradeAndOtherPayables" scale="3" id="Narr_1iFHaLGzJ0Od02EhkN1KHA">79,207</ix:nonFraction>k in trade and other payables was primarily due to less payables to suppliers as the CVnCoV project was stopped in FY 2021 Q4.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="Tb_gtetiRuoTEeE3h4SYlDX6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the six months ended June 30, 2022, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInOtherLiabilities" scale="3" id="Narr_0SSZAhG5oUCZRV56SpjI6g">77,314</ix:nonFraction>k in other liabilities was primarily due to a net decrease of contract termination provisions, due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate, due to a consumption of the CRO accrual for onerous losses and due to lower accruals for outstanding invoices. The change in estimate of the contract termination provisions resulted primarily from the Company now being able to avoid an outflow of resources since GSK took over from the Group reserved capacity at Novartis (see Note 3.4 and 3.6 for additional information).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="Tb_tJBOGE1hFEGr1qZ0S2OhXw" continuedAt="Tb_tJBOGE1hFEGr1qZ0S2OhXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_rLlLcOhKj0quwHGM4AqbUw">25</ix:nonFraction> million &#xA0;(plus accrued interest of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Qe5xZZRKBkalAhPMb0rKlw" decimals="-3" format="ixt:numdotdecimal" name="cvac:LineOfCreditAccruedInterestPayable" scale="3" id="Narr_cL2nG7KSdkyVQsmUjPHUaQ">1,726</ix:nonFraction>k) was outstanding on the loan as of that date.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tJBOGE1hFEGr1qZ0S2OhXw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Narr_AeQtVHkrH0u3C5mk4HkQvg">26,633</ix:nonFraction>k, which comprises of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg" decimals="-3" format="ixt:numdotdecimal" name="cvac:RepaymentsOfPrincipalAmountOfBorrowings" scale="3" id="Narr_fX3RhZjd_0GXiJmCQ50eoA">25,000</ix:nonFraction>k repayment of the loan and <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" scale="3" id="Narr_tstl-V22S0-yN3I_1rojcA">1,633</ix:nonFraction>k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb__HLtIcqCMkGc9JvkeQvnzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group booked the expected tax benefits or expenses based on a best estimate for a period of six months ended June, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the six months ended June 30, 2022 and 2021, the Group recorded a consolidated income tax benefit (June 30, 2021: tax expense) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Narr_J5iVjUTSDUO9UMUA_oYSFw">82</ix:nonFraction>k (June 30, 2021: EUR -<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Narr_xKlDZh9FQ0CgRFAB4WCarg">1,329</ix:nonFraction>k), respectively. The consolidated income tax benefit (June 30, 2021: income tax expense) for the six months ended June 30, 2022, resulted from income tax benefit from CureVac Corporate Service of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_OUBDouNJ3UGASomEVEai6w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="Narr_Yfrc3Mg5TUyLtvDHdZrWcQ">96</ix:nonFraction>k for current tax and tax expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_tG8hTQGLX0ejbiTFxdHWvg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_dG0sPL29X0eWtlN3zDpPhA">12</ix:nonFraction>k for releasing deferred tax benefit on loss carryforwards. CureVac Swiss AG has a current tax expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_Aoq6kdzIgEGb4JC-aygDJw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="Narr_FUaxmpCFo0ivzm9DtU1_Ng">2</ix:nonFraction>k (June 30, 2021: expenses from CureVac Inc. of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_uYl7CoErZUmkaktvlFSJJg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="Narr_4UuPFfWlmkuyfOOAeI7Yhg">146</ix:nonFraction>k and deferred tax expense on taxable temporary differences of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TemporaryDifferenceMember_xwvzCyZJjUu1_z9vpwK1lA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_p9yVEGT7U02IQ2WUWWXFqg">1,286</ix:nonFraction>k as well as a recognition of a deferred tax benefit on tax loss carryforwards of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_KdHhy8rMGkOPdf-0LDkcag" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_wIVrE-ArrES_WC5ZMNciBw">103</ix:nonFraction>k).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="Tb_qo_NOlsdDUa1t8IKGZWRgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Refer to note 15 to the consolidated financial statements as of December&#xA0;31, 2021 for additional information on the Group&#x2019;s risk management activities. As of June 30, 2022, the Group held cash and cash equivalents of USD <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_qQmrL-_ydUKYpfs05tBqjw">62,863</ix:nonFraction>k and CHF <ix:nonFraction unitRef="Unit_Standard_CHF_x9ufSMA390KJ8aeE_m0Llg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_sTG3gTwnF06uW__PG0Jy7Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_lIJ9c0jmGES8gBI2FH8w6A">110</ix:nonFraction>k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:EarningsPerShareExplanatory" id="Tb_S1353tnjvk-CHhwjqD772A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The weighted number of shares outstanding for the six months ended June 30, 2022 was <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_ybVDYkpgqUC18aE3q1hnOw">187,041,805</ix:nonFraction> (June 30, 2021: <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_EXfWi9d_tkqN6PvlHzjnrA">185,062,052</ix:nonFraction>). This has led to a basic loss per share for the six months ended June 30, 2022 and 2021 of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_edXIHRruJ06Su6yWf5wbWQ">0.39</ix:nonFraction> and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_MgEVMGsI3kGE04sWdluMvw">1.44</ix:nonFraction>, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the six months ended June 30, 2022 and 2021. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_cZBoFPz33kCJ7u1gAa3fgQ" continuedAt="Tb_cZBoFPz33kCJ7u1gAa3fgQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted <ix:nonFraction unitRef="Unit_Standard_loan_jqkBG3F-sEycxO6evEyZWQ" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember__uQ5VVHK0UWYczs0k7a3Uw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:RelatedPartyTransactionNumberOfLoansReceived" scale="0" id="Narr_Tn0h197jvUSXoaKlsRYBSg">two</ix:nonFraction> convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s largest shareholder, purchased EUR <ix:nonFraction unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg" contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Narr_CZVHpd_B2EiVB5tABlqDlg">100,000</ix:nonFraction>k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A" contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_CEoTcJkkQUyttwUBtxY7Rw">16.00</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and amounts to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_wjj_nYzRdkKzd4QyrVUUTw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CollaborationAgreementMilestonePayment" scale="3" id="Narr_DVttyU3iMUGx_C4ZpPemsQ">100</ix:nonFraction>k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. This function he executes by using Clarentis SRL. Related to these services CureVac paid until June 2022 an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_YvgJJg2RWkS_B2vVJFNGhA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PaymentsToRelatedPartyForServices" scale="3" id="Narr_yJdgKNq3tEiCIHilqWVeEw">34</ix:nonFraction>k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cZBoFPz33kCJ7u1gAa3fgQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of &#x20AC;<ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_sV-2gWepY06B0A8GEXWNAA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="6" id="Narr_tYZrKwKsDEGzPNVk8wLLOg">3.9</ix:nonFraction> million, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#xE9;phenne, our supervisory board member, holds directly and indirectly <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_Z1RDELYnhkW7Qf2dwfv-dg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_hs6wSdINtk2Peij-BtK_hw">15.61</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xE9;phenne&#x2019;s son, Vincent St&#xE9;phenne, holds <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_jk-0HXYllkOyUB1FBqMB3A" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_ZvR5jFGtRUqeykmvW4uNYQ">1.43</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_c5oqNQuCEkiepknGwVtfag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">18. Subsequent events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#x2018;closing date&#x2019;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#x2018;Frame Pharmaceuticals&#x2019;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling to identify structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#x2019;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#x2019;s broader oncology strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#x2018;SPA&#x2019;) dated June 8, 2022, a total purchase price of up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="6" id="Narr__Uun192pQkG0I0mVEdoV-Q">32.0</ix:nonFraction> million payable mainly in shares of CureVac N.V. (total of <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_lRFyfmERq0uuPoVe0UsRjg">1,783,460</ix:nonFraction>), as well as a certain amount of cash, was agreed. Additionally, a net amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesIncurred" scale="6" id="Narr_JHl39uJK1UiLUXxpBWchkg">0.66</ix:nonFraction> million for discharging contractual obligations for outstanding advisory agreements with former shareholders was also agreed to. The shares were valued in the SPA at an average share price of &#x20AC;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Narr_oQHDa-pjN0OkvVye5ubu0A">16.44</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At closing, CureVac paid <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="2" format="ixt:numdotdecimal" name="cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" scale="-2" id="Narr_1Q3MNXtzI0mRMu5GcfBFRA">50</ix:nonFraction>% of the agreed purchase price, i.e. <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_1kjsmcEc-ki0G4VK9p4hxA">810,242</ix:nonFraction> shares were issued and cash in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_RMhcUw7iwE2lpjvCLpz2Fw" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="6" id="Narr_Tq-sHkWPekKHjA-K-unJww">0.25</ix:nonFraction> million was paid. Further shares worth EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_v6FcOJX3ZkOQL_If3V44wQ" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="6" id="Narr_ZIRdonKWM0SDFlhRgX760w">0.66</ix:nonFraction> million were issued to pay certain liabilities towards former shareholders of Frame Pharmaceuticals. In addition, restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element of the transaction will be accounted for as a separate share-based transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_KAq3DEF70UWNcG0E7Qz2aw" decimals="2" format="ixt:numdotdecimal" name="cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" scale="-2" id="Narr_jOjUZTDAgUGwu9VionjsXA">50</ix:nonFraction>% of the purchase price is contingent upon achieving two milestones. A further <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_6Kj0uxl05kGcqv5cmngJhA" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_hPqEA_8vu0ieDFeq7KQqMg">194.647</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_i3Ky2o24PUOSBVz8jJnLZA" decimals="2" format="ixt:numdotdecimal" name="cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" scale="-2" id="Narr_iVL5peKHeEeBRE3KsqHFgw">10</ix:nonFraction>% of the purchase price) will be issued upon the achievement of the successful investigational new drug application filing and further <ix:nonFraction unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw" contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_0AMNouAweEWk9_wb8d_Q1A" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="0" id="Narr_YPYazqqDT0y_9Zp7Q1LEUg">778.588</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_nVyvmSWGc0qjWc-iNGi-MA" decimals="2" format="ixt:numdotdecimal" name="cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" scale="-2" id="Narr_t2-OuGaHpUONA51kWD9qAQ">40</ix:nonFraction>% of the purchase price) will be issued upon successful proof of mechanism in humans. The fair value of these contingent payments will be determined considering the likelihood of the events occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the transaction occurred only shortly after the reporting date, it is not practicable for the Company to provide information in relation to the initial accounting for the acquisition, in particular regarding the identification and measurement of identifiable assets and liabilities, including any goodwill, and the consideration transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the Purchase Price Allocation, the shares to be issued in exchange for Frame Pharmaceuticals shares will be based on the share price at closing, i.e. &#x20AC;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw" contextRef="Duration_7_1_2022_To_7_1_2022_DRz3CCZAlUWbryO3lgpfCw" decimals="2" format="ixt:numdotdecimal" name="cvac:PurchasePriceAllocationSharePriceAsOfClosingDate" scale="0" id="Narr_b_9DgwRF5EKSFJO30A0tNw">13.64</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="3" id="Narr_Qjkg9C89rUK7k5CRDUTHLw">308</ix:nonFraction>k was acquired. Transactions costs in relation to the acquisition amounting to total EUR <ix:nonFraction unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg" contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="6" id="Narr_dhSeTS4QE0OZnihuFLzOTQ">0.4</ix:nonFraction> million have been expensed within administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Infringement Lawsuit</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Germany on June 29, 2022, CureVac brought an infringement lawsuit under three utility models and one patent against BioNTech on the basis that the manufacture and sale of Comirnaty infringes CureVac&#x2019;s intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In the US on July 25, 2022, BioNTech and Pfizer jointly brought an action seeking a declaration that the manufacture and sale of Comirnaty does not infringe three CureVac US patents. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>cvac-20220630xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/18/2022 07:21:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes to the financial statements, which are included in this Report of Foreign Private Issuer on Form&#160;6-K. In addition, this information should also be read in conjunction with the information contained in our Annual Report on Form&#160;20-F for the&#160;year ended December&#160;31, 2021, filed with the Securities and Exchange Commission on April&#160;28, 2022, or the Annual Report, including the consolidated annual financial statements as of and for the year ended December&#160;31, 2021 and their accompanying notes included therein.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Forward-Looking Statements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form&#160;6-K contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of CureVac N.V. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate&#8221; and &#8220;potential,&#8221; and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of CureVac N.V. with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of CureVac N.V. to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, among others, our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs, the timing of and our ability to obtain and maintain regulatory approval for our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates and cost associated with cancellation of manufacture and supply agreements in the event of termination of our research and development programs, the exercise by the Bill&#160;&amp; Melinda Gates Foundation of withdrawal rights, our and our collaborators&#8217; ability to obtain, maintain, defend and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection, the rate and degree of market acceptance of our products, our ability to commercialize our product candidates, if approved, our ability and the potential to successfully manufacture our drug substances and delivery vehicles for preclinical use, for clinical trials and on a larger scale for commercial use, if approved, general economic, political, demographic and business conditions in the United States and Europe, fluctuations in inflation and exchange rates in Europe, our ability to implement our growth strategy, our ability to compete and conduct our business in the future, our ability to enroll patients for our clinical trials, the availability of qualified personnel and the ability to retain such personnel, regulatory developments and changes in the United States, Europe and countries outside of Europe including tax matters, our ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of our business and other various other factors, whether referenced or not referenced in this Report of Foreign Private Issuer on Form&#160;6-K, that may affect our financial condition, liquidity and results of operations. Various other risks and uncertainties may affect CureVac and its results of operations, as described in reports filed by CureVac with the Securities and Exchange Commission from time to time, including its Annual Report. CureVac does not assume any obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this Report of Foreign Private Issuer on Form&#160;6-K to &#8220;CureVac&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;ourselves,&#8221; &#8220;us&#8221; or similar terms refer to CureVac N.V. together with its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Overview</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a targeted approach to optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins using the cell&#8217;s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In prophylactic vaccines, we are advancing our second-generation mRNA program against coronavirus (SARS-CoV-2) and a range of infectious diseases including influenza in collaboration with GlaxoSmithKline Biologicals SA, or GSK.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The collaboration on second-generation COVID-19 vaccine candidates with GSK was initiated in April&#160;2021, and aims to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants. The collaboration extends the initial partnership we started with GSK in July&#160;2020, which focuses on the development of new products based on our second-generation mRNA backbone for different targets in the field of infectious diseases of which influenza was disclosed as the first indication. The improved second-generation mRNA backbone that is being used in this collaboration features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. These optimizations potentially allow for strong and early immune responses at low doses, which is intended to also support the development of multivalent vaccines to target rapidly spreading COVID-19 variants as well as combination vaccines against different viral diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CV2CoV was introduced as the first representative of our joint second-generation COVID-19 vaccine program. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the original SARS-CoV-2 virus, formulated within Lipid Nanoparticles, or LNPs. On May&#160;13, 2021, we announced that CV2CoV is able to induce high levels of antigen production in an in vitro setup as well as strong and dose-dependent immune responses in a preclinical study in rats. These data were complemented in June 2021, by preclinical data published in Nature Communications demonstrating full protection by CV2CoV and our first-generation vaccine candidate CVnCoV, from lethal infection caused by SARS-CoV-2 ancestral strain BavPat1 or the Beta variant (B.1.351) in a transgenic mouse model, expressing the human ACE2 receptor. In a preprint manuscript announced on August&#160;16, 2021, and a subsequent Nature publication issued on November&#160;18, 2021, we further presented preclinical data investigating immune responses as well as the protective efficacy of CV2CoV in comparison to CVnCoV, against SARS-CoV-2 challenge in non-human primates. The study, conducted in collaboration with Dan Barouch, MD, Ph.D., of Beth Israel Deaconess Medical Center, assessed cynomolgus macaques vaccinated with 12&#181;g of either the first or second-generation vaccine candidate. Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies and stronger memory B and T cell activation as compared to our first-generation candidate, CVnCoV. Higher antibody neutralizing capacity was observed with CV2CoV across a broad range of variants, including the Beta, Delta and Lambda variants. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected compared to CVnCoV based on effective clearance of the virus in the lungs and nasal passages. A direct comparison of CV2CoV with a licensed mRNA vaccine in non-human primates was able to show that neutralizing antibody levels measured following full vaccination of animals with either 12&#181;g of CV2CoV or a 30&#181;g standard dose of the licensed mRNA vaccine were highly comparable. Following these preclinical data, we announced the start of a Phase 1 clinical trial with CV2CoV on March&#160;30, 2022. The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and is expected to enroll up to 210 healthy adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2&#181;g to 20&#181;g.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within the joint vaccine program with GSK, we also extended our technology platform to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We announced the start of a Phase 1 clinical trial with a chemically modified second-generation COVID-19 mRNA vaccine candidate, CV0501, on August 18, 2022. CV0501 specifically targets the Omicron variant. The study will be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines and is expected to enroll up to 180 healthy, COVID-19-vaccinated adults to evaluate the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 12&#181;g to 50&#181;g. Additional dose levels below 12&#181;g and above 50&#181;g may be evaluated if supported by safety and immunogenicity data at these dose levels. Based on the results of both Phase 1 studies, selection of the best performing candidate for a subsequent pivotal study for advanced clinical development will be made in the fourth quarter of 2022. The pivotal trial may be initiated in the first quarter of 2023, contingent on discussion with regulatory authorities. Candidates further addressing relevant COVID-19 variants featuring the same second-generation mRNA backbone are currently in preclinical testing. On April&#160;21, 2022, the preclinical data for the second-generation mRNA backbone was extended by a study conducted in collaboration with the Friedrich-Loeffler-Institut, comparing immune responses and protective efficacy of monovalent and bivalent mRNA vaccines encoding Beta and/or Delta variants, primarily in a transgenic mouse model and a Wistar rat model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;12, 2021, we announced the strategic decision to withdraw our first-generation COVID-19 vaccine candidate, CVnCoV, from the approval process with the European Medicines Agency, or EMA, and to focus our COVID-19 vaccine program on the development of second-generation mRNA vaccine candidates in collaboration with GSK. The decision was aligned with the evolving dynamics of the pandemic response toward greater need for more differentiated vaccines. The rolling submission with the EMA was originally initiated in February&#160;2021 to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, the EMA informed us that it would not start reviewing the provided CVnCoV data packages before 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. By this time, we expected candidates from the second-generation vaccine program to be progressing through clinical development. Consequently, CVnCoV was also withdrawn from a rolling submission with Swissmedic, Switzerland&#8217;s authority responsible for the authorization and supervision of therapeutic products, initiated in April&#160;2021, to review the safety, efficacy and pharmaceutical quality of CVnCoV as a prerequisite for market authorization.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All clinical studies with first-generation candidate, CVnCoV, have completed the scheduled safety follow-up times for all trial participants as per the respective trial protocols, i.e., the Phase 2b/3 (HERALD) study in Europe and Latin America (initiated in December&#160;2020) and a Phase 3 study in healthcare workers in Germany (initiated in December&#160;2020). Both studies are under final data analysis. Primary data of the Phase 2b/3 (HERALD) trial was published in The Lancet Infectious Diseases on November&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a Phase 1 study in Germany (initiated in June&#160;2020), a Phase 2a study in Peru and Panama (initiated in September&#160;2020), and a Phase 3 study in participants with comorbidities in Belgium (initiated in April&#160;2021) all subject follow-up times have been completed as per the respective trial protocols. Data of an interim analysis of the Phase 1 trial in Germany was published in Wiener klinische Wochenschrift on August&#160;10, 2021. Safety and immunogenicity data of the Phase 2a clinical trial in Peru and Panama was uploaded to the SSRN preprint server on December 10, 2021 and published in Vaccine: X on July 1, 2022. Neutralizing antibody data against the ancestral strain and the beta variant after a third dose of CVnCoV in the same trial were posted on the MedRxiv preprint server on February 24, 2022 and published in Vaccines on March 25, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously announced studies to be initiated with CVnCoV, including a Phase 2 clinical trial, focusing on immunogenicity in older adults above the age of 65&#160;years old compared to younger adults and a flu-co-administration study, planned to be initiated together with Bayer AG to assess compatibility with established seasonal vaccines in an older population, were cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To assess the benefit of booster vaccinations, CVnCoV was also included in the Cov-Boost trial sponsored by the University of Southampton, UK, which is evaluating several COVID-19 vaccines and vaccine candidates as booster vaccines. Each participant in the Cov-Boost trial received one booster vaccine 84 or 70 days respectively after they completed their primary vaccination with two doses of either Comirnaty or Vaxzervia. The Cov-Boost trial started in June&#160;2021 across 18 sites in the United Kingdom and dosed overall 2,878 participants with a third dose vaccine. Initial results from the Cov-Boost trial were published in The Lancet on December&#160;2, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our pivotal Phase 2b/3 trial for CVnCoV, which included approximately 40,000 participants, reported interim analysis outcomes following a first interim analysis on May&#160;28, 2021, based on 59 adjudicated COVID-19 cases and a second interim analysis on June&#160;16, 2021, based on 134 adjudicated COVID-19 cases in the unprecedented context of at least 13 variants circulating within the assessed study population subset. Primary data of the study was published in The Lancet Infectious Diseases on November&#160;23, 2021. Overall, CVnCoV demonstrated a vaccine efficacy of 48% against COVID-19 disease of any severity. In the highly dynamic variant environment, the HERALD trial met the prespecified success criteria for efficacy against symptomatic COVID-19 of any severity and for efficacy against moderate-to-severe COVID-19, as defined in the protocol. The primary efficacy analysis included 12,851 participants in the CVnCoV group and 12,211 in the placebo group. The mean observation period, starting 15&#160;days after administration of the second dose, was 48.2&#160;days. Vaccine efficacy against COVID-19 of any severity was 48.2% in the overall primary efficacy analysis set of SARS-CoV-2-naive participants, and 52.5% in those aged 18&#8211;60&#160;years. Vaccine efficacy against moderate-to-severe COVID-19 was 70.7% overall and 77.2% in participants aged 18&#8211;60&#160;years. There were too few participants aged 61&#160;years or older who developed COVID-19 to allow a meaningful estimate of efficacy in this age group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HERALD was conducted in an unprecedented evolving landscape that reflects the changing reality of the global COVID-19 pandemic, with an increasing number of SARS-CoV-2 variants adding additional challenges to the assessment of COVID-19 vaccine candidates. Sequence data were available for 184 of 207 adjudicated cases in people aged 18&#8211;60&#160;years. About 50% of cases of COVID-19 in our trial were caused by variants of concern, 35% were caused by variants of interest, as classified by WHO in September&#160;2021, and about 3% were caused by wild-type, with the remaining 11% caused by other variants. Although we were only able to evaluate vaccine efficacy against these variants in participants aged 18&#8211;60&#160;years, the results indicate that the vaccine had similar efficacies against Alpha, Gamma, and Lambda variants. Many newly emerged strains have shown increased transmissibility, and differences in neutralizing antibody activity against these strains might alter vaccine efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">The first non-COVID-19 vaccine candidate within the broader second-generation infectious disease program we are developing in collaboration with GSK is the influenza candidate, CVSQIV, a differentiated multivalent vaccine candidate featuring multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February&#160;10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity and immunogenicity of CVSQIV in up to 240 healthy adult participants in the dose range of 3&#181;g to 28&#181;g. In line with the mRNA development strategy to also test chemically modified mRNA and similar to the setup of the COVID-19 vaccine program, CureVac and GSK have also announced the start of a Phase 1 dose-escalation study with a chemically modified influenza vaccine candidate, Flu SV mRNA. The candidate is a monovalent candidate. The Phase 1 dose-escalation study will be conducted in Canada, Spain, and Belgium, and is expected to enroll up to 198 healthy adult participants to evaluate the safety, reactogenicity and immunogenicity of FLU SV mRNA in the dose range of 2&#181;g to 54&#181;g. Later stage clinical development is expected to evaluate a multivalent form of the candidate, which could range in dose up to 200&#181;g &#8211; the upper limit of the dose range in the complementary study of the modified COVID-19 candidate, CV0501.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beyond the GSK COVID-19 and general infectious disease collaboration, our next advanced prophylactic vaccine program, CV7202, is being developed for prophylactic vaccination against rabies. CV7202 is an mRNA based on our first-generation backbone that encodes the rabies virus glycoprotein, RABV-G, formulated with Lipid Nanoparticles. Safety, reactogenicity, and immunogenicity of CV7202 was investigated in a Phase 1 clinical trial that has completed the scheduled follow-up time for all trial participants as per trial protocol. In January&#160;2021, we published data from our Phase 1 trial of CV7202 in rabies. CV7202 induced adaptive immune response as shown by rabies-specific virus-neutralizing antibodies above the World Health Organization thresholds considered to be protective, after the second dose in all subjects, at the lowest 1&#956;g and 2&#956;g dose levels. We also showed that the lowest dose levels (1&#956;g and 2&#956;g mRNA) were generally well tolerated. We are currently assessing the path forward for advancing CV7202.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In oncology, we plan to build a meaningful portfolio and create long-term value to accelerate growth beyond the recent progress in prophylactic vaccines. Developing new oncology candidates is characterized by similar medical challenges as in infectious diseases, including selection and accessibility of disease-relevant antigens, enhancing antigen-induced immune activation, and triggering immune responses led by a strong induction of tumor-killing T cells. Taking advantage of recent technology platform advances, particularly our second-generation mRNA backbone in COVID-19 and infectious diseases, we are evaluating targeted expansions of our unique mRNA approaches for the development of cancer vaccines based on three strategic pillars:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Validation and optimization of our broad mRNA technology approach for T cell mediated tumor control</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Build-up of a pipeline of cancer vaccine candidates targeting antigens predicted to be immuno&#173;genic and presented on tumors in cancer patients</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Addition of comple&#173;mentary platform technologies for improved antigen discovery, validation and optimization of vaccine design focusing on T cell activation</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To deliver on this strategy, we are exploring a range of potential approaches, including intratumoral therapy and novel cancer vaccines targeting neoantigens and tumor associated antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Our lead oncology candidate, CV8102, is a complex of single-stranded non-coding RNA, which has been optimized to maximize activation of cellular receptors that normally detect viral pathogens entering the cells (such as toll-like receptor 7, or TLR7, toll-like receptor 8, or TLR8, and retinoic acid inducible gene I, or RIG-I pathways), mimicking a viral infection of the tumor. CV8102 is designed to recruit and activate antigen-presenting cells at the site of injection to present tumor antigens released from tumor cells to T cells in the draining lymph node. This potentially leads to activation of tumor-specific T cells, which can kill tumor cells at the injected site, but also at distant non-injected tumor lesions or metastases. CV8102 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with anti-PD-1 antibodies for the treatment of four types of solid tumors&#8201;-&#8201;cutaneous melanoma, adenoidcystic carcinoma, squamous cell carcinoma of skin, and squamous cell carcinoma of head and neck, or HNSCC. Details of safety and efficacy observed in the dose-escalation portion of the trial were reported at ESMO 2021. As of June&#160;21, 2021, 58 patients were enrolled in the dose escalation part, 33 in the single-agent cohort and 25 in the combination cohort with anti-PD-1 antibodies. As of the same cutoff date, in the single-agent CV8102 dose escalation cohort, we observed one patient with a complete response and two patients with a partial response according to RECIST 1.1. In addition, twelve patients experienced a best response of stable disease. In the PD-1 dose escalation combination cohort, one PD-1 refractory melanoma patient experienced a partial response according to RECIST 1.1. In addition, three patients experienced a best response of stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">On November&#160;10, 2021, at the Society for Immunotherapy of Cancer, or the SITC conference, we further extended the ESMO update with an extensive analysis of immune cell activation to better understand the mobilization of the immune system against CV8102-injected as well as non-injected tumors. The data showed efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma. Serial tumor biopsies from individual patients demonstrated increased infiltration of tumor-fighting T cells in the micro-environment of injected as well as non-injected tumors. Both observations support the hypothesis that local injection of the RNA immuno-modulator into a single tumor lesion can induce a systemic response leading to immune attack against both injected and non-injected tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, we initiated the expansion of our Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose, the selected dose to be potentially advanced in a Phase 2 clinical trial. The expansion part of the Phase 1 trial completed enrollment in October&#160;2021 and involves 40 trial participants, with 10 patients in the single-agent cohort and 30 patients in the combination cohort with anti-PD-1. Comprehensive data from the expansion part of the study is expected in the fourth quarter of 2022.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">Within our oncology strategy to build a meaningful portfolio of new cancer vaccine candidates, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. To advance both approaches, in June 2022, CureVac acquired Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types. The acquisition complements existing inhouse expertise to identify and validate promising neoantigens for mRNA cancer vaccine candidates. The former Frame Cancer Therapeutics site was inaugurated as CureVac Amsterdam and will further develop the proprietary FramePro platform, which has the potential to identify a broad panel of neoantigens that go beyond conventional neoantigens and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer, both in a personalized and off-the-shelf manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">The acquisition of Frame Cancer Therapeutics follows a strategic oncology partnership with Belgium-based company myNEO, announced on May 25, 2022. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.&#160;myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">The highly synergistic technologies of Frame Cancer Therapeutics and myNEO are expected to accelerate CureVac&#8217;s oncology strategy by accessing novel classes of tumor antigens and making targeted selections of antigens with the highest confidence of success for potential clinical testing. In this context, we are committed to drive innovation in oncology by leveraging The RNA Printer<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, CureVac&#8217;s automated end-to-end manufacturing solution for GMP-grade mRNA vaccines and thera&#173;peutics. The highly standardized system is expected to allow for rapid and highly flexible availability of mRNA to screen new targets and transition promising mRNA product candidates more efficiently into the clinic. Designed for small-scale quantities, the automated GMP-grade output of The RNA Printer<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup> is designed to open avenues for personalized mRNA-based cancer therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;16, 2021, Boehringer Ingelheim expressed its intention to terminate the 2014 collaboration agreement on BI1361849 (previously CV9202). The termination became effective on November&#160;17, 2021. The legacy program, targeting specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer, or NSCLC, applies an older protamine formulation technology, which reflected the state of the technology development at the time. A Phase 1/2 clinical trial in NSCLC applying BI1361849 as a combination therapy is ongoing. Both companies are currently assessing options to continue a collaboration on our RNA technology platform based on state-of-the-art LNP-based formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In molecular therapies, we published preclinical mouse data in liver fibrosis in the Journal of Hepatology in August&#160;2021. Progression of liver fibrosis is associated with the gradual decrease of hepatocyte nuclear factor 4 alpha, or HNF4 alpha, an important regulator and key factor in liver metabolism. In the published study, four independent mouse models of the disease were treated with mRNA encoding HNF4A. The treatment was able to restore HNF4A levels and thereby significantly reduced liver injury. The study was conducted in collaboration with the REBIRTH-Research Center for Translational Regenerative Medicine and Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Hannover (Germany). It provides the first preclinical data demonstrating the therapeutic applicability of mRNA encoded HNF4A in the treatment of liver fibrosis and cirrhosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We further expect to publish data from our collaboration with the Schepens Eye Research Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Key Factors Affecting Our Results of Operations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the most significant factors affecting our results of operations include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Research and Development Expenses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully pioneer a robust mRNA technology platform and develop innovative product candidates will be the primary factor affecting our future growth and development. Our approach to the discovery and development of product candidates based on mRNA technology is still being demonstrated. As such, we do not know whether we will be able to successfully develop any products. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the product candidates are still in development, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Due to our accelerated efforts to develop our first-generation COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October&#160;2021 notification to the European Commission of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April&#160;2021, we entered into a collaboration agreement with GSK for the development of a broad second-generation COVID-19 vaccine program. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our second-generation COVID-19 vaccine program and presently in the Phase 1 clinical trial, as announced on March 30, 2022. Within the second-generation COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generation of our COVID-19 vaccine candidates, such as for our second-generation COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically funded the research and development expenses primarily through public offerings of our common stock, private placements of equity securities, convertible loans, grants from government agencies and similar bodies and payments for collaborative research and development services with strategic partners. In addition, we signed an advance purchase agreement, or APA, with the EC that provided substantial support for our efforts to advance our first-generation vaccine candidate, CVnCoV. In October&#160;2021, we notified the European Commission of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Our and Our Collaborators&#8217; Ability to Commercialize Our Product Candidates</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates depends on our and our collaborators&#8217; ability to successfully advance clinical trials for our product candidates and receive regulatory approval, particularly in the United States, Europe, and other major markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our broad portfolio of product candidates with both novel and validated targets enhances the likelihood that our research and development efforts will yield successful product candidates. Nonetheless, we cannot be certain if any of our product candidates will receive regulatory approvals. Even if such approvals are granted, we will thereafter need to maintain manufacturing and supply arrangements and engage in extensive marketing prior to generating any revenue from such products, and the ultimate commercial success of our products will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The competitive environment is also an important factor with the commercial success of our product candidates, and our ability to successfully commercialize a product candidate will depend on whether there are competing product candidates being developed or already marketed by other companies.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently do not have any product candidates that have received regulatory approval. As such, we have not incurred any material commercialization expenses in connection with an approved product candidate. In February&#160;2021, we initiated a rolling submission for our first generation COVID-19 vaccine candidate, CVnCoV, with the EMA, which was designed to allow the EMA to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, EMA informed us that the EMA would not start reviewing our submission for CVnCoV before the beginning of 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. Data on the efficacy of CVnCoV was generated and published in June&#160;2021. This efficacy data did not live up to our pre-trial expectations and fell behind the efficacy of competing COVID-19 vaccine products. The application for the marketing authorization for CVnCoV was withdrawn in early October&#160;2021, as a necessary reaction to the efficacy data as well as the concerns and uncertainties resulting from such data on the granting of a marketing authorization and the expected concerns of prescribers and patients to use a COVID-19 vaccine with a lower efficacy compared to the vaccines already available on the market. After the withdrawal of the application for a marketing authorization for CVnCoV, we have focused our efforts on second-generation mRNA vaccines. The decision is aligned with the evolving dynamics of the pandemic response toward greater need for differentiated vaccines with the gradual transition from an acute pandemic to an endemic SARS-CoV-2 environment. In connection with the regulatory approval process, and in preparation for the commercialization of a second-generation COVID-19 vaccine, we expect our expenses related to commercialization to significantly decrease in the short-term due to our past commercialization efforts for CVnCoV. However, we expect that our expenses related to commercialization will significantly increase in the long-term if a second-generation COVID-19 vaccine candidate reaches late clinical stages, but we expect that this increase in expenses will be mitigated by the GSK COVID Agreement, as described below. As part of the commercialization process of CVnCoV, we also entered into strategic partnerships with Bayer for the development, production and distribution of CVnCoV. In addition, pursuant to a preliminary agreement regarding the secondary manufacturing of CVnCoV we entered into with GSK, GSK would have supported the secondary manufacturing of up to 100 million doses of CVnCoV in 2021. Additionally, we also partnered with Fareva, Rentschler Biopharma SE, and Novartis AG, among others, to develop an integrated European manufacturing network. Due to our decision to withdraw CVnCoV from the regulatory approval process and focus our efforts on second-generation mRNA vaccine, separate agreements with Celonic and Wacker were terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Our Collaborations, Related License Agreements and Advance Purchase Agreements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our results of operations have been, and we expect them to continue to be, affected by our contractual collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, our future results of operation may be affected by future advance purchase agreements for our COVID-19 vaccine candidates. To date, our revenues have been recognized pursuant to license and collaboration agreements, which include up-front payments for licenses or options to obtain licenses, milestone payments, payments for product sales and payments for research and development services. Grants from government agencies or similar bodies are recognized as other operating income or as a reduction to depreciation and amortization expense recognized from assets purchased under the associated arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into strategic collaborations and license agreements with third parties. In addition, on November&#160;30, 2020, we entered into an advance purchase agreement, or APA, with the European Commission, or EC, which provided for the advance purchase by the commission of our first-generation vaccine candidate, CVnCoV. In October&#160;2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA. As part of our business development strategy, we aim to increase the number of our strategic collaborations in order to derive further value from our platform and more fully exploit the potential of our collaborations and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain key terms of our current material collaboration and license agreements, as well as our advance purchase agreement with the EC are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Option Agreement with myNEO</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, we entered into a Research and Option Agreement (&#8220;R&amp;O&#8221;) with myNEO NV (&#8220;myNEO&#8221;), pursuant to which we will both collaborate in research to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&amp;O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer, melanoma and potentially other indications. Under the R&amp;O, we have an obligation to pay myNEO an up-front one-time technology access fee of &#8364;138,000 and myNEO is eligible to receive up to &#8364;17.5 million in research and development milestone payments and &#8364;37.5 million in commercial milestone payments.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">GlaxoSmithKline</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. The 2020 GSK Agreement was amended and restated in April&#160;2021, September&#160;2021, February&#160;2022 and March&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GSK paid us an up-front payment of &#8364;120 million and is required to pay us a manufacturing capacity reservation fee of &#8364;30 million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between &#8364;28 million to &#8364;45 million in development milestone payments, &#8364;32 million to &#8364;35 million in regulatory milestone payments and &#8364;70 million to &#8364;100 million in commercial milestone payments, depending on the product. Under the 2020 GSK Agreement, we granted GSK an exclusive option to add additional products in the field of infectious diseases to the license granted under the 2020 GSK Agreement and upon each exercise of such option, and GSK is required to compensate us for certain development costs and pay any accrued milestone payments. GSK additionally has the right to replace products licensed under the 2020 GSK Agreement and if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are additionally eligible to receive tiered royalty payments ranging from a single-digit&#160;percentage to a low teens&#160;percentage on net sales, subject to certain customary reductions. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with our performance of our obligations under the 2020 GSK Agreement, and we are eligible to receive up to &#8364;20,000 in reimbursements for expenses incurred recording or registering the licenses granted under the 2020 GSK Agreement. We retain the right to commercialize products developed under the 2020 GSK Agreement in Germany, Austria and Switzerland, as GSK&#8217;s exclusive distributor in these markets. Under any such distribution agreement to be entered into between us and GSK, we will be required to purchase supply from GSK and pay GSK a low thirties&#160;percentage royalty on net sales. Pursuant to the amendment in September&#160;2021, we and GSK are required to complete certain development activities set forth in updated development plans. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in April&#160;2021, we entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID-19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September&#160;2021 and March&#160;2022. Pursuant to the amendment in September&#160;2021, we and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the GSK COVID Agreement, GSK has paid us an up-front payment of &#8364;75 million. We and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID Products, other than Combination Products, under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from a sub-teen&#160;percentage to a mid-teen&#160;percentage on net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement we have the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if we exercise such right, our sales of GSK COVID Products, other than Combination Products will be subject to the profit share and we will be required to pay GSK a high-teen&#160;percentage royalty on net sales of all Combination Products in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Genmab</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, we entered into a Collaboration and License Agreement, which we refer to as the Genmab Agreement, with Genmab to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases. We will collaborate on research to identify an initial product candidate designed to express a certain Genmab proprietary antibody, and we will contribute a portion of the overall costs for the development of such product candidate, until submission of an IND. Genmab will thereafter be responsible for the development and commercialization of the product candidate. Under the Genmab Agreement, we further grant Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under our mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Genmab Agreement, Genmab paid us a $10 million up-front fee and made a &#8364;20 million equity investment in March&#160;2020. Genmab will be obligated to pay us a $0.5 million reservation fee upon the selection of each additional product concept for development under the Genmab Agreement and $5 million upon selection of a product targeting Genmab&#8217;s proprietary antibody for further development and commercialization. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid single-digit to low teens&#160;percentage tiered royalty on aggregate net sales of licensed products, on a per-product basis and subject to certain customary reductions. If Genmab grants a sublicense to the initial product candidate developed under the Genmab Agreement before a certain milestone event, Genmab must pay us a one-time $10 million payment. We are responsible for any payments to third parties related to the LNP technology we license to Genmab for use in relation to the initial product candidate developed under the Genmab Agreement and a portion of such payments with respect to LNP technology used in the additional product concepts. We retain an option to participate in development and commercialization of one of the potential additional mRNA antibody product concepts under predefined terms and conditions. In the event we exercise such right, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of June 30, 2022, we have received $1.0 million in development cost reimbursements and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Arcturus</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2018, we entered into a Development and Option Agreement, which we refer to as the Arcturus Agreement, with Arcturus, which provides us with access to Arcturus LNP formulation technology which we use in combination with our mRNA technology. We paid Arcturus an up-front fee of $5 million and must pay an extension fee of $1 million if we exercise our option to extend the initial term of the Arcturus Agreement beyond July&#160;2023. We are required to reimburse Arcturus for certain costs incurred in connection with development activities and provide certain FTE funding. We are additionally required to pay up to an aggregate of $5 million in connection with our acceptance of the irrevocable offer to obtain licenses for further development and commercialization of selected targets. As of June 30, 2022, we have not accepted any such irrevocable offer. Under each license agreement to be entered into in connection with our acceptance of the irrevocable offer, to the extent applicable, we will additionally be required to make certain royalty payments, which are not in excess of 10% on net sales of licensed products, and pay Arcturus up to $6 million in development milestone payments, $9 million in regulatory milestone payments and $8 million in commercial milestone payments. As of June 30, 2022, we have made payments totaling $5.5 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations, and we have not accepted the irrevocable offer with respect to any target and therefore have not paid any acceptance fees or made any milestone or royalty payments to Arcturus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Acuitas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a Development and Option Agreement, which as amended we refer to as the Acuitas Agreement, with Acuitas, which provides us with access to Acuitas LNP formulation technology that we use in combination with our mRNA technology. We are required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement and to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option to obtain a license for further development and commercialization with respect to a selected target, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million up-front fee in connection with an amendment to the Acuitas Agreement dated July&#160;2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we are required to pay an exchange fee of $3 million. We additionally paid Acuitas a $3 million up-front fee in connection with an amendment to the Acuitas Agreement dated December&#160;2020 and are required to pay an additional $250,000 in April&#160;2022 and April&#160;2023 for each of certain options not yet exercised. Under each license agreement in connection with our exercise of our option, we will additionally be required to make low single-digit&#160;percentage tiered royalty payments and must pay up to between $1.1 million and $9 million in development milestone payments, $1.3 million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of June 30, 2022, we have exercised our option to obtain a non-exclusive license to sixteen targets, subject to customary closing conditions. As of June 30, 2022, we have paid Acuitas $3.7 million in reservation and option exercise fees and have made payments totaling $8.6 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">For each option that we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned target, all based on the same form agreement, which we refer to as the Acuitas License Agreements. We are required to pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement, and we must pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under each Acuitas License Agreement after a certain milestone event. We additionally are obligated to pay Acuitas a low single-digit&#160;percentage royalty on net sales of licensed products. As of June 30, 2022, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, we have made $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, and we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, and have not made any royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">CRISPR Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2017, we entered into a Development and License Agreement, which, as amended by an amendment entered into in June&#160;2020, we refer to as the CRISPR Therapeutics Agreement, with CRISPR Therapeutics, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics an exclusive worldwide license to use our improved Cas9 constructs for the development and commercialization of three of its in vivo gene-editing programs for certain diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CRISPR Therapeutics has paid us an up-front one-time technology access fee of $3 million and we are eligible to receive up to $13 million in development milestone payments, $33 million in regulatory milestone payments and $133 million in commercial milestone payments, as well as mid-single-digit&#160;percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. Additionally, CRISPR Therapeutics will make payments to us for services provided by us in conjunction with research programs under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the agreement, CRISPR Therapeutics must pay us a low teens to mid-twenties&#160;percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of June 30, 2022, we have received &#8364;3.6 million in payments and we have invoiced &#8364;0.6 million for the supply of materials and FTE cost, development reimbursements and up-front one-time technology access fee and no milestone, royalty or sublicense fee payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Boehringer Ingelheim</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2014, we entered into an Exclusive Collaboration and License Agreement, which we refer to as the Boehringer Agreement, with Boehringer Ingelheim GmbH, or Boehringer Ingelheim, whereby we granted Boehringer Ingelheim exclusive global rights for development and commercialization of our investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with our protamine technology. We received an up-front payment of &#8364;30 million, as well as, an option fee payment of &#8364;5 million and an additional &#8364;7 million in development milestone payments and as of June 30, 2022, we received &#8364;7.6 million for the supply of materials and reimbursing us for development costs. In June&#160;2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement. The termination became effective on November&#160;17, 2021. Upon termination of the Boehringer Agreement, the rights and licenses granted by us to Boehringer Ingelheim reverted back to us, provided that Boehringer Ingelheim has the right to sell off existing inventory of BI 1361849 (formerly CV9202) for a certain period. In addition, Boehringer Ingelheim must assign to us all regulatory approvals or applications and grant us a non-exclusive, cost-free, perpetual and worldwide license to intellectual property held by Boehringer Ingelheim that has been used in the development, manufacture or commercialization of BI 1361849 (formerly CV9202) or any other product developed under the Boehringer Agreement. We and Boehringer Ingelheim are currently assessing options to continue a collaboration based on state-of-the-art LNP-based formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Bill&#160;&amp; Melinda Gates Foundation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2014, we were awarded a grant from the Bill&#160;&amp; Melinda Gates Foundation for the development of a vaccine for rotaviruses, as amended in November&#160;2020, for up to $2.8 million in funding. As of June 30, 2022, we have received $3.0 million in funding under the agreement. In March&#160;2015, the Bill&#160;&amp; Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility. We entered into a Global Access Commitments Agreement with the Bill&#160;&amp; Melinda Gates Foundation in February&#160;2015 pursuant to which we are required to take certain actions to support the Bill&#160;&amp; Melinda Gates Foundation mission. In connection with the investment by the Bill&#160;&amp; Melinda Gates Foundation, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill&#160;&amp; Melinda Gates Foundation. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2016, in connection with the Global Access Commitments Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill&#160;&amp; Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of June 30, 2022, we have received $0.7 million in funding under the picornaviruses grant agreement. In November&#160;2017, we were awarded two additional grants each for up to $1.9 million and $1.5 million in funding from the Bill&#160;&amp; Melinda Gates Foundation for the development of a universal influenza and a malaria vaccine, respectively. By an amendment entered into November&#160;2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of June 30, 2022, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Coalition for Epidemic Preparedness Innovations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, we entered into a framework partnership agreement, which as amended we refer to as the CEPI Agreement, with the Coalition for Epidemic Preparedness, or CEPI, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products, as well as certain additional intellectual property licensed to us. In connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase 1 clinical trial for our first-generation COVID-19 vaccine candidate, CVnCoV. The CEPI Agreement terminated in Feburary 2022, except with respect to certain ongoing projects, which are contemplated to be completed in March&#160;2023. CEPI agreed to contribute up to $34 million in funding for projects undertaken under the CEPI Agreement and an additional $15.3 million in connection with development of CVnCoV. As of June 30, 2022, we have received &#8364;27.1 million in funding for projects undertaken under the CEPI Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Tesla Automation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2015, we entered into a development and intellectual property agreement, which we refer to as the Tesla Automation Agreement, with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of June 30, 2022, we have paid Tesla Automation &#8364;16 million to &#8364;17 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an up-front payment of &#8364;450 million. Such up-front payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the up-front payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October&#160;2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would only return the unspent amount of the up-front payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March&#160;8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the up-front payment. Due to the termination of the APA, we will not receive any further payments related to the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In other respects, upon the EC&#8217;s request, we will transfer any raw materials and/or primary components paid for with the up-front payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expires at the end of 2022.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition of Frame Pharmaceuticals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2022, we entered into a Share Purchase Agreement (&#8220;SPA&#8221;), to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., domiciled in Amsterdam, the Netherlands, a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>), organized and existing under the laws of the Netherlands, focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. Under the SPA, the total consideration for the purchase was &#8364;34 million, conditioned on certain development milestone payments, as described therein. This acquisition serves to complement and strengthen our discovery capabilities to identify and validate promising neoantigens for our mRNA cancer vaccine programs and could strongly increase the likelihood of developing highly effective cancer vaccines for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Financial Operations Overview</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Revenue</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, our revenues have consisted of up-front licensing payments, milestone payments, product sales and compensation for research and development services, all of which relate to our license and collaboration agreements. Certain of these payments are initially recorded on our statement of financial position and are subsequently recognized as revenue in accordance with our accounting policy as described further in note 3 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Cost of Sales</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales consists primarily of personnel costs, costs for materials and third party services, including any relating to written-off inventory, as well as maintenance and lease costs, and depreciation and amortization. Costs of sales includes costs of product sales, idle production costs and costs from set-up and quality assurance activities for our production processes, including those relating to pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues. See &#8220;Research and Development Expenses&#8221; below for additional information on recognition of costs relating to pre-launch products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Selling and Distribution Expenses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses primarily consist of personnel expenses which include salary and salary-related expenses and expenses from share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Research and Development Expenses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and preclinical and clinical development activities, including our product discovery efforts and certain activities relating to the design of GMP-manufacturing facilities. Research and development expenses contain wages and salaries, share-based compensation, fringe benefits and other personnel costs, the costs of clinical testing and the associated clinical production costs, research material production costs, fees for contractual partners, consultants and other third parties, fees to register legal rights, amortization of licensed software and intellectual property as well as costs for plant and facilities. Research and development expenses contain costs for independent research and development work as well as work carried out in the context of collaboration and licensing agreements; such expenses include all costs related to research and development services delivered under our collaboration arrangements. Additionally, prior to initial regulatory approval, if any, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin, as the underlying costs will not be included in cost of sales as they will have been recognized in research and development expense in the period incurred.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generations of our COVID-19 vaccine candidates, such as for our second-generation COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">General and Administrative Expenses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses generally include wages and salaries, share-based compensation, fringe benefits and other personnel costs of our senior management and administrative personnel, costs for professional services, including legal, audit and consulting services and costs of facilities and office expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Comparison of the Six&#160;Months Ended June 30, 2021 to the Six&#160;Months Ended June 30, 2022</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have based the following discussion of our financial condition and results of operations on our unaudited interim condensed consolidated financial statements for the six&#160;months ended June 30, 2021 and 2022 and the notes thereto, included elsewhere in this Report of Foreign Private Issuer on Form&#160;6-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical results for the six&#160;months ended June 30, 2021 and 2022 are not necessarily indicative of results to be expected for a full&#160;year or any other interim period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our consolidated results of operations for the six&#160;months ended June 30, 2021 and 2022:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros,&#160;except per&#160;share&#160;data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Operations and Comprehensive Income (Loss) Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32,425</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 44,519</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (53,156)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (79,913)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,029)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (819)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (236,267)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (22,422)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (50,651)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (51,678)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 45,234</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 35,207</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (214)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (461)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (263,658)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (75,567)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,296</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,343</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (8,065)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,535)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (264,427)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,759)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,329)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (265,756)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,677)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income/loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Items that may be subsequently reclassified to profit or loss</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (30)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (212)</font></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (265,786)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,889)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1.44)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.39)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue was &#8364;44.5 million for the six months ended June 30, 2022, representing an increase of &#8364;12.1 million, or 37%, from &#8364;32.4 million for the six months June 30, 2021. The increase was primarily driven by increased revenues from our collaborations with GSK including &#8364;5.3 million from recognition of a development milestone for advancing our seasonal influenza mRNA vaccine candidate into clinical trials. In total, for both the 2020 GSK agreement and the GSK COVID Agreement, revenue of &#8364;43.0 million was recognized for the six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cost of Sales</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales was &#8364;79.9 million for the six months ended June 30, 2022, representing an increase of &#8364;26.7 million, or 50%, from &#8364;53.2 million for the six months ended June 30, 2021. The increase was primarily attributable to increased write-off for raw materials which were procured for manufacturing products to sell to GSK, that are now no longer expected to be used due to a decline in production planning following the transfer of reserved production capacity to a CMO to GSK (as described in the &#8220;Other Operating Income&#8221; section below).</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended &#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,390)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,869)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,912)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (36,883)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (31,388)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (19,516)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,543)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,150)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization, depreciation and derecognition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,594)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (8,326)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,329)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (169)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (53,156)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,913)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Selling and Distribution Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses were &#8364;0.8 million for the six months ended June 30, 2022 and were relatively unchanged compared to the six months ended June 30, 2021.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Six&#160;Months&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (664)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (560)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (43)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (32)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (322)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (227)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (819)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="white-space:pre-wrap;">Research and development costs were &#8364;22.4 million for the six months ended June 30, 2022, representing a decrease of &#8364;214.0 million, or 91%, from &#8364;236.4 million for the six months ended June 30, 2021. The decrease was primarily attributable to significantly lower research and development costs. 2021 was highly impacted from the start of our Phase 2/3 clinical trial for CVnCoV. As of December 2021, we  recognized a provision for all remaining costs related to the CVnCoV clinical trials. During the first six months of 2022, thereafter, more participants exited the trials earlier than originally estimated and in addition, we were able to renegotiate the </font></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">existing contracts. As a result of these changes, our estimated remaining costs decreased and, thus, we recognized a gain from the reversal of &#8364;21.3 million of the provision.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Six Months&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,928)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (23,419)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (15,219)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (14,849)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,795)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,119)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,413)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,354)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (210,590)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 21,053</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (142)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (464)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,180)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,270)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (236,267)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (22,422)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table reflects our research and development costs for each of our programs for the six months ended June 30, 2021 and 2022:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Six Months&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Key Programs (CV8102, CV7202, CV2CoV and CVnCoV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CV8102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,051)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,414)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CV7202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (145)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (120)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CV2CoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,752)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (10,990)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CVnCoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (206,933)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 18,300</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Research and Development Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,116)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,215)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unallocated costs(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (21,270)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (24,983)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (236,267)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (22,422)</b></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third party service expenses and certain material expenses.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Due to our accelerated efforts in 2021 to develop our first-generation COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October&#160;2021 notification to the European Commission of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April&#160;2021, we entered into a collaboration agreement with GSK for the development of a broad second-generation COVID-19 vaccine program. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our second-generation COVID-19 vaccine program presently at a preclinical development stage. Within the second-generation COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Considering that, our research and development expenses primarily relate to the following key programs:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our second-generation mRNA vaccine program, CV2CoV against SARS-CoV-2, which is being co-developed with GSK. On March 30, 2022, we announced the start of the Phase 1 clinical trial for CV2CoV, with a study of modified mRNA expected to follow.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our lead oncology program, CV8102, which is currently in a Phase&#160;1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD-1 and an expansion of the Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#956;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">g dose, the selected dose to be advanced in a Phase 2 clinical trial.</font></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our vaccine program, CV7202, which is currently in a Phase&#160;1 clinical trial as a vaccine candidate for rabies.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were &#8364;51.7 million for the six months ended June 30, 2022, representing an increase of &#8364;1.0 million, or 2%, from &#8364;50.7 million. The increase was primarily attributable to increases in amortization and depreciation and legal and other professional services partially offset by less third-party services.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Six Months&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (19,362)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (18,971)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,230)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,704)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (18,785)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (12,796)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,491)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,320)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,325)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,091)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4,458)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,796)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (50,651)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (51,678)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Other Operating Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating income was &#8364;35.2 million for the six months ended June 30, 2022, representing a decrease of &#8364;10.0 million, or 22%, from &#8364;45.2 million for the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK Agreement and the GSK COVID Agreement in connection with GSK entering into a direct Agreement with Novartis relating to the use of the Novartis as CMO at the same time as CureVac exits its CMO agreement with Novartis and is released from its pre-existing capacity commitments under the agreement. As a result, the Company will avoid an outflow of resources. Additionally, under the restated agreement, CureVac was entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (&#8364;20.5 million) and for reimbursement of prepayments (&#8364;12.0 million). In 2021 the other income was primarily attributable to amounts recognized from grants from government agencies and similar bodies, primarily the German Federal Ministry of Education and Research, or BMBF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense was &#8364;0.5 million for the six months ended June 30, 2022, relatively unchanged compared to the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Finance Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance income was &#8364;5.3 million for the six months ended June 30, 2022, representing a decrease of &#8364;2.0 million, or 27%, from &#8364;7.3 million for the six months ended June 30, 2021. The decrease was attributable to lower foreign exchange gains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance expenses were &#8364;2.5 million for the six months ended June 30, 2022, representing a decrease of &#8364;5.6 million, or 69%, from &#8364;8.1 million for the six months ended June 30, 2021. The decrease was mainly attributable to less negative interest on cash, which is being held in liquid funds available for use for CV2CoV development and other manufacturing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Income Tax Benefit (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An income tax benefit of &#8364;0.1&#160;million was generated for the six months ended June 30, 2022, representing a decrease of &#8364;1.4 million, from an income tax expense of &#8364;1.3 million generated for the six months ended June 30, 2021. The decrease to a benefit was primarily attributable to deferred tax income on temporary differences.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial condition and liquidity is and will continue to be influenced by a variety of factors, including:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate cash flows from our operations;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future indebtedness and the interest we are obligated to pay on this indebtedness;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of public and private debt and equity financing;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in exchange rates which will impact our generation of cash flows from operations when measured in euros; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our capital expenditure requirements.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Overview</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. For the six months ended June 30, 2021 and 2022, we incurred net losses of &#8364;265.8 million and &#8364;72.7 million, respectively. To date, we have financed our operations primarily through the IPO in August&#160;2020, the public offering in February&#160;2021, private placements of equity securities, issuance of convertible debt, grants from government agencies and similar bodies and payments for collaborative research and development services. Our cash and cash equivalents as of June 30, 2022 were &#8364;573.6 million. Our primary cash needs are to fund our non-clinical and clinical development programs, for working capital requirements and for capital expenditures. We believe our existing cash, cash equivalents, borrowings available to us, receipts from grants and short-term investments will enable us to fund our operating expenses and capital expenditure requirements at least through the end of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Securities LLC, as sales agents, to establish an at-the-market offering program (&#8220;ATM Program&#8221;), pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. In June 2022, 340,015 shares were issued for the ATM and expenses in connection with the ATM were booked against equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Comparative Cash Flows</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Comparison of the six months ended June 30, 2021 and 2022</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Six Months&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash flow from (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (274,898)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (201,175)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (73,717)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (44,715)</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 378,845</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,409</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of currency translation gains on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,989</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,583</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Overall cash inflow</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 33,219</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (237,898)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the six months ended June 30, 2022 was &#8364;201.2 million as compared to net cash used in operating activities of &#8364;274.9 million for the six months ended June 30, 2021. The decrease in net cash in operating activities was primarily attributable to less prepayments for service agreements with Contract Research Organizations and Contract Manufacturing Organizations.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the six months ended June 30, 2022 was &#8364;44.7 million as compared to net cash used in investing activities of &#8364;73.7 million for the six months ended June 30, 2021. The change in cash flows from investing activities was primarily attributable to decreased purchases of property, plant and equipment for manufacturing facilities and intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used by financing activities was &#8364;3.4 million for the six months ended June 30, 2022 as compared to cash provided by financing activities of &#8364;378.8 million for the six months ended June 30, 2021. The decrease in cash flow provided by financing activities was mainly attributable to the raising of cash in the follow-on public offering, which closed in February&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for those noncancellable contractual obligations from certain of our arrangements with contract manufacturing organizations disclosed in &#8220;Liquidity and Capital Resources&#8221; and &#8220;Contractual Obligations and Commitments.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Safe Harbor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or the IFRS, as issued by the International Accounting Standards Board, or IASB. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders&#8217; equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies that we believe to be critical to the judgments and estimates used in the preparation of our financial statements are included in &#8220;note 3&#8201;&#8212; Basis of preparation&#8221; to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have applied, in our audited consolidated financial statements for the&#160;year ended December&#160;31, 2021, new standards and amendments as issued by IASB and that are mandatory as of January&#160;1, 2021. See note 2 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have applied, in our unaudited interim condensed consolidated financial statements for the six months ended June 30, 2022, new standards and amendments as issued by IASB and as issued by IASB and that are mandatory as of January&#160;1, 2021. See note 2 to our unaudited interim condensed consolidated financial statements included elsewhere in this Report of Foreign Private Issuer on Form&#160;6-K for further information on these new standards and amendments.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cvac-20220630xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20220630xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 2(# 2(  A$! Q$!_\0
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M2?VMT..?[0M>/^V451FN+J8.-)T_M347Z,UR3 T<?.LJVT(2DM;:JUCZ]!R
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MA0O&-91NGJU=V.9U#]KCPK;7;Q6NGZI>Q*<":.) K?0,X/YBJ_\ PV#X=_Z
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M:%IZ1K:Q8'V9#_ .22,D^YK;_P"$*T ?\P33\_\ 7JG^%=+J8&+:]D_O_P"
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M7;R:+XKNM.B?JKP[FQV&Y67^5,_X96UO'_(^W/\ X#O_ /':XL-AJU"E&E/
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cvac-20220630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/18/2022 7:20:55 PM-->
<!--Modified on: 8/18/2022 7:20:55 PM-->
<xsd:schema targetNamespace="http://www.curevac.com/20220630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cvac="http://www.curevac.com/20220630" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss">
        <link:definition>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" id="StatementInterimCondensedConsolidatedStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" id="StatementInterimCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails">
        <link:definition>40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" id="DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails">
        <link:definition>40310 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" id="DisclosureShareBasedPaymentsExpensesDetails">
        <link:definition>40501 - Disclosure - Share-based payments - Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" id="DisclosureShareBasedPaymentsTables">
        <link:definition>30503 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" id="DisclosureCorporateInformationDetails">
        <link:definition>40101 - Disclosure - Corporate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" id="DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails">
        <link:definition>40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" id="DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails">
        <link:definition>40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" id="DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails">
        <link:definition>40304 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails">
        <link:definition>40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails">
        <link:definition>40308 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails">
        <link:definition>40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails">
        <link:definition>40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" id="DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails">
        <link:definition>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" id="DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails">
        <link:definition>40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" id="DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails">
        <link:definition>40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" id="DisclosureShareBasedPaymentsDetails">
        <link:definition>40503 - Disclosure - Share-based payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" id="DisclosureFixedAssetsIntangibleAssetsDetails">
        <link:definition>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" id="DisclosureFixedAssetsPropertyPlantAndEquipmentDetails">
        <link:definition>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" id="DisclosureAssetsHeldForSaleDetails">
        <link:definition>40701 - Disclosure - Assets held for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40801 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" id="DisclosureOtherLiabilitiesDetails">
        <link:definition>41201 - Disclosure - Other liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureLoansDetails" id="DisclosureLoansDetails">
        <link:definition>41301 - Disclosure - Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" id="DisclosureIncomeTaxDetails">
        <link:definition>41401 - Disclosure - Income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails">
        <link:definition>41501 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" id="DisclosureRelatedPartyDisclosuresDetails">
        <link:definition>41701 - Disclosure - Related party disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41801 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" id="DisclosureCorporateInformation">
        <link:definition>10101 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" id="DisclosureBasisOfPreparation">
        <link:definition>10201 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" id="DisclosureNotesToConsolidatedFinancialStatements">
        <link:definition>10301 - Disclosure - Notes to the consolidated financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" id="DisclosureIssuedCapitalAndReserves">
        <link:definition>10401 - Disclosure - Issued Capital and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" id="DisclosureShareBasedPayments">
        <link:definition>10501 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>10601 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" id="DisclosureAssetsHeldForSale">
        <link:definition>10701 - Disclosure - Assets held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10801 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" id="DisclosurePrepaidExpensesAndOtherAssetsCurrent">
        <link:definition>10901 - Disclosure - Prepaid expenses and other assets (current)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" id="DisclosureFinancialAssetsAndFinancialLiabilities">
        <link:definition>11001 - Disclosure - Financial assets and financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" id="DisclosureTradeAndOtherPayables">
        <link:definition>11101 - Disclosure - Trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilities" id="DisclosureOtherLiabilities">
        <link:definition>11121 - Disclosure - Other liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureLoans" id="DisclosureLoans">
        <link:definition>11301 - Disclosure - Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTax" id="DisclosureIncomeTax">
        <link:definition>11401 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement">
        <link:definition>11501 - Disclosure - Disclosure of financial instruments and risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" id="DisclosureEarningsPerShare">
        <link:definition>11601 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" id="DisclosureRelatedPartyDisclosures">
        <link:definition>11701 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11801 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" id="DisclosureBasisOfPreparationPolicies">
        <link:definition>20202 - Disclosure - Basis of preparation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" id="DisclosureNotesToConsolidatedFinancialStatementsTables">
        <link:definition>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" id="DisclosureIssuedCapitalAndReservesTables">
        <link:definition>30403 - Disclosure - Issued Capital and Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" id="DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails">
        <link:definition>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" id="DisclosureFinancialAssetsAndFinancialLiabilitiesDetails">
        <link:definition>41001 - Disclosure - Financial assets and financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" id="DisclosureTradeAndOtherPayablesDetails">
        <link:definition>41101 - Disclosure - Trade and other payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" id="DisclosureEarningsPerShareDetails">
        <link:definition>41601 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220630_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd" />
  <xsd:element name="CorporateInformationAbstract" id="cvac_CorporateInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateInformationTextBlock" id="cvac_CorporateInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurevacN.v.Member" id="cvac_CurevacN.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateReorganizationStockSplitRatio" id="cvac_CorporateReorganizationStockSplitRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangesInWorkingCapitalAbstract" id="cvac_ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" id="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsProductMember" id="cvac_IfrsProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EliLillyAndCompanyMember" id="cvac_EliLillyAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoehringerIngelheimMember" id="cvac_BoehringerIngelheimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherCustomersMember" id="cvac_OtherCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CrisprMember" id="cvac_CrisprMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchServicesCombinedWithIpLicenseMember" id="cvac_ResearchServicesCombinedWithIpLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentServicesMember" id="cvac_ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GenmabMember" id="cvac_GenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentsReceivedOrReceivable" id="cvac_UpfrontPaymentsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentsIncludedInContractLiabilities" id="cvac_UpfrontPaymentsIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" id="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" id="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpensesByNatureTable" id="cvac_DisclosureOfExpensesByNatureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationAxis" id="cvac_IfrsIncomeStatementLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationDomain" id="cvac_IfrsIncomeStatementLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCostOfSalesMember" id="cvac_IfrsCostOfSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpensesByNatureLineItems" id="cvac_DisclosureOfExpensesByNatureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PersonnelExpenses" id="cvac_PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ThirdPartyServiceExpenses" id="cvac_ThirdPartyServiceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaintenanceAndLeaseExpenses" id="cvac_MaintenanceAndLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SellingAndDistributionExpensesMember" id="cvac_SellingAndDistributionExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="cvac_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentsAndFeesToRegisterLegalRight" id="cvac_PatentsAndFeesToRegisterLegalRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReversalOfProvisionsForPersonnelExpenses" id="cvac_ReversalOfProvisionsForPersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsGeneralAndAdministrativeExpenseMember" id="cvac_IfrsGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MiscellaneousOtherOperatingIncomeOther" id="cvac_MiscellaneousOtherOperatingIncomeOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsTable" id="cvac_DisclosureOfGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsAxis" id="cvac_GovernmentGrantsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsDomain" id="cvac_GovernmentGrantsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CoalitionForEpidemicPreparednessInnovationsMember" id="cvac_CoalitionForEpidemicPreparednessInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillAndMelindaGatesFoundationBmgfMember" id="cvac_BillAndMelindaGatesFoundationBmgfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsLineItems" id="cvac_DisclosureOfGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementMaximumAmount" id="cvac_PartnershipAgreementMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PartnershipAgreementTerm" id="cvac_PartnershipAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementPeriodOfCostsToBeCovered" id="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountDeductedFromCarryingAmountOfQualifyingAssets" id="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfAdditionalGrantsReceived" id="cvac_NumberOfAdditionalGrantsReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsAbstract" id="cvac_DisclosureOfFixedAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsExplanatory" id="cvac_DisclosureOfFixedAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesSharesMember" id="cvac_SeriesSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCSharesMember" id="cvac_SeriesCSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIMember" id="cvac_VirtualSharesProgramIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIiMember" id="cvac_VirtualSharesProgramIiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToThenChiefExecutiveOfficerMember" id="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingAxis" id="cvac_IfrsVestingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingDomain" id="cvac_IfrsVestingDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheOneMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="BenefitExpenseRecognizedForShareBasedPayment" id="cvac_BenefitExpenseRecognizedForShareBasedPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseRecognizedForEmployeeServices" id="cvac_ExpenseRecognizedForEmployeeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RittershausRechtsanwaelteMember" id="cvac_RittershausRechtsanwaelteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Dr.IngmarHoerrMember" id="cvac_Dr.IngmarHoerrMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DietmarHoppMember" id="cvac_DietmarHoppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" id="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionConsultingFees" id="cvac_RelatedPartyTransactionConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionAdvisoryFees" id="cvac_RelatedPartyTransactionAdvisoryFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNumberOfLoansReceived" id="cvac_RelatedPartyTransactionNumberOfLoansReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManagementBoardMember" id="cvac_ManagementBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseFeePayable" id="cvac_LicenseFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PayrollRelatedWithholdingTaxes" id="cvac_PayrollRelatedWithholdingTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="OtherOperatingIncomeGovernmentGrants" id="cvac_OtherOperatingIncomeGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialInstrumentsAndRiskManagementAbstract" id="cvac_FinancialInstrumentsAndRiskManagementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AllowanceAccountForExpectedCreditLossesOfFinancialAssets" id="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsCashAndCashEquivalentsMember" id="cvac_IfrsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherPayablesMember" id="cvac_TradeAndOtherPayablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherExpense" id="cvac_OtherExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" id="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherLiabilitiesAbstract" id="cvac_IfrsOtherLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" id="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" id="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GlaxosmithklineMember" id="cvac_GlaxosmithklineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanFederalMinistryOfEducationAndResearchMember" id="cvac_GermanFederalMinistryOfEducationAndResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EuropeanCommissionMember" id="cvac_EuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" id="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" id="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AmountEligibleToReceiveAsCommercialMilestonePayments" id="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" id="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfAdditionalDosesPurchaseOption" id="cvac_NumberOfAdditionalDosesPurchaseOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfMilestonePayments" id="cvac_NumberOfMilestonePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentGrantReceivable" id="cvac_CurrentGrantReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RealEstateTransferTaxes" id="cvac_RealEstateTransferTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaximumGrantToBeReceived" id="cvac_MaximumGrantToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsStockholdersEquityNoteStockSplitConversionRatio" id="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockAxis" id="cvac_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="cvac_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalIncreaseByGenmabMember" id="cvac_CapitalIncreaseByGenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrivatePlacementIsa2020Member" id="cvac_PrivatePlacementIsa2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfGreenshoeMember" id="cvac_ExerciseOfGreenshoeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfOptionsMember" id="cvac_ExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInNumberOfSharesOutstanding" id="cvac_IncreaseInNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsOverAllotmentOptionMember" id="cvac_IfrsOverAllotmentOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BepharbelManufacturingS.aMember" id="cvac_BepharbelManufacturingS.aMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaronJeanStephenneMember" id="cvac_BaronJeanStephenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VincentStphenneMember" id="cvac_VincentStphenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountPaidAtSigningOfAgreementRelatedPartyTransactions" id="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TerminationFeeRelatedPartyTransactions" id="cvac_TerminationFeeRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RepaymentsOfPrincipalAmountOfBorrowings" id="cvac_RepaymentsOfPrincipalAmountOfBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsLineOfCreditMember" id="cvac_IfrsLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsLineOfCreditFacilityMaximumBorrowingCapacity" id="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" id="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BorrowingsInEachTranche" id="cvac_BorrowingsInEachTranche" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsLossContingencyLossInPeriod" id="cvac_IfrsLossContingencyLossInPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMilestonePayment" id="cvac_CollaborationAgreementMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RightToExercisePercentageOfVestedVirtualShares" id="cvac_RightToExercisePercentageOfVestedVirtualShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionForEmployerTaxes" id="cvac_ProvisionForEmployerTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LockUpPeriodAfterInitialListing" id="cvac_LockUpPeriodAfterInitialListing" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermIncentivePlanMember" id="cvac_LongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefScientificOfficerMember" id="cvac_ChiefScientificOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefBusinessOfficerAndChiefCommercialOfficerMember" id="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThenChiefExecutiveOfficerMember" id="cvac_ThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShareOptionsVestedInShareBasedPaymentArrangement" id="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SoftwareMember" id="cvac_SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialPublicOfferingAndPrivatePlacementMember" id="cvac_InitialPublicOfferingAndPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonSharesIssuedAndOutstanding" id="cvac_CommonSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareOptionExercises" id="cvac_ShareOptionExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MinimumBorrowingsInEachTranche" id="cvac_MinimumBorrowingsInEachTranche" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfYearsDueForEachTrancheFromDisbursementDate" id="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" id="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumAggregateRemunerationCapitalAmount" id="cvac_MaximumAggregateRemunerationCapitalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" id="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaxmimumBorrowingsInterestRate" id="cvac_MaxmimumBorrowingsInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MinimumBorrowingsInterestRate" id="cvac_MinimumBorrowingsInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LineOfCreditAccruedInterestPayable" id="cvac_LineOfCreditAccruedInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DisclosureOfBasisOfPreparationAbstract" id="cvac_DisclosureOfBasisOfPreparationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EuropeanUnionAdvancePurchaseAgreementMember" id="cvac_EuropeanUnionAdvancePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cvac_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentExpenseIncl.DeferredTaxes" id="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangeInTradeAndOtherPayables" id="cvac_ChangeInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TechnicalEquipmentAndMachinesAndOtherEquipmentMember" id="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManufacturingFacilitiesMember" id="cvac_ManufacturingFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensesSoftwareAndPrepaymentsMember" id="cvac_LicensesSoftwareAndPrepaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CmoNetworkMember" id="cvac_CmoNetworkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountOfLiabilityCashClaimAwards" id="cvac_AmountOfLiabilityCashClaimAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentReceived" id="cvac_UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OptionFeePayment" id="cvac_OptionFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalDevelopmentMilestonePaymentsReceived" id="cvac_AdditionalDevelopmentMilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Gsk2ndGenMember" id="cvac_Gsk2ndGenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountOfRestrictedStockUnitsReceived" id="cvac_AmountOfRestrictedStockUnitsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ComprehensiveIncomeLoss" id="cvac_ComprehensiveIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NetLoss" id="cvac_NetLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Diluteeffectofordinarysharesissued" id="cvac_Diluteeffectofordinarysharesissued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MolecularhealthgmbhMember" id="cvac_MolecularhealthgmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdvancepaymentsintangibleassetMember" id="cvac_AdvancepaymentsintangibleassetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherReceivablesMember" id="cvac_TradeAndOtherReceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherPayablesOneMember" id="cvac_TradeAndOtherPayablesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MonetaryLiabilitiesInForeignCurrencyMember" id="cvac_MonetaryLiabilitiesInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MonetaryAssetsInForeignCurrencyMember" id="cvac_MonetaryAssetsInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherPayablesTwoMember" id="cvac_TradeAndOtherPayablesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherReceivablesTwoMember" id="cvac_OtherReceivablesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherReceivablesOneMember" id="cvac_OtherReceivablesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Commonsharesissuedandoutstanding" id="cvac_Commonsharesissuedandoutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="OtherreceivablesMember" id="cvac_OtherreceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" id="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ChangeInExpenseByNature" id="cvac_ChangeInExpenseByNature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ChiefDevelepmentOfficerMember" id="cvac_ChiefDevelepmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClarentisSrlMember" id="cvac_ClarentisSrlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ImpairmentsOfInventoryAndPrepayments" id="cvac_ImpairmentsOfInventoryAndPrepayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="BmbfMember" id="cvac_BmbfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCurrentGrantReceivables" id="cvac_IfrsCurrentGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" id="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PlanNameAxis" id="cvac_PlanNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PlanNameDomain" id="cvac_PlanNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" id="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsContractualObligation" id="cvac_IfrsContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractResearchOrganizationAgreementMember" id="cvac_ContractResearchOrganizationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesTable" id="cvac_DisclosureOfOtherLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesLineItems" id="cvac_DisclosureOfOtherLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractManufacturingOrganizationAgreementMember" id="cvac_ContractManufacturingOrganizationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsMember" id="cvac_RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MembersOfExecutiveBoardAndVariousKeyEmployeesMember" id="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TypeOfArrangementAxis" id="cvac_TypeOfArrangementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementsAndNonArrangementTransactionsMember" id="cvac_ArrangementsAndNonArrangementTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" id="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GlaxosmithklineCovidAgreementMember" id="cvac_GlaxosmithklineCovidAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAndLicenseAgreementMember" id="cvac_CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CrisprTherapeuticsMember" id="cvac_CrisprTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EliLillyMember" id="cvac_EliLillyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsOptionFeePaymentIncludedInContractLiabilities" id="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" id="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsDecreaseThroughGovernmentalContractLiabilities" id="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" id="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdvancedPurchaseAgreementWithEuropeanCommissionMember" id="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsMilestonePaymentReceived" id="cvac_IfrsMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRemainingGrantIncome" id="cvac_IfrsRemainingGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BundesministeriumFurBildungUndForschungMember" id="cvac_BundesministeriumFurBildungUndForschungMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrossCarryingAmountOfAcquisitionCostMember" id="cvac_GrossCarryingAmountOfAcquisitionCostMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CumulativeAmortizationAndImpairmentMember" id="cvac_CumulativeAmortizationAndImpairmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" id="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GskAgreement2020Member" id="cvac_GskAgreement2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DecreaseInNumberOfSharesDueToTreasuryOfShares" id="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CompanyOwnedGmpIvFacilityMember" id="cvac_CompanyOwnedGmpIvFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentPhysicallyLocatedAtCmoFacilitiesMember" id="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidCompensationForContractManufacturingOrganizationsTransfer" id="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ChangeInOtherLiabilities" id="cvac_ChangeInOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRestrictedStockUnitMember" id="cvac_IfrsRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfKeyEmployees" id="cvac_NumberOfKeyEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MilestoneRevenuesMember" id="cvac_MilestoneRevenuesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransfer" id="cvac_CompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReversalOfProvisionForOnerousContracts" id="cvac_ReversalOfProvisionForOnerousContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" id="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" id="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsOnExerciseOfOptions" id="cvac_ProceedsOnExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SettlementOfShareBasedPaymentAwardsAmount" id="cvac_SettlementOfShareBasedPaymentAwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsForNonCashIncomeFromReleaseOfProvisions" id="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" id="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" id="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" id="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" id="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" id="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CostOfReimbursementClaim" id="cvac_CostOfReimbursementClaim" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SaleOfEquipment" id="cvac_SaleOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AntonyBlancMember" id="cvac_AntonyBlancMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentsToRelatedPartyForServices" id="cvac_PaymentsToRelatedPartyForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncomeTaxDisclosureTable" id="cvac_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="cvac_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacCorporateServiceGmbhMember" id="cvac_CurevacCorporateServiceGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacSwissAgMember" id="cvac_CurevacSwissAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WriteOffOfRawMaterials" id="cvac_WriteOffOfRawMaterials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoriesTable" id="cvac_InventoriesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesLineItem" id="cvac_InventoriesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInInventory" id="cvac_IncreaseDecreaseInInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetValueOfInventoryTransferred" id="cvac_NetValueOfInventoryTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingProgramMember" id="cvac_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateGrossProceedsReceivableFromIssuingShares" id="cvac_AggregateGrossProceedsReceivableFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodForExercises" id="cvac_StockIssuedDuringPeriodForExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RestrictedStockUnitForKeyEmployeesMember" id="cvac_RestrictedStockUnitForKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="KeyEmployeesMember" id="cvac_KeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExecutiveBoardMembersMember" id="cvac_ExecutiveBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SupervisoryBoardMembersMember" id="cvac_SupervisoryBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" id="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" id="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" id="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" id="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationSharePriceAsOfClosingDate" id="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" id="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" id="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" id="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContingentLiabilityArisingFromPatentInfringementLawsuitMember" id="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" id="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LossContingencyPatentsAllegedlyInfringedNumber" id="cvac_LossContingencyPatentsAllegedlyInfringedNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LossContingencyPatentsFoundNotInfringedNumber" id="cvac_LossContingencyPatentsFoundNotInfringedNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetsHeldForSaleAxis" id="cvac_AssetsHeldForSaleAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleDomain" id="cvac_AssetsHeldForSaleDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedFromIssuingOtherEquityInstrument" id="cvac_ProceedFromIssuingOtherEquityInstrument" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonesMember" id="cvac_MilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsStockIssuedDuringPeriodValueNewIssues" id="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" id="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvac-20220630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/18/2022 7:20:55 PM-->
<!--Modified on: 8/18/2022 7:20:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637964472513283393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637964472513283393" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637964472513283393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_637964472513283393" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637964472513283393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637964472513283393" xlink:to="ifrs-full_ProfitLossBeforeTax_637964472513283393" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637964472513283393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637964472513283393" xlink:to="ifrs-full_FinanceIncome_637964472513283393" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637964472513283393" xlink:to="ifrs-full_FinanceCosts_637964472513293391" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637964472513283393" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637964472513293391" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_CostOfSales_637964472513293391" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_SalesAndMarketingExpense_637964472513293391" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637964472513293391" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637964472513293391" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_637964472513293391" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637964472513293391" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_637964472513293391" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472513293391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637964472513283393" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472513293391" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_637964472513303374" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637964472513303374" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637964472513303374" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637964472513303374" xlink:to="ifrs-full_PropertyPlantAndEquipment_637964472513303374" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637964472513303374" xlink:to="ifrs-full_OtherNoncurrentAssets_637964472513303374" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637964472513303374" xlink:to="ifrs-full_NetDeferredTaxAssets_637964472513303374" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637964472513303374" xlink:to="ifrs-full_RightofuseAssets_637964472513303374" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_637964472513303374" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637964472513303374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_Inventories_637964472513303374" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_CurrentTradeReceivables_637964472513313381" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_CurrentContractAssets_637964472513313381" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472513313381" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_OtherCurrentFinancialAssets_637964472513313381" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_CashAndCashEquivalents_637964472513313381" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637964472513303374" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_637964472513313381" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637964472513313381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_637964472513313381" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637964472513313381" xlink:to="ifrs-full_IssuedCapital_637964472513323378" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637964472513313381" xlink:to="ifrs-full_TreasuryShares_637964472513323378" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637964472513313381" xlink:to="ifrs-full_CapitalReserve_637964472513323378" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637964472513313381" xlink:to="ifrs-full_RetainedEarnings_637964472513323378" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637964472513313381" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_637964472513323378" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_637964472513323378" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637964472513323378" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637964472513323378" xlink:to="ifrs-full_NoncurrentLiabilities_637964472513323378" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637964472513323378" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637964472513333371" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637964472513323378" xlink:to="ifrs-full_NoncurrentContractLiabilities_637964472513333371" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637964472513323378" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_637964472513333371" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637964472513323378" xlink:to="ifrs-full_OtherNoncurrentLiabilities_637964472513333371" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637964472513323378" xlink:to="ifrs-full_CurrentLiabilities_637964472513333371" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_637964472513333371" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637964472513333371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_CurrentLeaseLiabilities_637964472513333371" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_637964472513343546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_637964472513343546" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_637964472513343546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_OtherCurrentLiabilities_637964472513343546" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_637964472513343546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_CurrentTaxLiabilities_637964472513343546" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_637964472513343546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637964472513333371" xlink:to="ifrs-full_CurrentContractLiabilities_637964472513343546" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_ProfitLossBeforeTax_637964472513353381" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_637964472513353381" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_637964472513353381" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_637964472513353381" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472513353381" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_637964472513353381" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637964472513353381" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637964472513353381" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637964472513353381" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637964472513363377" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_637964472513363377" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637964472513363377" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637964472513363377" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_637964472513363377" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472513363377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472513363377" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637964472513373391" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_637964472513373391" order="16" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637964472513373391" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637964472513373391" order="18" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_637964472513373391" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_637964472513373391" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472513353381" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_637964472513373391" order="20" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472513383377" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472513383377" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637964472513383377" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472513383377" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637964472513383377" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472513383377" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_637964472513383377" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637964472513383377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637964472513383377" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_637964472513393395" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_637964472513393395" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472513393395" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="ifrs-full_ProceedsFromIssuingShares_637964472513393395" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="cvac_ProceedsOnExerciseOfOptions_637964472513393395" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_637964472513393395" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_637964472513393395" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_637964472513403372" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472513383377" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_637964472513403372" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ExpenseByNature" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_PersonnelExpenses_637964472513403372" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_637964472513403372" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_ThirdPartyServiceExpenses_637964472513403372" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_MaintenanceAndLeaseExpenses_637964472513403372" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_637964472513403372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_637964472513403372" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_OtherExpense_637964472513413385" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_637964472513413385" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_ProfessionalFeesExpense_637964472513413385" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="MiscellaneousOtherOperatingIncome" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_SaleOfEquipment_637964472513413385" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CostOfReimbursementClaim_637964472513413385" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_637964472513413385" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_637964472513413385" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_637964472513413385" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_637964472513413385" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_637964472513423383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_637964472513423383" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="BenefitExpenseRecognizedForShareBasedPayment" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472513423383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472513423383" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_637964472513423383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_637964472513423383" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_637964472513423383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_637964472513423383" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cvac-20220630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/18/2022 7:20:55 PM-->
<!--Modified on: 8/18/2022 7:20:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureAssetsHeldForSaleDetails" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureOtherLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureLoansDetails" roleURI="http://www.curevac.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:title="RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="RestatedMember" xlink:title="RestatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="RestatedMember" xlink:title="definition: RetrospectiveApplicationAndRetrospectiveRestatementAxis to RestatedMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="IfrsSaleOfStockAxis" xlink:title="IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="IfrsSaleOfStockDomain" xlink:title="IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsSaleOfStockAxis" xlink:to="IfrsSaleOfStockDomain" xlink:title="definition: IfrsSaleOfStockAxis to IfrsSaleOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingAxis" xlink:label="IfrsVestingAxis" xlink:title="IfrsVestingAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingDomain" xlink:label="IfrsVestingDomain" xlink:title="IfrsVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsVestingAxis" xlink:to="IfrsVestingDomain" xlink:title="definition: IfrsVestingAxis to IfrsVestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="BusinessCombinationsAxis" xlink:title="BusinessCombinationsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="EntitysTotalForBusinessCombinationsMember" xlink:title="EntitysTotalForBusinessCombinationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessCombinationsAxis" xlink:to="EntitysTotalForBusinessCombinationsMember" xlink:title="definition: BusinessCombinationsAxis to EntitysTotalForBusinessCombinationsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="TimingOfTransferOfGoodsOrServicesAxis" xlink:title="TimingOfTransferOfGoodsOrServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="TimingOfTransferOfGoodsOrServicesMember" xlink:title="TimingOfTransferOfGoodsOrServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TimingOfTransferOfGoodsOrServicesAxis" xlink:to="TimingOfTransferOfGoodsOrServicesMember" xlink:title="definition: TimingOfTransferOfGoodsOrServicesAxis to TimingOfTransferOfGoodsOrServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="InitiallyAppliedIFRSsAxis" xlink:title="InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="InitiallyAppliedIFRSsMember" xlink:title="InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InitiallyAppliedIFRSsAxis" xlink:to="InitiallyAppliedIFRSsMember" xlink:title="definition: InitiallyAppliedIFRSsAxis to InitiallyAppliedIFRSsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ConcentrationsOfRiskAxis" xlink:title="ConcentrationsOfRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ConcentrationsOfRiskMember" xlink:title="ConcentrationsOfRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationsOfRiskAxis" xlink:to="ConcentrationsOfRiskMember" xlink:title="definition: ConcentrationsOfRiskAxis to ConcentrationsOfRiskMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="IntangibleAssetsOtherThanGoodwillMember" xlink:title="IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IntangibleAssetsOtherThanGoodwillMember" xlink:title="definition: ClassesOfIntangibleAssetsOtherThanGoodwillAxis to IntangibleAssetsOtherThanGoodwillMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="GeographicalAreasAxis" xlink:title="GeographicalAreasAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="GeographicalAreasMember" xlink:title="GeographicalAreasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GeographicalAreasAxis" xlink:to="GeographicalAreasMember" xlink:title="definition: GeographicalAreasAxis to GeographicalAreasMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="MajorCustomersMember" xlink:title="MajorCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="MajorCustomersMember" xlink:title="definition: MajorCustomersAxis to MajorCustomersMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="GovernmentGrantsAxis" xlink:title="GovernmentGrantsAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="GovernmentGrantsDomain" xlink:title="GovernmentGrantsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GovernmentGrantsAxis" xlink:to="GovernmentGrantsDomain" xlink:title="definition: GovernmentGrantsAxis to GovernmentGrantsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="IfrsIncomeStatementLocationAxis" xlink:title="IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="IfrsIncomeStatementLocationDomain" xlink:title="IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsIncomeStatementLocationAxis" xlink:to="IfrsIncomeStatementLocationDomain" xlink:title="definition: IfrsIncomeStatementLocationAxis to IfrsIncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ClassesOfFinancialInstrumentsAxis" xlink:title="ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ClassesOfFinancialInstrumentsMember" xlink:title="ClassesOfFinancialInstrumentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialInstrumentsAxis" xlink:to="ClassesOfFinancialInstrumentsMember" xlink:title="definition: ClassesOfFinancialInstrumentsAxis to ClassesOfFinancialInstrumentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="LevelsOfFairValueHierarchyAxis" xlink:title="LevelsOfFairValueHierarchyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="AllLevelsOfFairValueHierarchyMember" xlink:title="AllLevelsOfFairValueHierarchyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LevelsOfFairValueHierarchyAxis" xlink:to="AllLevelsOfFairValueHierarchyMember" xlink:title="definition: LevelsOfFairValueHierarchyAxis to AllLevelsOfFairValueHierarchyMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:title="LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="definition: LiabilitiesArisingFromFinancingActivitiesAxis to LiabilitiesArisingFromFinancingActivitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis_1" xlink:title="cvac_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain_1" xlink:title="cvac_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_PlanNameAxis_1" xlink:to="cvac_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_PlanNameAxis_1 To cvac_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_1" xlink:title="ifrs-full_TypesOfContractsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_1" xlink:title="ifrs-full_TypesOfContractsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfContractsAxis_1" xlink:to="ifrs-full_TypesOfContractsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfContractsAxis_1 To ifrs-full_TypesOfContractsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_1" xlink:title="cvac_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_1" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_TypeOfArrangementAxis_1" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_TypeOfArrangementAxis_1 To cvac_ArrangementsAndNonArrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1 To cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:title="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" xlink:title="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:to="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1 To ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_1" xlink:title="ifrs-full_ContingentLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:to="ifrs-full_ContingentLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfContingentLiabilitiesAxis_1 To ifrs-full_ContingentLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AssetsHeldForSaleAxis" xlink:label="cvac_AssetsHeldForSaleAxis_1" xlink:title="cvac_AssetsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AssetsHeldForSaleDomain" xlink:label="cvac_AssetsHeldForSaleDomain_1" xlink:title="cvac_AssetsHeldForSaleDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_AssetsHeldForSaleAxis_1" xlink:to="cvac_AssetsHeldForSaleDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_AssetsHeldForSaleAxis_1 To cvac_AssetsHeldForSaleDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="45" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_InAccordanceWithIFRS9Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_NetLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ComprehensiveIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_CurevacN.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CorporateReorganizationStockSplitRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_OtherCustomersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_IfrsProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_MilestoneRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GskAgreement2020Member" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="cvac_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_GlaxosmithklineCovidAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_OptionFeePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalDosesPurchaseOption" xlink:label="cvac_NumberOfAdditionalDosesPurchaseOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfAdditionalDosesPurchaseOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfMilestonePayments" xlink:label="cvac_NumberOfMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_NumberOfMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_Gsk2ndGenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BmbfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_CurrentTradeReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_CurrentContractAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsCostOfSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_DisclosureOfExpensesByNatureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_ChangeInExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_WriteOffOfRawMaterials" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_SellingAndDistributionExpensesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_DisclosureOfExpensesByNatureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_DisclosureOfExpensesByNatureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_ReversalOfProvisionForOnerousContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_DisclosureOfExpensesByNatureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_TravelExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="ifrs-full_InsuranceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_RealEstateTransferTaxes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GskAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumGrantToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_UpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsRemainingGrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_GovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementMaximumAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfAdditionalGrantsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsOverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_CapitalIncreaseByGenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PrivatePlacementIsa2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfGreenshoeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_AtMarketOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesCSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_CommonSharesIssuedAndOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_ShareOptionExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuedDuringPeriodForExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_IfrsRestrictedStockUnitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseRecognizedForEmployeeServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefScientificOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefDevelepmentOfficerMember" xlink:label="cvac_ChiefDevelepmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefDevelepmentOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ManagementBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ExecutiveBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_SupervisoryBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsVestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_LockUpPeriodAfterInitialListing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfKeyEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfLiabilityCashClaimAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_SoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_LicencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancepaymentsintangibleassetMember" xlink:label="cvac_AdvancepaymentsintangibleassetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_AdvancepaymentsintangibleassetMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_BuildingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CmoNetworkMember" xlink:label="cvac_CmoNetworkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_CmoNetworkMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManufacturingFacilitiesMember" xlink:label="cvac_ManufacturingFacilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_ManufacturingFacilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Assets held for sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:to="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:to="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_InventoriesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_IncreaseDecreaseInInventory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_NetValueOfInventoryTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_InventoryWritedown2011" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="ifrs-full_TypesOfContractsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="cvac_ContractResearchOrganizationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_ChangeInOtherLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="cvac_IfrsLineOfCreditMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInEachTranche" xlink:label="cvac_MinimumBorrowingsInEachTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_MinimumBorrowingsInEachTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsInEachTranche" xlink:label="cvac_BorrowingsInEachTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_BorrowingsInEachTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaxmimumBorrowingsInterestRate" xlink:label="cvac_MaxmimumBorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_MaxmimumBorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInterestRate" xlink:label="cvac_MinimumBorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_MinimumBorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumAggregateRemunerationCapitalAmount" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_MaximumAggregateRemunerationCapitalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLossContingencyLossInPeriod" xlink:label="cvac_IfrsLossContingencyLossInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_IfrsLossContingencyLossInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_LineOfCreditAccruedInterestPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_IncomeTaxDisclosureTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="cvac_CurevacCorporateServiceGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="cvac_CurevacSwissAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_IncomeTaxDisclosureTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceMember" xlink:label="ifrs-full_TemporaryDifferenceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="cvac_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_CurrentTaxExpenseIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherReceivablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesOneMember" xlink:label="cvac_OtherReceivablesOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_OtherReceivablesOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesTwoMember" xlink:label="cvac_OtherReceivablesTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_OtherReceivablesTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherreceivablesMember" xlink:label="cvac_OtherreceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_OtherreceivablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_BaronJeanStephenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_VincentStphenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_AntonyBlancMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_RittershausRechtsanwaelteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_Dr.IngmarHoerrMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DietmarHoppMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BepharbelManufacturingS.aMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MolecularhealthgmbhMember" xlink:label="cvac_MolecularhealthgmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_MolecularhealthgmbhMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ClarentisSrlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_TerminationFeeRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_CollaborationAgreementMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_PaymentsToRelatedPartyForServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_MilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_LiabilitiesIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cvac-20220630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/18/2022 7:20:55 PM-->
<!--Modified on: 8/18/2022 7:20:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit/ (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Financial Position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AssetsAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NoncurrentAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IntangibleAssetsOtherThanGoodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RightofuseAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CurrentAssetsAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets or disposal groups classified as held for sale or as held for distribution to owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EquityAndLiabilitiesAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NoncurrentLiabilitiesAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 9</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously stated</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetLoss" xlink:to="cvac_NetLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ComprehensiveIncomeLoss" xlink:to="cvac_ComprehensiveIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income (loss) in equity resulting from transactions and other events, other than those income (loss) resulting from transactions with owners in their capacity as owners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments (net of taxes)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through conversion of convertible instruments, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity component of convertible loans (net of tax)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease (increase) through tax on share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred taxes on convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on exercise of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based payment awards settled in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Of Share Based Payment Awards , Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of share capital (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through treasury share transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile loss before tax to net cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and impairment of property, plant and equipment and right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment to property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for gain (loss) on disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentsOfInventoryAndPrepayments" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of inventory and prepayments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Non Cash Income From Release Of Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash income from release of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangesInWorkingCapitalAbstract" xlink:to="cvac_ChangesInWorkingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Working Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital changes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in trade receivables and contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in prepaid expenses, and assets classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from government grants and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from Government Grants Classified as Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from grants from government agencies and similar bodies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant amount received/eligible to receive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Increase Decrease In Other Current Financial And Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in other current financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in deferred taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of other long-term assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing other equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedFromIssuingOtherEquityInstrument" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Proceed From Issuing Other Equity Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceed From Issuing Other Equity Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on / Proceeds from Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from at the market shares issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on At-the-market offering program (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsOnExerciseOfOptions" xlink:to="cvac_ProceedsOnExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds On Exercise Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of shares (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from borrowings obtained. [Refer: Borrowings]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (repayment of) the EIB loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in)provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation gains (losses) on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateInformationAbstract" xlink:label="cvac_CorporateInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationAbstract" xlink:to="cvac_CorporateInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationTextBlock" xlink:to="cvac_CorporateInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on corporate information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Basis of Preparation Explanatory [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of notes and other explanatory information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="cvac_DisclosureOfFixedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsExplanatory" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for fixed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Fixed Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-current assets held for sale and discontinued operations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_IfrsOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New standards, interpretations and amendments adopted by the Group</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Pre-launch products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Pre-Launch Products, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-launch products</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Covid-19 impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Covid-19 Impact, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of COVID-19 and the Russia-Ukraine Conflict</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue from contract with customers recognized</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about upfront payments and related revenues recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of upfront payments and related revenues recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of significant changes in contract assets and contract liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract balances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expenses by nature [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of number of shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIMember" xlink:to="cvac_VirtualSharesProgramIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program I.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIiMember" xlink:to="cvac_VirtualSharesProgramIiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program II (New VSOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Executive Officer Grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitsMember" xlink:to="cvac_RestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Restricted stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of outstanding awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inputs used in the measurement of the fair value at grant date</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expense recognized for employee services explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Expense Recognized For Employee Services Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expense recognized for employee services received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of expense recognized for the programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expense Recognized for the Programs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule for expense recognized for the programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacN.v.Member" xlink:to="cvac_CurevacN.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacN.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for CureVac N.V. , a former holding company to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacN.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac N.V.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Entities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Entities [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Vac B.V.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of voting equity interests acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting interests held</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateReorganizationStockSplitRatio" xlink:to="cvac_CorporateReorganizationStockSplitRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Reorganization, Stock Split Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customers [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineMember" xlink:to="cvac_GlaxosmithklineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GlaxoSmithKline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BoehringerIngelheimMember" xlink:to="cvac_BoehringerIngelheimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Boehringer Ingelheim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCustomersMember" xlink:to="cvac_OtherCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Other customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GenmabMember" xlink:to="cvac_GenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprMember" xlink:to="cvac_CrisprMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyAndCompanyMember" xlink:to="cvac_EliLillyAndCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly and Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research services combined with an IP license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research services combined with an IP license</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProductMember" xlink:to="cvac_IfrsProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Article or substance produced by nature, labor or machinery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MilestoneRevenuesMember" xlink:to="cvac_MilestoneRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for milestone revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone revenues</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchAndDevelopmentServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional development milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Development Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional development milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Development Milestone Payment Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GovernmentGrantsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for German Federal Ministry of Education and Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">German Federal Ministry of Education and Research</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EuropeanCommissionMember" xlink:to="cvac_EuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for European Commission.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">European Commission</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GskAgreement2020Member" xlink:to="cvac_GskAgreement2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GSK Agreement 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 GSK AGREEMENT</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprTherapeuticsMember" xlink:to="cvac_CrisprTherapeuticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR Therapeutics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR Therapeutics</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyMember" xlink:to="cvac_EliLillyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Non-arrangement Transactions [Member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineCovidAgreementMember" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GlaxoSmithKline COVID Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAndLicenseAgreementMember" xlink:to="cvac_CollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration And License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Collaboration Partners That Owed Hundred Percent Of All Receivables And Contract Assets Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Collaboration Partners With Balances Greater Than Ten Percent Of All Receivables And Contract Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue that was included in contract liability balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront and milestones payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsReceivedOrReceivable" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments received or receivable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Received Or Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payments received or receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible to Receive as One-Time Reimbursable Payment For Manufacturing Capacity Reservation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One-time reimbursable payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive development and regulatory milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible to Receive as Development and Regulatory Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount eligible to receive commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Eligible to Receive as Commercial Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentReceived" xlink:to="cvac_UpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionFeePayment" xlink:to="cvac_OptionFeePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionFeePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Option fee Payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionFeePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Fee payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OptionFeePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option fee payment received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalDosesPurchaseOption" xlink:label="cvac_NumberOfAdditionalDosesPurchaseOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfAdditionalDosesPurchaseOption" xlink:to="cvac_NumberOfAdditionalDosesPurchaseOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfAdditionalDosesPurchaseOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional doses purchase option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfAdditionalDosesPurchaseOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Additional Doses Purchase Option</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfMilestonePayments" xlink:label="cvac_NumberOfMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfMilestonePayments" xlink:to="cvac_NumberOfMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Milestone Payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" xlink:to="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Option fee Payment and additional development milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Fee Payment And Additional Development Mi lestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option fee payment and an additional development milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments of the company included in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestones payments included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Option fee payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Option Fee Payment Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option fee payment included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" xlink:to="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The decrease in contract liabilities resulting from governmental contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Decrease Through Governmental Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in outstanding balance due to release of government contractual liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Gsk2ndGenMember" xlink:to="cvac_Gsk2ndGenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Gsk2ndGenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GSK 2nd Gen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Gsk2ndGenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK 2nd Gen</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BmbfMember" xlink:to="cvac_BmbfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BmbfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BMBF</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BmbfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMBF</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to EU APA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EU APA</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpensesByNatureTable" xlink:to="cvac_DisclosureOfExpensesByNatureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpensesByNatureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of expenses by nature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpensesByNatureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Expenses By Nature [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsIncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCostOfSalesMember" xlink:to="cvac_IfrsCostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems" xlink:to="cvac_DisclosureOfExpensesByNatureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Expenses By Nature [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelExpenses" xlink:to="cvac_PersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials and consumables used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThirdPartyServiceExpenses" xlink:to="cvac_ThirdPartyServiceExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for third party services during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Service Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party services</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaintenanceAndLeaseExpenses" xlink:to="cvac_MaintenanceAndLeaseExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maintenance and lease expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance And Lease Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance and lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherExpense" xlink:to="cvac_OtherExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease through derecognition, financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on derecognition of fixed assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInExpenseByNature" xlink:to="cvac_ChangeInExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in expense by nature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Expense By Nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in cost of sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_WriteOffOfRawMaterials" xlink:to="cvac_WriteOffOfRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of raw materials written off during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write Off Of Raw Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write off of raw materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SellingAndDistributionExpensesMember" xlink:to="cvac_SellingAndDistributionExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which the reported facts about research and development expense have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PatentsAndFeesToRegisterLegalRight" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for registering a legal right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And Fees To Register Legal Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents and fees to register a legal right</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionForOnerousContracts" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of Provision for Onerous Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision of onerous contracts</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in expense related to in-effective set-up activities and settlement costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of expenses related to ineffective set-up activities and settlement costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and other professional services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RealEstateTransferTaxes" xlink:to="cvac_RealEstateTransferTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of real estate transfer taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Transfer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real estate transfer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for CMO transfer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CostOfReimbursementClaim" xlink:to="cvac_CostOfReimbursementClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost of reimbursement claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of reimbursement claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement claim</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SaleOfEquipment" xlink:to="cvac_SaleOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sale of equipment in operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherOperatingIncomeGovernmentGrants" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other operating income recognized in relation to government agencies and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Income, Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and other cost reimbursements from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses reversed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provisions For Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from reversal of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MiscellaneousOtherOperatingIncomeOther" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of miscellaneous other operating income, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Other Operating Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants related to Coalition for Epidemic Preparedness Innovations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coalition for Epidemic Preparedness Innovations</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BundesministeriumFurBildungUndForschungMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Bundesministerium fr Bildung und Forschung.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bundesministerium fr Bildung und Forschung</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Advance Purchase Agreement with European Commission</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Purchase Agreement with European Commission</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumGrantToBeReceived" xlink:to="cvac_MaximumGrantToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum grant receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Grant To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from release of governmental contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsMilestonePaymentReceived" xlink:to="cvac_IfrsMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRemainingGrantIncome" xlink:to="cvac_IfrsRemainingGrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of remaining grant income classified as other operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Remaining Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining grant income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants received and deferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementMaximumAmount" xlink:to="cvac_PartnershipAgreementMaximumAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount agreed under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Maximum Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount under the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementTerm" xlink:to="cvac_PartnershipAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered by the funds received under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Period Of Costs To Be Covered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from government grants, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount pertaining to grants deducted from the carrying amount of qualifying assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Deducted From Carrying Amount Of Qualifying Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount deducted from the carrying amount of qualifying assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfAdditionalGrantsReceived" xlink:to="cvac_NumberOfAdditionalGrantsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Additional Grants Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist for set-up activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist of Manufacturing Interim Period Reimbursable Expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsSaleOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FollowOnPublicOfferingMember" xlink:to="cvac_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering, incl. Greenshoe</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOverAllotmentOptionMember" xlink:to="cvac_IfrsOverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right given to the underwriter to sell additional shares over the initial allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional value per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for legal, accounting, printing and registration fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CapitalIncreaseByGenmabMember" xlink:to="cvac_CapitalIncreaseByGenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab, capital increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrivatePlacementIsa2020Member" xlink:to="cvac_PrivatePlacementIsa2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for private Placement "ISA 2020".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Private Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for initial public offering and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and Private Placement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfGreenshoeMember" xlink:to="cvac_ExerciseOfGreenshoeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of Greenshoe.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise "Greenshoe"</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AtMarketOfferingProgramMember" xlink:to="cvac_AtMarketOfferingProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to at the market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Offering Program</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesSharesMember" xlink:to="cvac_SeriesSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series A shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesCSharesMember" xlink:to="cvac_SeriesCSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series C shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share transaction</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CommonSharesIssuedAndOutstanding" xlink:to="cvac_CommonSharesIssuedAndOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued and outstanding for during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares Issued And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding beginning</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInNumberOfSharesOutstanding" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in the number of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Increase (in shares)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareOptionExercises" xlink:to="cvac_ShareOptionExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share option exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share option exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents for decrease in number of shares due to treasury of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Number Of Shares Due To Treasury Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market offering program issuances</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuedDuringPeriodForExercises" xlink:to="cvac_StockIssuedDuringPeriodForExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period, upon exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, For Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuances for exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate gross proceeds receivable from issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Gross Proceeds Receivable From Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of benefit expense benefit recognized for share-based payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit Expense Recognized For Share Based Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanMember" xlink:to="cvac_LongTermIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRestrictedStockUnitMember" xlink:to="cvac_IfrsRestrictedStockUnitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents for restricted stock unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for RSU for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU for key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized for employee services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfOptionsMember" xlink:to="cvac_ExerciseOfOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefScientificOfficerMember" xlink:to="cvac_ChiefScientificOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Scientific Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Scientific Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of Chief operating officer and Chief development officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer and Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer and Chief Commercial Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer and Chief Commercial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefDevelepmentOfficerMember" xlink:label="cvac_ChiefDevelepmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefDevelepmentOfficerMember" xlink:to="cvac_ChiefDevelepmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefDevelepmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of Chief development officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefDevelepmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThenChiefExecutiveOfficerMember" xlink:to="cvac_ThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dan Menichella, then Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dan Menichella, then Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ManagementBoardMember" xlink:to="cvac_ManagementBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for management board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Board</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for person or persons designated as part of Executive board and various key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of executive board and various key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_KeyEmployeesMember" xlink:to="cvac_KeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExecutiveBoardMembersMember" xlink:to="cvac_ExecutiveBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive board members</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SupervisoryBoardMembersMember" xlink:to="cvac_SupervisoryBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for supervisory board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory board members</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsVestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based based payments expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of awards granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the right to exercise percentage of vested virtual shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Exercise Percentage Of Vested Virtual Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to exercise percentage of vested virtual shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LockUpPeriodAfterInitialListing" xlink:to="cvac_LockUpPeriodAfterInitialListing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the lock-up period, which is days after the initial listing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lock Up Period, After Initial Listing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock-up period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercised</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfKeyEmployees" xlink:to="cvac_NumberOfKeyEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Key Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of key employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU's awarded</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionForEmployerTaxes" xlink:to="cvac_ProvisionForEmployerTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of provision for employer taxes arising according to US regulations for future exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Employer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for employer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfLiabilityCashClaimAwards" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability recognized in financial statements towards cash claim of Awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Liability, Cash Claim Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability, cash claim awards</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfRestrictedStockUnitsReceived" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of restricted stock units received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options vested in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options Vested In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options vested</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of other equity instruments settled in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs settled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CumulativeAmortizationAndImpairmentMember" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for accumulated depreciation, amortization and impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Amortization And Impairment [Member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Carrying Amount of Acquisition Cost [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative amortization and impairment charges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of intangible assets other than goodwill [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LicensesSoftwareAndPrepaymentsMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SoftwareMember" xlink:to="cvac_SoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member stands for software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicencesMember" xlink:to="ifrs-full_LicencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LicencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licences</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancepaymentsintangibleassetMember" xlink:label="cvac_AdvancepaymentsintangibleassetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancepaymentsintangibleassetMember" xlink:to="cvac_AdvancepaymentsintangibleassetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancepaymentsintangibleassetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AdvancePaymentsIntangibleAsset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancepaymentsintangibleassetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortisation, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through net exchange differences, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for technical equipment and machines and other equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment, furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstructionInProgressMember" xlink:to="ifrs-full_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets under construction</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CmoNetworkMember" xlink:label="cvac_CmoNetworkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CmoNetworkMember" xlink:to="cvac_CmoNetworkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CmoNetworkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CMO Network</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CmoNetworkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO Network</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManufacturingFacilitiesMember" xlink:label="cvac_ManufacturingFacilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ManufacturingFacilitiesMember" xlink:to="cvac_ManufacturingFacilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ManufacturingFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for manufacturing facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ManufacturingFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GMP facilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompanyOwnedGmpIvFacilityMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for company-owned GMP IV facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company-owned GMP IV facility</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for equipment physically located at the CMO facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment physically located at the CMO facilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in PPE off set by impairment in equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Property and Equipment Off Set By Impairment of Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partial Offset of increase in property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attributions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" xlink:to="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to  non-current assets or disposal groups classified as held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent Assets Or Disposal Groups Classified As Held For Sale [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:to="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to  non-current assets or disposal groups classified as held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent Assets Or Disposal Groups Classified As Held For Sale [Line Item}</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Disposal Group, Including Discontinued Operation, Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesTable" xlink:to="cvac_InventoriesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesLineItem_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Line item</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseInInventory" xlink:to="cvac_IncreaseDecreaseInInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in inventory during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in inventory</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetValueOfInventoryTransferred" xlink:to="cvac_NetValueOfInventoryTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net value of inventory transferred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Value Of Inventory Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net inventory transferred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-offs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current advances to suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for material</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax claims against the tax authorities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurrentGrantReceivable" xlink:label="cvac_CurrentGrantReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentGrantReceivable" xlink:to="cvac_CurrentGrantReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Grant Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current grant receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding VAT refund claims</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCurrentGrantReceivables" xlink:label="cvac_IfrsCurrentGrantReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCurrentGrantReceivables" xlink:to="cvac_IfrsCurrentGrantReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current grant receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Current Grant Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for compensation for CMO transfer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets" xlink:label="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets" xlink:to="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of an allowance account used to record impairments to financial assets due to expected credit losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance Account For Expected Credit Losses OF Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected credit loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LicenseFeePayable" xlink:label="cvac_LicenseFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LicenseFeePayable" xlink:to="cvac_LicenseFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of license fee payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees payable</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInTradeAndOtherPayables" xlink:to="cvac_ChangeInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Trade and Other Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in trade and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PayrollRelatedWithholdingTaxes" xlink:label="cvac_PayrollRelatedWithholdingTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PayrollRelatedWithholdingTaxes" xlink:to="cvac_PayrollRelatedWithholdingTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PayrollRelatedWithholdingTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payment due on payroll related withholding taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PayrollRelatedWithholdingTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll Related Withholding Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_PayrollRelatedWithholdingTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll-related taxes and social-security liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractResearchOrganizationAgreementMember" xlink:to="cvac_ContractResearchOrganizationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractResearchOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for contract research organization Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractResearchOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRO agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractManufacturingOrganizationAgreementMember" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for contract manufacturing organization Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInOtherLiabilities" xlink:to="cvac_ChangeInOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsLineOfCreditMember" xlink:to="cvac_IfrsLineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsLineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsLineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" xlink:to="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum financing as percentage of cost of investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, Maximum Financing as Percentage of Cost of Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum financing as percentage of cost of investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInEachTranche" xlink:label="cvac_MinimumBorrowingsInEachTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MinimumBorrowingsInEachTranche" xlink:to="cvac_MinimumBorrowingsInEachTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MinimumBorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum borrowing amount available under EIB finanacing in three tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MinimumBorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Borrowings In Each Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MinimumBorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount of borrowing in each tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsInEachTranche" xlink:label="cvac_BorrowingsInEachTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BorrowingsInEachTranche" xlink:to="cvac_BorrowingsInEachTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of borrowing in each tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings in Each Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BorrowingsInEachTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of borrowing in each tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" xlink:to="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years due for each tranche from disbursement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Years Due For Each Tranche From Disbursement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years due for each tranche</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate per annum</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaxmimumBorrowingsInterestRate" xlink:label="cvac_MaxmimumBorrowingsInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaxmimumBorrowingsInterestRate" xlink:to="cvac_MaxmimumBorrowingsInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaxmimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum interest rate on borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaxmimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maxmimum Borrowings Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaxmimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maxmimum borrowings Interest Rate of outstanding principal of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInterestRate" xlink:label="cvac_MinimumBorrowingsInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MinimumBorrowingsInterestRate" xlink:to="cvac_MinimumBorrowingsInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MinimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum interest rate on borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MinimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Borrowings Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MinimumBorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum borrowings Interest Rate of outstanding principal of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" xlink:to="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commitment made to pay variable remuneration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Variable Remuneration For Output Produced On Manufacturing Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of variable remuneration on GMP IV manufacturing facilities per batch</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumAggregateRemunerationCapitalAmount" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumAggregateRemunerationCapitalAmount" xlink:to="cvac_MaximumAggregateRemunerationCapitalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate remuneration capital amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Remuneration Capital Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate remuneration capital amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" xlink:to="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payment for option buy-out variable remuneration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Facility Payment Option For Variable Remuneration On Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment option to buy-out variable remuneration by loan agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLossContingencyLossInPeriod" xlink:label="cvac_IfrsLossContingencyLossInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsLossContingencyLossInPeriod" xlink:to="cvac_IfrsLossContingencyLossInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsLossContingencyLossInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsLossContingencyLossInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Loss Contingency, Loss in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsLossContingencyLossInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of land charge (mortgage) not in favour of entity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount drawn</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LineOfCreditAccruedInterestPayable" xlink:to="cvac_LineOfCreditAccruedInterestPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lin of credit accrued interest payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Accrued Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to settle principal amount of borrowings, classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Principal Amount of Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of principal amount of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Repayments Of Accrued Interest And Fees Of Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of accrued interest and fees of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxDisclosureTable" xlink:to="cvac_IncomeTaxDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to income tax disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for subsidiaries [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacCorporateServiceGmbhMember" xlink:to="cvac_CurevacCorporateServiceGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacCorporateServiceGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CureVac Corporate Service GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacCorporateServiceGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Corporate Service GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacSwissAgMember" xlink:to="cvac_CurevacSwissAgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacSwissAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CureVac Swiss AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacSwissAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Swiss AG</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceMember" xlink:label="ifrs-full_TemporaryDifferenceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceMember" xlink:to="ifrs-full_TemporaryDifferenceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="cvac_IncomeTaxDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CHF" xlink:to="currency_CHF_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CHF_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EUR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GBP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCashAndCashEquivalentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesMember" xlink:to="cvac_TradeAndOtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherReceivablesMember" xlink:to="cvac_TradeAndOtherReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Receivables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesOneMember" xlink:to="cvac_TradeAndOtherPayablesOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Payables One</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a type
 of market risk representing the
 risk that the fair value or future
 cash flows of a financial
 instrument will fluctuate
 because of changes in foreign
 exchange rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary Liabilities In Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryAssetsInForeignCurrencyMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary Assets In Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesTwoMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Payables Two</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesOneMember" xlink:label="cvac_OtherReceivablesOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherReceivablesOneMember" xlink:to="cvac_OtherReceivablesOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherReceivablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherReceivablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables One</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesTwoMember" xlink:label="cvac_OtherReceivablesTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherReceivablesTwoMember" xlink:to="cvac_OtherReceivablesTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherReceivablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherReceivablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables Two</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherreceivablesMember" xlink:label="cvac_OtherreceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherreceivablesMember" xlink:to="cvac_OtherreceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherreceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherreceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk exposure associated with instruments sharing characteristic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exposure in (foreign) currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Diluteeffectofordinarysharesissued" xlink:label="cvac_Diluteeffectofordinarysharesissued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Diluteeffectofordinarysharesissued" xlink:to="cvac_Diluteeffectofordinarysharesissued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Diluteeffectofordinarysharesissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of dilutive potential ordinary shares that relate to the assumed issuance of new shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Diluteeffectofordinarysharesissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DiluteEffectOfOrdinarySharesIssued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Diluteeffectofordinarysharesissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New issue of shares for the purpose of calculating earning per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Commonsharesissuedandoutstanding" xlink:label="cvac_Commonsharesissuedandoutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Commonsharesissuedandoutstanding" xlink:to="cvac_Commonsharesissuedandoutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Commonsharesissuedandoutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued and outstanding for during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Commonsharesissuedandoutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CommonSharesIssuedAndOutstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Commonsharesissuedandoutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BaronJeanStephenneMember" xlink:to="cvac_BaronJeanStephenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Baron Jean Stephenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VincentStphenneMember" xlink:to="cvac_VincentStphenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Vincent Stphenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stphenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AntonyBlancMember" xlink:to="cvac_AntonyBlancMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Antony Blanc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RittershausRechtsanwaelteMember" xlink:to="cvac_RittershausRechtsanwaelteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Rittershaus Rechtsanwaelte , a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Dr.IngmarHoerrMember" xlink:to="cvac_Dr.IngmarHoerrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Dr.IngmarHoerrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Dr. Ingmar Hoerr, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Dr.IngmarHoerrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hoerr</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DietmarHoppMember" xlink:to="cvac_DietmarHoppMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BepharbelManufacturingS.aMember" xlink:to="cvac_BepharbelManufacturingS.aMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BePharBel Manufacturing S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MolecularhealthgmbhMember" xlink:label="cvac_MolecularhealthgmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MolecularhealthgmbhMember" xlink:to="cvac_MolecularhealthgmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MolecularhealthgmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Molecular health</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MolecularhealthgmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Molecular Health Gmbh</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClarentisSrlMember" xlink:to="cvac_ClarentisSrlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of notice for termination of the agreement at the option of the party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination at the option</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionConsultingFees" xlink:to="cvac_RelatedPartyTransactionConsultingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consulting fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">consulting fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionAdvisoryFees" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of advisory fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Advisory Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advisory fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loans received from a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of Loans Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible loans</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid at signing of the agreement in related party transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Paid at Signing of Agreement, Related Party Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid at signing of the agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of goods, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TerminationFeeRelatedPartyTransactions" xlink:to="cvac_TerminationFeeRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of termination fee in related party transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination Fee, Related Party Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interest held</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAgreementMilestonePayment" xlink:to="cvac_CollaborationAgreementMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received from the participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsContractualObligation" xlink:to="cvac_IfrsContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual obligation amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments made by entity, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum settlement amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PaymentsToRelatedPartyForServices" xlink:to="cvac_PaymentsToRelatedPartyForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments made to related party by the company for services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Related Party For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to related party for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals B.V., Amsterdam, Netherlands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of contingent liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="ifrs-full_ContingentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherContingentLiabilitiesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other contingent liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than contingent liability arising from patent Infringement lawsuit .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Infringement Lawsuit</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MilestonesMember" xlink:to="cvac_MilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">These member stand for milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred, acquisition-date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total purchase price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments or interests issued or issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares transferred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesIncurred" xlink:to="ifrs-full_LiabilitiesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amount of discharging contractual obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashTransferred" xlink:to="ifrs-full_CashTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days used for calculation of preliminary total purchase price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary Purchase Price Allocation, Number of Trading Days Used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the signing date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary Purchase Price Allocation, Calculation of Volume Weighted Average Share Price over Sixty Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing date share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the closing date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Share Price as of Closing Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing date share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total number of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Number of Milestones Used for Payment of Fifty Percent of Purchase Price to be Paid in Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of first milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Percent of First Milestone Payment Due Upon Achievement of Successful Investigational New Drug Application Filing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of first milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of second milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Percent of Second Milestone Payment Due Upon Successful Proof of Mechanism in Humans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of second milestone payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary aggregated consideration transferred used for PPA</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identifiable intangible assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash acquired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions costs related to acquisition</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity has allegedly infringed in the utility model.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Allegedly Infringed, Number Of Utility Models</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of utility models infringed</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity has allegedly infringed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Allegedly Infringed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents infringed</label>
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity was found not to have infringed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Found Not Infringed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents that does not infringe</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average share price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial liabilities</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cvac-20220630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/18/2022 7:20:55 PM-->
<!--Modified on: 8/18/2022 7:20:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureCorporateInformation" roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureBasisOfPreparation" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatements" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReserves" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPayments" roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFixedAssets" roleURI="http://www.curevac.com/role/DisclosureFixedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureAssetsHeldForSale" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureInventories" roleURI="http://www.curevac.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrent" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFinancialAssetsAndFinancialLiabilities" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureTradeAndOtherPayables" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureOtherLiabilities" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureLoans" roleURI="http://www.curevac.com/role/DisclosureLoans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIncomeTax" roleURI="http://www.curevac.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureEarningsPerShare" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureRelatedPartyDisclosures" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureSubsequentEvents" roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureBasisOfPreparationPolicies" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsTables" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReservesTables" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureAssetsHeldForSaleDetails" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureOtherLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureLoansDetails" roleURI="http://www.curevac.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_637964472514673495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637964472514673495" xlink:to="dei_EntityAddressesAddressTypeAxis_637964472514673495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_637964472514673495" xlink:to="dei_AddressTypeDomain_637964472514673495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_637964472514673495" xlink:to="dei_BusinessContactMember_637964472514673495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637964472514673495" xlink:to="dei_DocumentInformationLineItems_637964472514673495" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentType_637964472514673495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentRegistrationStatement_637964472514673495" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637964472514673495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentAnnualReport_637964472514673495" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentTransitionReport_637964472514683412" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentShellCompanyReport_637964472514683412" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityRegistrantName_637964472514683412" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentPeriodEndDate_637964472514683412" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityIncorporationStateCountryCode_637964472514683412" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressAddressLine1_637964472514683412" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637964472514683412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressAddressLine2_637964472514683412" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressCityOrTown_637964472514693411" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressStateOrProvince_637964472514693411" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressCountry_637964472514693411" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityAddressPostalZipCode_637964472514693411" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_CityAreaCode_637964472514693411" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_LocalPhoneNumber_637964472514693411" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_ContactPersonnelName_637964472514693411" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_637964472514693411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_CountryRegion_637964472514693411" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_ContactPersonnelEmailAddress_637964472514703399" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_Security12bTitle_637964472514703399" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_TradingSymbol_637964472514703399" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_SecurityExchangeName_637964472514703399" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityFileNumber_637964472514703399" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityWellKnownSeasonedIssuer_637964472514703399" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637964472514703399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityCurrentReportingStatus_637964472514703399" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityFilerCategory_637964472514713394" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityInteractiveDataCurrent_637964472514713394" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityEmergingGrowthCompany_637964472514713394" order="28" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityExTransitionPeriod_637964472514713394" order="29" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentAccountingStandard_637964472514713394" order="30" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityShellCompany_637964472514713394" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637964472514713394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityCommonStockSharesOutstanding_637964472514713394" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_CurrentFiscalYearEndDate_637964472514723391" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentFiscalYearFocus_637964472514723391" order="34" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_DocumentFiscalPeriodFocus_637964472514723391" order="35" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityCentralIndexKey_637964472514723391" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_AmendmentFlag_637964472514723391" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_IcfrAuditorAttestationFlag_637964472514723391" order="38" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription_637964472514723391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_AmendmentDescription_637964472514723391" order="39" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637964472514733393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityVoluntaryFilers_637964472514733393" order="40" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637964472514733393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_EntityPublicFloat_637964472514733393" order="41" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637964472514733393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_AuditorName_637964472514733393" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637964472514733393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_AuditorFirmId_637964472514733393" order="43" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637964472514733393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637964472514673495" xlink:to="dei_AuditorLocation_637964472514733393" order="44" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637964472514743399" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_CostOfSales_637964472514743399" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_637964472514743399" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637964472514743399" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637964472514743399" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_637964472514743399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_637964472514743399" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_637964472514753406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637964472514753406" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncome_637964472514753406" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceCosts_637964472514753406" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_637964472514753406" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472514753406" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_637964472514753406" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_637964472514753406" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637964472514753406" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637964472514753406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_637964472514753406" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_637964472514753406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_637964472514753406" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_637964472514763396" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_637964472514763396" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637964472514763396" xlink:to="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637964472514763396" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_PropertyPlantAndEquipment_637964472514763396" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_RightofuseAssets_637964472514763396" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_OtherNoncurrentAssets_637964472514763396" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_NetDeferredTaxAssets_637964472514763396" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637964472514763396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637964472514763396" xlink:to="ifrs-full_NoncurrentAssets_637964472514763396" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637964472514763396" xlink:to="ifrs-full_CurrentAssetsAbstract_637964472514773406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_637964472514773406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_Inventories_637964472514773406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_CurrentTradeReceivables_637964472514773406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_CurrentContractAssets_637964472514773406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_OtherCurrentFinancialAssets_637964472514773406" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472514773406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_CashAndCashEquivalents_637964472514773406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637964472514773406" xlink:to="ifrs-full_CurrentAssets_637964472514773406" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637964472514773406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637964472514763396" xlink:to="ifrs-full_Assets_637964472514773406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_637964472514783396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" xlink:to="ifrs-full_EquityAbstract_637964472514783396" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637964472514783396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_IssuedCapital_637964472514783396" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_637964472514783396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_CapitalReserve_637964472514783396" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_TreasuryShares_637964472514793414" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_RetainedEarnings_637964472514793414" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_637964472514793414" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637964472514783396" xlink:to="ifrs-full_Equity_637964472514793414" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_637964472514793414" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637964472514793414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637964472514793414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" xlink:to="ifrs-full_NoncurrentContractLiabilities_637964472514803397" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" xlink:to="ifrs-full_OtherNoncurrentLiabilities_637964472514803397" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637964472514793414" xlink:to="ifrs-full_NoncurrentLiabilities_637964472514803397" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_CurrentLeaseLiabilities_637964472514803397" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_637964472514803397" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_637964472514803397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_OtherCurrentLiabilities_637964472514803397" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_637964472514813397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_CurrentTaxLiabilities_637964472514813397" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_637964472514813397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_CurrentContractLiabilities_637964472514813397" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637964472514813397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637964472514803397" xlink:to="ifrs-full_CurrentLiabilities_637964472514813397" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637964472514813397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" xlink:to="ifrs-full_Liabilities_637964472514813397" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_637964472514813397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637964472514783396" xlink:to="ifrs-full_EquityAndLiabilities_637964472514813397" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_637964472514823394" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637964472514823394" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_637964472514823394" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637964472514823394" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" xlink:to="ifrs-full_PreviouslyStatedMember_637964472514823394" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637964472514823394" xlink:to="ifrs-full_RestatedMember_637964472514823394" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637964472514823394" xlink:to="ifrs-full_ComponentsOfEquityAxis_637964472514823394" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_IssuedCapitalMember_637964472514823394" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_CapitalReserveMember_637964472514823394" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_637964472514823394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_TreasurySharesMember_637964472514823394" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_RetainedEarningsMember_637964472514833404" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637964472514833404" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472514823394" xlink:to="ifrs-full_EquityMember_637964472514833404" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637964472514823394" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_Equity_637964472514833404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="cvac_NetLoss_637964472514833404" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_ProfitLoss_637964472514833404" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_OtherComprehensiveIncome_637964472514833404" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="cvac_ComprehensiveIncomeLoss_637964472514833404" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_ComprehensiveIncome_637964472514833404" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_637964472514833404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_637964472514833404" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_637964472514843395" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_637964472514843395" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_637964472514843395" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_637964472514843395" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_IssueOfEquity_637964472514843395" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_637964472514843395" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_NumberOfSharesOutstanding_637964472514843395" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637964472514843395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637964472514833404" xlink:to="ifrs-full_Equity_637964472514843395" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637964472514853397" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637964472514853397" xlink:to="ifrs-full_ProfitLossBeforeTax_637964472514853397" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_637964472514853397" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_637964472514853397" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637964472514853397" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472514853397" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637964472514853397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637964472514853397" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_637964472514863406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_637964472514863406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637964472514853397" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_637964472514863406" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637964472514853397" xlink:to="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637964472514863406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637964472514863406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637964472514863406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_637964472514863406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472514863406" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637964472514863406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637964472514863406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_637964472514873476" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_637964472514873476" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_637964472514873476" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637964472514873476" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637964472514873476" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_637964472514863406" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637964472514873476" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637964472514883399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637964472514883399" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637964472514883399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637964472514883399" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_637964472514883399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_637964472514883399" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472514883399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637964472514873476" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637964472514883399" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637964472514893416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637964472514893416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_637964472514893416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_637964472514893416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_637964472514893416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_637964472514893416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_637964472514893416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_637964472514893416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="cvac_ProceedsOnExerciseOfOptions_637964472514903494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_ProceedsFromIssuingShares_637964472514903494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472514903494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_637964472514903494" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_637964472514903494" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472514903494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637964472514883399" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637964472514903494" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637964472514913399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637964472514913399" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637964472514913399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637964472514913399" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637964472514913399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_637964472514913399" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6379644725149133991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6379644725149133991" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformation" xlink:type="extended" xlink:title="10101 - Disclosure - Corporate Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock_637964472514923404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="cvac_CorporateInformationTextBlock_637964472514923404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of preparation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_637964472514923404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_637964472514923404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xlink:type="extended" xlink:title="10301 - Disclosure - Notes to the consolidated financial statements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_637964472514923404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_637964472514923404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xlink:type="extended" xlink:title="10401 - Disclosure - Issued Capital and Reserves" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_637964472514923404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_637964472514923404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPayments" xlink:type="extended" xlink:title="10501 - Disclosure - Share-based payments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637964472514933408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637964472514933408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="10601 - Disclosure - Fixed Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_637964472514933408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_637964472514933408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xlink:type="extended" xlink:title="10701 - Disclosure - Assets held for sale" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_637964472514933408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_637964472514933408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10801 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_637964472514943407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_637964472514943407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xlink:type="extended" xlink:title="10901 - Disclosure - Prepaid expenses and other assets (current)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_637964472514943407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_637964472514943407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - Financial assets and financial liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_637964472514943407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_637964472514943407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xlink:type="extended" xlink:title="11101 - Disclosure - Trade and other payables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_637964472514943407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_637964472514943407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilities" xlink:type="extended" xlink:title="11121 - Disclosure - Other liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_637964472514953407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_637964472514953407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureLoans" xlink:type="extended" xlink:title="11301 - Disclosure - Loans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_637964472514993419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_637964472514993419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="11401 - Disclosure - Income tax" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_637964472514993419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_637964472514993419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xlink:type="extended" xlink:title="11501 - Disclosure - Disclosure of financial instruments and risk management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_637964472514993419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_637964472514993419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShare" xlink:type="extended" xlink:title="11601 - Disclosure - Earnings per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory_637964472515003420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory_637964472515003420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xlink:type="extended" xlink:title="11701 - Disclosure - Related party disclosures" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_637964472515003420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_637964472515003420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11801 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637964472515003420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637964472515003420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of preparation (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637964472515013410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_637964472515013410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_637964472515013410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_637964472515013410" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_637964472515013410" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Notes to the consolidated financial statements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637964472515013410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_637964472515013410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_637964472515013410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_637964472515013410" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_637964472515013410" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_637964472515013410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_637964472515013410" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_637964472515023398" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Issued Capital and Reserves (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_637964472515023398" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515023398" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515023398" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515023398" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515023398" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" xlink:to="cvac_VirtualSharesProgramIMember_637964472515023398" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" xlink:to="cvac_VirtualSharesProgramIiMember_637964472515023398" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515023398" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_637964472515023398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515023398" xlink:to="cvac_RestrictedStockUnitsMember_637964472515023398" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515023398" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_637964472515033406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_637964472515033406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_637964472515033406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515033406" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_637964472515033406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515033406" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515033406" xlink:to="ifrs-full_BusinessCombinationsAxis_637964472515033406" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_637964472515033406" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515033406" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515033406" xlink:to="cvac_CurevacN.v.Member_637964472515033406" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515033406" xlink:to="srt_ConsolidatedEntitiesAxis_637964472515033406" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_637964472515033406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_637964472515033406" xlink:to="srt_ConsolidatedEntitiesDomain_637964472515033406" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_637964472515033406" xlink:to="srt_ParentCompanyMember_637964472515043407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515033406" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515043407" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515043407" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_637964472515043407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515043407" xlink:to="cvac_CorporateReorganizationStockSplitRatio_637964472515043407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515043407" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_637964472515043407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" xlink:to="ifrs-full_GeographicalAreasAxis_637964472515043407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_637964472515043407" xlink:to="ifrs-full_GeographicalAreasMember_637964472515043407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637964472515043407" xlink:to="country_BE_637964472515043407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE_637964472515043407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637964472515043407" xlink:to="country_DE_637964472515043407" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637964472515043407" xlink:to="country_NL_637964472515053407" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637964472515043407" xlink:to="country_CH_637964472515053407" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637964472515043407" xlink:to="country_US_637964472515053407" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" xlink:to="ifrs-full_MajorCustomersAxis_637964472515053407" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_637964472515053407" xlink:to="ifrs-full_MajorCustomersMember_637964472515053407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_GlaxosmithklineMember_637964472515053407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_BoehringerIngelheimMember_637964472515053407" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_OtherCustomersMember_637964472515053407" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_GenmabMember_637964472515053407" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_CrisprMember_637964472515053407" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_637964472515053407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515053407" xlink:to="cvac_EliLillyAndCompanyMember_637964472515053407" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" xlink:to="ifrs-full_ProductsAndServicesAxis_637964472515063451" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_637964472515063451" xlink:to="ifrs-full_ProductsAndServicesMember_637964472515063451" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515063451" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_637964472515063451" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515063451" xlink:to="cvac_IfrsProductMember_637964472515063451" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515063451" xlink:to="cvac_MilestoneRevenuesMember_637964472515063451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515063451" xlink:to="cvac_ResearchAndDevelopmentServicesMember_637964472515063451" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515043407" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515063451" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515063451" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637964472515063451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_637964472515063451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515063451" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_637964472515063451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515063451" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_637964472515073400" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="cvac_GovernmentGrantsAxis_637964472515073400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_637964472515073400" xlink:to="cvac_GovernmentGrantsDomain_637964472515073400" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515073400" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515073400" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515073400" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_637964472515073400" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515073400" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_637964472515073400" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515073400" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515073400" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_637964472515073400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="ifrs-full_MajorCustomersAxis_637964472515073400" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_637964472515073400" xlink:to="ifrs-full_MajorCustomersMember_637964472515083407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515083407" xlink:to="cvac_GlaxosmithklineMember_637964472515083407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515083407" xlink:to="cvac_BoehringerIngelheimMember_637964472515083407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515083407" xlink:to="cvac_GenmabMember_637964472515083407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515083407" xlink:to="cvac_EliLillyAndCompanyMember_637964472515083407" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515083407" xlink:to="cvac_EuropeanCommissionMember_637964472515083407" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="srt_CounterpartyNameAxis_637964472515083407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637964472515083407" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_6379644725150834071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_GlaxosmithklineMember_6379644725150834071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_GskAgreement2020Member_637964472515093424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_BoehringerIngelheimMember_637964472515093424" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_CrisprTherapeuticsMember_637964472515093424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_GenmabMember_637964472515093424" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515083407" xlink:to="cvac_EliLillyMember_637964472515093424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="srt_StatementScenarioAxis_637964472515093424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637964472515093424" xlink:to="srt_ScenarioUnspecifiedDomain_637964472515093424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637964472515093424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637964472515093424" xlink:to="srt_ScenarioForecastMember_637964472515093424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="cvac_TypeOfArrangementAxis_637964472515103402" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_TypeOfArrangementAxis_637964472515103402" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515103402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515103402" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_637964472515103402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515103402" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_637964472515103402" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515103402" xlink:to="cvac_CollaborationAndLicenseAgreementMember_637964472515103402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515073400" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding" xlink:label="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding_637964472515103402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets" xlink:label="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets_637964472515103402" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637964472515103402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637964472515103402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="ifrs-full_ProceedsFromIssuingShares_637964472515113400" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637964472515113400" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_637964472515113400" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation" xlink:label="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation_637964472515113400" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments_637964472515113400" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountEligibleToReceiveAsCommercialMilestonePayments" xlink:label="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_AmountEligibleToReceiveAsCommercialMilestonePayments_637964472515113400" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived_637964472515113400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_UpfrontPaymentReceived_637964472515113400" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePayment" xlink:label="cvac_OptionFeePayment_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_OptionFeePayment_637964472515123401" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_637964472515123401" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalDosesPurchaseOption" xlink:label="cvac_NumberOfAdditionalDosesPurchaseOption_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_NumberOfAdditionalDosesPurchaseOption_637964472515123401" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfMilestonePayments" xlink:label="cvac_NumberOfMilestonePayments_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_NumberOfMilestonePayments_637964472515123401" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments" xlink:label="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments_637964472515123401" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_637964472515123401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_637964472515123401" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOptionFeePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_637964472515133402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_IfrsOptionFeePaymentIncludedInContractLiabilities_637964472515133402" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_637964472515133402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_637964472515133402" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637964472515133402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637964472515133402" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDecreaseThroughGovernmentalContractLiabilities" xlink:label="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_637964472515133402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515103402" xlink:to="cvac_IfrsDecreaseThroughGovernmentalContractLiabilities_637964472515133402" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" xlink:to="ifrs-full_ProductsAndServicesAxis_637964472515143413" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_637964472515143413" xlink:to="ifrs-full_ProductsAndServicesMember_637964472515143413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515143413" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_637964472515143413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" xlink:to="ifrs-full_RangeAxis_637964472515143413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637964472515143413" xlink:to="ifrs-full_RangesMember_637964472515143413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637964472515143413" xlink:to="ifrs-full_BottomOfRangeMember_637964472515143413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" xlink:to="ifrs-full_MajorCustomersAxis_637964472515143413" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_637964472515143413" xlink:to="ifrs-full_MajorCustomersMember_637964472515143413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_EliLillyAndCompanyMember_637964472515143413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_CrisprMember_637964472515143413" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_BoehringerIngelheimMember_637964472515143413" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_637964472515143413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_GenmabMember_637964472515143413" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_GlaxosmithklineMember_637964472515153403" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_Gsk2ndGenMember_637964472515153403" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_BmbfMember_637964472515153403" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515153403" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember_637964472515153403" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637964472515143413" xlink:to="cvac_EuropeanCommissionMember_637964472515153403" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515143413" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515153403" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515153403" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_637964472515153403" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515153403" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_637964472515153403" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637964472515153403" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515153403" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637964472515153403" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515163399" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515163399" xlink:to="srt_StatementScenarioAxis_637964472515163399" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637964472515163399" xlink:to="srt_ScenarioUnspecifiedDomain_637964472515163399" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637964472515163399" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515163399" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515163399" xlink:to="ifrs-full_CurrentTradeReceivables_637964472515163399" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515163399" xlink:to="ifrs-full_CurrentContractAssets_637964472515163399" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637964472515163399" xlink:to="ifrs-full_ContractLiabilities_637964472515163399" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfExpensesByNatureTable_637964472515163399" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515163399" xlink:to="cvac_IfrsIncomeStatementLocationAxis_637964472515163399" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_637964472515163399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_637964472515163399" xlink:to="cvac_IfrsIncomeStatementLocationDomain_637964472515163399" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_637964472515163399" xlink:to="cvac_IfrsCostOfSalesMember_637964472515173407" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515163399" xlink:to="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_PersonnelExpenses_637964472515173407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_637964472515173407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_ThirdPartyServiceExpenses_637964472515173407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_MaintenanceAndLeaseExpenses_637964472515173407" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_637964472515173407" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_OtherExpense_637964472515173407" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="ifrs-full_ExpenseByNature_637964472515173407" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_637964472515173407" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_ChangeInExpenseByNature_637964472515173407" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials_637964472515173407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515173407" xlink:to="cvac_WriteOffOfRawMaterials_637964472515173407" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfExpensesByNatureTable_637964472515183402" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515183402" xlink:to="cvac_IfrsIncomeStatementLocationAxis_637964472515183402" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_637964472515183402" xlink:to="cvac_IfrsIncomeStatementLocationDomain_637964472515183402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_637964472515183402" xlink:to="cvac_SellingAndDistributionExpensesMember_637964472515183402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515183402" xlink:to="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="cvac_PersonnelExpenses_637964472515183402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="cvac_MaintenanceAndLeaseExpenses_637964472515183402" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_637964472515183402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="cvac_OtherExpense_637964472515183402" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="ifrs-full_ExpenseByNature_637964472515183402" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515183402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515183402" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515183402" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515193422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfExpensesByNatureTable_637964472515193422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515193422" xlink:to="cvac_IfrsIncomeStatementLocationAxis_637964472515193422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_637964472515193422" xlink:to="cvac_IfrsIncomeStatementLocationDomain_637964472515193422" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_637964472515193422" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_637964472515193422" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515193422" xlink:to="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_637964472515193422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_PersonnelExpenses_637964472515193422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_637964472515193422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_637964472515193422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_637964472515193422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_ThirdPartyServiceExpenses_637964472515203414" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_MaintenanceAndLeaseExpenses_637964472515203414" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_OtherExpense_637964472515203414" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="ifrs-full_ExpenseByNature_637964472515203414" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515203414" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515203414" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_637964472515203414" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515193422" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_637964472515203414" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureTable" xlink:label="cvac_DisclosureOfExpensesByNatureTable_637964472515203414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfExpensesByNatureTable_637964472515203414" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515203414" xlink:to="cvac_IfrsIncomeStatementLocationAxis_637964472515213414" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_637964472515213414" xlink:to="cvac_IfrsIncomeStatementLocationDomain_637964472515213414" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_637964472515213414" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_637964472515213414" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfExpensesByNatureLineItems" xlink:label="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureTable_637964472515203414" xlink:to="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="cvac_PersonnelExpenses_637964472515213414" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="cvac_MaintenanceAndLeaseExpenses_637964472515213414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="cvac_ThirdPartyServiceExpenses_637964472515213414" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_ProfessionalFeesExpense_637964472515213414" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_637964472515213414" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="cvac_OtherExpense_637964472515213414" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_ExpenseByNature_637964472515213414" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_637964472515213414" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515213414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637964472515213414" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_TravelExpense_637964472515223404" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="ifrs-full_InsuranceExpense_637964472515223404" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfExpensesByNatureLineItems_637964472515213414" xlink:to="cvac_RealEstateTransferTaxes_637964472515223404" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_637964472515223404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_CostOfReimbursementClaim_637964472515223404" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_SaleOfEquipment_637964472515223404" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_637964472515223404" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_637964472515223404" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_637964472515223404" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_637964472515223404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_637964472515223404" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" xlink:to="srt_StatementScenarioAxis_637964472515233407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637964472515233407" xlink:to="srt_ScenarioUnspecifiedDomain_637964472515233407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" xlink:to="cvac_GovernmentGrantsAxis_637964472515233407" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_637964472515233407" xlink:to="cvac_GovernmentGrantsDomain_637964472515233407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515233407" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_637964472515233407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515233407" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_637964472515233407" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_637964472515233407" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515233407" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515233407" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_637964472515233407" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515233407" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_637964472515233407" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_637964472515233407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_637964472515233407" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_637964472515233407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" xlink:to="srt_CounterpartyNameAxis_637964472515243406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637964472515243406" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_GlaxosmithklineMember_637964472515243406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_GskAgreement2020Member_637964472515243406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_BoehringerIngelheimMember_637964472515243406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_CrisprTherapeuticsMember_637964472515243406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_GenmabMember_637964472515243406" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515243406" xlink:to="cvac_EliLillyMember_637964472515243406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" xlink:to="cvac_TypeOfArrangementAxis_637964472515243406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_TypeOfArrangementAxis_637964472515243406" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515243406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_637964472515243406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_637964472515243406" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_637964472515243406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_637964472515233407" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_637964472515253404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_MaximumGrantToBeReceived_637964472515253404" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_UpfrontPaymentReceived_637964472515253404" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="ifrs-full_RevenueFromGovernmentGrants_637964472515253404" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_IfrsMilestonePaymentReceived_637964472515253404" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_IfrsRemainingGrantIncome_637964472515253404" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="ifrs-full_GovernmentGrants_637964472515253404" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount_637964472515253404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_PartnershipAgreementMaximumAmount_637964472515253404" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_PartnershipAgreementTerm_637964472515263402" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_637964472515263402" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_637964472515263402" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_637964472515263402" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_NumberOfAdditionalGrantsReceived_637964472515263402" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_637964472515263402" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_637964472515263402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_637964472515263402" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_637964472515273402" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_637964472515253404" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_637964472515273402" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515273402" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515273402" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515273402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515273402" xlink:to="cvac_VirtualSharesProgramIMember_637964472515273402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637964472515273402" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637964472515273402" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637964472515273402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_637964472515273402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637964472515273402" xlink:to="ifrs-full_OrdinarySharesMember_637964472515273402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637964472515273402" xlink:to="ifrs-full_PreferenceSharesMember_637964472515283411" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" xlink:to="cvac_IfrsSaleOfStockAxis_637964472515283411" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_637964472515283411" xlink:to="cvac_IfrsSaleOfStockDomain_637964472515283411" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515283411" xlink:to="cvac_FollowOnPublicOfferingMember_637964472515283411" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515283411" xlink:to="cvac_IfrsOverAllotmentOptionMember_637964472515283411" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" xlink:to="ifrs-full_ComponentsOfEquityAxis_637964472515283411" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637964472515283411" xlink:to="ifrs-full_EquityMember_637964472515283411" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_637964472515283411" xlink:to="ifrs-full_TreasurySharesMember_637964472515283411" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515273402" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_637964472515283411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" xlink:to="ifrs-full_NumberOfSharesAuthorised_637964472515283411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_637964472515293415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" xlink:to="ifrs-full_ParValuePerShare_637964472515293415" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_637964472515293415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" xlink:to="ifrs-full_NumberOfSharesIssued_637964472515293415" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost_637964472515293415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" xlink:to="ifrs-full_ShareIssueRelatedCost_637964472515293415" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_637964472515293415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515283411" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_637964472515293415" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" xlink:to="cvac_IfrsSaleOfStockAxis_637964472515303424" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_637964472515303424" xlink:to="cvac_IfrsSaleOfStockDomain_637964472515303424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_CapitalIncreaseByGenmabMember_637964472515303424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_PrivatePlacementIsa2020Member_637964472515303424" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_637964472515303424" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_ExerciseOfGreenshoeMember_637964472515303424" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_FollowOnPublicOfferingMember_637964472515303424" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515303424" xlink:to="cvac_AtMarketOfferingProgramMember_637964472515303424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637964472515303424" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637964472515303424" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637964472515303424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637964472515303424" xlink:to="cvac_SeriesSharesMember_637964472515303424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637964472515303424" xlink:to="cvac_SeriesCSharesMember_637964472515303424" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_637964472515303424" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_637964472515303424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_637964472515303424" xlink:to="ifrs-full_NonadjustingEventsMember_637964472515303424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_637964472515303424" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_637964472515313405" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_637964472515293415" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_CommonSharesIssuedAndOutstanding_637964472515313405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_637964472515313405" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_ShareOptionExercises_637964472515313405" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_637964472515313405" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_637964472515313405" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_StockIssuedDuringPeriodForExercises_637964472515313405" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_6379644725153134051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_CommonSharesIssuedAndOutstanding_6379644725153134051" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_637964472515313405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_637964472515313405" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_637964472515313405" xlink:to="ifrs-full_ProceedsFromIssuingShares_637964472515323402" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515323402" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515323402" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515323402" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515323402" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515323402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515323402" xlink:to="cvac_VirtualSharesProgramIMember_637964472515323402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515323402" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_637964472515323402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_637964472515323402" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472515323402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472515323402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515323402" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_637964472515333414" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515333414" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515333414" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515333414" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515333414" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_LongTermIncentivePlanMember_637964472515333414" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_IfrsRestrictedStockUnitMember_637964472515333414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember_637964472515333414" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515333414" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_VirtualSharesProgramIiMember_637964472515333414" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515333414" xlink:to="cvac_VirtualSharesProgramIMember_637964472515333414" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515333414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515333414" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515333414" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515333414" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_637964472515343409" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="cvac_IfrsSaleOfStockAxis_637964472515343409" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_637964472515343409" xlink:to="cvac_IfrsSaleOfStockDomain_637964472515343409" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_637964472515343409" xlink:to="cvac_ExerciseOfOptionsMember_637964472515343409" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="srt_TitleOfIndividualAxis_637964472515343409" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637964472515343409" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ChiefScientificOfficerMember_637964472515343409" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_637964472515343409" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_637964472515343409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_637964472515343409" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="srt_ChiefOperatingOfficerMember_637964472515353411" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChiefDevelepmentOfficerMember" xlink:label="cvac_ChiefDevelepmentOfficerMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ChiefDevelepmentOfficerMember_637964472515353411" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ThenChiefExecutiveOfficerMember_637964472515353411" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ManagementBoardMember_637964472515353411" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_637964472515353411" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_KeyEmployeesMember_637964472515353411" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_ExecutiveBoardMembersMember_637964472515353411" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515343409" xlink:to="cvac_SupervisoryBoardMembersMember_637964472515353411" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="ifrs-full_RangeAxis_637964472515353411" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637964472515353411" xlink:to="ifrs-full_RangesMember_637964472515353411" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637964472515353411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="srt_StatementScenarioAxis_637964472515353411" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637964472515353411" xlink:to="srt_ScenarioUnspecifiedDomain_637964472515363404" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="ifrs-full_MaturityAxis_637964472515363404" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_637964472515363404" xlink:to="ifrs-full_AggregatedTimeBandsMember_637964472515363404" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_637964472515363404" xlink:to="ifrs-full_NotLaterThanOneYearMember_637964472515363404" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_637964472515363404" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_637964472515363404" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="cvac_IfrsVestingAxis_637964472515363404" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingAxis_637964472515363404" xlink:to="cvac_IfrsVestingDomain_637964472515363404" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_637964472515363404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_637964472515363404" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_637964472515363404" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515373406" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515373406" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" xlink:to="cvac_LongTermIncentivePlanMember_637964472515373406" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_637964472515373406" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" xlink:to="cvac_VirtualSharesProgramIMember_637964472515373406" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515373406" xlink:to="cvac_VirtualSharesProgramIiMember_637964472515373406" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637964472515343409" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637964472515373406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637964472515373406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637964472515383406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_637964472515383406" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_637964472515383406" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_637964472515383406" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_637964472515383406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing_637964472515383406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_LockUpPeriodAfterInitialListing_637964472515383406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_637964472515394215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_637964472515394215" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees_637964472515394215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_NumberOfKeyEmployees_637964472515394215" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637964472515394215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637964472515394215" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_637964472515394215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_637964472515394215" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_637964472515394215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_ProvisionForEmployerTaxes_637964472515394215" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_637964472515403419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_637964472515403419" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_637964472515403419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_637964472515403419" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_637964472515403419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_637964472515403419" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_637964472515403419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637964472515373406" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_637964472515403419" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_637964472515413418" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_637964472515413418" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515413418" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515413418" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" xlink:to="ifrs-full_GrossCarryingAmountMember_637964472515413418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_637964472515413418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_637964472515413418" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515413418" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_637964472515413418" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_637964472515413418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_637964472515413418" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_637964472515413418" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_637964472515413418" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_637964472515473416" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" xlink:to="cvac_SoftwareMember_637964472515473416" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" xlink:to="ifrs-full_LicencesMember_637964472515473416" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AdvancepaymentsintangibleassetMember" xlink:label="cvac_AdvancepaymentsintangibleassetMember_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637964472515463399" xlink:to="cvac_AdvancepaymentsintangibleassetMember_637964472515473416" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_637964472515413418" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_637964472515473416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_637964472515473416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_637964472515473416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_637964472515473416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_637964472515473416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_637964472515473416" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_637964472515473416" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_637964472515483413" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_637964472515483413" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515483413" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_637964472515483413" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" xlink:to="ifrs-full_GrossCarryingAmountMember_637964472515483413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_637964472515483413" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_637964472515483413" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_637964472515483413" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_637964472515483413" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_637964472515483413" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637964472515483413" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637964472515483413" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="ifrs-full_BuildingsMember_637964472515483413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_637964472515483413" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_637964472515483413" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember_637964472515483413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="ifrs-full_ConstructionInProgressMember_637964472515483413" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CmoNetworkMember" xlink:label="cvac_CmoNetworkMember_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="cvac_CmoNetworkMember_637964472515493418" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ManufacturingFacilitiesMember" xlink:label="cvac_ManufacturingFacilitiesMember_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="cvac_ManufacturingFacilitiesMember_637964472515493418" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_637964472515493418" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637964472515483413" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_637964472515493418" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_637964472515483413" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_637964472515493418" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_637964472515493418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_637964472515493418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_637964472515503554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_637964472515503554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_637964472515503554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_637964472515503554" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_637964472515503554" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_637964472515493418" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_637964472515503554" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Assets held for sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_637964472515503554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_637964472515503554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem" xlink:label="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable_637964472515503554" xlink:to="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem_637964472515513416" xlink:to="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="cvac_InventoriesTable_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_637964472515513416" xlink:to="srt_CounterpartyNameAxis_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637964472515513416" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637964472515513416" xlink:to="cvac_GlaxosmithklineMember_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_637964472515513416" xlink:to="cvac_InventoriesLineItem_637964472515513416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_637964472515513416" xlink:to="cvac_IncreaseDecreaseInInventory_637964472515513416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_637964472515513416" xlink:to="cvac_NetValueOfInventoryTransferred_637964472515513416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_637964472515513416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_637964472515513416" xlink:to="ifrs-full_InventoryWritedown2011_637964472515513416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Prepaid expenses and other assets (current) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_637964472515523452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_637964472515523452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_637964472515523452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurrentGrantReceivable" xlink:label="cvac_CurrentGrantReceivable_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_CurrentGrantReceivable_637964472515523452" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_637964472515523452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCurrentGrantReceivables" xlink:label="cvac_IfrsCurrentGrantReceivables_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_IfrsCurrentGrantReceivables_637964472515523452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_637964472515523452" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Financial assets and financial liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_637964472515523452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_637964472515523452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_637964472515533415" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_637964472515533415" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_637964472515533415" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_637964472515533415" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_637964472515533415" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_637964472515533415" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_637964472515533415" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets" xlink:label="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets_637964472515533415" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_637964472515533415" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LicenseFeePayable" xlink:label="cvac_LicenseFeePayable_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_LicenseFeePayable_637964472515533415" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables_637964472515533415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_ChangeInTradeAndOtherPayables_637964472515533415" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherCurrentPayables_637964472515543416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PayrollRelatedWithholdingTaxes" xlink:label="cvac_PayrollRelatedWithholdingTaxes_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_PayrollRelatedWithholdingTaxes_637964472515543416" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_637964472515543416" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_637964472515543416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_637964472515543416" xlink:to="ifrs-full_TypesOfContractsAxis_637964472515543416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis_637964472515543416" xlink:to="ifrs-full_TypesOfContractsMember_637964472515543416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember_637964472515543416" xlink:to="cvac_ContractResearchOrganizationAgreementMember_637964472515543416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember_637964472515543416" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember_637964472515543416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_637964472515543416" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_637964472515543416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities_637964472515543416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_637964472515543416" xlink:to="cvac_ChangeInOtherLiabilities_637964472515543416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637964472515553416" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637964472515553416" xlink:to="ifrs-full_BorrowingsByNameAxis_637964472515553416" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_637964472515553416" xlink:to="ifrs-full_BorrowingsByNameMember_637964472515553416" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_637964472515553416" xlink:to="cvac_IfrsLineOfCreditMember_637964472515553416" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637964472515553416" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity_637964472515553416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment" xlink:label="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment_637964472515553416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInEachTranche" xlink:label="cvac_MinimumBorrowingsInEachTranche_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_MinimumBorrowingsInEachTranche_637964472515553416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BorrowingsInEachTranche" xlink:label="cvac_BorrowingsInEachTranche_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_BorrowingsInEachTranche_637964472515553416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate" xlink:label="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate_637964472515553416" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_637964472515553416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="ifrs-full_BorrowingsInterestRate_637964472515553416" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaxmimumBorrowingsInterestRate" xlink:label="cvac_MaxmimumBorrowingsInterestRate_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_MaxmimumBorrowingsInterestRate_637964472515563412" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MinimumBorrowingsInterestRate" xlink:label="cvac_MinimumBorrowingsInterestRate_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_MinimumBorrowingsInterestRate_637964472515563412" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities" xlink:label="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities_637964472515563412" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MaximumAggregateRemunerationCapitalAmount" xlink:label="cvac_MaximumAggregateRemunerationCapitalAmount_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_MaximumAggregateRemunerationCapitalAmount_637964472515563412" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity" xlink:label="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity_637964472515563412" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsLossContingencyLossInPeriod" xlink:label="cvac_IfrsLossContingencyLossInPeriod_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_IfrsLossContingencyLossInPeriod_637964472515563412" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637964472515563412" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_LineOfCreditAccruedInterestPayable_637964472515563412" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637964472515563412" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_637964472515563412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings_637964472515563412" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637964472515553416" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_637964472515573408" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_IncomeTaxDisclosureTable_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureTable_637964472515573408" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_637964472515573408" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_637964472515573408" xlink:to="cvac_CurevacCorporateServiceGmbhMember_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_637964472515573408" xlink:to="cvac_CurevacSwissAgMember_637964472515573408" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureTable_637964472515573408" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_637964472515573408" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_637964472515573408" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember_637964472515573408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_637964472515573408" xlink:to="ifrs-full_UnusedTaxLossesMember_637964472515573408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceMember" xlink:label="ifrs-full_TemporaryDifferenceMember_637964472515583411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_637964472515573408" xlink:to="ifrs-full_TemporaryDifferenceMember_637964472515583411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems_637964472515583411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureTable_637964472515573408" xlink:to="cvac_IncomeTaxDisclosureLineItems_637964472515583411" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472515583411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_637964472515583411" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637964472515583411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome_637964472515583411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_637964472515583411" xlink:to="ifrs-full_CurrentTaxExpenseIncome_637964472515583411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome_637964472515583411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_637964472515583411" xlink:to="ifrs-full_DeferredTaxExpenseIncome_637964472515583411" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" xlink:to="srt_CurrencyAxis_637964472515593408" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_637964472515593408" xlink:to="currency_AllCurrenciesDomain_637964472515593408" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637964472515593408" xlink:to="currency_USD_637964472515593408" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637964472515593408" xlink:to="currency_CHF_637964472515593408" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637964472515593408" xlink:to="currency_EUR_637964472515593408" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637964472515593408" xlink:to="currency_GBP_637964472515593408" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" xlink:to="ifrs-full_TypesOfRisksAxis_637964472515593408" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637964472515593408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_637964472515593408" xlink:to="ifrs-full_TypesOfRisksMember_637964472515593408" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637964472515593408" xlink:to="ifrs-full_CurrencyRiskMember_637964472515603418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_637964472515603418" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_637964472515603418" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_637964472515603418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_TradeAndOtherPayablesMember_637964472515603418" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_TradeAndOtherReceivablesMember_637964472515603418" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_TradeAndOtherPayablesOneMember_637964472515603418" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_637964472515603418" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_637964472515603418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_637964472515603418" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_TradeAndOtherPayablesTwoMember_637964472515613424" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesOneMember" xlink:label="cvac_OtherReceivablesOneMember_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_OtherReceivablesOneMember_637964472515613424" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherReceivablesTwoMember" xlink:label="cvac_OtherReceivablesTwoMember_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_OtherReceivablesTwoMember_637964472515613424" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_OtherreceivablesMember" xlink:label="cvac_OtherreceivablesMember_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_637964472515603418" xlink:to="cvac_OtherreceivablesMember_637964472515613424" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637964472515593408" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637964472515613424" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_637964472515613424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637964472515613424" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_637964472515613424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Diluteeffectofordinarysharesissued" xlink:label="cvac_Diluteeffectofordinarysharesissued_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="cvac_Diluteeffectofordinarysharesissued_637964472515623424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares_637964472515623424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_637964472515623424" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Commonsharesissuedandoutstanding" xlink:label="cvac_Commonsharesissuedandoutstanding_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="cvac_Commonsharesissuedandoutstanding_637964472515623424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" xlink:to="ifrs-full_RangeAxis_637964472515623424" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637964472515623424" xlink:to="ifrs-full_RangesMember_637964472515623424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637964472515623424" xlink:to="ifrs-full_BottomOfRangeMember_637964472515623424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637964472515623424" xlink:to="ifrs-full_TopOfRangeMember_637964472515623424" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" xlink:to="srt_TitleOfIndividualAxis_637964472515623424" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515623424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637964472515623424" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515623424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515623424" xlink:to="cvac_BaronJeanStephenneMember_637964472515633419" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515623424" xlink:to="cvac_VincentStphenneMember_637964472515633419" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637964472515623424" xlink:to="cvac_AntonyBlancMember_637964472515633419" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637964472515633419" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637964472515633419" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_RittershausRechtsanwaelteMember_637964472515633419" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_Dr.IngmarHoerrMember_637964472515633419" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_DietmarHoppMember_637964472515633419" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_BepharbelManufacturingS.aMember_637964472515633419" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MolecularhealthgmbhMember" xlink:label="cvac_MolecularhealthgmbhMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_MolecularhealthgmbhMember_637964472515633419" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember_637964472515633419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637964472515633419" xlink:to="cvac_ClarentisSrlMember_637964472515633419" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515643411" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637964472515643411" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637964472515643411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637964472515643411" xlink:to="cvac_VirtualSharesProgramIMember_637964472515643411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637964472515623424" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_637964472515643411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_637964472515643411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="ifrs-full_WeightedAverageSharePrice2019_637964472515643411" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_637964472515643411" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_RelatedPartyTransactionConsultingFees_637964472515643411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_637964472515643411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees_637964472515643411" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_637964472515653406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_637964472515653406" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_637964472515653406" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_TerminationFeeRelatedPartyTransactions_637964472515653406" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_637964472515653406" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_CollaborationAgreementMilestonePayment_637964472515653406" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_637964472515653406" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation_637964472515653406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_IfrsContractualObligation_637964472515653406" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_637964472515663406" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637964472515643411" xlink:to="cvac_PaymentsToRelatedPartyForServices_637964472515663406" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" xlink:to="ifrs-full_BusinessCombinationsAxis_637964472515663406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_637964472515663406" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515663406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_637964472515663406" xlink:to="ifrs-full_BusinessCombinationsMember_637964472515663406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsMember_637964472515663406" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_637964472515663406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637964472515663406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" xlink:to="ifrs-full_RangeAxis_637964472515663406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637964472515663406" xlink:to="ifrs-full_RangesMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637964472515673417" xlink:to="ifrs-full_BottomOfRangeMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637964472515673417" xlink:to="ifrs-full_TopOfRangeMember_637964472515673417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis_637964472515673417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_637964472515673417" xlink:to="ifrs-full_ContingentLiabilitiesMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContingentLiabilitiesMember_637964472515673417" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContingentLiabilitiesMember_637964472515673417" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_637964472515673417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" xlink:to="ifrs-full_ProductsAndServicesAxis_637964472515673417" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_637964472515673417" xlink:to="ifrs-full_ProductsAndServicesMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637964472515673417" xlink:to="cvac_MilestonesMember_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_637964472515663406" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_637964472515673417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_637964472515673417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_637964472515683409" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_LiabilitiesIncurred_637964472515683409" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_CashTransferred_637964472515683409" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_637964472515683409" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_637964472515683409" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_637964472515683409" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_637964472515683409" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_637964472515683409" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_637964472515683409" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_637964472515683409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_637964472515683409" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_637964472515693407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_637964472515693407" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_637964472515693407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_637964472515693407" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_637964472515693407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_637964472515693407" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_637964472515707077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_637964472515707077" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_637964472515707077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_637964472515707077" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_637964472515707077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber_637964472515707077" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_637964472515713425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber_637964472515713425" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_637964472515713425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_637964472515673417" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_637964472515713425" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511460448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CureVac N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511821168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 44,519<span></span>
</td>
<td class="nump">&#8364; 32,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(79,913)<span></span>
</td>
<td class="num">(53,156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and distribution expenses</a></td>
<td class="num">(819)<span></span>
</td>
<td class="num">(1,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(22,422)<span></span>
</td>
<td class="num">(236,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(51,678)<span></span>
</td>
<td class="num">(50,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">35,207<span></span>
</td>
<td class="nump">45,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(461)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(75,567)<span></span>
</td>
<td class="num">(263,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">5,343<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(2,535)<span></span>
</td>
<td class="num">(8,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">(72,759)<span></span>
</td>
<td class="num">(264,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(1,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(72,677)<span></span>
</td>
<td class="num">(265,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency adjustments</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">&#8364; (72,889)<span></span>
</td>
<td class="num">&#8364; (265,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="num">&#8364; (0.39)<span></span>
</td>
<td class="num">&#8364; (1.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="num">&#8364; (0.39)<span></span>
</td>
<td class="num">&#8364; (1.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509383504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 12,281<span></span>
</td>
<td class="nump">&#8364; 13,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">192,015<span></span>
</td>
<td class="nump">168,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">42,996<span></span>
</td>
<td class="nump">32,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">250,231<span></span>
</td>
<td class="nump">218,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Assets held for sale</a></td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">13,241<span></span>
</td>
<td class="nump">56,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">13,341<span></span>
</td>
<td class="nump">18,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">3,608<span></span>
</td>
<td class="nump">4,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">70,968<span></span>
</td>
<td class="nump">49,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">573,566<span></span>
</td>
<td class="nump">811,464<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">675,589<span></span>
</td>
<td class="nump">940,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">925,820<span></span>
</td>
<td class="nump">1,158,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">22,496<span></span>
</td>
<td class="nump">22,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">1,732,148<span></span>
</td>
<td class="nump">1,728,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury Shares</a></td>
<td class="num">(1,734)<span></span>
</td>
<td class="num">(5,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(1,129,462)<span></span>
</td>
<td class="num">(1,056,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">623,202<span></span>
</td>
<td class="nump">688,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">35,931<span></span>
</td>
<td class="nump">25,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">70,790<span></span>
</td>
<td class="nump">86,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">106,985<span></span>
</td>
<td class="nump">112,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">4,278<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">48,496<span></span>
</td>
<td class="nump">127,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">92,758<span></span>
</td>
<td class="nump">170,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income taxes payable</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">49,488<span></span>
</td>
<td class="nump">55,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">195,633<span></span>
</td>
<td class="nump">357,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">302,618<span></span>
</td>
<td class="nump">469,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 925,820<span></span>
</td>
<td class="nump">&#8364; 1,158,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511636032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Capital reserve</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Currency translation reserve</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">&#8364; 21,655,000<span></span>
</td>
<td class="nump">&#8364; 1,334,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (645,069,000)<span></span>
</td>
<td class="nump">&#8364; 57,000<span></span>
</td>
<td class="nump">&#8364; 711,347,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,756,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,756,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,756,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="num">(265,786,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,382,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,382,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">690,000<span></span>
</td>
<td class="nump">403,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,062,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,739,000)<span></span>
</td>
<td class="num">&#8364; (3,022,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,761,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2021</a></td>
<td class="nump">22,425,000<span></span>
</td>
<td class="nump">1,726,713,000<span></span>
</td>
<td class="num">(3,022,000)<span></span>
</td>
<td class="num">(910,825,000)<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">835,318,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">22,454,000<span></span>
</td>
<td class="nump">1,728,658,000<span></span>
</td>
<td class="num">(5,817,000)<span></span>
</td>
<td class="num">(1,056,785,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="nump">688,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212,000)<span></span>
</td>
<td class="num">(212,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677,000)<span></span>
</td>
<td class="num">(212,000)<span></span>
</td>
<td class="num">(72,889,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,262,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SettlementOfShareBasedPaymentAwardsAmount', window );">Settlement of share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,452,000)<span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">4,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,721,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2022</a></td>
<td class="nump">&#8364; 22,496,000<span></span>
</td>
<td class="nump">&#8364; 1,732,148,000<span></span>
</td>
<td class="num">&#8364; (1,734,000)<span></span>
</td>
<td class="num">&#8364; (1,129,462,000)<span></span>
</td>
<td class="num">&#8364; (246,000)<span></span>
</td>
<td class="nump">&#8364; 623,202,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SettlementOfShareBasedPaymentAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based payment awards settled in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SettlementOfShareBasedPaymentAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Share-based payment expense (incl. deferred taxes)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511647712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Cash Flows<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">&#8364; (72,759)<span></span>
</td>
<td class="num">&#8364; (264,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile loss before tax to net cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(5,343)<span></span>
</td>
<td class="num">(7,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">8,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and impairment of property, plant and equipment and right-of-use assets</a></td>
<td class="nump">16,651<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentsOfInventoryAndPrepayments', window );">Impairment of inventory and prepayments</a></td>
<td class="nump">25,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">3,597<span></span>
</td>
<td class="nump">8,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions', window );">Non-cash income from release of provisions</a></td>
<td class="num">(47,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangesInWorkingCapitalAbstract', window );"><strong>Working capital changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in trade receivables and contract assets</a></td>
<td class="nump">5,164<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventory</a></td>
<td class="nump">16,367<span></span>
</td>
<td class="num">(48,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Decrease / (increase) in other assets</a></td>
<td class="num">(14,051)<span></span>
</td>
<td class="num">(135,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</a></td>
<td class="num">(129,038)<span></span>
</td>
<td class="nump">165,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities', window );">(Decrease) / increase in other current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Decrease / (increase) in deferred taxes</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(2,608)<span></span>
</td>
<td class="num">(5,210)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flow (used in) operating activities</a></td>
<td class="num">(201,175)<span></span>
</td>
<td class="num">(274,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(43,507)<span></span>
</td>
<td class="num">(69,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(3,966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flow (used in) investing activities</a></td>
<td class="num">(44,715)<span></span>
</td>
<td class="num">(73,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments on lease obligations</a></td>
<td class="num">(1,943)<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProceedFromIssuingOtherEquityInstrument', window );">Payment on / Proceeds from Treasury Shares</a></td>
<td class="nump">631<span></span>
</td>
<td class="num">(23,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues', window );">Proceeds on At-the-market offering program (net of transaction costs)</a></td>
<td class="nump">4,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the issuance of shares (net of transaction costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flow (used in)provided by financing activities</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="nump">378,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(242,481)<span></span>
</td>
<td class="nump">30,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Currency translation gains (losses) on cash and cash equivalents</a></td>
<td class="nump">4,583<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">811,464<span></span>
</td>
<td class="nump">1,322,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">&#8364; 573,566<span></span>
</td>
<td class="nump">&#8364; 1,355,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from at the market shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentsOfInventoryAndPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments of inventory and prepayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentsOfInventoryAndPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProceedFromIssuingOtherEquityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Proceed From Issuing Other Equity Instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProceedFromIssuingOtherEquityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612516911792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationAbstract', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationTextBlock', window );">Corporate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#8220;CureVac&#8221; or &#8220;CV&#8221; or the &#8220;Company&#8221;) is the parent company of CureVac Group (&#8220;Group&#8221;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under RSIN 861149336. The Company&#8217;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 46 &#8211; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on corporate information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612516947776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the six months ended June 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 18, 2022. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the six months ended June 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512314816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">Notes to the consolidated financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,041</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 892</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 32,425</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,519</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2022 EUR 31,818k (2021: EUR 27,730k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR 431k (2021: EUR 338k) related to delivery of products and (iii) EUR 12,270k (2021: EUR 4,357k) were recognized from those research and development services considered distinct within the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the six months ended June 30, 2022, EUR 43,041k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#8221;GSK I&#8221;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#8217;s second-generation COVID-19 vaccine candidate, CV2CoV (&#8220;GSK II&#8221;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2022, also includes recognition of EUR 5,321k of the milestone amount. The remaining EUR 4,679k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2021, revenue primarily consisted of EUR 29,335k recognized from the upfront payments under the collaboration with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront&#160;payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,769</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 30,000k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142,095</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 120,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,731</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,818</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Contract balances:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,341</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120,278</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,869)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,883)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,388)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,516)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,150)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,594)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,326)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (53,156)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (79,913)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, cost of sales mainly increased compared to the same period of 2021 due to increased write-offs for raw materials amounting to EUR 34,640k, which were procured for manufacture into products to sell to GSK are now no longer expected to be purchased. The prior year Third Party Services have been higher due to last year&#8217;s set-up activities for production process for CVnCoV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (560)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (227)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (819)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR 499k (June 30, 2021: 543) and share-based payment expense of EUR 61k (June 30, 2021: 121k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,928)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,419)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,849)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,119)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,413)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,354)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (210,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,053</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (464)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,270)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (236,267)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,422)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#180;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the six months ended June 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased resulting in reversal of provision for onerous contracts in the amount of EUR 21,303k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, in the six months ended on June 30, 2022 the balance was impacted by further consumption of inventory. As of June 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR 14,759k (June 30, 2021: EUR 14,849k) and share-based payment expense of EUR 90k (June 30, 2021: 370k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,971)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,704)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,796)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,320)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,091)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,796)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (50,651)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51,678)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022, of EUR 15,525k (June 30, 2021: EUR 11,642k) and share-based payment expense of EUR 3,446k (June 30, 2021: EUR 7,720k). During the six months ended June 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The increase in &#8220;Other&#8221; mainly result from additional insurance costs of EUR 2,769k, mainly related to the D&amp;O insurance (June 30, 2021: EUR  2,343k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,961</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 45,234</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the six months ended June 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research (BMBF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant terminated in 2021. With regard to the grant component, during the six months ended June 30, 2021, the Group has recognized grant income in the amount of EUR 44,090k (June 30, 2022: EUR 0).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations (CEPI)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 8k (June 30, 2021: EUR 23k) as &#8220;other operating income&#8221;. As of June 30, 2022, EUR 1,281k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR 1,288k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the six months ended June 30, 2022, CureVac recognized EUR 96k (June 30, 2021: EUR 211k) from the amortization of the grants on a straight-line basis into other operating income. As of June 30, 2022, EUR 1,782k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR 1,879k). </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612516959808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Issued Capital and Reserves</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#8217;s articles of association, the Company&#8217;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a <span style="-sec-ix-hidden:Hidden_G3msjGiE3kqZNUEVJNk5yA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR 0.12. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#8217;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. In June 2022, 340,015 shares were issued under the ATM program, raising USD 4.8 million in net proceeds; related offering expenses were recorded against the proceeds in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,732</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,732)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,015</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,211</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,418</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,418)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,466,954</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512295152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based payments.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR 3,597k and EUR 8,212k, respectively, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Six months period ended June 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,446</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Six months ended June 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,078</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. On June 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 of his options in May 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On June 30, 2022, none of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June all his options forfeited. All expenses recognized up to him leaving were reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted 11,500 options to two key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the COO and CDO under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac granted 130,000 options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP during the six months ended June 30, 2022, is in an amount of EUR 3,078k (2021; EUR 7,331k) and is included in general and administrative expenses and sales and marketing expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, the group awarded 10,956 RSUs to supervisory board members and on December 23, 2021, the group awarded 63,095 RSUs to the executive board and various key employees. Within the first half of 2022, 10,238 RSU&#8217;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, the group awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded 36,000 options to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; 101,609 options were exercised within the first and second quarter of 2022 at a weighted average share price of USD 19.24.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612516953920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsExplanatory', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, the Group acquired intangible assets of EUR 1,207k (six months ended June 30, 2021: EUR 3,966k). The acquisitions during the six months ended June 30, 2022 and 2021 mainly related to licenses, software and prepayments made to acquire those.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR 3,034k (June 30, 2021: EUR 6,302k) as well as additional amounts recognized as construction in progress of EUR 39,386k for Company-owned GMP IV facility (EUR 29,552k) and equipment physically located at the CMO facilities (EUR 3,657k) and the remaining amount mainly for Company&#8217;s GMP facilities. The increase was partially offset by EUR 5,854k impairment of equipment located at a CMO facility, which was recognized in cost of sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511841632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organizations for the sale of Ultra-Low Temperature freezers for a total price of EUR 865k. The actual sale of the assets occurred in July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Section Presentation and disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512265312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials. During the six months ended June 30, 2022, the decrease in inventory of EUR 42,918k is due primarily to transfer of inventory EUR <span style="-sec-ix-hidden:Hidden_jkLIgqZzAkOONGLtAkGXdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9,8</span></span> million (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR 34,640k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512272720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other assets (current)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory', window );">Prepaid expenses and other assets (current)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of June 30, 2022 amounted to EUR 70,968k (December 31, 2021: 49,244k) and mainly include receivables for the GSK compensation of EUR 45,801k (December 31, 2021; EUR 0k). For more details we refer to note 3.6. In addition, other assets include further prepayments for material in the amount of EUR 4,653k (December 31, 2021:EUR 5,724k) and tax claims against the tax authorities of EUR 15,160k (December 31, 2021: EUR 35,234k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509217696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial assets and financial liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2022 and 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512277264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the six months ended June 30, 2022, the decrease of EUR 79,207k in trade and other payables was primarily due to less payables to suppliers as the CVnCoV project was stopped in FY 2021 Q4.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512277520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsOtherLiabilitiesAbstract', window );"><strong>Other liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the six months ended June 30, 2022, the decrease of EUR 77,314k in other liabilities was primarily due to a net decrease of contract termination provisions, due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate, due to a consumption of the CRO accrual for onerous losses and due to lower accruals for outstanding invoices. The change in estimate of the contract termination provisions resulted primarily from the Company now being able to avoid an outflow of resources since GSK took over from the Group reserved capacity at Novartis (see Note 3.4 and 3.6 for additional information).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512211056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Loans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR 25 million &#160;(plus accrued interest of EUR 1,726k) was outstanding on the loan as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR 26,633k, which comprises of EUR 25,000k repayment of the loan and 1,633k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512211312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group booked the expected tax benefits or expenses based on a best estimate for a period of six months ended June, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the six months ended June 30, 2022 and 2021, the Group recorded a consolidated income tax benefit (June 30, 2021: tax expense) EUR 82k (June 30, 2021: EUR -1,329k), respectively. The consolidated income tax benefit (June 30, 2021: income tax expense) for the six months ended June 30, 2022, resulted from income tax benefit from CureVac Corporate Service of EUR 96k for current tax and tax expenses of EUR 12k for releasing deferred tax benefit on loss carryforwards. CureVac Swiss AG has a current tax expense of EUR 2k (June 30, 2021: expenses from CureVac Inc. of EUR 146k and deferred tax expense on taxable temporary differences of EUR 1,286k as well as a recognition of a deferred tax benefit on tax loss carryforwards of EUR 103k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512242192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Disclosure of financial instruments and risk management</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Refer to note 15 to the consolidated financial statements as of December&#160;31, 2021 for additional information on the Group&#8217;s risk management activities. As of June 30, 2022, the Group held cash and cash equivalents of USD 62,863k and CHF 110k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612510487392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The weighted number of shares outstanding for the six months ended June 30, 2022 was 187,041,805 (June 30, 2021: 185,062,052). This has led to a basic loss per share for the six months ended June 30, 2022 and 2021 of EUR 0.39 and EUR 1.44, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the six months ended June 30, 2022 and 2021. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612510256144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s largest shareholder, purchased EUR 100,000k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s common shares at a price of USD 16.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and amounts to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. This function he executes by using Clarentis SRL. Related to these services CureVac paid until June 2022 an amount of EUR 34k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of &#8364;3.9 million, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#233;phenne, our supervisory board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds 1.43% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512341888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">18. Subsequent events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#8216;closing date&#8217;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#8216;Frame Pharmaceuticals&#8217;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling to identify structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#8217;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#8217;s broader oncology strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#8216;SPA&#8217;) dated June 8, 2022, a total purchase price of up to EUR 32.0 million payable mainly in shares of CureVac N.V. (total of 1,783,460), as well as a certain amount of cash, was agreed. Additionally, a net amount of EUR 0.66 million for discharging contractual obligations for outstanding advisory agreements with former shareholders was also agreed to. The shares were valued in the SPA at an average share price of &#8364;16.44.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At closing, CureVac paid 50% of the agreed purchase price, i.e. 810,242 shares were issued and cash in the amount of EUR 0.25 million was paid. Further shares worth EUR 0.66 million were issued to pay certain liabilities towards former shareholders of Frame Pharmaceuticals. In addition, restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element of the transaction will be accounted for as a separate share-based transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining 50% of the purchase price is contingent upon achieving two milestones. A further 194.647 shares (representing 10% of the purchase price) will be issued upon the achievement of the successful investigational new drug application filing and further 778.588 shares (representing 40% of the purchase price) will be issued upon successful proof of mechanism in humans. The fair value of these contingent payments will be determined considering the likelihood of the events occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the transaction occurred only shortly after the reporting date, it is not practicable for the Company to provide information in relation to the initial accounting for the acquisition, in particular regarding the identification and measurement of identifiable assets and liabilities, including any goodwill, and the consideration transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the Purchase Price Allocation, the shares to be issued in exchange for Frame Pharmaceuticals shares will be based on the share price at closing, i.e. &#8364;13.64.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash in the amount of EUR 308k was acquired. Transactions costs in relation to the acquisition amounting to total EUR 0.4 million have been expensed within administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Infringement Lawsuit</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Germany on June 29, 2022, CureVac brought an infringement lawsuit under three utility models and one patent against BioNTech on the basis that the manufacture and sale of Comirnaty infringes CureVac&#8217;s intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In the US on July 25, 2022, BioNTech and Pfizer jointly brought an action seeking a declaration that the manufacture and sale of Comirnaty does not infringe three CureVac US patents. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511922400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the six months ended June 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 18, 2022. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock', window );">New standards, interpretations and amendments adopted by the Group</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the six months ended June 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory', window );">Impact of COVID-19 and the Russia-Ukraine Conflict</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for Covid-19 impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511785632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue from contract with customers recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,041</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 892</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 32,425</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,519</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory', window );">Summary of upfront payments and related revenues recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront&#160;payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,769</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 30,000k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142,095</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 120,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,731</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,818</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Schedule of contract balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,341</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120,278</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,869)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,883)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,388)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,516)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,150)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,594)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,326)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td></tr><tr><td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (53,156)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (79,913)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (560)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (227)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (819)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,928)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,419)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,849)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,119)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,413)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,354)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (210,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,053</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (464)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,270)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (236,267)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,422)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,971)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,230)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,704)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,796)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,320)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,091)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,796)</p></td></tr><tr><td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (50,651)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51,678)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Schedule of other operating income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,961</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 45,234</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about upfront payments and related revenues recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511739632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of number of shares issued and outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,732</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,732)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,015</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,211</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,418</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,418)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,466,954</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509283216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of expense recognized for employee services received</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Six months period ended June 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,446</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock', window );">Schedule for expense recognized for the programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Six months ended June 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,078</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expense recognized for employee services explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of expense recognized for the programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509130000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Revenue from contract with customers (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 44,519<span></span>
</td>
<td class="nump">&#8364; 32,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">31,818<span></span>
</td>
<td class="nump">27,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember', window );">Milestone revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">5,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived', window );">Additional development milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities', window );">Development milestone payment included in contract liabilities</a></td>
<td class="nump">4,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">12,270<span></span>
</td>
<td class="nump">4,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BE', window );">Belgium | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">43,041<span></span>
</td>
<td class="nump">29,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Switzerland | CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 586<span></span>
</td>
<td class="nump">&#8364; 169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional development milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalDevelopmentMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payment included in contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511923456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the issuance of shares (net of transaction costs)</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 404,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,519<span></span>
</td>
<td class="nump">&#8364; 32,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508920336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">&#8364; 120,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 142,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">31,818<span></span>
</td>
<td class="nump">&#8364; 27,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront payments received or receivable</a></td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront payments received or receivable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront payments received or receivable</a></td>
<td class="nump">8,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">4,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront payments received or receivable</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">114,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 135,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">30,769<span></span>
</td>
<td class="nump">&#8364; 24,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Minimum | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront payments received or receivable</a></td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments of the company included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received or receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612510469952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 13,341<span></span>
</td>
<td class="nump">&#8364; 18,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 120,278<span></span>
</td>
<td class="nump">&#8364; 142,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508901552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Cost of sales (Details) - Cost of sales - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpensesByNatureLineItems', window );"><strong>Disclosure Of Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (13,869)<span></span>
</td>
<td class="num">&#8364; (9,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(36,883)<span></span>
</td>
<td class="num">(2,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(19,516)<span></span>
</td>
<td class="num">(31,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(1,150)<span></span>
</td>
<td class="num">(2,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(8,326)<span></span>
</td>
<td class="num">(1,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(5,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(79,913)<span></span>
</td>
<td class="num">&#8364; (53,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WriteOffOfRawMaterials', window );">Write off of raw materials</a></td>
<td class="nump">&#8364; 34,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_WriteOffOfRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of raw materials written off during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_WriteOffOfRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509440368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Selling and distribution expenses (Details) - Selling and distribution expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpensesByNatureLineItems', window );"><strong>Disclosure Of Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (560)<span></span>
</td>
<td class="num">&#8364; (664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(819)<span></span>
</td>
<td class="num">(1,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">&#8364; 61<span></span>
</td>
<td class="nump">&#8364; 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508959456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Research and development expenses (Details) - Research and development expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpensesByNatureLineItems', window );"><strong>Disclosure Of Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">&#8364; (23,419)<span></span>
</td>
<td class="num">&#8364; (5,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(14,849)<span></span>
</td>
<td class="num">(15,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(1,354)<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="nump">21,053<span></span>
</td>
<td class="num">(210,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(464)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="num">(1,180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(22,422)<span></span>
</td>
<td class="num">(236,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">14,759<span></span>
</td>
<td class="nump">14,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">&#8364; 370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionForOnerousContracts', window );">Reversal of provision of onerous contracts</a></td>
<td class="nump">&#8364; 21,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PatentsAndFeesToRegisterLegalRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for registering a legal right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PatentsAndFeesToRegisterLegalRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionForOnerousContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionForOnerousContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508922896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - General and administrative expenses (Details) - General and administrative expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpensesByNatureLineItems', window );"><strong>Disclosure Of Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (18,971)<span></span>
</td>
<td class="num">&#8364; (19,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(2,704)<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(12,796)<span></span>
</td>
<td class="num">(18,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(5,320)<span></span>
</td>
<td class="num">(3,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(6,091)<span></span>
</td>
<td class="num">(3,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(5,796)<span></span>
</td>
<td class="num">(4,458)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(51,678)<span></span>
</td>
<td class="num">(50,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">15,525<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">7,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">&#8364; 2,769<span></span>
</td>
<td class="nump">&#8364; 2,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509267936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Other operating income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransfer', window );">Compensation for CMO transfer</a></td>
<td class="nump">&#8364; 33,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CostOfReimbursementClaim', window );">Reimbursement claim</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SaleOfEquipment', window );">Sale of equipment</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherOperatingIncomeGovernmentGrants', window );">Grants and other cost reimbursements from government agencies and similar bodies</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">&#8364; 45,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MiscellaneousOtherOperatingIncomeOther', window );">Other</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Total</a></td>
<td class="nump">&#8364; 35,207<span></span>
</td>
<td class="nump">&#8364; 45,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CostOfReimbursementClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of reimbursement claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CostOfReimbursementClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MiscellaneousOtherOperatingIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MiscellaneousOtherOperatingIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherOperatingIncomeGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other operating income recognized in relation to government agencies and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherOperatingIncomeGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of equipment in operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509214352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver', window );">Reversal of provision recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities', window );">Compensation consist for set-up activities</a></td>
<td class="nump">&#8364; 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses', window );">Compensation consist of Manufacturing Interim Period Reimbursable Expenses</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember', window );">German Federal Ministry of Education and Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 44,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumGrantToBeReceived', window );">Maximum grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">&#8364; 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">1,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember', window );">Bill &amp; Melinda Gates Foundation (BMGF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">&#8364; 1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaximumGrantToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum grant receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaximumGrantToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509247008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Issued Capital and Reserves - Overview and General Remarks (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509191088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Impact of share split (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareOptionExercises', window );">Share option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,418<span></span>
</td>
<td class="nump">78,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,418)<span></span>
</td>
<td class="num">(78,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">At-the-market offering program issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StockIssuedDuringPeriodForExercises', window );">Share issuances for exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding ending</a></td>
<td class="nump">187,466,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,466,954<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 404,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">At-the-market offering program issuances</a></td>
<td class="nump">340,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate gross proceeds receivable from issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AggregateGrossProceedsReceivableFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued and outstanding for during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents for decrease in number of shares due to treasury of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StockIssuedDuringPeriodForExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period, upon exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StockIssuedDuringPeriodForExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511483136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="nump">&#8364; 370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">7,720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_BenefitExpenseRecognizedForShareBasedPayment', window );">Total</a></td>
<td class="nump">&#8364; 3,597<span></span>
</td>
<td class="nump">&#8364; 8,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_BenefitExpenseRecognizedForShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit expense benefit recognized for share-based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_BenefitExpenseRecognizedForShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511579888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expense recognized for the program (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">&#8364; 3,597<span></span>
</td>
<td class="nump">&#8364; 8,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">7,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember', window );">RSU for key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="nump">&#8364; 308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedForEmployeeServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized for employee services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedForEmployeeServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612505846384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>Option </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 10, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 23, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>Option </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based based payments expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Thereof exercisable</a></td>
<td class="nump">101,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember', window );">Chief Scientific Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember', window );">Chief Operating Officer and Chief Development Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember', window );">Chief Business Officer and Chief Commercial Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelepmentOfficerMember', window );">Chief Development Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember', window );">Dan Menichella, then Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember', window );">Members of executive board and various key employees | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember', window );">Key employees | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfKeyEmployees', window );">Number of key employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember', window );">Executive board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember', window );">Executive board members | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory board members | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfKeyEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of key employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfKeyEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments settled in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelepmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefDevelepmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612510444000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs | licenses, software and prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">&#8364; 1,207<span></span>
</td>
<td class="nump">&#8364; 3,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508942064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment', window );">Partial Offset of increase in property, plant and equipment</a></td>
<td class="nump">&#8364; 5,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">39,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember', window );">Company-owned GMP IV facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">29,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember', window );">Equipment physically located at the CMO facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">3,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">&#8364; 3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs | Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in PPE off set by impairment in equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612512433232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets held for sale (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem', window );"><strong>Noncurrent Assets Or Disposal Groups Classified As Held For Sale [Line Item}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration</a></td>
<td class="nump">&#8364; 865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>"
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule disclosing information related to  non-current assets or disposal groups classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508873104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - GSK<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Inventories [Line item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseInInventory', window );">Decrease in inventory</a></td>
<td class="nump">&#8364; 42,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetValueOfInventoryTransferred', window );">Net inventory transferred</a></td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-offs</a></td>
<td class="nump">&#8364; 34,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseInInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in inventory during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseInInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetValueOfInventoryTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net value of inventory transferred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetValueOfInventoryTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509274480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other assets (current)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">&#8364; 70,968<span></span>
</td>
<td class="nump">&#8364; 49,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments for material</a></td>
<td class="nump">4,653<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Tax claims against the tax authorities</a></td>
<td class="nump">15,160<span></span>
</td>
<td class="nump">35,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer', window );">Prepayments for compensation for CMO transfer</a></td>
<td class="nump">&#8364; 45,801<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612510477024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets', window );">Transfer from Level 1 to Level 2, Assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets', window );">Transfer from Level 2 to Level 1, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities', window );">Transfer from Level 1 to Level 2, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities', window );">Transfer from Level 2 to Level 1, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets', window );">Transfers into Level 3, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Transfers out of Level 3, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities', window );">Transfers into Level 3, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfers out of Level 3, Liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509122144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInTradeAndOtherPayables', window );">Amount of decrease in trade and other payables</a></td>
<td class="nump">&#8364; 79,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511115120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Disclosure of Other liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInOtherLiabilities', window );">Decrease in other liabilities</a></td>
<td class="nump">&#8364; 77,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508972368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans (Details) - Line of credit - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Amount drawn</a></td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_LineOfCreditAccruedInterestPayable', window );">Accrued interest</a></td>
<td class="nump">&#8364; 1,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RepaymentsOfPrincipalAmountOfBorrowings', window );">Repayment of principal amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings', window );">Repayment of accrued interest and fees of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_LineOfCreditAccruedInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lin of credit accrued interest payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_LineOfCreditAccruedInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RepaymentsOfPrincipalAmountOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle principal amount of borrowings, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RepaymentsOfPrincipalAmountOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=cvac_IfrsLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=cvac_IfrsLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612509337792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="nump">&#8364; 82<span></span>
</td>
<td class="num">&#8364; (1,329)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember', window );">CureVac Corporate Service GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember', window );">CureVac Corporate Service GmbH | Loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember', window );">CureVac Swiss AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember', window );">CureVac Swiss AG | Loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">&#8364; 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember', window );">CureVac Swiss AG | Temporary difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508969968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management - Foreign currency risk (Details) - Jun. 30, 2022 - Foreign currency risk - Cash and cash equivalents<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="nump">$ 62,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612511458064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares outstanding</a></td>
<td class="nump">187,041,805<span></span>
</td>
<td class="nump">185,062,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="num">&#8364; (0.39)<span></span>
</td>
<td class="num">&#8364; (1.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508787248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>loan</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember', window );">Dietmar Hopp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInNumberOfSharesOutstanding', window );">Capital Increase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionNumberOfLoansReceived', window );">Number of convertible loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember', window );">BePharBel Manufacturing S.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Maximum settlement amount</a></td>
<td class="nump">&#8364; 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember', window );">Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CollaborationAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember', window );">Baron Jean Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember', window );">Vincent Stphenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember', window );">Antony Blanc | Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PaymentsToRelatedPartyForServices', window );">Payments to related party for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CollaborationAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CollaborationAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PaymentsToRelatedPartyForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made to related party by the company for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PaymentsToRelatedPartyForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionNumberOfLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of loans received from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionNumberOfLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_VincentStphenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_AntonyBlancMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140612508824032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>EUR (&#8364;) </div>
<div>USD ($) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares transferred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncurred', window );">Net amount of discharging contractual obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PurchasePriceAllocationSharePriceAsOfClosingDate', window );">Closing date share price | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling', window );">Percent of first milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transactions costs related to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Average share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestonesMember', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling', window );">Percent of first milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares transferred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans', window );">Percent of second milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares transferred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778.588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans', window );">Percent of second milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember', window );">Frame Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares transferred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of first milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of second milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PurchasePriceAllocationSharePriceAsOfClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the closing date share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PurchasePriceAllocationSharePriceAsOfClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_MilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>cvac-20220630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:cvac="http://www.curevac.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvac-20220630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KhUGmIdimECoLuArSGzN7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_sTG3gTwnF06uW__PG0Jy7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CreBB5VP3EKrtTllWwe7cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_josAwYgRAUikV20Ufw6ucQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_TujPDblK1EuxI80RvU-NLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ukmwgK4pjkeQL_CmzxJNpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_hBqt_J_E8U2Ykx9xI6ZM9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_Niu8fCC5EEeSADXrcrVtmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_d2Hm2LGP_ke9M8xIEktJpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_skb-i2lgmkG-FxOxet3a0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_cvXKLI50Ok29UKYe1Lppng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Pyt_GawsiEiGAxSCTTHNSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_YkJamxu9vUOFt13D2FrYnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_PImd1JWYGUuBROPVuT6t1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_Lc0XNMKuKEqN_5NhPdFzTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_m6vvO3sZ60-XG1n4n_R1BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_kJmg11wUDk6B6oaK6o4npw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_J42m4KTLKUOHHRX1Xm1Ajg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_IZKQNmwJz0Otp2sIpw7z9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_IbyWgW8zTka7Hdyj-GqiEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_ygWZIJY7-ECXlg47u0aOrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_2xzoP9RNVk-PMBP-aAb16g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_jk-0HXYllkOyUB1FBqMB3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_Z1RDELYnhkW7Qf2dwfv-dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_SdTrfxiB0U-Z0Gmk5GUxOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_TtMaJsFnHU-GN-4kQhkccg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_94_eUZcr1k6ch6WDNbNttg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelepmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9FShId--2E63ykkNfrEmmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_w31L0BBG7UmU35R2D2Zt4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_G2czk_grS0e2UewXI2oR9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_9BE_1GHmUECsOC7edBk3kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Ke6127tPckS7cBQb7_LfxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_zpKYCdvoIkWzWr5AFwv_Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_IfolEyZFMEKGD2w2ivzW5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_z5pHV_ql802Y2Ej33MoQPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_MC60TuOPQEegv3N3oZBOrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_vdvY7bSHZkecZoTxnUfO6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-23</startDate>
            <endDate>2021-12-23</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_Ucvqwtp93kihEInyQPUvNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_0AMNouAweEWk9_wb8d_Q1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_6Kj0uxl05kGcqv5cmngJhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_9XL-YVNtDkqObkYAyoA2kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_8Pr5Ggh9JEajOUbg_YKR8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_fTCAXcXeVEGq1xPWfKyuDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_z_OM4LPemU2vaJCSSgPmxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_zRxCoItDgkao45OmbONCMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_7UE4OxQYgE2K901Hl7Dixg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zKdBd8Au7EmwSNmyKFumnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_-c6P1_7DkUS3B8fykDBDmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0ytFSqcEM0C2FCZayK49MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_vsww_6W8XEuzXqcrXTgKVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6BsM7vzIFU2WSKtxlf-yDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_F5SaMz-K80GYDBc1b5afng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_bnkru9QQjkyVNYTwKq09QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_HZud9yt_LUuUPbn-LCJnCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_EJ4D4Sg-IEKFiOm7DAMDwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xukue48ZDEGBV7izRS3Mlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_MRAiZ2HMfU6clBflMMQ4Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_iUPLBTtqT0GEW_-lUGmSbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_gNxzEodT6kKGuBFaWKy0eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_GtBW4y4FQU2LNtgqNQvYqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Une6DLwLW0WGIfTxv_fmOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Dav_DW2ztk6-ETIcsBP69w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lSeomaiJs0W8Yf_-pG_B6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VUFJcmrBx0OexVdaoisNAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_YkmeTmz-k0ywp539pQH2GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_KdHhy8rMGkOPdf-0LDkcag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_tG8hTQGLX0ejbiTFxdHWvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TemporaryDifferenceMember_xwvzCyZJjUu1_z9vpwK1lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_Aoq6kdzIgEGb4JC-aygDJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_OUBDouNJ3UGASomEVEai6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_uYl7CoErZUmkaktvlFSJJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_sV-2gWepY06B0A8GEXWNAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_v6FcOJX3ZkOQL_If3V44wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_RMhcUw7iwE2lpjvCLpz2Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_D9PmNvxW2EyJO-U9VmXN0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qKO-s7r8BUa2lgRm6ekFrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_5j4KchYGIk-8GogPJ3dGGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:EquipmentPhysicallyLocatedAtCmoFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_EQdNS6liQkqj9HAUfbkJkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_smq0Fsap1kGMdfi_JvJUpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_i0uFtxo5n0yyYkb8Bj-Qmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_LesCyMz7FUK3ZxQEsZWNEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_nDNQwxmp00GQTEs0t5pDCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_fVqKtHZJh0ajtDFuaqC7Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4HZPRvJI5kWlz0cNNfXq8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2PVjDRq_NEuYUZZxVJgpqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_VcYuM-X1zEyJpdM394rd0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_v2Ngz-T8qke5OXbIqZxvLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_U6gYHkTqeUaGi_F9UXcWaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember__uQ5VVHK0UWYczs0k7a3Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_DRz3CCZAlUWbryO3lgpfCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_nVyvmSWGc0qjWc-iNGi-MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_i3Ky2o24PUOSBVz8jJnLZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_KAq3DEF70UWNcG0E7Qz2aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_YvgJJg2RWkS_B2vVJFNGhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9v7ROjz4KUq67xb-vGVl4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_SgeNIgwqzk63aou9DXpoZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_6VL2por91EyDuYch-uIbWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelepmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_npRUdd2jrEKdKNSOmQ2E7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefOperatingOfficerAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_mNAuTnZ79kmgMEM_evAL-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_MEfyfKoJLka_FnOTfjHVVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Qe5xZZRKBkalAhPMb0rKlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_FFHzzrCoqEGuPsRnxpT4pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember___Jw5IM-M0uiIYastW7Ohw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_bCZajafyHk2TYShK6GXT_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Dnjk8zLjh0uRxWQLYgQLtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_Z76paJTu3EqO8ZEo9vC15A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitForKeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_dVCXiI28WUKjmh4pxWG7HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_37SI7EeG40qNRBNVTiXh4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_eqJNUVFrwEyBJVapO8-7UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3nipjvAshE6IJam5p-Fh3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_07cYvreliEeikUXp57lJ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_vwSDHWlV6k6kvpxM2G58Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_ZrMDEhuAEUCN6lkugW0ldw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_PD-hd6qO7kyci1VNI1JU4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_wjj_nYzRdkKzd4QyrVUUTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_sc6LsyPDbUSO09oxzVOOUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_employee_2xPxwRpHIkSSwvWmnWr95Q">
        <measure>cvac:employee</measure>
    </unit>
    <unit id="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">
        <measure>cvac:Option</measure>
    </unit>
    <unit id="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_loan_jqkBG3F-sEycxO6evEyZWQ">
        <measure>cvac:loan</measure>
    </unit>
    <unit id="Unit_Standard_CHF_x9ufSMA390KJ8aeE_m0Llg">
        <measure>iso4217:CHF</measure>
    </unit>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Narr_DZtvmPd3eUCn7s3L-Z9zuw">6-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Narr_vOo4an9x-EG5_ebx_aQMWw">CureVac N.V.</dei:EntityRegistrantName>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="2"
      id="Hidden_TRglPcGML0e_hUXjrMmiTQ"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-1.44</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="2"
      id="Hidden_FZYYIZzFzEG5z9weWkLHmw"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-0.39</ifrs-full:DilutedEarningsLossPerShare>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc__0PEvMYZiEKJvl9qAGCAiQ_1_1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_BKAvsUb9nkONpy04ND3m2g_6_1">CureVac N.V.</dei:EntityRegistrantName>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_v8qFBEhVFECIi9HAu8pCQQ_7_1">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_502bDbvpWUSUJ-YVwmVhEw_15_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_qkuS5_rNYkiiNATBtjyZIg_16_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_uSIE1RQJZkKQU4Gb7CmB-A_17_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_FPf0TbwlwE6JoQa9FlugTQ_18_1">0001809122</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tc_xFN4dQxQ9kes232XoWp34A_19_1">false</dei:AmendmentFlag>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_paLxtlx0ME-S6iMem_-Thw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_ax13MWhvAkygsY3Qa2lubQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_VaaVoc4-BUS38rqyfpqYaA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_QA1a_vf9GkqcKLlbclhWew"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_63o3hDQhqUq352WtyGlB1Q"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_N47nZFniJECqb2Lp26J_Lw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_Lnb8kAVvp0G7sN4zz77g-w"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_uSbXAWSAcEOq0VSQLDDkMg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_4fCn4I71xkWAphcGg6A1Hg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_3YDIfJwocUSKswvm-giWwg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Hidden_GGwjEWJr3ECslJpKAubuAw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Hidden_rOAP57ONDkCcfobBYmvLlw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ"
      decimals="2"
      id="Hidden_G3msjGiE3kqZNUEVJNk5yA"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">0.12</ifrs-full:ParValuePerShare>
    <cvac:NetValueOfInventoryTransferred
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"
      decimals="-6"
      id="Hidden_jkLIgqZzAkOONGLtAkGXdA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">98000000</cvac:NetValueOfInventoryTransferred>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_A_zx8R3WLUSN7_enqbZ_yQ_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">32425000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_IUtnWmHW9Emjn_Ssrhe-MA_4_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">44519000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_An-IhNr0XkGf4PXQ9EfP1g_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">53156000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_BUI4ZUJguUScgbUJAIdAug_5_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">79913000</ifrs-full:CostOfSales>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_95iIScviE02USXJHapM2Ig_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1029000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_Xfk8Zo_0VkKyBW95phrKxA_6_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">819000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_GKh37xONSEWBx2S0KaKt0g_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">236267000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_TNQquZ1tBkCPdJLUmJK2sw_7_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22422000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_1I3mYbLWFECgDQSQTI5rBw_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">50651000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_tljYrWlmD0m63VXcYQbiJQ_8_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">51678000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_K9xZGRs3e0a87AERNp2SAw_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">45234000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_McFdM0xFDEqQd7NLEGXAMw_9_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">35207000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_hUepJmI7XEGV-FVkIrH7OQ_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">214000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_SXGNeXN7SEqAEeKHdoaagA_10_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">461000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_FdyEwyH0aEmzSYjOfd5o7w_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-263658000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_wKkO-tIiQEm3-ofrWbd3NQ_11_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-75567000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_ABZp4V1HvUOPgowVVgqbVA_12_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7296000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_xY1wuODh9EKohem9Iz70Nw_12_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5343000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_-u9-DOdph0qRTO3tMXfrxg_13_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8065000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_RAM5MfXo5k6HgVoBDtgRuw_13_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2535000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_PyW48IARmUmTUFuWDEtL3Q_14_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-264427000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_PbkfwEGoJ0ygVV-gyzub_w_14_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72759000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_K930oT0IL0i-LAhtRoPQbQ_15_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1329000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_bwGtOGqjaUib-pSrdn_7eA_15_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-82000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_gVMWt2Q94kuwT7qMxa3IFg_16_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265756000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_JCH4tynesUyzxI_p1IEqhw_16_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_Y4ZHfujhr0SRKu0qQ14UBg_18_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-30000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_rBpglPbnIECnStk0z2K9sA_18_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-212000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_fX18lHmNwkGNdmtyp7sTfg_19_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265786000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_U4c04oiaekWUHf_z73EPYA_19_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72889000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="2"
      id="Tc_SklGBmgkvUSmuc7W63QlhQ_20_4"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-1.44</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="2"
      id="Tc__FcR6fcV_U6AzgToO4r8Lw_20_6"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-0.39</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_rIjWQpQTZkS2Ykg2k9qLJA_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">13238000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_RU3BpphwyUOidrT71nFoDQ_6_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">12281000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_8YqPmOZTaEOcA6X6hGHzUw_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">168264000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_i9FaQUVvY0eL6zrOxBe8VQ_7_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">192015000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_INtFs7-E90WCUNXmqyX0ZQ_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">32129000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_ZRqvI8bcLkOjwtR1lo4zAQ_8_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">42996000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_pAGkMBiAYEu6giVmILO5lw_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1731000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_xVFyURfaH0S1KY_uq9nUMg_9_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1663000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_pO-8rKHk5kKgYr-UC2bLxQ_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2861000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_djkAnyaQUE-eOkYQj1kJgw_10_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1276000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_aqaLBijzsUKeFVJOqtDi7Q_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">218223000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_HmiRsZVi90utVZWP9QsWdg_11_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">250231000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_o7zLwSw5WE6oZWvFfQQ9Vw_13_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">865000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_Wff4ZkRMC0CHswddhJzIUw_14_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">56159000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_Vk6YoCywkk2tCE-Jo3SP_g_14_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">13241000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_jY8K8UvThUCnCG5nms8SaA_15_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">18504000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_ohaeu3XZJ0ygo1HC0Qi1tQ_15_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">13341000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_b9mDMHFTs0uYm2n3lgUL-g_16_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4648000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_xuzF4m2BQUCWwH2Mc6dDog_16_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3608000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_L4CNnVJ0OUGFLQxSInzZQw_17_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">49244000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_g0ZwSRcj10Kf-D6DetpeYA_17_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">70968000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_Cy2Pku6t0km2x1wvfnQNqA_18_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_IF09K5rV6U6j7NAFBLlrAQ_18_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">573566000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_o5EAxx-ZtkGoyZZY_siDZA_19_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">940019000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_3L_xT6PchUae9A0NvKrduw_19_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">675589000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_eEBimCmXNUyLW7rUd8LH2w_20_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1158242000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_D06llgRHska8nXEwwNgK6A_20_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">925820000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_JeUHIT46D0WPkBOvPn9aQQ_23_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22454000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_F_Et38xYrk2mvE1OppxgYQ_23_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22496000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_gDWAvP1_o0qoGiWDjyD39g_24_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1728658000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_nfJuijQtNEaLS83wMI7KjA_24_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1732148000</ifrs-full:CapitalReserve>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_jq9KkUA8_ESaQ3giXDX4aw_25_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5817000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_VRy-wO4ZxUe41CAMfkZTAw_25_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1734000</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_cm80f0UKtUGU1JWJhvDL_g_26_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-1056785000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_IHtbKmKitECNOmHpK12Lpg_26_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-1129462000</ifrs-full:RetainedEarnings>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_h3BWMK27H02IKttCsFozIw_27_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-34000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_FcxV06KV_Uu-B6s16UVYyg_27_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-246000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_BwNV6pb1nkum3UC5-gCLGw_28_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">688476000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_lGZjz5zMQkOfC012soT8rA_28_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">623202000</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_P4xyzjUpOk6Y_HOX3efaag_30_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">25423000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_GYAP_ozfWEmZn5np2B2SQQ_30_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">35931000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_nm5J5rHbFUGGDpgsx2DP_Q_31_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">86345000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_ltkBj-YpwUuBcS_pt-ptXQ_31_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">70790000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_ezHr2WVeXUWUloToqvF3Mg_32_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">264000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_Vh3NiAIoqkKPIP4tXJN_Dg_32_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">264000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_VogM8ginLEuRmh3fVwK__Q_33_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">112032000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_wp7bW97txk-BA26kF9PYEA_33_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">106985000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_Tt_fBHJfgUWu_Ql2cFHL9Q_35_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3469000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_wIc5OPOIJkCrvE0vmVkFZA_35_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4278000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_hYh2RTFCFku3mK0xh4XI1A_36_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">127703000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_0VPe7wAk6ku600BZGwYN6Q_36_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">48496000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_U2jJ-uynNkuy0yReOqIQwA_37_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">170073000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_PPWr2qv4WkCJWuJ-D3Uw7g_37_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">92758000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_uP0AwpglX0GJtIcuFGcseg_38_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">739000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_eotOxDhs7UqXI8y4XLWl_g_38_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">613000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_cV0gLGeGL0mCbWX-kllefA_39_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">55750000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_ByhTykhUVEuBioRckRaEJg_39_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">49488000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc__ByFqfTQTk2JsGx290c_1A_40_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">357734000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_YGrmkzj1gky-WpIdNF-bfg_40_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">195633000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_SVOC8zTFvUO1Mespnliy3g_41_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">469766000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_dhx7PUCmkkW-VowwUNPqhg_41_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">302618000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_3JQPhEuOkE6--uQI0EpkHg_42_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1158242000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc__P7U9dI6B0Gtj_847EkWvA_42_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">925820000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg"
      decimals="-3"
      id="Tc_0uN4IImhtk29MylD3AVWoA_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">21655000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_YkmeTmz-k0ywp539pQH2GQ"
      decimals="-3"
      id="Tc_dYuMMAUCJ0-2M2O0W-X_Hw_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1334704000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lSeomaiJs0W8Yf_-pG_B6Q"
      decimals="-3"
      id="Tc_fasPfzi3TUupnWMoMnfB6Q_4_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-645069000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VUFJcmrBx0OexVdaoisNAg"
      decimals="-3"
      id="Tc_CjFvRn9yL0e7JX9pUYW3uQ_4_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">57000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g"
      decimals="-3"
      id="Tc_3C-nmDg8f0CsNxc5-JCW6w_4_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">711347000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag"
      decimals="-3"
      id="Tc_sxz0m3dYC06VxVJXcSBQ0g_5_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265756000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_eXfI_oLfU06BkC8n083odQ_5_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265756000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w"
      decimals="-3"
      id="Tc_sd1lq2ISAUmcqKVVIuBVJQ_6_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-30000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_9IINRowfIEK7ZXjW5nEZeQ_6_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-30000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_TBabhvYLcUKtTGSHY-xKag"
      decimals="-3"
      id="Tc_8g5gfzPUuUGPJhpELtX3RA_7_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265756000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_zuaLDMSZm0exwX1VSDp-4w"
      decimals="-3"
      id="Tc_yygkdTfr60OY8xwOTzrw5A_7_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-30000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_V6g1mkDMVECIROO3cAm4Lg_7_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-265786000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w"
      decimals="3"
      id="Tc_QNrB8DRSBEKUVOfl4MBShw_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">9382000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_7ReaadY0nkGdOjJxzS90zA_8_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">9382000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA"
      decimals="-3"
      id="Tc_zwQkKqW0zEW2hN8mxOxtHg_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">690000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w"
      decimals="-3"
      id="Tc_POIRRA_pTEOuzEkJgvNBqQ_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">403372000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_mPJ_lhK21UGum4Lg9xEAzQ_9_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">404062000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_DZeRezBvyk-RTQmLymrSQA"
      decimals="-3"
      id="Tc_g-B5HNlAW0WFChv0tnwvHw_10_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">80000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w"
      decimals="-3"
      id="Tc_-PFKqHY4RUu4zITIbZ5EbQ_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1994000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_M_C0TtuXqEuXbm9aOYD_Sw_10_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2074000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_sfY35PL0XE2ZBbqXP96v5w"
      decimals="-3"
      id="Tc_vcOF-pVwZE-21VyHdZL4Ew_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-22739000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_9XL-YVNtDkqObkYAyoA2kA"
      decimals="-3"
      id="Tc_4YXJp1wWJ0W08Iq4YpVn9Q_11_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-3022000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_EyMB5Vyrc0-HTzkbaAfeSw_11_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-25761000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Une6DLwLW0WGIfTxv_fmOA"
      decimals="3"
      id="Tc_NYtR-sO_1U2fc1-1Jlc_1A_12_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22425000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Dav_DW2ztk6-ETIcsBP69w"
      decimals="-3"
      id="Tc_AQ8Rks4JkUusQxmiOmnz7A_12_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1726713000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_iUPLBTtqT0GEW_-lUGmSbA"
      decimals="-3"
      id="Tc_WHnfD_QdwkK-Z_hWR9a70Q_12_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-3022000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_gNxzEodT6kKGuBFaWKy0eA"
      decimals="-3"
      id="Tc_FoDMewB2okG4eHwQWBJmjw_12_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-910825000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_GtBW4y4FQU2LNtgqNQvYqw"
      decimals="-3"
      id="Tc_LoxNtWxKjkuGCU75znMTig_12_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">27000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A"
      decimals="-3"
      id="Tc_QEY4ZLeuz0aIJ87W2rmo7g_12_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">835318000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xukue48ZDEGBV7izRS3Mlw"
      decimals="-3"
      id="Tc_kwm5E-s8KUK3kdiSXAoL5w_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22454000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_MRAiZ2HMfU6clBflMMQ4Iw"
      decimals="-3"
      id="Tc_vb1WYzwk0ESNeRIl8JjxCA_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1728658000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_bnkru9QQjkyVNYTwKq09QA"
      decimals="-3"
      id="Tc_rhsBPVVcPUKB2QBC7kqvgA_4_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-5817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_HZud9yt_LUuUPbn-LCJnCQ"
      decimals="-3"
      id="Tc_Aa3R3HRdLUWzpPFPP3fjNQ_4_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-1056785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_EJ4D4Sg-IEKFiOm7DAMDwQ"
      decimals="-3"
      id="Tc_roPgynPGzU2Jh4WXMBx3ew_4_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-34000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_A1Q5Lyq1SUyYjQdPhA8CgA_4_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">688476000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g"
      decimals="-3"
      id="Tc_18lKrKpaakKTebeqePQcmg_5_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_n_Vpwmvdr06oz9T2zf8ebg_5_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig"
      decimals="-3"
      id="Tc_m7VkqCvcsk-9OTaALjvoMw_6_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-212000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_7IWlBWBeekurGcaYGJ1aZw_6_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-212000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_abrAWs25xkuCMOJlFmIz8g"
      decimals="-3"
      id="Tc_kuIfUkdCPkW8axxSnBZedg_7_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72677000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_FmoZyd6sa0m6zeRaUetWig"
      decimals="-3"
      id="Tc_slr43G4fgEWqv8r08SbPRQ_7_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-212000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_mcUsYvJb1U2ghnq5eplCcg_7_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72889000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g"
      decimals="-3"
      id="Tc_TJkOFqAW4EWggt95HRxA9g_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2262000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_jIvA7lmi1kScFGLNnuzAcA_8_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2262000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg"
      decimals="-3"
      id="Tc_GAZJFykryEaicwr0Jf75_Q_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">41000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g"
      decimals="-3"
      id="Tc_0whWC4jCRE-f1IzMnQyreg_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4680000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_8EAONjNAhUG4YC-7B2z1tg_9_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4721000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r66GnyMOhUCY6XIZC5neVg"
      decimals="-3"
      id="Tc_Pbyvm-CWoEiPz-lSHz66aw_10_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_XSZX1EGjY0aYQFWfYQzk-Q_10_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_yVxcMGDzEU-AMNRz2IpE4g"
      decimals="-3"
      id="Tc_9lWr6fSWK0uuXuWJ3M_thw_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-3452000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_v2Ngz-T8qke5OXbIqZxvLg"
      decimals="-3"
      id="Tc_AcxrJaCrvUW7dtGukxw6Hg_11_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4083000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_7VynHZywKk2AddlpTXQmwA_11_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">631000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6BsM7vzIFU2WSKtxlf-yDQ"
      decimals="-3"
      id="Tc_CU5rdBl540K0Amx8lvo1lA_12_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22496000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_F5SaMz-K80GYDBc1b5afng"
      decimals="-3"
      id="Tc_TKAMdUT_DU-9xjmW0k1q6Q_12_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1732148000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_-c6P1_7DkUS3B8fykDBDmw"
      decimals="-3"
      id="Tc_5hUItKl5HkCIy5Fqm1wFOg_12_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-1734000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0ytFSqcEM0C2FCZayK49MQ"
      decimals="-3"
      id="Tc_FFADtThVh0SkyzxKivIFwA_12_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-1129462000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_vsww_6W8XEuzXqcrXTgKVg"
      decimals="-3"
      id="Tc_tGz4_3AOckmzTdA2KqCLmQ_12_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-246000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_Lcyb7UaUQ0a8dGfRvtew-g_12_12"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">623202000</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_WQjwTnI66k2vFt3ndO5eyQ_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-264427000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_ze_lZmwEu0yXMFlxttTnRA_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-72759000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_B9zrJWGkS0qSnbFtZ5-Big_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7296000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_OjA9BFA_1k6fqnfxc92Z8Q_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5343000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_U30CKO_640itGmOSv4dAlg_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8066000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_iEya1sMBI0iFM8-ZuEcbqQ_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2536000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_D7bLen1bS0KnXHgb3rZrWg_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">6623000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_MwvkCaXnQUeZo7t8SIzOBQ_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">16651000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <cvac:ImpairmentsOfInventoryAndPrepayments
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_fHjmAro6TUWEtHzpaqk4Nw_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">25687000</cvac:ImpairmentsOfInventoryAndPrepayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_5HNqpP8eHUidFXhmgIEBaQ_11_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8212000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_u8LJ02Pq_EWvikysN7jn3g_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3597000</ifrs-full:AdjustmentsForSharebasedPayments>
    <cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_55OEjohX2E6Vb0bUlz18YQ_12_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">47242000</cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_EnWVjENr4ke72GYZGt_T3w_15_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-3072000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_-nzS7tB09EmCXAhsrbZ2UQ_15_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5164000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_SESyTeb2Nk6iiTrIKuZUcA_16_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-48381000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_h7E6-1kUNE2QxJXh8dxlcg_16_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">16367000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_LS7d9S54fkqd9WsdIYPBZA_17_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-135440000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_qd8SvnqQ_0eTq1tLrXDDEg_17_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-14051000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_1G0cjunlBEueEDWMDzuOAQ_18_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">165912000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_WfVvHCwsJ0SPU5vMu9a0GQ_18_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-129038000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_buJ4oECAzEayMnpHWKP-9Q_19_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">96000</cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_tbWxlAeyqkWKsOUHFKhM9Q_20_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-10000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_Oi97-PqQp0SbiVO5JIOLYQ_21_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">126000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_6MJbJANBNkmt0Y0_xjZeUQ_22_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">19000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_sAf_Yg8wOkuL20B7gmAFPQ_23_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5210000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_Dj_TRDK2jUijuhdbP0eVNA_23_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2608000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_ACgxTz7N80KUJfJcNAzsaA_24_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-274898000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_UobZ_lafdEyiijJWm9aAsQ_24_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-201175000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_cRvWSxc2BkanR5M0zB9LfA_27_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">69751000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_obvvrN1W5UiOajlRu8ZFdw_27_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">43507000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_0soS4HaTY0KWJVT9jp6DqA_28_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3966000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_veIbtgGMEkaT3icsEltIKQ_28_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1208000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_wMAecLQuCECt47qvrJCxzg_30_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-73717000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_fy3yeQ1Uq0yHYxtKofh_eg_30_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-44715000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_ih99Ht3GCUSTXLW6ZPk0Ag_33_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1531000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_FBV4jIMl8Em8RyI3TdmWzQ_33_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1943000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <cvac:ProceedFromIssuingOtherEquityInstrument
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_mgSJINGFdUeuSqdfTU2e7Q_34_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-23767000</cvac:ProceedFromIssuingOtherEquityInstrument>
    <cvac:ProceedFromIssuingOtherEquityInstrument
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_x_rjgLua10C02jYb_heEAw_34_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">631000</cvac:ProceedFromIssuingOtherEquityInstrument>
    <cvac:IfrsStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc__cK75nCSKk-71S89_g6Kng_35_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-4721000</cvac:IfrsStockIssuedDuringPeriodValueNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_IQXubA4hLUmaWPUWVuj73w_36_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">404143000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_-L56zjXS70KQwgFiUICZtA_37_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">378845000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_jaULv35vbU-7y_qndO88Zg_37_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3409000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_hG40cl88l06DLtZDVAwDPQ_38_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">30230000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_Zfg_dr7Z8060bz-vn5xYxA_38_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-242481000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_zzkTYoeQr0q4eREG1NhaTg_39_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2989000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_3BZ_Zsq4q0-BsRZLFRtfZg_39_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4583000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_JfHS_Vu5SEOcqsmfjgw64g"
      decimals="-3"
      id="Tc__tu1csoefEmGRtg-CpflQw_40_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1322593000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_tokMOYKakkWQ6VZYC810_g_40_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_wZL4qhtZLESE69nBPneQ2A"
      decimals="-3"
      id="Tc_lgIUHdweaUGh4rtayIYyDg_41_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1355812000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_mtfpRpH_lECOUGh-aYd-XQ_41_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">573566000</ifrs-full:CashAndCashEquivalents>
    <cvac:CorporateInformationTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_yefHbHxeEkGg_c8HRKrCoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Corporate Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac N.V. (&#x201c;CureVac&#x201d; or &#x201c;CV&#x201d; or the &#x201c;Company&#x201d;) is the parent company of CureVac Group (&#x201c;Group&#x201d;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under RSIN 861149336. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 46 &#x2013; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.&lt;/p&gt;</cvac:CorporateInformationTextBlock>
    <cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_KmVv7-FaT0KX4EImSu_XpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of preparation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the six months ended June 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 18, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the six months ended June 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_kx3g3dpArUmi4FdkYA6okg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the six months ended June 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 18, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_YmkVTop99UCdOunuD0ROgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the six months ended June 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock>
    <cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_k-eHf3rkeEqSJGQubt-mGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory>
    <ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_v49KF3SWJUCHMw_GLX5Wnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Notes to the consolidated financial statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.1 Revenue from contract with customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognized the following revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,041&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 32,425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,519&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2022 EUR 31,818k (2021: EUR 27,730k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR 431k (2021: EUR 338k) related to delivery of products and (iii) EUR 12,270k (2021: EUR 4,357k) were recognized from those research and development services considered distinct within the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of the total revenues recognized, in the six months ended June 30, 2022, EUR 43,041k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201d;GSK I&#x201d;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201c;GSK II&#x201d;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2022, also includes recognition of EUR 5,321k of the milestone amount. The remaining EUR 4,679k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2021, revenue primarily consisted of EUR 29,335k recognized from the upfront payments under the collaboration with GSK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;upfront and milestones payments &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 30,000k&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 142,095&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 120,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,731&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,818&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Contract balances:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 120,278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.2 Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,869)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,912)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,883)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,388)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,516)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,150)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,594)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (53,156)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (79,913)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022, cost of sales mainly increased compared to the same period of 2021 due to increased write-offs for raw materials amounting to EUR 34,640k, which were procured for manufacture into products to sell to GSK are now no longer expected to be purchased. The prior year Third Party Services have been higher due to last year&#x2019;s set-up activities for production process for CVnCoV.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.3 Selling and distribution expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (560)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,029)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (819)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR 499k (June 30, 2021: 543) and share-based payment expense of EUR 61k (June 30, 2021: 121k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.4 Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,928)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,419)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,219)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,849)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,119)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,354)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (210,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (464)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (236,267)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,422)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#xb4;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the six months ended June 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased resulting in reversal of provision for onerous contracts in the amount of EUR 21,303k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, in the six months ended on June 30, 2022 the balance was impacted by further consumption of inventory. As of June 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the six months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022 of EUR 14,759k (June 30, 2021: EUR 14,849k) and share-based payment expense of EUR 90k (June 30, 2021: 370k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.5 General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,971)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,704)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,796)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,491)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,091)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,796)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (50,651)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (51,678)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the six months ended June 30, 2022, of EUR 15,525k (June 30, 2021: EUR 11,642k) and share-based payment expense of EUR 3,446k (June 30, 2021: EUR 7,720k). During the six months ended June 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The increase in &#x201c;Other&#x201d; mainly result from additional insurance costs of EUR 2,769k, mainly related to the D&amp;amp;O insurance (June 30, 2021: EUR  2,343k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.6 Other operating income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 45,234&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,207&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the six months ended June 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;German Federal Ministry of Education and Research (BMBF)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant terminated in 2021. With regard to the grant component, during the six months ended June 30, 2021, the Group has recognized grant income in the amount of EUR 44,090k (June 30, 2022: EUR 0).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Coalition for Epidemic Preparedness Innovations (CEPI)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the six months ended June 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 8k (June 30, 2021: EUR 23k) as &#x201c;other operating income&#x201d;. As of June 30, 2022, EUR 1,281k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR 1,288k). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Bill &amp;amp; Melinda Gates Foundation (BMGF)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the six months ended June 30, 2022, CureVac recognized EUR 96k (June 30, 2021: EUR 211k) from the amortization of the grants on a straight-line basis into other operating income. As of June 30, 2022, EUR 1,782k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR 1,879k). &lt;/p&gt;</ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_wncZWgBtwUC88fUhg_pT2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,041&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 32,425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,519&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w"
      decimals="-3"
      id="Tc_mxFKd7NtT0yW0eQjP6D4cQ_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">29335000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw"
      decimals="-3"
      id="Tc_lDXiljhyZkOAr9NlDGzGCA_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">43041000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_IZKQNmwJz0Otp2sIpw7z9g"
      decimals="-3"
      id="Tc_30cDkBq6k02SlPoGprAtdA_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2051000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_IbyWgW8zTka7Hdyj-GqiEQ"
      decimals="-3"
      id="Tc_N-chJcvoYkS5GZLSXVNoyw_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">169000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_Lc0XNMKuKEqN_5NhPdFzTw"
      decimals="-3"
      id="Tc_bmlrQ4jaek-V-p3wn9J6dw_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">586000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_J42m4KTLKUOHHRX1Xm1Ajg"
      decimals="-3"
      id="Tc_i3sosvnP2kOs5zNvzGAYrQ_11_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">870000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_PImd1JWYGUuBROPVuT6t1w"
      decimals="-3"
      id="Tc_xkLNAjLg90aR6WkPN8pAvQ_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">892000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_FN89pEk9Q0it8m4WiUjvAw_12_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">32425000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_PEa-wbXhpE2-cC_6uL0jrg_12_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">44519000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ"
      decimals="-3"
      id="Narr_Au00DK75gUGk_Jvb_LBT4A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">31818000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g"
      decimals="-3"
      id="Narr_roPpiGHf9UmoLJCfWf2DTg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">27730000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_kJmg11wUDk6B6oaK6o4npw"
      decimals="-3"
      id="Narr_98A7MrKID0SskXxy5DlPpg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">431000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_2xzoP9RNVk-PMBP-aAb16g"
      decimals="-3"
      id="Narr_qOqsRaoHmEujjcIe2uaMUg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">338000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_m6vvO3sZ60-XG1n4n_R1BQ"
      decimals="-3"
      id="Narr_IF-MlLR_n0CcpMR4fGwfwQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">12270000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_ygWZIJY7-ECXlg47u0aOrA"
      decimals="-3"
      id="Narr_Ye0WlQCu5kWwc3u0tttoQA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4357000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_LrH2vegc_0qfouwK0ftYAw"
      decimals="-3"
      id="Narr_dTJNHdYX8kCCVgsPZaawyA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">43041000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:AdditionalDevelopmentMilestonePaymentsReceived
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog"
      decimals="-3"
      id="Narr_CDZAEfZCm0WdvZiP5QOCUQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">10000000</cvac:AdditionalDevelopmentMilestonePaymentsReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_CiWnept0U0KOmg4vCHFVog"
      decimals="-3"
      id="Narr_VEr1wMzBXEuBCEX2Gu1Trg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5321000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
      contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember___Jw5IM-M0uiIYastW7Ohw"
      decimals="-3"
      id="Narr_bSQbtzFmgkOAudDcuzW6ng"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4679000</cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_vMfV_hwHi0aKavI3fTXj8w"
      decimals="-3"
      id="Narr_7X6GqIb4Pk-B4oPO0h6l8g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">29335000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_Yt5fmAVG70So2liGkPPdug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;upfront and milestones payments &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 30,000k&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 142,095&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 120,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,731&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,818&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;</cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ"
      decimals="-3"
      id="Narr_MMftP5xcEUaQcw9Is72raQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">205000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_LesCyMz7FUK3ZxQEsZWNEw"
      decimals="-3"
      id="Narr_xV8XRavTMEyOi97sxurzUA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_fVqKtHZJh0ajtDFuaqC7Fg"
      decimals="-3"
      id="Tc_Pb0u8sig0kC_pztRaGxB_w_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">135494000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_J_NHY27UUkeRHQTfYgQblQ"
      decimals="-3"
      id="Tc_7KO8bRA7QEuIlbe-Nav9MA_7_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">114725000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ukmwgK4pjkeQL_CmzxJNpw"
      decimals="-3"
      id="Tc_yRNxI6BbeEKyvbLbO0TGAQ_7_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">24631000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CreBB5VP3EKrtTllWwe7cw"
      decimals="-3"
      id="Tc_LZ0iLLiu-UG_P4kqr7ioZg_7_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">30769000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA"
      decimals="-3"
      id="Narr__-RIL4iyM0mjf65gtV0MUQ"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">3000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA"
      decimals="-3"
      id="Narr_0sIwgHPtnEeQxWqsrUKluA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2524000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2PVjDRq_NEuYUZZxVJgpqg"
      decimals="-3"
      id="Tc_lWwTb_YNlUirYiii3-XTNg_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1239000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_OnR7C0j-zU-DynN44jLFoA"
      decimals="-3"
      id="Tc_unIzDyAVwE2ndWmMh5yGTA_8_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1084000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_Niu8fCC5EEeSADXrcrVtmA"
      decimals="-3"
      id="Tc_GmbqFsEZAEW1j0J8OJo8lw_8_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">155000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_TujPDblK1EuxI80RvU-NLQ"
      decimals="-3"
      id="Tc_wztsqFy0_EGC9CZ0Rj1eKg_8_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">155000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_nDNQwxmp00GQTEs0t5pDCg"
      decimals="-3"
      id="Narr_6HQ_MSNcN0-sbjGak0Fw6A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">30000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_d2Hm2LGP_ke9M8xIEktJpg"
      decimals="-3"
      id="Tc_Y5adTHVLUEar8FKYgciE6w_9_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2051000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g"
      decimals="-3"
      id="Narr_fCb9uvT8EkSbTwrtQ7P6DQ"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g"
      decimals="-3"
      id="Narr_A1K2Ub5TF0-XNcmUeZX1zA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8937000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4HZPRvJI5kWlz0cNNfXq8w"
      decimals="-3"
      id="Tc_Gz7g1kEXBkiN-chDncu85w_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5362000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_R8WYQeZX7kqKoBc48gS53g"
      decimals="-3"
      id="Tc_8YPjlUQrjk-NTrRHSzd0Yw_10_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4469000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_hBqt_J_E8U2Ykx9xI6ZM9g"
      decimals="-3"
      id="Tc_6L7Dxo3C5kWEXwWwuEtYqg_10_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">894000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_josAwYgRAUikV20Ufw6ucQ"
      decimals="-3"
      id="Tc_K9gT0wycJk6CFZh-ohEJdQ_10_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">894000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_VcYuM-X1zEyJpdM394rd0Q"
      decimals="-3"
      id="Tc_1CLJozD7GkaGhLVcyJWkhA_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">142095000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ"
      decimals="-3"
      id="Tc_AMkhj2ybDE64ZWUfPWrh9Q_11_6"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">120278000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_EI0VaLLswkiqzg5xVfhm3g"
      decimals="-3"
      id="Tc_8ohJGXs2QkyA-Bmhh7aCOA_11_8"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">27731000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ"
      decimals="-3"
      id="Tc_gYwMT3lsI0OGZ5UEJ9dQ8g_11_10"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">31818000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_oAtysuPHtU-6xkuXVs0mYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 120,278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_25NQDVhhJkOtHGoxsX4d5A_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">18504000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_CKFUie7fIk-EUMfUeF1HcQ_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">13341000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Tc_DeuaZ0ZMWkCjgG8eAzHAFw_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">142095000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Tc_zStEtLKBEES3hT0f4-vlHw_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">120278000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Group_N3j4INlhzUW5WtSQHuwrLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,869)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,912)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,883)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,388)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,516)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,150)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,594)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (53,156)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (79,913)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (560)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,029)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (819)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,928)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,419)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,219)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,849)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,119)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,354)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (210,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (464)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (236,267)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,422)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,971)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,230)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,704)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,796)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,491)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,091)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,458)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,796)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (50,651)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (51,678)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_DViOEqayy06mtNWeTRSfoQ_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">9390000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_1WvHxFwCsECbkUkWAncOOg_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">13869000</cvac:PersonnelExpenses>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_I_B6dPSz0U6sX_WBXqm7bg_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2912000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_IP3wx92lgUW6y1e8u8a6QA_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">36883000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_sEgqNsyFOkG6tFRAZJyXMg_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">31388000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_XRAt8ahHG0CJkXWYpNgY0A_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">19516000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_dZ4DvLySwkSk2JSIGAEGSA_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2543000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_ls1Llc0AV0ypo2ugW85erA_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1150000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_hqJpaKxRKE23I-6kpnOsew_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1594000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_g-IkmV8g4EiGVY8cEyobyw_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8326000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_ZZaHoA7qmU-WNDExUIshLQ_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5329000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_-jMAMMu-8U-YZLnUTgxiiA_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">169000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_quS-KLuCyUiY5KwGgUtJKA"
      decimals="-3"
      id="Tc_zRGoMSvqK0iaRTOhAPZb7w_10_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">53156000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Tc_Zwp59rq3wUykmZr69VHt-A_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">79913000</ifrs-full:ExpenseByNature>
    <cvac:WriteOffOfRawMaterials
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg"
      decimals="-3"
      id="Narr_W_zFcjaOyUG2-s5EzLfbmg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">34640000</cvac:WriteOffOfRawMaterials>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Tc_bqfBaGUWVEqsE_DP0CifNA_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">664000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Tc_rDIIccLFLEiLFc_W3p6OIA_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">560000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Tc_kuUnlj4gW0Wg9fmjJItFYw_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">43000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Tc_wTEy7n39E0aUdL7VI_71ww_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">32000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Tc_FfyaxZBI20WijbY1j0MbFQ_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">322000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Tc_epHLsX8dRUurjW2sH0Ns5Q_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">227000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Tc_4eGhcRMEUkaTZva7Rgz8CA_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1029000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Tc_hPfKGvUtEkGXhTmfg_44sQ_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">819000</ifrs-full:ExpenseByNature>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Narr_yyUB2XuVYkuRz7H7EmYF1Q"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">499000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Narr_eV2R3GqAhEanLlv5FOLHlQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">543000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g"
      decimals="-3"
      id="Narr_aj0uVo6yJEqi0r754ZYRXw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">61000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_JO7EtHXPBU2qvQ8Md-DdVA"
      decimals="-3"
      id="Narr_q-iOJdHU4U6vhQRLWud3iQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">121000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_bfmtKDeZSES3cofZtQeskw_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5928000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_J7ZftD09W0ikqmtQwWUCVQ_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">23419000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_VAVJ7deRpEamM2DWNG5ObA_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">15219000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_bMxUv210PkyleoFeR1dYqw_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">14849000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_1xRLS50jckCjQdFXTGnnEw_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1795000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_1Tr4E8IIwUiSwNtcrPSr_w_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2119000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_R1feLbloDEOuNBzgv2-Xlg_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1413000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_3hKNTUa2e0OxUyAuv9xfsQ_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1354000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_86zBd9CNSki_VH9mgUrRbw_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">210590000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_caTKdrLHdkq3rHpvh78twQ_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-21053000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_bC9jt3AuPky-g35q3jwJXA_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">142000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_uvVaTd5O8UStGy-8il7kGw_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">464000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_FLAkJYVXpkCYQVQT_O5zUg_10_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1180000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_HudfQsVy-0Wna8JFM8SVMw_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1270000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Tc_pgQSsPBhxEaqfVQlZKY-_A_11_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">236267000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Tc_FOVrNAtbKkyi4XBUl3FPig_11_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">22422000</ifrs-full:ExpenseByNature>
    <cvac:ReversalOfProvisionForOnerousContracts
      contextRef="As_Of_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_U6gYHkTqeUaGi_F9UXcWaw"
      decimals="-3"
      id="Narr_RvHI7hvkn0u65Zzp1U-lCA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">21303000</cvac:ReversalOfProvisionForOnerousContracts>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Narr_nhX8lFjthka1hauXzwyXaQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">14759000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Narr_FOhorJi0vUmNLs2-eeQawg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">14849000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w"
      decimals="-3"
      id="Narr_uVpvkWZ7hEaBnfhl_j8sUA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">90000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_Fk7cOrYEgkmDJ19UuE8Zzw"
      decimals="-3"
      id="Narr_KD23XunahUS_X9uPo-cq4A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">370000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_gFAPfqCZ0Ey1pSJ-8uZBdA_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">19362000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_Rk_Vwjp1LUSAcvRc16cZVg_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">18971000</cvac:PersonnelExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_4CPrMvf2PEqPFJqd-ojflQ_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1230000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_q8OtamhTn0y9RlVjaSlT7g_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2704000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_4nfjBz-mZ0OvKIOUpGae7g_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">18785000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_sYs50Hqky0iLWJmgs5La0g_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">12796000</cvac:ThirdPartyServiceExpenses>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_SymS6EZkjU6K_N5xkmxRUw_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3491000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_AbRj1Ce9iEaVKPddUt2ylQ_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5320000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_iZXz4QDDGkmmnlWvfAB-Kw_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3325000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_1_VJM8GLy0i3IYnyeDAagw_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">6091000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_6XS2sGmXmUegyOszebcdkQ_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4458000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_J90ix0NfwEew-DcXDVsskQ_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5796000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Tc_nFcwXiOuM0WyPmVW-8j73A_10_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">50651000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Tc_ez8n-TLzWkuP4B4k7Ktd_Q_10_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">51678000</ifrs-full:ExpenseByNature>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Narr_SsxUL6MplkmfLU4fNwRsCQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">15525000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Narr_sWnEKll5Z0KW7zd3MbaHIA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">11642000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Narr_0-7LT1CoIUSiR3vQe8EaQQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3446000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Narr_H52DU50nU02_PXMzV3-o6g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7720000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw"
      decimals="-3"
      id="Narr_uiswK7dEFU6aP9XZrhs39g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2769000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KsrxOj7NeEe6aRmKa2IOOQ"
      decimals="-3"
      id="Narr_-cczUUwtrkiqoh9Xx6WlTw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2343000</ifrs-full:InsuranceExpense>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_2pJ5xMgFvkKDGyTdzPAHXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 45,234&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,207&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_DuOqXE-WiUOkAPMLnvaNVg_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">33961000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_b6Nknr9qHUKEUbrVJeU6hQ_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">610000</cvac:CostOfReimbursementClaim>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_v6qSd-zEKkiAu_RNxyNRuA_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">310000</cvac:SaleOfEquipment>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_g-gr9Ze1XEuLTgnqZTZi_w_7_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">45110000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_i-i7-EGMKUuqtZCTXM3-4A_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">104000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_IMAGf8Ey0kKs6wvs3pf-5g_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">124000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_8cy8dwkm5kqh6kaD054XPQ_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">222000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_ZiipVWgKKkaCj3TSK1IM9Q_9_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">45234000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_X4domwyp-kqeA2GNLgn2Nw_9_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">35207000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"
      decimals="-3"
      id="Narr_6gzLLnu7IU2rDjrPWfCi8g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">20500000</cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities>
    <cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"
      decimals="-3"
      id="Narr_uoHG0__WKEmHv8S-0j413A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">12000000</cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses>
    <cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver
      contextRef="Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg"
      decimals="-3"
      id="Narr_d6VMMVIgn0OTlMurMXIO0Q"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">25059000</cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_6_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_zKdBd8Au7EmwSNmyKFumnw"
      decimals="-3"
      id="Narr_RHfpSoff20OC8oFmjMj96A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">44090000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_8Pr5Ggh9JEajOUbg_YKR8Q"
      decimals="-3"
      id="Narr_6fd4hUAIK0KrXsQjDyt70A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:GovernmentGrants>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_MEfyfKoJLka_FnOTfjHVVg"
      decimals="-3"
      id="Narr_40GsJC1RVEqf56ColKmJGg"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">8300000</cvac:MaximumGrantToBeReceived>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_mNAuTnZ79kmgMEM_evAL-A"
      decimals="-3"
      id="Narr_kaOsbs-0NkOCOFQkFoNLSA"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">15300000</cvac:MaximumGrantToBeReceived>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_skb-i2lgmkG-FxOxet3a0w"
      decimals="-3"
      id="Narr_2TSSSTYylkyJ76mUKSCetQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Pyt_GawsiEiGAxSCTTHNSw"
      decimals="-3"
      id="Narr_EHR6QoEhiE-v6RNK5eFieg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">23000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_fTCAXcXeVEGq1xPWfKyuDQ"
      decimals="-3"
      id="Narr_hHgTqFP6z063gFNnrFy_iQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1281000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_zRxCoItDgkao45OmbONCMw"
      decimals="-3"
      id="Narr_hvHFAOYAFUmTtsypvYtbIg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1288000</ifrs-full:GovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_cvXKLI50Ok29UKYe1Lppng"
      decimals="-3"
      id="Narr_65S44xsq7U60P4eH-UDY0A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">96000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_YkJamxu9vUOFt13D2FrYnA"
      decimals="-3"
      id="Narr_FqOBE3N5O0O4qRUzIY3S4Q"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">211000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_6_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_z_OM4LPemU2vaJCSSgPmxQ"
      decimals="-3"
      id="Narr_M0-E5puvv0aHo18e_m6_5A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1782000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_7UE4OxQYgE2K901Hl7Dixg"
      decimals="-3"
      id="Narr_45JhgT22BUKV-C9yrXYlQg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1879000</ifrs-full:GovernmentGrants>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_VimYx0VGG0Cym0WsGxVJQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;4. Issued Capital and Reserves&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a &lt;span style="-sec-ix-hidden:Hidden_G3msjGiE3kqZNUEVJNk5yA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;nominal&lt;/span&gt;&lt;/span&gt; value of EUR 0.12. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2022, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. In June 2022, 340,015 shares were issued under the ATM program, raising USD 4.8 million in net proceeds; related offering expenses were recorded against the proceeds in equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The number of shares issued and outstanding developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Jan and March 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Apr and June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,418)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,466,954&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ"
      decimals="INF"
      id="Narr_yfH60iO9pkW74IGWws2yIw"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ"
      decimals="INF"
      id="Narr_lhCIGVrQzUKQI-sRXptCCQ"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ"
      decimals="2"
      id="Narr_iWZCtorh2EORXbkJzQ0tiw"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_9Blg8Iy4CkeEuY7Xe8l4UQ"
      decimals="0"
      id="Narr_2tp7xS_pzEqi19apLBfPLQ"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">0</ifrs-full:NumberOfSharesIssued>
    <cvac:AggregateGrossProceedsReceivableFromIssuingShares
      contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_sc6LsyPDbUSO09oxzVOOUw"
      decimals="-5"
      id="Narr__9kEBf2etku8J4ljBvU6wg"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">600000000.0</cvac:AggregateGrossProceedsReceivableFromIssuingShares>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2022_To_6_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_FFHzzrCoqEGuPsRnxpT4pQ"
      decimals="INF"
      id="Narr_gxJtvMgTBk63fs8GehAyXA"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">340015</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_6_1_2022_To_6_30_2022_SdTrfxiB0U-Z0Gmk5GUxOg"
      decimals="-5"
      id="Narr_8qidjZ2IPEmaswdq8JKaBQ"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">4800000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_U7vNJdlrcUagsx0y6o8mlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Jan and March 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Apr and June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,418)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,466,954&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="INF"
      id="Tc_mOwk0-VwLUiHcmdopBJhmg_1_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">187120728</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:ShareOptionExercises
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="INF"
      id="Tc_i0LEhxnufEufRoV8_895ig_2_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">78732</cvac:ShareOptionExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="INF"
      id="Tc_qK9ga3dyOkaxFr7TbOtOVw_3_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">-78732</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_3_31_2022_PD-hd6qO7kyci1VNI1JU4g"
      decimals="INF"
      id="Tc_fBJjFGbqAkCeXfZY_y8eWg_4_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">187120728</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA"
      decimals="INF"
      id="Tc_bXhUc4lJzUOJrDpUkFHN3g_5_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">340015</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:StockIssuedDuringPeriodForExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA"
      decimals="INF"
      id="Tc_2FA2MUmuyU2_hIQcp6GIDw_6_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">6211</cvac:StockIssuedDuringPeriodForExercises>
    <cvac:ShareOptionExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA"
      decimals="INF"
      id="Tc_eveALTUbs0S7UKOTZkD3Gg_7_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">39418</cvac:ShareOptionExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_4_1_2022_To_6_30_2022_w_nH-e-QRkOTxcczrh1UCA"
      decimals="INF"
      id="Tc_yHLFTQEHx0G8_Z8w3tA-Bw_8_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">-39418</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="INF"
      id="Tc_0ZxAkDNns0WHRejQSSjqBA_9_2"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">187466954</cvac:CommonSharesIssuedAndOutstanding>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_sO7UhmDUBkuKlR39AK0jhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;5. Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR 3,597k and EUR 8,212k, respectively, as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"&gt;Six months period ended June 30,&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expense recognized for the equity-settled programs was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Six months ended June 30:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU for key employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. On June 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 of his options in May 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On June 30, 2022, none of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June all his options forfeited. All expenses recognized up to him leaving were reversed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2022, CureVac granted 11,500 options to two key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the COO and CDO under the LTIP were vested and hence, were not exercisable at that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, CureVac granted 130,000 options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by Curevac N.V. Options will be settled in shares of Curevac N.V. As of June 30, 2022, none of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expenses recognized for employee services received under the LTIP during the six months ended June 30, 2022, is in an amount of EUR 3,078k (2021; EUR 7,331k) and is included in general and administrative expenses and sales and marketing expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, the group awarded 10,956 RSUs to supervisory board members and on December 23, 2021, the group awarded 63,095 RSUs to the executive board and various key employees. Within the first half of 2022, 10,238 RSU&#x2019;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 10, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, the group awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, CureVac awarded 36,000 options to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise of share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; 101,609 options were exercised within the first and second quarter of 2022 at a weighted average share price of USD 19.24.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Narr_xknoQOOL50q1Ma2lAJEUCA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3597000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Narr_yh5kQmgJMUqSqaY207LguQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8212000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_7RDgTEzgj0u93xy5XFAZEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"&gt;Six months period ended June 30,&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_LRw1LY2yLEGIu8vrGKa07A_3_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">370000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_BpG0lfVSekaXWvfTkFepXg_3_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">90000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_EEaVbbCq_E6jMEEHXZWgDQ_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">122000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_4g8dYHNKmkeS9Mv-1pnfLw_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">61000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_wb6BWBH0lkW5zeyYEdVX1w_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7720000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_EzK6cYM9yEebsF24n9Ijjg_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3446000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_NBwprsDUfUWuK7iuhzO2zA_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8212000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_8JlYzLItak6DCEdE2DvSmA_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3597000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_GQ_P5_vfo0iaxBG72itZeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Six months ended June 30:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU for key employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,212&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3nipjvAshE6IJam5p-Fh3Q"
      decimals="-3"
      id="Tc_ONsL4LDqH0GvwldHoIZG8A_3_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7331000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ"
      decimals="-3"
      id="Tc_QXG7f3n3JkWLBsR13KEpQg_3_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3078000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_07cYvreliEeikUXp57lJ0A"
      decimals="-3"
      id="Tc_3lI_Dy6sJEaiAyE8UP574A_4_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">250000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_dVCXiI28WUKjmh4pxWG7HQ"
      decimals="-3"
      id="Tc_7uAdDaW7wkeNpdTRatuXBA_4_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">87000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_eqJNUVFrwEyBJVapO8-7UA"
      decimals="-3"
      id="Tc_A8NEPDbfkEy21A9b9oj5sw_5_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">323000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Dnjk8zLjh0uRxWQLYgQLtw"
      decimals="-3"
      id="Tc_AVixmlIkrEOQk_Tagc3LYA_5_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-82000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_37SI7EeG40qNRBNVTiXh4A"
      decimals="-3"
      id="Tc_IjJEFUJbKUCD4Ji5NxEbfw_6_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">308000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_bCZajafyHk2TYShK6GXT_Q"
      decimals="-3"
      id="Tc_ssIlfEAtAU6JcKG9YQXXgw_6_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">17000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_Z76paJTu3EqO8ZEo9vC15A"
      decimals="-3"
      id="Tc_0Dkss-FYN0OHfcaA5Dj4pg_7_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">497000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Tc_gl9UAGy-KkK8sT4hpOOotw_8_2"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">8212000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Tc_0nUAwyIxJ06YlmXKVASXTw_8_4"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3597000</cvac:ExpenseRecognizedForEmployeeServices>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_G2czk_grS0e2UewXI2oR9w"
      decimals="INF"
      id="Narr_Xq74ixliT0OZHJZmbUce2A"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">266155</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_w31L0BBG7UmU35R2D2Zt4A"
      decimals="INF"
      id="Narr_2XQPDaUQ3k-Oxq0NZZZ_jQ"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">266156</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_9BE_1GHmUECsOC7edBk3kw"
      decimals="INF"
      id="Narr_BT62Irbn40OvILmzuo_4ug"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">6303</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9FShId--2E63ykkNfrEmmw"
      decimals="INF"
      id="Narr_zIEoIcKyc0Ohc6jFanCtYQ"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">20000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_94_eUZcr1k6ch6WDNbNttg"
      decimals="INF"
      id="Narr_JnEd5BsfQk27n_IEtVbdaw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">30000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_9v7ROjz4KUq67xb-vGVl4g"
      decimals="INF"
      id="Narr_FHPmuUh3dEGiBwXUey7sDw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelepmentOfficerMember_6VL2por91EyDuYch-uIbWw"
      decimals="INF"
      id="Narr_UdPQCq3v40-tMVTbrSRSmg"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w"
      decimals="INF"
      id="Narr_GKRrWR1rz0WI6IJqljAkdw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">11500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfKeyEmployees
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_oXYVj_KX3EWzG6Z3vERg_w"
      decimals="INF"
      id="Narr_A8G-rTsF-ke2Af8hwEl7LQ"
      unitRef="Unit_Standard_employee_2xPxwRpHIkSSwvWmnWr95Q">2</cvac:NumberOfKeyEmployees>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_npRUdd2jrEKdKNSOmQ2E7A"
      decimals="0"
      id="Narr_KvtGP2VbVkmAfzA2GGfenw"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_TtMaJsFnHU-GN-4kQhkccg"
      decimals="INF"
      id="Narr__ZERAqIItEGN5JNvGjtLHQ"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">130000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_6_30_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_SgeNIgwqzk63aou9DXpoZA"
      decimals="INF"
      id="Narr_GGUduZl79kCIVbMLqOeoKw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_vwSDHWlV6k6kvpxM2G58Vw"
      decimals="-3"
      id="Narr_avmE7Hlhaky1f8Rx3wG3cg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3078000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_ZrMDEhuAEUCN6lkugW0ldw"
      decimals="-3"
      id="Narr_OFcnnzqehU2SxH4E_mFDKw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">7331000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_Ucvqwtp93kihEInyQPUvNA"
      decimals="INF"
      id="Narr_pg2x-_HFBUSrmHLlOCFFFg"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">10956</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_vdvY7bSHZkecZoTxnUfO6g"
      decimals="INF"
      id="Narr_BxIt3mr4fUi-tfclgJumow"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">63095</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_3lf9kVQbs0Wrq53Q5kzAVQ"
      decimals="INF"
      id="Narr_8IiNdakVxE-w4AwwYKAZfQ"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">10238</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_MC60TuOPQEegv3N3oZBOrA"
      decimals="INF"
      id="Narr_U3Kz-erzmECYbLbWsIOSFg"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">5000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_IfolEyZFMEKGD2w2ivzW5A"
      decimals="INF"
      id="Narr_sgsBzkco6EyPkcV0wolzbw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">37868</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_z5pHV_ql802Y2Ej33MoQPA"
      decimals="INF"
      id="Narr_9LaWtEyL30S4HdIgLf81Sg"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">193340</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_zpKYCdvoIkWzWr5AFwv_Hg"
      decimals="INF"
      id="Narr_AwkV71TvAEarnCygpxhOtA"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">36000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_Ke6127tPckS7cBQb7_LfxA"
      decimals="INF"
      id="Narr_-zN8iqC7Vk217Yj6UFcgpw"
      unitRef="Unit_Standard_Option_qKfXWFcG1USm8qH76AIYjQ">101609</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_KhUGmIdimECoLuArSGzN7Q"
      decimals="2"
      id="Narr_To-8cLlaiE-mold3jj8xgA"
      unitRef="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A">19240000</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:DisclosureOfFixedAssetsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_BRd-JecBz0KqlsDVQaW5YQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6. Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.1 Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022, the Group acquired intangible assets of EUR 1,207k (six months ended June 30, 2021: EUR 3,966k). The acquisitions during the six months ended June 30, 2022 and 2021 mainly related to licenses, software and prepayments made to acquire those.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.2 Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR 3,034k (June 30, 2021: EUR 6,302k) as well as additional amounts recognized as construction in progress of EUR 39,386k for Company-owned GMP IV facility (EUR 29,552k) and equipment physically located at the CMO facilities (EUR 3,657k) and the remaining amount mainly for Company&#x2019;s GMP facilities. The increase was partially offset by EUR 5,854k impairment of equipment located at a CMO facility, which was recognized in cost of sales.&lt;/p&gt;</cvac:DisclosureOfFixedAssetsExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw"
      decimals="-3"
      id="Narr_-ZmiL_KXCUK6mCbAQsGsqg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1207000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_i0uFtxo5n0yyYkb8Bj-Qmw"
      decimals="-3"
      id="Narr_3cCIZ2RmVUu7Rx_OjJRM0A"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3966000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_D9PmNvxW2EyJO-U9VmXN0Q"
      decimals="-3"
      id="Narr_FiNaeAH0Wkq_dV4A_qJwHw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3034000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_smq0Fsap1kGMdfi_JvJUpw"
      decimals="-3"
      id="Narr_BJDysr29UkG1_75OP06FOg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">6302000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_qKO-s7r8BUa2lgRm6ekFrA"
      decimals="-3"
      id="Narr_1v5akhmv9kSyLrXVEPmyqA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">39386000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_EQdNS6liQkqj9HAUfbkJkQ"
      decimals="-3"
      id="Narr_1-m3KyMPBEu25ggym57qoQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">29552000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_5j4KchYGIk-8GogPJ3dGGg"
      decimals="-3"
      id="Narr_9SvN5QoxPkCSKSz5pd7k-g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3657000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Narr_e-s8G1i3606dq0ZOS8MsMg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5854000</cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_dgcr2wGE4UOc6YrCJV36Bg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;7. Assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organizations for the sale of Ultra-Low Temperature freezers for a total price of EUR 865k. The actual sale of the assets occurred in July 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.&lt;/p&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_1HoF7JNMmU-E_bV-sJyVUw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">865000</cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_sy4vNW_4lEGfEv8Gn4IFoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;8. Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The inventories include only raw materials. During the six months ended June 30, 2022, the decrease in inventory of EUR 42,918k is due primarily to transfer of inventory EUR &lt;span style="-sec-ix-hidden:Hidden_jkLIgqZzAkOONGLtAkGXdA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;9,8&lt;/span&gt;&lt;/span&gt; million (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR 34,640k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <cvac:IncreaseDecreaseInInventory
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"
      decimals="-3"
      id="Narr_jUPcs3lhnUqKpEfB3cSsXQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">42918000</cvac:IncreaseDecreaseInInventory>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg"
      decimals="-3"
      id="Narr_-cn-5Zqckk29YBft4DbMbA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">34640000</ifrs-full:InventoryWritedown2011>
    <cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_Uqe74iPIhE6YumZM8UVaSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;9. Prepaid expenses and other assets (current)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets as of June 30, 2022 amounted to EUR 70,968k (December 31, 2021: 49,244k) and mainly include receivables for the GSK compensation of EUR 45,801k (December 31, 2021; EUR 0k). For more details we refer to note 3.6. In addition, other assets include further prepayments for material in the amount of EUR 4,653k (December 31, 2021:EUR 5,724k) and tax claims against the tax authorities of EUR 15,160k (December 31, 2021: EUR 35,234k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.&lt;/p&gt;</cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_4-rTojgVZkWQ0jzII0CzvQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">70968000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Narr_8Qxzc0d9hE2Aj5HK5U8x4g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">49244000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_aIxGBGj0WkSXGOxLLCc1hA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">45801000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Narr_ep_o1p0mAEin2Osqr2UUpA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_L4bdJ1cEw0izL8wj0BDBzA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">4653000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Narr_x6KOnLhIpUm3xk1_LkVUZw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">5724000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_jPOoHYXHn0K7SKJADJJ14Q"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">15160000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ"
      decimals="-3"
      id="Narr_sw192lM6Y0SLGb-Hs2DahQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">35234000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_MkBA8QIe3EKE0tb4PzFi0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;10. Financial assets and financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2022 and 2021.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Narr_Cu0gox-LKU2qnRmqgBgivQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Narr_DJ7Vp8AVfEiwCAIPuk089w"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw"
      decimals="0"
      id="Narr_JKKQ8MjqX0ebgJKFEU-BsA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Narr_6Az2mQZsKEmq4gwsQYLheA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_63kCQ2zkd0mc3EJcz7Mnzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;11. Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the six months ended June 30, 2022, the decrease of EUR 79,207k in trade and other payables was primarily due to less payables to suppliers as the CVnCoV project was stopped in FY 2021 Q4.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <cvac:ChangeInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Narr_1iFHaLGzJ0Od02EhkN1KHA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">79207000</cvac:ChangeInTradeAndOtherPayables>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_gtetiRuoTEeE3h4SYlDX6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;12. Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the six months ended June 30, 2022, the decrease of EUR 77,314k in other liabilities was primarily due to a net decrease of contract termination provisions, due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate, due to a consumption of the CRO accrual for onerous losses and due to lower accruals for outstanding invoices. The change in estimate of the contract termination provisions resulted primarily from the Company now being able to avoid an outflow of resources since GSK took over from the Group reserved capacity at Novartis (see Note 3.4 and 3.6 for additional information).&lt;/p&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <cvac:ChangeInOtherLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Narr_0SSZAhG5oUCZRV56SpjI6g"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">77314000</cvac:ChangeInOtherLiabilities>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_tJBOGE1hFEGr1qZ0S2OhXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR 25 million &#160;(plus accrued interest of EUR 1,726k) was outstanding on the loan as of that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR 26,633k, which comprises of EUR 25,000k repayment of the loan and 1,633k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w"
      decimals="-6"
      id="Narr_rLlLcOhKj0quwHGM4AqbUw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <cvac:LineOfCreditAccruedInterestPayable
      contextRef="As_Of_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Qe5xZZRKBkalAhPMb0rKlw"
      decimals="-3"
      id="Narr_cL2nG7KSdkyVQsmUjPHUaQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1726000</cvac:LineOfCreditAccruedInterestPayable>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg"
      decimals="-3"
      id="Narr_AeQtVHkrH0u3C5mk4HkQvg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">26633000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <cvac:RepaymentsOfPrincipalAmountOfBorrowings
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg"
      decimals="-3"
      id="Narr_fX3RhZjd_0GXiJmCQ50eoA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">25000000</cvac:RepaymentsOfPrincipalAmountOfBorrowings>
    <cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_qXiiCF_1hUSUqYRLB9UIQg"
      decimals="-3"
      id="Narr_tstl-V22S0-yN3I_1rojcA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1633000</cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb__HLtIcqCMkGc9JvkeQvnzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;14. Income tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group booked the expected tax benefits or expenses based on a best estimate for a period of six months ended June, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the six months ended June 30, 2022 and 2021, the Group recorded a consolidated income tax benefit (June 30, 2021: tax expense) EUR 82k (June 30, 2021: EUR -1,329k), respectively. The consolidated income tax benefit (June 30, 2021: income tax expense) for the six months ended June 30, 2022, resulted from income tax benefit from CureVac Corporate Service of EUR 96k for current tax and tax expenses of EUR 12k for releasing deferred tax benefit on loss carryforwards. CureVac Swiss AG has a current tax expense of EUR 2k (June 30, 2021: expenses from CureVac Inc. of EUR 146k and deferred tax expense on taxable temporary differences of EUR 1,286k as well as a recognition of a deferred tax benefit on tax loss carryforwards of EUR 103k).&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-3"
      id="Narr_J5iVjUTSDUO9UMUA_oYSFw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">-82000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="-3"
      id="Narr_xKlDZh9FQ0CgRFAB4WCarg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1329000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_OUBDouNJ3UGASomEVEai6w"
      decimals="-3"
      id="Narr_Yfrc3Mg5TUyLtvDHdZrWcQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">96000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_tG8hTQGLX0ejbiTFxdHWvg"
      decimals="-3"
      id="Narr_dG0sPL29X0eWtlN3zDpPhA"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">12000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_Aoq6kdzIgEGb4JC-aygDJw"
      decimals="-3"
      id="Narr_FUaxmpCFo0ivzm9DtU1_Ng"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">2000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_uYl7CoErZUmkaktvlFSJJg"
      decimals="-3"
      id="Narr_4UuPFfWlmkuyfOOAeI7Yhg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">146000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_TemporaryDifferenceMember_xwvzCyZJjUu1_z9vpwK1lA"
      decimals="-3"
      id="Narr_p9yVEGT7U02IQ2WUWWXFqg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">1286000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_KdHhy8rMGkOPdf-0LDkcag"
      decimals="-3"
      id="Narr_wIVrE-ArrES_WC5ZMNciBw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">103000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_qo_NOlsdDUa1t8IKGZWRgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;15. Disclosure of financial instruments and risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Refer to note 15 to the consolidated financial statements as of December&#160;31, 2021 for additional information on the Group&#x2019;s risk management activities. As of June 30, 2022, the Group held cash and cash equivalents of USD 62,863k and CHF 110k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. &lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g"
      decimals="-3"
      id="Narr_qQmrL-_ydUKYpfs05tBqjw"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">62863000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_sTG3gTwnF06uW__PG0Jy7Q"
      decimals="-3"
      id="Narr_lIJ9c0jmGES8gBI2FH8w6A"
      unitRef="Unit_Standard_CHF_x9ufSMA390KJ8aeE_m0Llg">110000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_S1353tnjvk-CHhwjqD772A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;16. Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Earnings per share is calculated pursuant to &lt;i style="font-style:italic;"&gt;IAS 33 Earnings per Share&lt;/i&gt; by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The weighted number of shares outstanding for the six months ended June 30, 2022 was 187,041,805 (June 30, 2021: 185,062,052). This has led to a basic loss per share for the six months ended June 30, 2022 and 2021 of EUR 0.39 and EUR 1.44, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the six months ended June 30, 2022 and 2021. &lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="0"
      id="Narr_ybVDYkpgqUC18aE3q1hnOw"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">187041805</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="0"
      id="Narr_EXfWi9d_tkqN6PvlHzjnrA"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">185062052</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="2"
      id="Narr_edXIHRruJ06Su6yWf5wbWQ"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-0.39</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_kbIDUoKeFUK1EnU9ZoWWoA"
      decimals="2"
      id="Narr_MgEVMGsI3kGE04sWdluMvw"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">-1.44</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_cZBoFPz33kCJ7u1gAa3fgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;17. Related party disclosures&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dietmar Hopp&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s largest shareholder, purchased EUR 100,000k of the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s common shares at a price of USD 16.00 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Antony Blanc&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and amounts to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. This function he executes by using Clarentis SRL. Related to these services CureVac paid until June 2022 an amount of EUR 34k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;BePharBel Manufacturing S.A.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of &#x20ac;3.9 million, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#xe9;phenne, our supervisory board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xe9;phenne&#x2019;s son, Vincent St&#xe9;phenne, holds 1.43% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <cvac:RelatedPartyTransactionNumberOfLoansReceived
      contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember__uQ5VVHK0UWYczs0k7a3Uw"
      decimals="INF"
      id="Narr_Tn0h197jvUSXoaKlsRYBSg"
      unitRef="Unit_Standard_loan_jqkBG3F-sEycxO6evEyZWQ">2</cvac:RelatedPartyTransactionNumberOfLoansReceived>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA"
      decimals="INF"
      id="Narr_CZVHpd_B2EiVB5tABlqDlg"
      unitRef="Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg">100000</cvac:IncreaseInNumberOfSharesOutstanding>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA"
      decimals="2"
      id="Narr_CEoTcJkkQUyttwUBtxY7Rw"
      unitRef="Unit_Divide_USD_shares_sVQDnmtsyUGHfAQnKvvX8A">16.00</ifrs-full:WeightedAverageSharePrice2019>
    <cvac:CollaborationAgreementMilestonePayment
      contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_wjj_nYzRdkKzd4QyrVUUTw"
      decimals="-3"
      id="Narr_DVttyU3iMUGx_C4ZpPemsQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">100000</cvac:CollaborationAgreementMilestonePayment>
    <cvac:PaymentsToRelatedPartyForServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_YvgJJg2RWkS_B2vVJFNGhA"
      decimals="-3"
      id="Narr_yJdgKNq3tEiCIHilqWVeEw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">34000</cvac:PaymentsToRelatedPartyForServices>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_sV-2gWepY06B0A8GEXWNAA"
      decimals="-5"
      id="Narr_tYZrKwKsDEGzPNVk8wLLOg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">3900000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_Z1RDELYnhkW7Qf2dwfv-dg"
      decimals="4"
      id="Narr_hs6wSdINtk2Peij-BtK_hw"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.1561</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_jk-0HXYllkOyUB1FBqMB3A"
      decimals="4"
      id="Narr_ZvR5jFGtRUqeykmvW4uNYQ"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.0143</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      id="Tb_c5oqNQuCEkiepknGwVtfag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;18. Subsequent events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Frame Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective July 1, 2022 (&#x2018;closing date&#x2019;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#x2018;Frame Pharmaceuticals&#x2019;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling to identify structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#x2019;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#x2019;s broader oncology strategy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the purchase price agreement (&#x2018;SPA&#x2019;) dated June 8, 2022, a total purchase price of up to EUR 32.0 million payable mainly in shares of CureVac N.V. (total of 1,783,460), as well as a certain amount of cash, was agreed. Additionally, a net amount of EUR 0.66 million for discharging contractual obligations for outstanding advisory agreements with former shareholders was also agreed to. The shares were valued in the SPA at an average share price of &#x20ac;16.44.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At closing, CureVac paid 50% of the agreed purchase price, i.e. 810,242 shares were issued and cash in the amount of EUR 0.25 million was paid. Further shares worth EUR 0.66 million were issued to pay certain liabilities towards former shareholders of Frame Pharmaceuticals. In addition, restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element of the transaction will be accounted for as a separate share-based transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Payment of the remaining 50% of the purchase price is contingent upon achieving two milestones. A further 194.647 shares (representing 10% of the purchase price) will be issued upon the achievement of the successful investigational new drug application filing and further 778.588 shares (representing 40% of the purchase price) will be issued upon successful proof of mechanism in humans. The fair value of these contingent payments will be determined considering the likelihood of the events occurring.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since the transaction occurred only shortly after the reporting date, it is not practicable for the Company to provide information in relation to the initial accounting for the acquisition, in particular regarding the identification and measurement of identifiable assets and liabilities, including any goodwill, and the consideration transferred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For purposes of the Purchase Price Allocation, the shares to be issued in exchange for Frame Pharmaceuticals shares will be based on the share price at closing, i.e. &#x20ac;13.64.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash in the amount of EUR 308k was acquired. Transactions costs in relation to the acquisition amounting to total EUR 0.4 million have been expensed within administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Patent Infringement Lawsuit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In Germany on June 29, 2022, CureVac brought an infringement lawsuit under three utility models and one patent against BioNTech on the basis that the manufacture and sale of Comirnaty infringes CureVac&#x2019;s intellectual property rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In the US on July 25, 2022, BioNTech and Pfizer jointly brought an action seeking a declaration that the manufacture and sale of Comirnaty does not infringe three CureVac US patents. &lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ"
      decimals="-5"
      id="Narr__Uun192pQkG0I0mVEdoV-Q"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">32000000.0</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_gMrMrj-AtE-59jQ4bsw3sQ"
      decimals="INF"
      id="Narr_lRFyfmERq0uuPoVe0UsRjg"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">1783460</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:LiabilitiesIncurred
      contextRef="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w"
      decimals="-4"
      id="Narr_JHl39uJK1UiLUXxpBWchkg"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">660000</ifrs-full:LiabilitiesIncurred>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_8_2022_T8JeWkU3nkyWLpAkIHRd7w"
      decimals="2"
      id="Narr_oQHDa-pjN0OkvVye5ubu0A"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">16.44</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="2"
      id="Narr_1Q3MNXtzI0mRMu5GcfBFRA"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.50</cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="INF"
      id="Narr_1kjsmcEc-ki0G4VK9p4hxA"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">810242</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:CashTransferred
      contextRef="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_RMhcUw7iwE2lpjvCLpz2Fw"
      decimals="-4"
      id="Narr_Tq-sHkWPekKHjA-K-unJww"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">250000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="As_Of_6_30_2022_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_v6FcOJX3ZkOQL_If3V44wQ"
      decimals="-4"
      id="Narr_ZIRdonKWM0SDFlhRgX760w"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">660000</ifrs-full:CashTransferred>
    <cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_KAq3DEF70UWNcG0E7Qz2aw"
      decimals="2"
      id="Narr_jOjUZTDAgUGwu9VionjsXA"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.50</cvac:PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_6Kj0uxl05kGcqv5cmngJhA"
      decimals="3"
      id="Narr_hPqEA_8vu0ieDFeq7KQqMg"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">194.647</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_i3Ky2o24PUOSBVz8jJnLZA"
      decimals="2"
      id="Narr_iVL5peKHeEeBRE3KsqHFgw"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.10</cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_0AMNouAweEWk9_wb8d_Q1A"
      decimals="3"
      id="Narr_YPYazqqDT0y_9Zp7Q1LEUg"
      unitRef="Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw">778.588</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestonesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_nVyvmSWGc0qjWc-iNGi-MA"
      decimals="2"
      id="Narr_t2-OuGaHpUONA51kWD9qAQ"
      unitRef="Unit_Standard_pure_ph7XrKHV50Gab9TRIl90jA">0.40</cvac:PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans>
    <cvac:PurchasePriceAllocationSharePriceAsOfClosingDate
      contextRef="Duration_7_1_2022_To_7_1_2022_DRz3CCZAlUWbryO3lgpfCw"
      decimals="2"
      id="Narr_b_9DgwRF5EKSFJO30A0tNw"
      unitRef="Unit_Divide_EUR_shares_x4bGdVZABEiVrXrl8otoUw">13.64</cvac:PurchasePriceAllocationSharePriceAsOfClosingDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw"
      decimals="-3"
      id="Narr_Qjkg9C89rUK7k5CRDUTHLw"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">308000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw"
      decimals="-5"
      id="Narr_dhSeTS4QE0OZnihuFLzOTQ"
      unitRef="Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg">400000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ^YR1<F2,F4@_W_;MN+I1KTRLG_-:?8?4$L#!!0    ( )B"$E6@)T,$20<
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M<VAE971S+W-H965T-BYX;6RE5FU/XS@0_BNCK Z!U$W;M!06VDJ\W )W@D/
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MWX0MZ W_O1:.5IX9?:5J2*?RXO,ME87N!O>9>HXT1A@>]N H&QQ-X*G&!94
M30^ND!0W+RE<UHZK0G,\)"9!:3!VTX-+A6ME%%S;JH)S99\P+Z"P6K+Q5;FX
MACU15J=$,84_KV!?-O8'/=@4Q"*VA2%Q2.Y0[C:>Y )'>:DT+(^O*Q(\L"2-
M#?%G52E#31W'BFNU)+M<H<G;EHNU%&Y%Z."IY9"IM;HV;4T*VE54_K5S'>H8
MF68AQ.9M6<>^*5#+!JLI\]H&SM7QO1$);>=E@6&#2#=65;D4QI,X>$.:P_$7
M^ UDHV=LQPJ=LC+MPD3BM:<\Z=:4L8XDPJ)I38FPI$O0;B>59X.VXSRF7(]
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M-?AM*MG(8>ZZ$B+]5$/;N1[GF86=<+?2'G1D2PUTJ4+HG<=/XXP[W#A);P(
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M=#&Z1B[7!* ]+\#OE<.4DF_8P? %^OPO4$L#!!0    ( )B"$E6/++)#_Q$
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M:P9YF<DU(!QMBX-P:WD?@__7L$P*]ED^0CX#Q8*AW628R;>5@F\\9AB<PF"
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MN_W@F=</O*%_U@"S<VY9[5836\@QH_#O.VY2[-6;VD*MC",_W8-2X\.QCB_
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MH/M[JQ]8U?B[8JLLW3S^M:*K'K4+H.^E4O8T< L,?Q[6?P%02P,$%     @
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M5AO0+IK0W,"WZK.)')?N4!ZLIEU.>79VI[%B/ ?<TC$;-,!D#LH6J($9@];
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M9R/X>WZX%I)@(U3+MJV@$*Z.V=' QU;R&1KO3L"3*)$GN4".K10.H49L=WX
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M)C]J!Z#OI5)VOW$!QO^2Y5]02P,$%     @ F((259G,D:<V P  W@<  !D
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M:!R^>1V Z5^3?N%TXR?X1CMZ#_QG20\P&G:@_4)K=UAP@/%)7_\#4$L#!!0
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M0,,J+FOZ=8".#>B^M-0=PX8)QM\;FS\!4$L#!!0    ( )B"$E7\0AAFW (
M .0&   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*55;4_;,!#^*Z=,
MFC:IREM?*%U;B3*F,0D)T;%]=I-K8^'8P78(_'O.3IN542JF?4ELWSW//6<[
M3Z:-TG>F0+3P6 II9D%A;36)(I,56#(3J@HE1=9*E\S25&\B4VEDN0>5(DKC
M>!25C,M@/O5KUWH^5;457.*U!E.7)=-/"Q2JF05)L%NXX9O"NH5H/JW8!I=H
M;ZMK3;.H8\EYB=)P)4'C>A:<)9/%P.7[A%\<&[,W!M?)2JD[-[G,9T'L!*'
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M;"]W;W)K<VAE971S+W-H965T,C,N>&ULI5AM;]M&$OXK"Q4M$D"A7BVKB6W
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M3T;VN:X7""\3%88H*%2"RIG.F/'YG6AKA82]^GS[Q;U^C*/#0%6CS8$" FA
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M<-]M9PJ]7?/[,>\6O!MCSAR$Y1=9UR]H7VZCNRC;Z5GG;@^*3:XV6%>M^,M
M'Z1.0I":@".Z"[Q'C\FU[!C^]UTH#,6FT/F2(MA%'1ACU #[J?>QT<D+,B;V
M-OP,P$0#A>*[<G^W_Z7A.KY@'\7CSQ1_A+7,"4T;'!UGYV>#&+'NPILFO&ZO
MC<?+>_A:$B_!+(#G&V-\=\$&^M]?KOX'4$L#!!0    ( )B"$E4R6K5G]0@
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MSE;XV9;U9L*S7:!OG3 %0 #FDB',8@N>N&JIU3[KD/N^3!&F/#"Q44O)ERV
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M*(R#MF><J^W"!.C?N_@/4$L#!!0    ( )B"$E6":)",-@,  "\(   9
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M1PD)JYKQU&R,K-U(N)2&!HQ;%C3145D#NE]*:6XW-D#[/\+T#U!+ P04
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MOK_?K_[0'QYT]?$H.!@$7G=7#VMR0R.Y.6=Q'LDN5L; <PM@":RE<51K'%U
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M*ER)3KEKL_T=AWQ"@*51%)ZP'>8F$90=.=,.8(Z@E;I_BV^##CN -'T$D Z
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M&O6H70"]+Q6U_[!QTV3\\\C^ %!+ P04    " "8@A)5HFMRXG\#  "!"@
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M0F,!TC5KK!%!&@.<KP26#4/'+#!6G?G?4$L#!!0    ( )B"$E6Z!3?40 ,
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MQI4'(;Z9S74Y]P)#!#44VIB@^/<(%U#7QA)R?.^,>OT[C>+N>FO]=^L\.O-
M%5R(^A]6ZFKN33Q2PH*N:WTG-G]"Y]#8V"M$K>POV72R@4>*M=*BZ921H&&\
M_:=/72!V%-".6R'J%*)]A>2(0MPIV,CY+9EUZY)JFL^DV!!II-&:6=C86&WT
MAG&3QGLM\2E#/9U_$AH4T8+H"D@AN!(U*ZF&DBP8I[Q@M"9*XP&F3BLR(G\
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M;"]W;W)K<VAE971S+W-H965T,S<N>&ULK9IK;]LV%(;_"N$610JTL23?4\=
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MI7B27>X)CH@P%?3S+>?JJ6 :*,\5K_X'4$L#!!0    ( )B"$E7U/Z]#M0(
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MI@K(_Q>4BLV%JJ#>!AO_!U!+ P04    " "8@A)5'Z.*L^P"  #F!P  &0
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M(;"!5F0VK'NL<#P4?(V$L=9J9F!S8[UU-(294YPIH;\2[:?B688%7)A$I*C
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M0Z&#\VLU-M.SGPHFG[E]QFQ-9/UC6$E(ZW(D&;%\C)5O!,WT).B!"D$3O8P
MA\"4@7R^HE3L-NH%Y3!Q]AU02P,$%     @ F((2501-SEX*#P  B @! !D
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M_,$3RP<T;+S+?%(N/FH/R^_M'VB7=V653Y>#ZRV8CF=/_V??ES^(%P,,?<<
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M<-JY98[?(U#V I[/I33KC7U!]X5+_@!02P,$%     @ F((252WD+B42!
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MABEPG:#.<\;D+M "_7A.?@-02P,$%     @ F((25?I0.PVL @  60<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULK55K;YLP%/TK%I6J5MK*FZ0M
M05K33=ND:E$?VV<7;H)5P,PV2?KO=VT(2A.2;=J^@*]]S^'<8WP=K[AXD3F
M(NNRJ.3$RI6JKVQ;ICF45%[P&BI<F7-14H6A6-BR%D S RH+VW.<R"XIJZPD
M-G,SD<2\406K8":(;,J2BM<;*/AJ8KG69N*>+7*E)^PDKND"'D ]U3.!D=VS
M9*R$2C)>$0'SB?7!O9I&.M\D?&>PDEMCHBMYYOQ%!U^RB>5H05! JC0#Q=<2
MIE 4F@AE_.PXK?Z3&K@]WK!_,K5C+<]4PI07/UBF\HDUMD@&<]H4ZIZO/D-7
M3ZCY4EY(\R2K-G=T:9&TD8J7'1@5E*QJWW3=^; %<(,# *\#>'\*\#N ;PIM
ME9FR;JFB22SXB@B=C6QZ8+PQ:*R&57H7'Y3 588XE<P$U)1E!-;X7TB0A%89
MX2H'0:B4H"0Y2QLAH%+GY.P6%&6%/"?OR<>G>W)V>C+VH^#ZG'0#PBKRF/-&
M(HF,;87Z]%?LM--RTVKQ#FCYVE07Q'?>$<_QO 'X]#C\%E*$NP;NOH7;Z$IO
MC==;XQD^_]^M&:JU)0^&R?7AO)(U36%BX>F3()9@):<G;N1<#U7^G\C>^.#W
M/OC'V(_YT-7?^3'D0DL=&FK=49;)R+F,QK&]W"YO/RNX](*@SWJC.^AU![_7
M_8H=!W<*VQV>&@6"T6)(9LL4;0N(0G]'Y7Y2./(.B Q[D>%1D8]T3=*"LA)M
M76#3E8J@LT3A-&U4S@53# :=#??4N"'N^([F_2P_]/P#HJ->=/17SJ:\U+\&
M-8U93TSOOA$E:"7G((:T1_O['8X==T?[?I:SH]O>:GSZTKFC8H$>D@+FB'$N
M1@@6;2-O \5KTPN?N<+.:H8YWGT@= *NSSE7FT"WU_XV37X!4$L#!!0    (
M )B"$E6T!21SUP(  +4*   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;*V6;T_;,!#&OXJ520@D1O[1M$ ;"0IHFT!",+;7;G)I+1R[L]V6??O93AH:
M*7,ZV)O&=NYY_+M+&M]XP\6+7  H]%I2)B?>0JGEN>_+; $EEB=\"4S?*;@H
ML=)3,??E4@#.K:BD?A0$B5]BPKQT;-<>1#KF*T4)@P>!Y*HLL?A]!91O)E[H
M;1<>R7RAS(*?CI=X#D^@GI</0L_\QB4G)3!).$,"BHEW&9Y/0RNP$3\(;.3.
M&)E49IR_F,G7?.(%A@@H9,I88'U9PQ0H-4Z:XU=MZC5[&N'N>.M^:Y/7R<RP
MA"FG/TFN%A-OY*$<"KRBZI%OOD"=T,#X99Q*^XLV56P2>RA;2<7+6JP)2L*J
M*WZM"[$CT#[=@J@61/L*XEH0VT0K,IO6-58X'0N^0<)$:S<SL+6Q:IT-8>8Q
M/BFA[Q*M4^DM89AE!%.$I00E$68Y*II%2O",4*((2'1X#0H3*H_09W3S_(@.
M#SZ-XN3TXFCL*TUB_/RLWO6JVC7ZRZXQNN=,+22Z83GD'?JI6Y\X]+ZN0%.&
M:%N&J\AI>(_%"8K#8Q0%4=3%XY9_6S$M#[KD+9RX>2JQ]8L__%2Z:E]YGW9[
MF^_"N5SB#":>_N-+$&OPTH-/81)<="7^G\Q:93AMRG#J<D^_"\QD 0(5@I?H
M#M9 48@4KX?1,;JTY>DJ0N4\L,[F6[9.@[&_WLW,%='"'32X@W_&C=YP0Q=N
MY9PX<%T1+=RDP4T^6-T[]WN6]#*[(EK,PX9Y^,$2]S />YE=$2WF4<,\VHM9
M(L(:TMCU,HQZ(5T1+<BS!O)L3TA]UB->[(-YUHOIBFAAAL';>16\JYH]S[UV
M=<$Z0]JT.Z=K^,ZR]O&&O=\O9TC%Z^\T!B6(N>V7),KXBJFJ1VA6FY[LTG8B
M_EMXU=#I$W).F$04"BT-3H9Z7U'U2-5$\:5M,V9<Z:;%#A>ZKP1A O3]@G.U
MG9@-FDXU_0-02P,$%     @ F((255D5ZH(L @  S@0  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#DN>&ULE51M:]LP$/XK0H72PH@<)TVZU#8D;<<Z*(2T
MW3XK]CD6U8LGR4G[[R?)CI=!$M@76R?=\W+RG9.=TN^F K#H0W!I4EQ96\\(
M,7D%@IJ!JD&ZDU)I0:T+]8:86@,M DAP$D?1A C*),Z2L+?46:(:RYF$I4:F
M$8+JSP5PM4OQ$.\W5FQ36;]!LJ2F&W@!^U8OM8M(SU(P =(P)9&&,L7SX6PQ
M]ODAX2>#G3E8(U_)6JEW'SP5*8Z\(>"06\] W6L+]\"Y)W(V?G><N)?TP,/U
MGOU;J-W5LJ8&[A7_Q0I;I?@6HP)*VG"[4KOOT-5SX_ERQ4UXHEV;>Q-AE#?&
M*M&!G0/!9/NF']T]' #B^ 0@[@!Q\-T*!9</U-(LT6J'M,]V;'X12@UH9XY)
M_U%>K':GS.%L]JII 8C* BE;@48U_:1K#@9=/8"EC)MK='EQ.YJ,[Q"3Z+52
MC7'))B'6B7L*DG="BU8H/B$T0<]*VLJ@1UE \2^>.-.]\WCO?!&?)?S1R $:
M15]0',4Q>GQ;H:O.Z?49]E%_+Z/ /OK/>QD<J[RE&A^G\F,U,S7-(<5N;@SH
M+>#L\F(XB>[.&!WW1L?GV+.Y4(VT2)6N%W,WE@;\A[(G[!]SW_+?!'X_P]ML
M^C6.I@G9'MHB!STF0&_")!F4>_6VW?K=?ECG;8_^36\G_9GJ#9,&<2@=-!I,
MG;9NIZ<-K*I#QZZ5=?T?EI7[X8#V">Z\5,KN R_0_\*R/U!+ P04    " "8
M@A)58_ZU'C@"  #)!   &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q]
M5%%OFS 0_BL6E:I6FF(")*E20&J:3NNT:E&Z;@_3'APX@E5C,]N$[M_/-H1E
M6Y(7[#O?]]UWYLYQ*^2K*@$T>JL85XE7:EW/,599"151(U$#-R>%D!71QI1;
MK&H))'>@BN' ]Z>X(I1[:>Q\*YG&HM&,<EA)I)JJ(O+7 IAH$V_L[1UKNBVU
M=> TKLD6GD&_U"MI+#RPY+0"KJC@2$*1>'?C^2*R\2[@*X56'>R1K60CQ*LU
M'O/$\ZT@8)!IRT#,LH-[8,P2&1D_>TYO2&F!A_L]^WM7NZEE0Q3<"_:-YKI,
MO!L/Y5"0ANFU:#] 7\_$\F6"*?=%;1<;33R4-4J+J@<;!17EW4K>^GLX  3!
M"4#0 P*GNTOD5"Z))FDL18NDC39L=N-*=6@CCG+[4YZU-*?4X'3Z69<@$:-D
M0QG5%!2Z6H(FE*EK='EQ$TZC6T0Y^E**1A&>JQAKD]5B<=9G6'09@A,9INA)
M<%TJ],!SR/_&8Z-VD!SL)2^"LX0?&SY"H?\.!7X0H(>7-;KJE5Z?80^'"PD=
M>WB"?4E5QH1J)"!1H/^OY_LG T"/&BKUX]AE=.S1<78[8G-5DPP2S\R0 KD#
M+[V\&$_]VS/:HT%[=(X]74)F!E.!_6/B7^7'Q'9T$T=GQW>7SF;A.(KQ[E %
M/FBO"N36#9%"F6BX[CIM\ YS>M>UYY_P;LB?B-Q2KA"#PD#]T<SDEMW@=(86
MM6O6C="F]=VV-&\-2!M@S@LA]-ZP"8;7*_T-4$L#!!0    ( )B"$E7&(P^3
M_P(  &D)   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;*U644_;,!#^
M*U:0$$@;29,VK:"-!(5IFT!"96P/TQ[<Y-I8)'9F.RW\^YV=-&MI&@VTE]9V
M_'UWW]W9Y_%:R">5 FCRG&=<39Q4Z^+<=56<0D[5F2B XY>%D#G5.)5+5Q42
M:&)!>>;ZGA>Z.67<B<9V[5Y&8U'JC'&XET25>4[ERQ5D8CUQ>LYF8<:6J38+
M;C0NZ!(>0#\6]Q)G;L.2L!RX8H(3"8N)<]D[GX[,?KOA.X.UVAH3HV0NQ).9
M?$DFCF<<@@QB;1@H_JU@"EEFB-"-WS6GTY@TP.WQAOV3U8Y:YE3!5&0_6*+3
MB3-R2 (+6F9Z)M:?H=8S,'RQR)3])>MJ;SAP2%PJ+?(:C![DC%?_]+F.PQ:@
M=PC@UP#_-2 \  AJ0&"%5IY96==4TV@LQ9I(LQO9S,#&QJ)1#>,FBP]:XE>&
M.!W="LH5.;D&35FF3LE'<HL[B%B06$+"-"[</,[(R?'1* C[%Z>D'A#&R;=4
ME(KR1(U=C:X80C>NS5Y59OT#9D-R)[A.%;GA"20M^&DWON=W$+@8@R80_B80
M5WXGX]>2GY' ^T!\S^^U.=0-OX88X;TV^(X[09.7P/(%A_B8BC.A2FESD=CT
M0()1KPZN/0%S/)5D+B12,[Y4Y*<A(4Q#KGZUI:2RV&^W:*Z+<U70&"8.W@<*
MY J<Z/BH%WH7;>'X3V0[P>DWP>EWL4>7N2BY)HFD:]XFM$(/+-I<8ZO('WB>
M-W97VPHZ;;Q3P:!1,.A6$,>RM/G4@.RZ3<5@3T5OZ(>O1'2:>:>(L!$1=HJ8
M4I626."-GH"T-=DFHY/CK547[F<V#(.@"<J.CF&C8]BI8P8%?<'.I,U1*R3C
M,2MH1FA59;B6X279)JV3]JW2*K+P8-'N2!LUTD;_+HV^*CJ"=S=9 *@NC9W\
M;]4XVB_I_>RY6]TL![FT35YAH6$VJL;6K#;OB$O;/MV_VZM'R!V52X;]+8,%
M0KVS(9J656.O)EH4MC?.A<9.:X<IOH5 F@WX?2&$WDR,@>9U%?T!4$L#!!0
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M=#4T+GAM;*U56V_:,!C]*U8J59NTXMR@K V1"NVT3:J$6FU]-LD'L>K8F>U
M]^_G2\@H2ED?]D)\^<[Q.5_B0[83\EE5 !J]U(RK65!IW5QAK(H*:J)&H@%N
M=M9"UD2;J=Q@U4@@I0/5#,=A.,$UH3S(,[>VE'DF6LTHAZ5$JJUK(G_/@8G=
M+(B"_<(#W53:+N \:\@&'D'_:);2S'#/4M(:N**"(PGK67 372W&MMX5_*2P
M4P=C9)VLA'BVDV_E+ BM(&!0:,M S&,+"V#,$AD9OSK.H#_2 @_'>_8OSKOQ
MLB(*%H(]T5)7LV :H!+6I&7Z0>R^0N?'"2P$4^X7[7QM&@>H:)46=0<V"FK*
M_9.\='TX !B>84#< >)C0/H&(.D B3/JE3E;MT23/)-BAZ2M-FQVX'KCT,8-
MY?8M/FII=JG!Z?R.2$[Y1J$&S+NMB 3TX18TH4Q]1!?H_&R:3-)KA/V>RK V
MAUHH+KH#YOZ ^(T#)NA><%TI=,=+*%_CL1';*X[WBN?Q2<+O+1^A)/R$XC".
M!_0LW@^/3LA)^@8FCB]Y=P.'>N0YTF$.>U.O5$,*F 7F*BJ06PCR\[-H$EX/
M&?Q/9*_LIKW=]!1[_N3N!92(M_7*.!;K[LM )B*4)KPTS1CJ@*>=.%H;+=L\
MFEZ&:30-QQG>'MH;JAR'DS@<QWWE*^WC7OOXI/8Y4;1 3*A_O"S/<GD@X"(<
M)9^/9 Y41:,T/9*(#ZYF#7+C$DNA0K1<^V^^7^U#\<9EP='ZW(2ES[:_-#YI
M[XG<4*X0@[6A#$>71IGTZ>4G6C0N %9"FSAQP\H$/DA;8/;70NC]Q![0_X7D
M?P!02P,$%     @ F((25;((ZS.1!0  3RL  !D   !X;"]W;W)K<VAE971S
M+W-H965T-34N>&ULO9I=;]LV%(;_"N$.10L,D2E_)$X= W$DH2V6(8C7[F+8
M!2,?VT0E4A6I. ;ZXT=]6+(\F:V!@^0BEF2=YU!\J4/I-:=;F7Y3&P!-7N)(
MJ)O>1NODVG%4N(&8J0N9@##?K&0:,VUVT[6CDA38L@B*(\?M]\=.S+CHS:;%
ML8=T-I69CKB AY2H+(Y9NIM#)+<W/=K;'WCDZXW.#SBS:<+6L #])7E(S9Y3
M4Y8\!J&X%"2%U4WOEEX'KIL'%&=\Y;!5!]LDOY0G*;_E.Y^6-[U^WB*((-0Y
M@IF/9[B#*,I)IAW?*VBOSID''F[OZ4%Q\>9BGIB".QG]S9=Z<].[ZI$EK%@6
MZ4>Y_0C5!8UR7B@C5?PGV_+<\;!'PDQI&5?!I@4Q%^4G>ZDZXB# I2<"W"K
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M[UOO\7OVPN,L)@JTCB &H0F+929TYSMYR1H=U*O!Y/CIY<Z>\5SA4&D^*BW
MHK6U.W!;J/V9-C*//D)S11:/?W3J98T_]WY$I7FH-!^5%F#1VKJZC:[N:Q?F
M*B/62,"D>:@T'Y468-':(Z'QH:C=B+KG$2@MC;0)V^7%N5-;5#L*E>:ATGQ4
M6E#1#F<S>C"9M25KK"9JM3%F<Y9*03X#$V2A(=F $-"I&JJ#A$KS4&D^*BW
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M'G^C38,F6B]FF:C^HL?ZN]/)",6ED"QO@M4=Y&E1_R??&Q [ ?A0 &X"\%Z
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M@"%!4+X'M]Y'WOH]Y36_C8[^ E!+ P04    " "8@A)5EXJ[',     3 @
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MLKX;L_SK-_GM-:UUV1SR6?>YQ.034$L! A0#%     @ F((250=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "8@A)59D:D0NX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "8@A)5F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )B"
M$E7Y4;IPO@(  +0(   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "8@A)5"2.4)K@$  #.$0  &
M        @($!"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ F((258*(#%L[!@  ,QT  !@              ("![P\  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )B"$E7]% ;+_ 4  /(D   8
M              " @6 6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " "8@A)5H"=#!$D'  #8'P  &               @(&2'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ F((251>+U$-F!
M?PD  !@              ("!$20  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( )B"$E5"7^!XQP@  (T6   8              " @:TH
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "8@A)5CRRR
M0_\1  "$-P  &               @(&J,0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ F((25179,3%"!0  O0P  !@
M ("!WT,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( )B"
M$E7-7]>>)P<  #07   9              " @5=)  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ F((25>3Y5QJ7 P  2 @  !D
M         ("!M5   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " "8@A)5:;P;[98$  !A"@  &0              @(&#5   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )B"$E408 <=20(  # %
M   9              " @5!9  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ F((255N59>4< P  7@<  !D              ("!T%L
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "8@A)5.:G7
MG+@"  "'!@  &0              @($C7P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( )B"$E4= CED8@(  '\%   9
M  " @1)B  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MF((25>Y/W_DI P  , <  !D              ("!JV0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " "8@A)5'@>?(MP"  !7!@  &0
M            @($+:   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( )B"$E69S)&G-@,  -X'   9              " @1YK  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ F((258.0TD.8 P
M>P@  !D              ("!BVX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " "8@A)5_$(89MP"  #D!@  &0              @(%:
M<@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )B"$E7.
MI5K6W@8   <0   9              " @6UU  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ F((25?I^*^2/!P  BQ$  !D
M     ("!@GP  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B"$E5JW.S,+ 4  (D>   9              "
M@2^;  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ F((2
M59>"]AP4 P  G@@  !D              ("!DJ   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " "8@A)55NA@$^L%  #Y*P  &0
M        @('=HP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( )B"$E5/#&ZZJ (  $@&   9              " @?^I  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ F((25:)K<N)_ P  @0H
M !D              ("!WJP  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " "8@A)5N@4WU$ #   \"0  &0              @(&4L
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )B"$E4:HIHC
M$P0  -P,   9              " @0NT  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ F((252<R?!W? P    P  !D
M ("!5;@  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "8
M@A)5Q#E%A#,#  "R"0  &0              @(%KO   >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )B"$E4'L]^M^@4  &,L   9
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M970T,2YX;6Q02P$"% ,4    " "8@A)5!$W.7@H/  "(" $ &0
M    @($=U0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M )B"$E7!X1Y-J0(  .T&   9              " @5[D  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ F((252WD+B42!   &Q4  !D
M             ("!/N<  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " "8@A)52 G<\2P"  !4!   &0              @(&'ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )B"$E4#?%$-: (
M *H%   9              " @>KM  !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ F((25?I0.PVL @  60<  !D              ("!
MB?   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "8@A)5
MM 4D<]<"  "U"@  &0              @(%L\P  >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( )B"$E59%>J"+ (  ,X$   9
M      " @7KV  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ F((256/^M1XX @  R00  !D              ("!W?@  'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "8@A)5QB,/D_\"  !I"0
M&0              @(%,^P  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( )B"$E4FFM6)S0,  *P3   9              " @8+^  !X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ F((253*5X730
M @  O D  !D              ("!A@(! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " "8@A)5 '(,J7$"  !.!@  &0
M@(&-!0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( )B"
M$E6R".LSD04  $\K   9              " @34( 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ F((250)Q3![2!0  H2@  !D
M         ("!_0T! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M    " "8@A)5S0'SQF #   H%0  #0              @ $&% $ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( )B"$E67BKL<P    !,"   +
M  "  9$7 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )B"$E7DHBT#=@0  !XE
M   /              "  7H8 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "8@A)5##^0_.4!  !_(0  &@              @ $='0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "8@A)5C^&W:=,!   V(0
M$P              @ $Z'P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..0 !  '<1   ^(0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>218</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Interim Condensed Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Notes to the consolidated financial statements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</Role>
      <ShortName>Notes to the consolidated financial statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Issued Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</Role>
      <ShortName>Issued Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Prepaid expenses and other assets (current)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</Role>
      <ShortName>Prepaid expenses and other assets (current)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Financial assets and financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</Role>
      <ShortName>Financial assets and financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11121 - Disclosure - Other liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilities</Role>
      <ShortName>Other liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureLoans</Role>
      <ShortName>Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Disclosure of financial instruments and risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement</Role>
      <ShortName>Disclosure of financial instruments and risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of preparation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies</Role>
      <ShortName>Basis of preparation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables</Role>
      <ShortName>Notes to the consolidated financial statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Issued Capital and Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables</Role>
      <ShortName>Issued Capital and Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPayments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Revenue from contract with customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Cost of sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Selling and distribution expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40308 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Research and development expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - General and administrative expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40310 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Other operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails</Role>
      <ShortName>Issued Capital and Reserves - Overview and General Remarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails</Role>
      <ShortName>Issued Capital and Reserves - Impact of share split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Share-based payments - Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails</Role>
      <ShortName>Share-based payments - Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails</Role>
      <ShortName>Share-based payments - Expense recognized for the program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Share-based payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails</Role>
      <ShortName>Share-based payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails</Role>
      <ShortName>Fixed Assets - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Fixed Assets - Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Assets held for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails</Role>
      <ShortName>Assets held for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAssetsHeldForSale</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureInventories</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails</Role>
      <ShortName>Prepaid expenses and other assets (current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Financial assets and financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails</Role>
      <ShortName>Financial assets and financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails</Role>
      <ShortName>Trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Other liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails</Role>
      <ShortName>Other liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureLoansDetails</Role>
      <ShortName>Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureLoans</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxDetails</Role>
      <ShortName>Income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIncomeTax</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails</Role>
      <ShortName>Disclosure of financial instruments and risk management - Foreign currency risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureEarningsPerShare</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Related party disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails</Role>
      <ShortName>Related party disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvac-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 16 fact(s) appearing in ix:hidden were eligible for transformation: cvac:NetValueOfInventoryTransferred, ifrs-full:DilutedEarningsLossPerShare, ifrs-full:ParValuePerShare, ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities -  cvac-20220630xex99d1.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="6-K" original="cvac-20220630x6k.htm">cvac-20220630x6k.htm</File>
    <File doctype="6-K" original="cvac-20220630xex99d1.htm">cvac-20220630xex99d1.htm</File>
    <File>cvac-20220630.xsd</File>
    <File>cvac-20220630_cal.xml</File>
    <File>cvac-20220630_def.xml</File>
    <File>cvac-20220630_lab.xml</File>
    <File>cvac-20220630_pre.xml</File>
    <File>cvac-20220630xex99d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvac-20220630xex99d1001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="375">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvac-20220630x6k.htm cvac-20220630xex99d1.htm": {
   "axisCustom": 4,
   "axisStandard": 19,
   "contextCount": 163,
   "dts": {
    "calculationLink": {
     "local": [
      "cvac-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvac-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvac-20220630x6k.htm",
      "cvac-20220630xex99d1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvac-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvac-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvac-20220630.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 640,
   "entityCount": 1,
   "hidden": {
    "http://www.curevac.com/20220630": 1,
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 15,
    "http://xbrl.sec.gov/dei/2021q4": 8,
    "total": 24
   },
   "keyCustom": 67,
   "keyStandard": 151,
   "memberCustom": 46,
   "memberStandard": 21,
   "nsprefix": "cvac",
   "nsuri": "http://www.curevac.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": null,
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.curevac.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Share-based payments",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fixed Assets",
     "role": "http://www.curevac.com/role/DisclosureFixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Assets held for sale",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSale",
     "shortName": "Assets held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Inventories",
     "role": "http://www.curevac.com/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Prepaid expenses and other assets (current)",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent",
     "shortName": "Prepaid expenses and other assets (current)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Financial assets and financial liabilities",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities",
     "shortName": "Financial assets and financial liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Trade and other payables",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11121 - Disclosure - Other liabilities",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilities",
     "shortName": "Other liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Loans",
     "role": "http://www.curevac.com/role/DisclosureLoans",
     "shortName": "Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income tax",
     "role": "http://www.curevac.com/role/DisclosureIncomeTax",
     "shortName": "Income tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "shortName": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Disclosure of financial instruments and risk management",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement",
     "shortName": "Disclosure of financial instruments and risk management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Earnings per share",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Related party disclosures",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures",
     "shortName": "Related party disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - Subsequent events",
     "role": "http://www.curevac.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of preparation (Policies)",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies",
     "shortName": "Basis of preparation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Notes to the consolidated financial statements (Tables)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables",
     "shortName": "Notes to the consolidated financial statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Issued Capital and Reserves (Tables)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables",
     "shortName": "Issued Capital and Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Share-based payments (Tables)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
     "shortName": "Notes to the consolidated financial statements - Revenue from contract with customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_rKWTzSzrUUy9RPTjww94FQ",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_6_1_2022_To_6_30_2022_SdTrfxiB0U-Z0Gmk5GUxOg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
     "shortName": "Notes to the consolidated financial statements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Interim Condensed Consolidated Statements of Financial Position",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition",
     "shortName": "Interim Condensed Consolidated Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
     "shortName": "Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_pPIcw0OITEqx6syOrQRgwQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
     "shortName": "Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40306 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
     "shortName": "Notes to the consolidated financial statements - Cost of sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_xiiA6KLzAUqdeRaUtJTWbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40307 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_qpb9Yfx65U2oK_7gy-W5_g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40308 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - Research and development expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_HabSgf9Zr0-dc5cpw2Jl8w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40309 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_YsYHK_1xZUSjvuQGh12Rjw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40310 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
     "shortName": "Notes to the consolidated financial statements - Other operating income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40311 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
     "shortName": "Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021__nNRlT525kqKltjeba72zg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
     "shortName": "Issued Capital and Reserves - Overview and General Remarks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_VGzcQRXsR0e6HQKzFJdPlQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_3_31_2022_PD-hd6qO7kyci1VNI1JU4g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
     "shortName": "Issued Capital and Reserves - Impact of share split (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_12_31_2021_WMfS8kdIEkK4-LjQz4prRQ",
      "decimals": "INF",
      "lang": null,
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
     "shortName": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_L8Tu4QgXHkOdVu86LMt3Xg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Share-based payments - Expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
     "shortName": "Share-based payments - Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
     "shortName": "Share-based payments - Expense recognized for the program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Share-based payments (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
     "shortName": "Share-based payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fixed Assets - Intangible assets (Details)",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
     "shortName": "Fixed Assets - Intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_IBGFDD6Q-UKSNA9hn9EeRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
     "shortName": "Fixed Assets - Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Assets held for sale (Details)",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails",
     "shortName": "Assets held for sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseDecreaseInInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Inventories (Details)",
     "role": "http://www.curevac.com/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_ZqX9nEK7ikyRu-BFS7QUtg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseDecreaseInInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Prepaid expenses and other assets (current) (Details)",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
     "shortName": "Prepaid expenses and other assets (current) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CurrentAdvancesToSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Financial assets and financial liabilities (Details)",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails",
     "shortName": "Financial assets and financial liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_ZDLEGSg4VE-so_khCQJ0pw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Trade and other payables (Details)",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
     "shortName": "Trade and other payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Interim Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Other liabilities (Details)",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails",
     "shortName": "Other liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Loans (Details)",
     "role": "http://www.curevac.com/role/DisclosureLoansDetails",
     "shortName": "Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_vhGQUf85hEili4hRHk662w",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxExpenseContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income tax (Details)",
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
     "shortName": "Income tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_OUBDouNJ3UGASomEVEai6w",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_COppSuJXUU2lcO6f1BjqDg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails",
     "shortName": "Disclosure of financial instruments and risk management - Foreign currency risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_D7XYK_2-BUqrhdARk5AO9g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Earnings per share (Details)",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInNumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Related party disclosures (Details)",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
     "shortName": "Related party disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_rzi-GXW2RUuwHFSnzwlQRA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInNumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_vf1_uxsC4kWtPwbIfbfPQg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - Subsequent events (Details)",
     "role": "http://www.curevac.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_GjYkdxMWMkmwwikCBjR0sw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_MsUlnBoGrE2L3hmet0mNaw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Corporate Information",
     "role": "http://www.curevac.com/role/DisclosureCorporateInformation",
     "shortName": "Corporate Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of preparation",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparation",
     "shortName": "Basis of preparation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Notes to the consolidated financial statements",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements",
     "shortName": "Notes to the consolidated financial statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Issued Capital and Reserves",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves",
     "shortName": "Issued Capital and Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_jBZWCJQFPk27MLv3vu2IQw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belgium"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AdditionalDevelopmentMilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional development milestone payment received.",
        "label": "Additional Development Milestone Payments Received",
        "terseLabel": "Additional development milestone payments"
       }
      }
     },
     "localname": "AdditionalDevelopmentMilestonePaymentsReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.",
        "label": "Adjustments For Increase Decrease In Other Current Financial And Other Liabilities",
        "terseLabel": "(Decrease) / increase in other current financial liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Non Cash Income From Release Of Provisions",
        "negatedLabel": "Non-cash income from release of provisions"
       }
      }
     },
     "localname": "AdjustmentsForNonCashIncomeFromReleaseOfProvisions",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Advance Purchase Agreement with European Commission",
        "label": "Advance Purchase Agreement with European Commission"
       }
      }
     },
     "localname": "AdvancedPurchaseAgreementWithEuropeanCommissionMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AdvancepaymentsintangibleassetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AdvancePaymentsIntangibleAsset",
        "label": "Advance Payments"
       }
      }
     },
     "localname": "AdvancepaymentsintangibleassetMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AggregateGrossProceedsReceivableFromIssuingShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate gross proceeds receivable from issuance of shares.",
        "label": "Aggregate Gross Proceeds Receivable From Issuing Shares",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "AggregateGrossProceedsReceivableFromIssuingShares",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AllowanceAccountForExpectedCreditLossesOfFinancialAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an allowance account used to record impairments to financial assets due to expected credit losses.",
        "label": "Allowance Account For Expected Credit Losses OF Financial Assets",
        "verboseLabel": "Expected credit loss"
       }
      }
     },
     "localname": "AllowanceAccountForExpectedCreditLossesOfFinancialAssets",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount pertaining to grants deducted from the carrying amount of qualifying assets.",
        "label": "Amount Deducted From Carrying Amount Of Qualifying Assets",
        "terseLabel": "Amount deducted from the carrying amount of qualifying assets"
       }
      }
     },
     "localname": "AmountDeductedFromCarryingAmountOfQualifyingAssets",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountEligibleToReceiveAsCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive commercial milestone payments.",
        "label": "Amount Eligible to Receive as Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "AmountEligibleToReceiveAsCommercialMilestonePayments",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive development and regulatory milestone payments.",
        "label": "Amount Eligible to Receive as Development and Regulatory Milestone Payments",
        "terseLabel": "Development and regulatory milestone payments"
       }
      }
     },
     "localname": "AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.",
        "label": "Amount Eligible to Receive as One-Time Reimbursable Payment For Manufacturing Capacity Reservation",
        "terseLabel": "One-time reimbursable payment"
       }
      }
     },
     "localname": "AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfLiabilityCashClaimAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized in financial statements towards cash claim of Awards.",
        "label": "Amount of Liability, Cash Claim Awards",
        "terseLabel": "Amount of liability, cash claim awards"
       }
      }
     },
     "localname": "AmountOfLiabilityCashClaimAwards",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfRestrictedStockUnitsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Restricted Stock Units Received.",
        "label": "Amount of Restricted Stock Units Received",
        "terseLabel": "Amount of restricted stock units received"
       }
      }
     },
     "localname": "AmountOfRestrictedStockUnitsReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid at signing of the agreement in related party transactions.",
        "label": "Amount Paid at Signing of Agreement, Related Party Transactions",
        "terseLabel": "Amount paid at signing of the agreement"
       }
      }
     },
     "localname": "AmountPaidAtSigningOfAgreementRelatedPartyTransactions",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AntonyBlancMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Antony Blanc.",
        "label": "Antony Blanc"
       }
      }
     },
     "localname": "AntonyBlancMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ArrangementsAndNonArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Non-arrangement Transactions [Member]"
       }
      }
     },
     "localname": "ArrangementsAndNonArrangementTransactionsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to at the market offering program.",
        "label": "ATM Offering Program"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BaronJeanStephenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Baron Jean Stephenne.",
        "label": "Baron Jean Stephenne"
       }
      }
     },
     "localname": "BaronJeanStephenneMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BenefitExpenseRecognizedForShareBasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit expense benefit recognized for share-based payment.",
        "label": "Benefit Expense Recognized For Share Based Payment",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BenefitExpenseRecognizedForShareBasedPayment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_BepharbelManufacturingS.aMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BePharBel Manufacturing S.A.",
        "label": "BePharBel Manufacturing S.A"
       }
      }
     },
     "localname": "BepharbelManufacturingS.aMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillAndMelindaGatesFoundationBmgfMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF)"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationBmgfMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BmbfMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BMBF",
        "label": "BMBF"
       }
      }
     },
     "localname": "BmbfMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BoehringerIngelheimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Boehringer Ingelheim.",
        "label": "Boehringer Ingelheim"
       }
      }
     },
     "localname": "BoehringerIngelheimMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BorrowingsInEachTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of borrowing in each tranche.",
        "label": "Borrowings in Each Tranche",
        "terseLabel": "Amount of borrowing in each tranche"
       }
      }
     },
     "localname": "BorrowingsInEachTranche",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum financing as percentage of cost of investment.",
        "label": "Borrowings, Maximum Financing as Percentage of Cost of Investment",
        "terseLabel": "Maximum financing as percentage of cost of investment"
       }
      }
     },
     "localname": "BorrowingsMaximumFinancingAsPercentageOfCostOfInvestment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_BundesministeriumFurBildungUndForschungMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Bundesministerium fr Bildung und Forschung.",
        "label": "Bundesministerium fr Bildung und Forschung"
       }
      }
     },
     "localname": "BundesministeriumFurBildungUndForschungMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CapitalIncreaseByGenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab, capital increase.",
        "label": "Genmab Investment"
       }
      }
     },
     "localname": "CapitalIncreaseByGenmabMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA.",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChangeInExpenseByNature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in expense by nature.",
        "label": "Change in Expense By Nature",
        "terseLabel": "Increase in cost of sales"
       }
      }
     },
     "localname": "ChangeInExpenseByNature",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInOtherLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in other liabilities.",
        "label": "Change in Other Liabilities",
        "verboseLabel": "Decrease in other liabilities"
       }
      }
     },
     "localname": "ChangeInOtherLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInTradeAndOtherPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in trade and other payables.",
        "label": "Change in Trade and Other Payables",
        "terseLabel": "Amount of decrease in trade and other payables"
       }
      }
     },
     "localname": "ChangeInTradeAndOtherPayables",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Changes in Working Capital [Abstract]",
        "terseLabel": "Working capital changes"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer and Chief Commercial Officer.",
        "label": "Chief Business Officer and Chief Commercial Officer"
       }
      }
     },
     "localname": "ChiefBusinessOfficerAndChiefCommercialOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefDevelepmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of Chief development officer.",
        "label": "Chief Development Officer"
       }
      }
     },
     "localname": "ChiefDevelepmentOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of Chief operating officer and Chief development officer.",
        "label": "Chief Operating Officer and Chief Development Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefScientificOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Scientific Officer.",
        "label": "Chief Scientific Officer"
       }
      }
     },
     "localname": "ChiefScientificOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ClarentisSrlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.",
        "label": "Clarentis SRL"
       }
      }
     },
     "localname": "ClarentisSrlMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CmoNetworkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CMO Network",
        "label": "CMO Network"
       }
      }
     },
     "localname": "CmoNetworkMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CoalitionForEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants related to Coalition for Epidemic Preparedness Innovations.",
        "label": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.",
        "label": "Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines"
       }
      }
     },
     "localname": "CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CollaborationAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payment receivable.",
        "label": "Collaboration Agreement, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePayment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration And License Agreement.",
        "label": "Collaboration And License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CommonSharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued and outstanding for during the period.",
        "label": "Common Shares Issued And Outstanding",
        "periodEndLabel": "Common shares issued and outstanding ending",
        "periodStartLabel": "Common shares issued and outstanding beginning"
       }
      }
     },
     "localname": "CommonSharesIssuedAndOutstanding",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_Commonsharesissuedandoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued and outstanding for during the period.",
        "label": "CommonSharesIssuedAndOutstanding",
        "terseLabel": "Share options outstanding"
       }
      }
     },
     "localname": "Commonsharesissuedandoutstanding",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_CompanyOwnedGmpIvFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for company-owned GMP IV facility.",
        "label": "Company-owned GMP IV facility"
       }
      }
     },
     "localname": "CompanyOwnedGmpIvFacilityMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.",
        "label": "Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Compensation for CMO transfer"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities",
        "terseLabel": "Compensation consist for set-up activities"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses",
        "terseLabel": "Compensation consist of Manufacturing Interim Period Reimbursable Expenses"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ComprehensiveIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income (loss) in equity resulting from transactions and other events, other than those income (loss) resulting from transactions with owners in their capacity as owners.",
        "label": "Comprehensive Income (Loss)",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeLoss",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than contingent liability arising from patent Infringement lawsuit .",
        "label": "Patent Infringement Lawsuit"
       }
      }
     },
     "localname": "ContingentLiabilityArisingFromPatentInfringementLawsuitMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ContractManufacturingOrganizationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for contract manufacturing organization Agreement",
        "label": "CMO agreement"
       }
      }
     },
     "localname": "ContractManufacturingOrganizationAgreementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ContractResearchOrganizationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for contract research organization Agreement.",
        "label": "CRO agreement"
       }
      }
     },
     "localname": "ContractResearchOrganizationAgreementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CorporateInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_CorporateInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on corporate information.",
        "label": "Corporate Information [Text Block]",
        "terseLabel": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationTextBlock",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_CorporateReorganizationStockSplitRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.",
        "label": "Corporate Reorganization, Stock Split Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "CorporateReorganizationStockSplitRatio",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_CostOfReimbursementClaim": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost of reimbursement claim.",
        "label": "Cost of reimbursement claim",
        "terseLabel": "Reimbursement claim"
       }
      }
     },
     "localname": "CostOfReimbursementClaim",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CrisprMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR.",
        "label": "CRISPR"
       }
      }
     },
     "localname": "CrisprMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CrisprTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR Therapeutics",
        "label": "CRISPR Therapeutics"
       }
      }
     },
     "localname": "CrisprTherapeuticsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CumulativeAmortizationAndImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortization and impairment.",
        "label": "Cumulative Amortization And Impairment [Member]"
       }
      }
     },
     "localname": "CumulativeAmortizationAndImpairmentMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacCorporateServiceGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CureVac Corporate Service GmbH.",
        "label": "CureVac Corporate Service GmbH"
       }
      }
     },
     "localname": "CurevacCorporateServiceGmbhMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacN.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for CureVac N.V. , a former holding company to the entity.",
        "label": "CureVac N.V."
       }
      }
     },
     "localname": "CurevacN.v.Member",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacSwissAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CureVac Swiss AG.",
        "label": "CureVac Swiss AG"
       }
      }
     },
     "localname": "CurevacSwissAgMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurrentGrantReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant receivable, classified as current.",
        "label": "Current Grant Receivable",
        "terseLabel": "Current grant receivable"
       }
      }
     },
     "localname": "CurrentGrantReceivable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents for decrease in number of shares due to treasury of shares.",
        "label": "Decrease In Number Of Shares Due To Treasury Of Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "DecreaseInNumberOfSharesDueToTreasuryOfShares",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Covid-19 impact.",
        "label": "Description of Accounting Policy for Covid-19 Impact, Explanatory",
        "terseLabel": "Impact of COVID-19 and the Russia-Ukraine Conflict"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCovid19ImpactExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Pre-launch products.",
        "label": "Description of Accounting Policy for Pre-Launch Products, Explanatory",
        "terseLabel": "Pre-launch products"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.",
        "label": "Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]",
        "terseLabel": "New standards, interpretations and amendments adopted by the Group"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DietmarHoppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.",
        "label": "Dietmar Hopp"
       }
      }
     },
     "localname": "DietmarHoppMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_Diluteeffectofordinarysharesissued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed issuance of new shares.",
        "label": "DiluteEffectOfOrdinarySharesIssued",
        "terseLabel": "New issue of shares for the purpose of calculating earning per share"
       }
      }
     },
     "localname": "Diluteeffectofordinarysharesissued",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Disclosure of Basis of Preparation Explanatory [Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationExplanatoryTextBlock",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense recognized for employee services explanatory.",
        "label": "Disclosure of Expense Recognized For Employee Services Explanatory",
        "terseLabel": "Schedule of expense recognized for employee services received"
       }
      }
     },
     "localname": "DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfExpensesByNatureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure Of Expenses By Nature [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureLineItems",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfExpensesByNatureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of expenses by nature.",
        "label": "Disclosure Of Expenses By Nature [Table]"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfFixedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfFixedAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for fixed assets.",
        "label": "Disclosure Of Fixed Assets, Explanatory",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure Of Government Grants [Line Items]",
        "verboseLabel": "Disclosure Of Government Grants"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsLineItems",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of government grants.",
        "label": "Disclosure Of Government Grants [Table]"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Disclosure of Other liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesLineItems",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other liabilities.",
        "label": "Disclosure of Other liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other current assets.",
        "label": "Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory",
        "terseLabel": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about upfront payments and related revenues recognized.",
        "label": "Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory",
        "terseLabel": "Summary of upfront payments and related revenues recognized"
       }
      }
     },
     "localname": "DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_Dr.IngmarHoerrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Dr. Ingmar Hoerr, a related party.",
        "label": "Dr. Ingmar Hoerr"
       }
      }
     },
     "localname": "Dr.IngmarHoerrMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly and Company.",
        "label": "Eli Lilly."
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly",
        "label": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for equipment physically located at the CMO facilities.",
        "label": "Equipment physically located at the CMO facilities"
       }
      }
     },
     "localname": "EquipmentPhysicallyLocatedAtCmoFacilitiesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for European Commission.",
        "label": "European Commission"
       }
      }
     },
     "localname": "EuropeanCommissionMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EuropeanUnionAdvancePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to EU APA.",
        "label": "EU APA"
       }
      }
     },
     "localname": "EuropeanUnionAdvancePurchaseAgreementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExecutiveBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for executive board members.",
        "label": "Executive board members"
       }
      }
     },
     "localname": "ExecutiveBoardMembersMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfGreenshoeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of Greenshoe.",
        "label": "Exercise \"Greenshoe\""
       }
      }
     },
     "localname": "ExerciseOfGreenshoeMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of options.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "ExerciseOfOptionsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 1.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 2.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 3.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses",
        "verboseLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseRecognizedForEmployeeServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized for employee services.",
        "label": "Expense Recognized For Employee Services",
        "positiveTerseLabel": "Expense Recognized For Employee Services"
       }
      }
     },
     "localname": "ExpenseRecognizedForEmployeeServices",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_FinancialInstrumentsAndRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to follow on public offering.",
        "label": "Follow-on public offering, incl. Greenshoe"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.",
        "label": "Frame Pharmaceuticals B.V., Amsterdam, Netherlands [Member]",
        "terseLabel": "Frame Pharmaceuticals"
       }
      }
     },
     "localname": "FramePharmaceuticalsB.v.AmsterdamNetherlandsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab.",
        "label": "Genmab"
       }
      }
     },
     "localname": "GenmabMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GermanFederalMinistryOfEducationAndResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for German Federal Ministry of Education and Research.",
        "label": "German Federal Ministry of Education and Research"
       }
      }
     },
     "localname": "GermanFederalMinistryOfEducationAndResearchMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GlaxosmithklineCovidAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.",
        "label": "GlaxoSmithKline COVID Agreement"
       }
      }
     },
     "localname": "GlaxosmithklineCovidAgreementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GlaxosmithklineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GlaxoSmithKline.",
        "label": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GovernmentGrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to government grants.",
        "label": "Government Grants [Axis]"
       }
      }
     },
     "localname": "GovernmentGrantsAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_GovernmentGrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to government grants.",
        "label": "Government Grants [Domain]"
       }
      }
     },
     "localname": "GovernmentGrantsDomain",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GrossCarryingAmountOfAcquisitionCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.",
        "label": "Gross Carrying Amount of Acquisition Cost [Member]"
       }
      }
     },
     "localname": "GrossCarryingAmountOfAcquisitionCostMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_Gsk2ndGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GSK 2nd Gen.",
        "label": "GSK 2nd Gen"
       }
      }
     },
     "localname": "Gsk2ndGenMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GskAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GSK Agreement 2020.",
        "label": "2020 GSK AGREEMENT"
       }
      }
     },
     "localname": "GskAgreement2020Member",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "IfrsCashAndCashEquivalentsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "IFRS Contractual Obligation",
        "terseLabel": "Contractual obligation amount"
       }
      }
     },
     "localname": "IfrsContractualObligation",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales"
       }
      }
     },
     "localname": "IfrsCostOfSalesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsCurrentGrantReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current grant receivables.",
        "label": "IFRS Current Grant Receivables",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "IfrsCurrentGrantReceivables",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsDecreaseThroughGovernmentalContractLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from governmental contract liabilities.",
        "label": "IFRS Decrease Through Governmental Contract Liabilities",
        "terseLabel": "Decrease in outstanding balance due to release of government contractual liabilities"
       }
      }
     },
     "localname": "IfrsDecreaseThroughGovernmentalContractLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payment included in contract liabilities",
        "label": "IFRS Development Milestone Payment Included In Contract Liabilities",
        "terseLabel": "Development milestone payment included in contract liabilities"
       }
      }
     },
     "localname": "IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"\t\nAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.\"",
        "label": "Ifrs Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "IfrsGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Ifrs Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsIncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Ifrs Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationDomain",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Ifrs Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease / (increase) in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in expense related to in-effective set-up activities and settlement costs",
        "label": "IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs",
        "terseLabel": "Recognition of expenses related to ineffective set-up activities and settlement costs"
       }
      }
     },
     "localname": "IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsLineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "IFRS Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "IfrsLineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsLineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of credit"
       }
      }
     },
     "localname": "IfrsLineOfCreditMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsLossContingencyLossInPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.",
        "label": "Ifrs Loss Contingency, Loss in Period",
        "terseLabel": "Amount of land charge (mortgage) not in favour of entity"
       }
      }
     },
     "localname": "IfrsLossContingencyLossInPeriod",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received.",
        "label": "IFRS Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "IfrsMilestonePaymentReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares received from the participants.",
        "label": "IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "localname": "IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsOptionFeePaymentIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Option fee payment included in contract liabilities",
        "label": "IFRS Option Fee Payment Included In Contract Liabilities",
        "terseLabel": "Option fee payment included in contract liabilities"
       }
      }
     },
     "localname": "IfrsOptionFeePaymentIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities."
       }
      }
     },
     "localname": "IfrsOtherLiabilitiesAbstract",
     "nsuri": "http://www.curevac.com/20220630",
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "IfrsOverAllotmentOptionMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product"
       }
      }
     },
     "localname": "IfrsProductMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsRemainingGrantIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining grant income classified as other operating income.",
        "label": "IFRS Remaining Grant Income",
        "terseLabel": "Remaining grant income"
       }
      }
     },
     "localname": "IfrsRemainingGrantIncome",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.",
        "label": "IFRS Repayments Of Accrued Interest And Fees Of Borrowings",
        "terseLabel": "Repayment of accrued interest and fees of loan"
       }
      }
     },
     "localname": "IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents for restricted stock unit.",
        "label": "RSU"
       }
      }
     },
     "localname": "IfrsRestrictedStockUnitMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsSaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "IFRS Sale of Stock [Axis]"
       }
      }
     },
     "localname": "IfrsSaleOfStockAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsSaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "IFRS Sale of Stock [Domain]"
       }
      }
     },
     "localname": "IfrsSaleOfStockDomain",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "First tranche"
       }
      }
     },
     "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Ifrs Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "At-the-market offering program issuances"
       }
      }
     },
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from at the market shares issued during the period.",
        "label": "Ifrs Stock Issued During Period Value New Issues",
        "negatedLabel": "Proceeds on At-the-market offering program (net of transaction costs)"
       }
      }
     },
     "localname": "IfrsStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "IfrsStockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_IfrsVestingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Axis]"
       }
      }
     },
     "localname": "IfrsVestingAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsVestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Domain]"
       }
      }
     },
     "localname": "IfrsVestingDomain",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ImpairmentsOfInventoryAndPrepayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments of inventory and prepayments",
        "label": "Impairments of inventory and prepayments",
        "terseLabel": "Impairment of inventory and prepayments"
       }
      }
     },
     "localname": "ImpairmentsOfInventoryAndPrepayments",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to income tax disclosures.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IncreaseDecreaseInInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in inventory during the period.",
        "label": "Increase (Decrease) In Inventory",
        "terseLabel": "Decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventory",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncreaseInNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in the number of shares outstanding.",
        "label": "Increase In Number Of Shares Outstanding",
        "terseLabel": "Capital Investment",
        "verboseLabel": "Capital Increase (in shares)"
       }
      }
     },
     "localname": "IncreaseInNumberOfSharesOutstanding",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in PPE off set by impairment in equipment.",
        "label": "Increase In Property and Equipment Off Set By Impairment of Equipment",
        "terseLabel": "Partial Offset of increase in property, plant and equipment"
       }
      }
     },
     "localname": "IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_InitialPublicOfferingAndPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for initial public offering and private placement.",
        "label": "Initial Public Offering and Private Placement"
       }
      }
     },
     "localname": "InitialPublicOfferingAndPrivatePlacementMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_InventoriesLineItem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Line item"
       }
      }
     },
     "localname": "InventoriesLineItem",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_KeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for key employees.",
        "label": "Key employees"
       }
      }
     },
     "localname": "KeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LicenseFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of license fee payables.",
        "label": "License Fee Payable",
        "terseLabel": "License fees payable"
       }
      }
     },
     "localname": "LicenseFeePayable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LicensesSoftwareAndPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "licenses, software and prepayments",
        "label": "licenses, software and prepayments"
       }
      }
     },
     "localname": "LicensesSoftwareAndPrepaymentsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LineOfCreditAccruedInterestPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lin of credit accrued interest payable.",
        "label": "Line of Credit Accrued Interest Payable",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "LineOfCreditAccruedInterestPayable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment for option buy-out variable remuneration.",
        "label": "Line Of Credit Facility Payment Option For Variable Remuneration On Maximum Borrowing Capacity",
        "terseLabel": "Payment option to buy-out variable remuneration by loan agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityPaymentOptionForVariableRemunerationOnMaximumBorrowingCapacity",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LockUpPeriodAfterInitialListing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the lock-up period, which is days after the initial listing.",
        "label": "lock Up Period, After Initial Listing",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockUpPeriodAfterInitialListing",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-Term Incentive Plan.",
        "label": "LTIP"
       }
      }
     },
     "localname": "LongTermIncentivePlanMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed in the utility model.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number Of Utility Models",
        "terseLabel": "Number of utility models infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_LossContingencyPatentsFoundNotInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity was found not to have infringed.",
        "label": "Loss Contingency, Patents Found Not Infringed, Number",
        "terseLabel": "Number of patents that does not infringe"
       }
      }
     },
     "localname": "LossContingencyPatentsFoundNotInfringedNumber",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_MaintenanceAndLeaseExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maintenance and lease expenses incurred by the company during the period.",
        "label": "Maintenance And Lease Expenses",
        "negatedLabel": "Maintenance and lease"
       }
      }
     },
     "localname": "MaintenanceAndLeaseExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ManagementBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for management board of the entity's key management personnel.",
        "label": "Management Board"
       }
      }
     },
     "localname": "ManagementBoardMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ManufacturingFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for manufacturing facilities.",
        "label": "GMP facilities"
       }
      }
     },
     "localname": "ManufacturingFacilitiesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MaximumAggregateRemunerationCapitalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate remuneration capital amount.",
        "label": "Maximum Aggregate Remuneration Capital Amount",
        "terseLabel": "Maximum aggregate remuneration capital amount"
       }
      }
     },
     "localname": "MaximumAggregateRemunerationCapitalAmount",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MaximumGrantToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum grant receivable.",
        "label": "Maximum Grant To Be Received",
        "terseLabel": "Maximum grant"
       }
      }
     },
     "localname": "MaximumGrantToBeReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MaxmimumBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum interest rate on borrowings.",
        "label": "Maxmimum Borrowings Interest Rate",
        "terseLabel": "Maxmimum borrowings Interest Rate of outstanding principal of loan"
       }
      }
     },
     "localname": "MaxmimumBorrowingsInterestRate",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for person or persons designated as part of Executive board and various key employees.",
        "label": "Members of executive board and various key employees"
       }
      }
     },
     "localname": "MembersOfExecutiveBoardAndVariousKeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MilestoneRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for milestone revenues.",
        "label": "Milestone revenues"
       }
      }
     },
     "localname": "MilestoneRevenuesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These member stand for milestones.",
        "label": "Milestones"
       }
      }
     },
     "localname": "MilestonesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MinimumBorrowingsInEachTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum borrowing amount available under EIB finanacing in three tranches.",
        "label": "Minimum Borrowings In Each Tranche",
        "terseLabel": "Minimum amount of borrowing in each tranche"
       }
      }
     },
     "localname": "MinimumBorrowingsInEachTranche",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MinimumBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum interest rate on borrowings.",
        "label": "Minimum Borrowings Interest Rate",
        "terseLabel": "Minimum borrowings Interest Rate of outstanding principal of loan"
       }
      }
     },
     "localname": "MinimumBorrowingsInterestRate",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_MiscellaneousOtherOperatingIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income, classified as other.",
        "label": "Miscellaneous Other Operating Income, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncomeOther",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MolecularhealthgmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular health",
        "label": "Molecular Health Gmbh"
       }
      }
     },
     "localname": "MolecularhealthgmbhMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MonetaryAssetsInForeignCurrencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Monetary Assets In Foreign Currency"
       }
      }
     },
     "localname": "MonetaryAssetsInForeignCurrencyMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MonetaryLiabilitiesInForeignCurrencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a type\n of market risk representing the\n risk that the fair value or future\n cash flows of a financial\n instrument will fluctuate\n because of changes in foreign\n exchange rates.",
        "label": "Monetary Liabilities In Foreign Currency"
       }
      }
     },
     "localname": "MonetaryLiabilitiesInForeignCurrencyMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_NetLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.",
        "label": "Net Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetLoss",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NetValueOfInventoryTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net value of inventory transferred during the period.",
        "label": "Net Value Of Inventory Transferred",
        "terseLabel": "Net inventory transferred"
       }
      }
     },
     "localname": "NetValueOfInventoryTransferred",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to  non-current assets or disposal groups classified as held for sale.",
        "label": "Noncurrent Assets Or Disposal Groups Classified As Held For Sale [Line Item}"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleLineItem",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to  non-current assets or disposal groups classified as held for sale.",
        "label": "Noncurrent Assets Or Disposal Groups Classified As Held For Sale [Table]"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleTable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_NumberOfAdditionalDosesPurchaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional doses purchase option.",
        "label": "Number of Additional Doses Purchase Option"
       }
      }
     },
     "localname": "NumberOfAdditionalDosesPurchaseOption",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfAdditionalGrantsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional grants received by the company.",
        "label": "Number Of Additional Grants Received",
        "terseLabel": "Number of additional grants received"
       }
      }
     },
     "localname": "NumberOfAdditionalGrantsReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.",
        "label": "Number Of Collaboration Partners That Owed Hundred Percent Of All Receivables And Contract Assets Outstanding",
        "terseLabel": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding"
       }
      }
     },
     "localname": "NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.",
        "label": "Number Of Collaboration Partners With Balances Greater Than Ten Percent Of All Receivables And Contract Assets",
        "terseLabel": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets"
       }
      }
     },
     "localname": "NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.",
        "label": "Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement",
        "terseLabel": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement"
       }
      }
     },
     "localname": "NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfKeyEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of key employees.",
        "label": "Number of Key Employees",
        "terseLabel": "Number of key employees"
       }
      }
     },
     "localname": "NumberOfKeyEmployees",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone payments.",
        "label": "Number of Milestone Payments"
       }
      }
     },
     "localname": "NumberOfMilestonePayments",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of other equity instruments settled in a share-based payment arrangement.",
        "label": "Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement",
        "terseLabel": "Number of RSUs settled"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options vested in a share-based payment arrangement.",
        "label": "Number Of Share Options Vested In Share-Based Payment Arrangement",
        "verboseLabel": "Number of options vested"
       }
      }
     },
     "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cvac_NumberOfYearsDueForEachTrancheFromDisbursementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years due for each tranche from disbursement date.",
        "label": "Number of Years Due For Each Tranche From Disbursement Date",
        "terseLabel": "Number of years due for each tranche"
       }
      }
     },
     "localname": "NumberOfYearsDueForEachTrancheFromDisbursementDate",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_OptionFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Option fee Payment received.",
        "label": "Option Fee payment",
        "terseLabel": "Option fee payment received"
       }
      }
     },
     "localname": "OptionFeePayment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Option fee Payment and additional development milestone payment.",
        "label": "Option Fee Payment And Additional Development Mi lestone Payments",
        "terseLabel": "Option fee payment and an additional development milestone payment"
       }
      }
     },
     "localname": "OptionFeePaymentAndAdditionalDevelopmentMiLestonePayments",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OptionsGrantedToThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).",
        "label": "Former Chief Executive Officer Grant"
       }
      }
     },
     "localname": "OptionsGrantedToThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Other customers.",
        "label": "Others"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expense.",
        "label": "Other Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherExpense",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherOperatingIncomeGovernmentGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other operating income recognized in relation to government agencies and similar bodies.",
        "label": "Other Operating Income, Government Grants",
        "verboseLabel": "Grants and other cost reimbursements from government agencies and similar bodies"
       }
      }
     },
     "localname": "OtherOperatingIncomeGovernmentGrants",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherReceivablesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Other Receivables One"
       }
      }
     },
     "localname": "OtherReceivablesOneMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherReceivablesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Other Receivables Two"
       }
      }
     },
     "localname": "OtherReceivablesTwoMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherreceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivables.",
        "label": "Other Receivables"
       }
      }
     },
     "localname": "OtherreceivablesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PartnershipAgreementMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount agreed under the partnership agreement.",
        "label": "Partnership Agreement, Maximum Amount",
        "terseLabel": "Maximum amount under the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementMaximumAmount",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PartnershipAgreementPeriodOfCostsToBeCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the costs are to be covered by the funds received under the partnership agreement.",
        "label": "Partnership Agreement, Period Of Costs To Be Covered",
        "terseLabel": "Period for which the costs are to be covered"
       }
      }
     },
     "localname": "PartnershipAgreementPeriodOfCostsToBeCovered",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PartnershipAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the partnership agreement.",
        "label": "Partnership Agreement, Term",
        "terseLabel": "Term of the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementTerm",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PatentsAndFeesToRegisterLegalRight": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for registering a legal right.",
        "label": "Patents And Fees To Register Legal Right",
        "negatedLabel": "Patents and fees to register a legal right"
       }
      }
     },
     "localname": "PatentsAndFeesToRegisterLegalRight",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment made to pay variable remuneration.",
        "label": "Payment of Variable Remuneration For Output Produced On Manufacturing Facilities",
        "terseLabel": "Payment of variable remuneration on GMP IV manufacturing facilities per batch"
       }
      }
     },
     "localname": "PaymentOfVariableRemunerationForOutputProducedOnManufacturingFacilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PaymentsToRelatedPartyForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made to related party by the company for services.",
        "label": "Payments To Related Party For Services",
        "terseLabel": "Payments to related party for services"
       }
      }
     },
     "localname": "PaymentsToRelatedPartyForServices",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PayrollRelatedWithholdingTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment due on payroll related withholding taxes.",
        "label": "Payroll Related Withholding Taxes",
        "verboseLabel": "Withholding taxes"
       }
      }
     },
     "localname": "PayrollRelatedWithholdingTaxes",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses incurred by the company during the period.",
        "label": "Personnel Expenses",
        "negatedLabel": "Personnel"
       }
      }
     },
     "localname": "PersonnelExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the signing date share price.",
        "label": "Preliminary Purchase Price Allocation, Calculation of Volume Weighted Average Share Price over Sixty Trading Days",
        "terseLabel": "Signing date share price"
       }
      }
     },
     "localname": "PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days used for calculation of preliminary total purchase price.",
        "label": "Preliminary Purchase Price Allocation, Number of Trading Days Used",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of prepaid compensation for contract manufacturing organizations transfer.",
        "label": "Prepaid Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Prepayments for compensation for CMO transfer"
       }
      }
     },
     "localname": "PrepaidCompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PrivatePlacementIsa2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for private Placement \"ISA 2020\".",
        "label": "2020 Private Investment"
       }
      }
     },
     "localname": "PrivatePlacementIsa2020Member",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ProceedFromIssuingOtherEquityInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Proceed From Issuing Other Equity Instrument",
        "label": "Proceed From Issuing Other Equity Instrument",
        "terseLabel": "Payment on / Proceeds from Treasury Shares"
       }
      }
     },
     "localname": "ProceedFromIssuingOtherEquityInstrument",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]",
        "label": "Proceeds from (Repayments of) borrowings, classified as financing activities",
        "terseLabel": "Proceeds from (repayment of) the EIB loan"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsOnExerciseOfOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds on exercise of options.",
        "label": "Proceeds On Exercise Of Options",
        "negatedLabel": "Proceeds on exercise of options"
       }
      }
     },
     "localname": "ProceedsOnExerciseOfOptions",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProvisionForEmployerTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of provision for employer taxes arising according to US regulations for future exercises.",
        "label": "Provision for Employer Taxes",
        "verboseLabel": "Provision for employer taxes"
       }
      }
     },
     "localname": "ProvisionForEmployerTaxes",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total number of milestones.",
        "label": "Purchase Price Allocation, Number of Milestones Used for Payment of Fifty Percent of Purchase Price to be Paid in Shares",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of first milestone payment.",
        "label": "Purchase Price Allocation, Percent of First Milestone Payment Due Upon Achievement of Successful Investigational New Drug Application Filing",
        "terseLabel": "Percent of first milestone payment"
       }
      }
     },
     "localname": "PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of second milestone payment.",
        "label": "Purchase Price Allocation, Percent of Second Milestone Payment Due Upon Successful Proof of Mechanism in Humans",
        "terseLabel": "Percent of second milestone payment"
       }
      }
     },
     "localname": "PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PurchasePriceAllocationSharePriceAsOfClosingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the closing date share price.",
        "label": "Purchase Price Allocation, Share Price as of Closing Date",
        "terseLabel": "Closing date share price"
       }
      }
     },
     "localname": "PurchasePriceAllocationSharePriceAsOfClosingDate",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_RealEstateTransferTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of real estate transfer taxes.",
        "label": "Real Estate Transfer Taxes",
        "terseLabel": "Real estate transfer taxes"
       }
      }
     },
     "localname": "RealEstateTransferTaxes",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from government grants and similar bodies.",
        "label": "Receipts from Government Grants Classified as Operating Activities",
        "terseLabel": "Receipts from grants from government agencies and similar bodies",
        "verboseLabel": "Grant amount received/eligible to receive"
       }
      }
     },
     "localname": "ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionAdvisoryFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advisory fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionAdvisoryFees",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Consulting Fees",
        "terseLabel": "consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingFees",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of notice for termination of the agreement at the option of the party.",
        "label": "Related Party Transaction, Notice Period for Termination of Agreement",
        "terseLabel": "Notice period for termination at the option"
       }
      }
     },
     "localname": "RelatedPartyTransactionNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_RelatedPartyTransactionNumberOfLoansReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of loans received from a related party.",
        "label": "Related Party Transaction, Number of Loans Received",
        "terseLabel": "Number of convertible loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfLoansReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_RepaymentsOfPrincipalAmountOfBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle principal amount of borrowings, classified as financing activities.",
        "label": "Repayments of Principal Amount of Borrowings",
        "verboseLabel": "Repayment of principal amount of loan"
       }
      }
     },
     "localname": "RepaymentsOfPrincipalAmountOfBorrowings",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development services.",
        "label": "Research and development services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ResearchServicesCombinedWithIpLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research services combined with an IP license.",
        "label": "Research services combined with an IP license"
       }
      }
     },
     "localname": "ResearchServicesCombinedWithIpLicenseMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_RestrictedStockUnitForKeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for RSU for key employees.",
        "label": "RSU for key employees"
       }
      }
     },
     "localname": "RestrictedStockUnitForKeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted stock Units",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ReversalOfProvisionForOnerousContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.",
        "label": "Reversal of Provision for Onerous Contracts",
        "terseLabel": "Reversal of provision of onerous contracts"
       }
      }
     },
     "localname": "ReversalOfProvisionForOnerousContracts",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.",
        "label": "Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over",
        "terseLabel": "Reversal of provision recognized"
       }
      }
     },
     "localname": "ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReversalOfProvisionsForPersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses reversed during the period.",
        "label": "Reversal Of Provisions For Personnel Expenses",
        "verboseLabel": "Income from reversal of provisions"
       }
      }
     },
     "localname": "ReversalOfProvisionsForPersonnelExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RightToExercisePercentageOfVestedVirtualShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the right to exercise percentage of vested virtual shares.",
        "label": "Right To Exercise Percentage Of Vested Virtual Shares",
        "terseLabel": "Right to exercise percentage of vested virtual shares"
       }
      }
     },
     "localname": "RightToExercisePercentageOfVestedVirtualShares",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_RittershausRechtsanwaelteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Rittershaus Rechtsanwaelte , a related party.",
        "label": "Rittershaus Rechtsanwaelte"
       }
      }
     },
     "localname": "RittershausRechtsanwaelteMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SaleOfEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sale of equipment in operating income.",
        "label": "Sale of equipment",
        "terseLabel": "Sale of equipment"
       }
      }
     },
     "localname": "SaleOfEquipment",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of expense recognized for the programs.",
        "label": "Schedule of Expense Recognized for the Programs [Table Text Block]",
        "terseLabel": "Schedule for expense recognized for the programs"
       }
      }
     },
     "localname": "ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_SellingAndDistributionExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for selling and distribution expenses.",
        "label": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SellingAndDistributionExpensesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesCSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C shares.",
        "label": "Series C"
       }
      }
     },
     "localname": "SeriesCSharesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series A shares.",
        "label": "Series A"
       }
      }
     },
     "localname": "SeriesSharesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SettlementOfShareBasedPaymentAwardsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based payment awards settled in cash.",
        "label": "Settlement Of Share Based Payment Awards , Amount",
        "terseLabel": "Settlement of share-based payment awards"
       }
      }
     },
     "localname": "SettlementOfShareBasedPaymentAwardsAmount",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Share-based payment expense (incl. deferred taxes)",
        "label": "Share-based payment expense (incl. deferred taxes)",
        "terseLabel": "Share-based payments (net of taxes)"
       }
      }
     },
     "localname": "ShareBasedPaymentExpenseIncl.DeferredTaxes",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareOptionExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share option exercises.",
        "label": "Share Option Exercises",
        "terseLabel": "Share option exercises"
       }
      }
     },
     "localname": "ShareOptionExercises",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for software.",
        "label": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_StockIssuedDuringPeriodForExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period, upon exercises.",
        "label": "Stock Issued During Period, For Exercises",
        "terseLabel": "Share issuances for exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForExercises",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_SupervisoryBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for supervisory board members.",
        "label": "Supervisory board members"
       }
      }
     },
     "localname": "SupervisoryBoardMembersMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for technical equipment and machines and other equipment.",
        "label": "Technical equipment and machines"
       }
      }
     },
     "localname": "TechnicalEquipmentAndMachinesAndOtherEquipmentMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TerminationFeeRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of termination fee in related party transactions.",
        "label": "Termination Fee, Related Party Transactions",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "TerminationFeeRelatedPartyTransactions",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dan Menichella, then Chief Executive Officer.",
        "label": "Dan Menichella, then Chief Executive Officer"
       }
      }
     },
     "localname": "ThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ThirdPartyServiceExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for third party services during the period.",
        "label": "Third Party Service Expenses",
        "negatedLabel": "Third-party services"
       }
      }
     },
     "localname": "ThirdPartyServiceExpenses",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_TradeAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for trade and other payables.",
        "label": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherPayablesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Payables One"
       }
      }
     },
     "localname": "TradeAndOtherPayablesOneMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherPayablesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Payables Two"
       }
      }
     },
     "localname": "TradeAndOtherPayablesTwoMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TypeOfArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment received.",
        "label": "Upfront Payment Received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments of the company included in contract liabilities.",
        "label": "Upfront Payments Included In Contract Liabilities",
        "terseLabel": "Upfront and milestones payments included in contract liabilities"
       }
      }
     },
     "localname": "UpfrontPaymentsIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsReceivedOrReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments received or receivable by the company.",
        "label": "Upfront Payments Received Or Receivable",
        "terseLabel": "Upfront payments received or receivable"
       }
      }
     },
     "localname": "UpfrontPaymentsReceivedOrReceivable",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_VincentStphenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Vincent Stphenne.",
        "label": "Vincent Stphenne"
       }
      }
     },
     "localname": "VincentStphenneMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program I.",
        "label": "Prior VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program II (New VSOP).",
        "label": "New VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIiMember",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_WriteOffOfRawMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of raw materials written off during the period.",
        "label": "Write Off Of Raw Materials",
        "terseLabel": "Write off of raw materials"
       }
      }
     },
     "localname": "WriteOffOfRawMaterials",
     "nsuri": "http://www.curevac.com/20220630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "auth_ref": [
      "r63",
      "r72",
      "r99",
      "r108",
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cumulative amortization and impairment charges"
       }
      }
     },
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination",
        "terseLabel": "Transactions costs related to acquisition"
       }
      }
     },
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease / (increase) in inventory"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Decrease / (increase) in other assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease / (increase) in trade receivables and contract assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax expense",
        "terseLabel": "Decrease / (increase) in deferred taxes"
       }
      }
     },
     "localname": "AdjustmentsForDeferredTaxExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and impairment of property, plant and equipment and right-of-use assets"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedLabel": "Finance income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment to property, plant and equipment"
       }
      }
     },
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "(Decrease) / increase in trade and other payables, other liabilities and contract liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments to reconcile loss before tax to net cash flows"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "Share-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r27",
      "r74",
      "r164",
      "r172",
      "r173",
      "r205",
      "r218",
      "r219",
      "r236",
      "r237",
      "r239",
      "r245"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r25",
      "r150",
      "r151",
      "r154",
      "r227",
      "r230"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssetsAbstract",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "verboseLabel": "Interest rate per annum"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r217",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BusinessCombinationsMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for transactions or other events in which an acquirer obtains control of one or more businesses. Transactions sometimes referred to as 'true mergers' or 'mergers of equals' are also business combinations as that term is used in IFRS 3."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [member]"
       }
      }
     },
     "localname": "BusinessCombinationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CapitalReserve": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve.",
        "terseLabel": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserve",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CapitalReserveMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserveMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r20",
      "r126",
      "r144"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents.",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "terseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r110",
      "r127"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flow (used in)provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r110",
      "r127"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash flow (used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r127"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flow (used in) operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashTransferred": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash transferred",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "CashTransferred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "auth_ref": [
      "r97",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of contingent liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r209",
      "r212",
      "r213",
      "r215"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r209",
      "r212",
      "r213",
      "r215"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories."
       }
      }
     },
     "localname": "ClassesOfInventoriesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Maximum settlement amount"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r43",
      "r132",
      "r134",
      "r137",
      "r142"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income (loss)",
        "totalLabel": "Total comprehensive loss for the period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets under construction"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date",
        "terseLabel": "Preliminary aggregated consideration transferred used for PPA"
       }
      }
     },
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "auth_ref": [
      "r98",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities [member]"
       }
      }
     },
     "localname": "ContingentLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r2",
      "r49"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales.",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r223",
      "r240",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      },
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Prepayments for material"
       }
      }
     },
     "localname": "CurrentAdvancesToSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r28",
      "r137",
      "r138"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CurrentAssetsAbstract",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentContractAssets": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract assets. [Refer: Contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract assets",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "CurrentContractAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r30",
      "r137",
      "r140"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments and other current assets",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current receivables from taxes other than income tax",
        "terseLabel": "Outstanding VAT refund claims"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax expense"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r29",
      "r33"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) through tax on share-based payment transactions, equity",
        "negatedLabel": "Deferred taxes on convertible loan"
       }
      }
     },
     "localname": "DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": {
     "auth_ref": [
      "r209",
      "r210",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through derecognition, financial assets",
        "terseLabel": "Loss on derecognition of fixed assets"
       }
      }
     },
     "localname": "DecreaseThroughDerecognitionFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "terseLabel": "Deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r49",
      "r146",
      "r225",
      "r232"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "verboseLabel": "Schedule of number of shares issued and outstanding"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Loans"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue from contract with customers recognized"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Schedule of inputs used in the measurement of the fair value at grant date"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]",
        "terseLabel": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of reconciliation of outstanding awards"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other liabilities [text block]",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Schedule of other operating expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Schedule of other operating income"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "verboseLabel": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments."
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]",
        "terseLabel": "Schedule of Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedTerseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Currency translation gains (losses) on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r197",
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r88",
      "r90",
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r25",
      "r34",
      "r131",
      "r133",
      "r150",
      "r151",
      "r154"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity.",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityAndLiabilitiesAbstract",
        "terseLabel": "Equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseByNature": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "ExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Expenses from share-based payments"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based based payments expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Schedule of contract balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r73",
      "r166",
      "r234",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r73",
      "r166",
      "r234",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r197",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill recognised as of acquisition date",
        "terseLabel": "Preliminary goodwill"
       }
      }
     },
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GovernmentGrants": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Government grants",
        "terseLabel": "Grants received and deferred"
       }
      }
     },
     "localname": "GovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r63",
      "r99",
      "r108",
      "r109",
      "r199",
      "r211",
      "r213",
      "r214",
      "r249",
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition costs"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r195",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Identifiable intangible assets recognised as of acquisition date",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48",
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "verboseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InAccordanceWithIFRS9Member": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information reported in accordance with IFRS 9."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 9"
       }
      }
     },
     "localname": "InAccordanceWithIFRS9Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r45",
      "r54",
      "r56",
      "r57",
      "r86",
      "r147",
      "r226"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit/ (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "negatedLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 15"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through conversion of convertible instruments, equity",
        "positiveTerseLabel": "Equity component of convertible loans (net of tax)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Shares issued on exercise of option",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency translation",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, property, plant and equipment",
        "terseLabel": "Attributions"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InsuranceExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      },
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "terseLabel": "Insurance expense"
       }
      }
     },
     "localname": "InsuranceExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r16",
      "r104"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "IntangibleAssetsOtherThanGoodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r96",
      "r105",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "verboseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r19",
      "r29",
      "r75"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r48",
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Inventory write-offs"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r18",
      "r148",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "terseLabel": "Equity investment"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Issuance of share capital (net of transaction costs)"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital.",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r12",
      "r172",
      "r173",
      "r218",
      "r222",
      "r245"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "2022"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r25",
      "r150",
      "r151",
      "r154",
      "r227",
      "r231"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesIncurred": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities incurred",
        "terseLabel": "Net amount of discharging contractual obligations"
       }
      }
     },
     "localname": "LiabilitiesIncurred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LicencesMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Licences"
       }
      }
     },
     "localname": "LicencesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share transaction"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r27",
      "r74",
      "r164",
      "r172",
      "r173",
      "r205",
      "r216",
      "r218",
      "r236",
      "r237",
      "r239",
      "r245"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "negatedLabel": "Other operating expenses"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other operating income",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r28",
      "r137",
      "r139"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NoncurrentAssets",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial liabilities",
        "terseLabel": "Finance Liabilities"
       }
      }
     },
     "localname": "NoncurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r30",
      "r137",
      "r141"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NoncurrentLiabilitiesAbstract",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r26",
      "r172",
      "r173",
      "r218",
      "r222",
      "r245"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Within one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r175",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of awards granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "terseLabel": "Shares transferred"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU's awarded"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "terseLabel": "Thereof exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "terseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted",
        "verboseLabel": "Number of share options granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance at the end (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r39",
      "r93"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Common shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r7",
      "r42",
      "r47",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r31",
      "r47"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Foreign currency adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherContingentLiabilitiesMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other contingent liabilities"
       }
      }
     },
     "localname": "OtherContingentLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r23",
      "r145"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Miscellaneous liabilities"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets.",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities.",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other equipment, furniture and fixtures"
       }
      }
     },
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Notional value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Payables on social security and taxes other than income tax",
        "verboseLabel": "Payroll-related taxes and social-security liabilities"
       }
      }
     },
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments on lease obligations"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired",
        "terseLabel": "Voting interests held"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PreferenceSharesMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Preferred shares"
       }
      }
     },
     "localname": "PreferenceSharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r5",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Amount drawn"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from government grants, classified as financing activities",
        "verboseLabel": "Government grants"
       }
      }
     },
     "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of bonds, notes and debentures",
        "verboseLabel": "Proceeds from the convertible loan"
       }
      }
     },
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing other equity instruments",
        "terseLabel": "Payment on Treasury Shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Cash received from issuance of shares",
        "verboseLabel": "Proceeds from the issuance of shares (net of transaction costs)"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r165",
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r165",
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "negatedLabel": "Legal and other professional services"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r41",
      "r117",
      "r132",
      "r134",
      "r137",
      "r227",
      "r229",
      "r238",
      "r248"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r202",
      "r227",
      "r229"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r46",
      "r92"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r69"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment.",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r70",
      "r96",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r87",
      "r89",
      "r136"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Equity interest held"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r87",
      "r89",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of other long-term assets, classified as investing activities",
        "negatedLabel": "Purchases of financial assets"
       }
      }
     },
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchases of goods, related party transactions",
        "terseLabel": "Total payments"
       }
      }
     },
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r217",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r217",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "auth_ref": [
      "r1",
      "r49"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      },
      "en-us": {
       "role": {
        "label": "Raw materials and consumables used",
        "negatedTerseLabel": "Materials"
       }
      }
     },
     "localname": "RawMaterialsAndConsumablesUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Receivables from taxes other than income tax",
        "terseLabel": "Tax claims against the tax authorities"
       }
      }
     },
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "negatedLabel": "Repayments of convertible loan"
       }
      }
     },
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r11",
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency translation reserve"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r5",
      "r14",
      "r128",
      "r129",
      "r130",
      "r238"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r34",
      "r50"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r10",
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r5",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Total revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenues",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "verboseLabel": "Income from release of governmental contract liabilities"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Revenue recognized from upfront and milestones payments",
        "verboseLabel": "Revenue recognized from contract liabilities"
       }
      }
     },
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "RightofuseAssets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk exposure associated with instruments sharing characteristic",
        "terseLabel": "Exposure in (foreign) currency"
       }
      }
     },
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "terseLabel": "Offering costs for legal, accounting, printing and registration fees"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Salary and salary-related expenses",
        "verboseLabel": "Salary and salary-related expenses"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r88",
      "r90",
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Financial Position"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference"
       }
      }
     },
     "localname": "TemporaryDifferenceMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r217",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables."
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r32",
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers into Level 3, Assets"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers into Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of research and development to the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expenses.",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers out of Level 3, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers out of Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TravelExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      },
      "en-us": {
       "role": {
        "label": "Travel expense",
        "terseLabel": "Travel expenses"
       }
      }
     },
     "localname": "TravelExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r34",
      "r91"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury Shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r167",
      "r246"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r167",
      "r246"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [member]"
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r240",
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r240",
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Loss carryforwards"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Average share price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r176",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "terseLabel": "Average share price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "WeightedAverageSharePrice2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cure Vac B.V."
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r183": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r184": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r185": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r186": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r187": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r188": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r189": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r191": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r192": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r194": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r196": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r197": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r198": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r199": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r200": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r201": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r202": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r203": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2021-03-24"
  },
  "r204": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r205": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r206": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r207": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r208": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r209": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r210": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r211": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r212": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r213": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r214": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r215": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r216": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r217": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r218": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r219": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r220": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r221": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r222": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r223": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2021-03-24"
  },
  "r224": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24"
  },
  "r225": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r226": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r227": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r228": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r229": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r230": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r231": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r232": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r233": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r234": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r235": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r236": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r237": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r238": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r239": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r240": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r241": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r242": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r243": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r244": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r245": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r246": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r247": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r248": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r249": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r250": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r251": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r252": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r253": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r254": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r255": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r256": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r257": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r258": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r259": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r260": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r261": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "88",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001410578-22-002669-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-22-002669-xbrl.zip
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M3'Z[)IS,3&(#RF9\F&4#P,(&7NZRZ78QL%P!*/P13PM67);WKV,ZH!,O6J&
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M:2]UTLEA2*14SR /Y.J!O(&?L(="])<B>ZM6BD,2Q1R.]&*Y)7_O28A+.HP
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MCN!$.,?K/ ]4)[K"F**R!\<.X2Q-L$15:%A]<1;G<Q:F":5P@/.3>!J+@'%
M3?N6F/*;E0PBW<"O[J**0^JG(1%S2L)D/HONZZD?6F"<U S:CF#V<(S#$JUN
MF1-,-5*CKA^XBX263E_YA=R.I%H60.>),T=+6R;Y+D 7B;O.=%HA-=0(/3:4
MS;B^9>TO+=.P?R67B3;9X_O2VP'O(JE6F9P\QOV$MP#H(G%5+6*CJP7F+9!D
MTS,M,"Z2I"-ZBIL-PH.X)?BG#?19=RD]T\**E@6N"<!%QE0/R>K]'>N9\JHQ
MC<@6;3B[M38VY<QL?K;\0I)44(O5N0;A,$V,3A4_:/:,=DLD<#.<BV(\A/,
M!FK+.Q'6Z;$4ND@$YE]D(KL^B+>H./JGRS;@8E!H+W!7O1]GT?VTQJGB1R<Y
MA+F.K7F'JDE3&J&>@1_6Y2NG?TI"V<B[5E*+UUDK43(@9O@J0L,]V$TJ/_/
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M6<E0]PL-T<>"C^I6(X^W:V8S8_-+!"5O2)>)/]Y^A/*6-ABD9_?+EDC0\1V
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M\EFL%LBESB6/J=E66>;C[FSTZ]=_99GXZ0A'0OIS&I&__2]02P,$%     @
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M2\G]5[*6QOJ_2GLHY2ZN9WBX&T\ HN(OT5N*7/Z4 6_@+G]NDS>,I*EG?>N
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M64MC/5^E/:*CD-E+V[4-&2FV%"MAK/QA^Y3B2:.=['"2O_W#]JKF,/8%X*>
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MX0 D@E>EYL\/)"HZ^/1N.Y82@O]U4H"=\*]./GP\^?3A[3,-W^0H\I\-!BG
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MHNQR4P^VO=Y4@0U/E=3*J@?44.:!W54K%VQ!8_7N4]XQUW)=A^/8-FX(#M-
M!.'?\1S40*KT-5 YUY10OE,LW2-JX=14>[ 'U$D,FQ-8G@R*;OE<T'0WCJG
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ML71R0:PG:%C_:F9-7"(:@.@_(2#J(#PU:+\B:7D(5Y/AQ:ZQP^N2?:-+WCF
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MK%:5%CT.6I6\ UUI0?H8=$4Q%2Z>(0D0A?/%?*-7#?,.!JV)[F[5D%#JW@"
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M QB';H).I,:A@NC!9)5C\36F&QB@!8*ATAK4P'I@_6FU;LM]-0E#2^ 2$Q@
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MM$81(*<X1-;WG!\^M+_G%-A-GAAZD^46OPG($13WGS1#<?(@</3BVG/'RHP
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M7]D]3< ?.=FG7J:6=NW]N[/K3F_L..&?3[."<7ZVLW5S'J2!Z]V<$[(=<[+
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MPSMWNE#(Y,#3_<[A(XSPAN-?^$K+H4EE1JFW\/8]^W$N[U+=.F"*^_=WXH!
MP"OD%2^99POD/$UH N*0G;ID>X11,S\< .TE:D[Q&,SUWR%:KAC%TT=(P!(*
M*FX("N#']Q]^44[PFE9^>!JZG+PU!/?PJIET3?B"$X9#]N(F.UC>0[)&<?9\
MZF*Z)!#FV]"A1[I5?WYX,3J:RNU8,93DSQBA:<1?7N4/>5F(>+^A'QX2M[+<
MIWDHH4W#1T0Q>;$46;69'QF.;@56I7BPU37?VJ\P^RI+3(/2MY_MVON1'^EX
M]923[CYN1;Q:>0-0.$W$HU_QLK1<&QYD6O7D1_YE1])MRH0Q6+XW*3N! 9$K
M^1GCD%J?<LT[\"0WM$N#V)QX]T4$=J89VR]LYKAIRW[EY]#Y947U*"8QP1M,
M,JM\_A3S2!2T*5ZYG<7;[#_U)#;NH%\EZ,4E94Z\^RM>'#'9X.Q!E.T.<XTB
MA@F.8>[8EU[[&K;L5WZN'5"F5/?R9+?2!W:_(CA=K@K7)\_G%3 K'#$VT<+C
M*?4I=M)OOT)WZ(KJD">]J 1_YH@G5J<@FC]$:"GT5"5G!7"_PG/M9](0.H:=
M]@ROURA[-_D:A/#TI>'=D'4__6J!0P]5"QXXG[+Y?L%6B3(2_*G@[)%EJ?EL
MT*A?X;GV5AD0/%C]"/ZF,_PS9>A=/'(<[0I'_'Q8.&+7X02*'E]+P8C3E#()
M4[88KQ_R<Y!%C0A-:U^6:AF*VI [=0-?BT;4RG O.5Y)H*>[[5[$J Q_NPP@
M70_>1-35*:XV TA'H:=2;B#6(>38*HNHGL;ZJ>HR'/*2@#6\80>E-0A@FJ
M1/3T[>/;Z9HFD(1@_07R\G@1.V1IJ@(VZ<4/<9G)IS&1GLX\WRLG&;G_+#?!
M8[&D8[&D8[&D8[$D1^)0+EF#%$MR_(!/]HK[DAV+2Y7NS1YPTC3UM?B"Y49C
M0JJO I9A7#/OM&V\V9_,57??5ZFASE,IBH+63419W]"/'<Z MJH4ZPES<ZF[
M/^!+J;+O#> 5?V?Q@B=SB^O+*_!$4Y1H4GS;=>C'?F@HO"X(]G1^WA <ID%"
MIW%8>,ZU>Z<2WM<,8,L-4TG?>.17L[!J6GBS0]9H9:W(7*ZDV\ .C0_J$,:/
MS:I66W8U)@XH\'0"U,WU@RM$ZRNE4@^^Y-L:$:I.L=6LB:\IJW8:_)FR#9K3
M$K+M^1(@\@U$*;]XYAYQGHJ"&,\%_46L#CE(*^B@/S^,G98*U)CZ,834%*%<
MI5<IYJ0(OZ0S2E,8LB_8_]K;:=MN_$O$;: 8MD2/01\JCR8&J799D,+ZEW?;
M0+)2RL8@/OY0LLF*?@#G7SIM [$=4.4^9HW "/%,!O)29*.(E.QI)'I!NRPT
M_K0B.R&?@Q?ZE<I3^%ITYE\&K;'XVI+N@8S/0,3+TF5)#-]PQ/8"9;+^G'UQ
MAYY%=&5!2#-E:#^J?VF\76M->QZY5R\YYCN\IMQASA@D4#I((VK8AW\)P):B
MMZ9X*$$6"]?.L<#7K4M,\DA>_DSF(GFY@200?U6ZN<>GD*>^SC+*Y"M%+^/Z
MEU/<B<)TS*6AE&R+WR4B]" %ZSR%7S=,7L$*P4>8D767!@%C'N/J+'YDT'DB
M"(B^P*=SDBZGFTV$LLXOF2DL+[HT)#8>)C1WHI&],&]P/;V# 8Y#!74[@FX(
MQ@LV.R'K+$9T/8M_2]= GDGM?$@/4["[U;C6'!K%$7E[G5GQW-TRVI>,&F88
M,LNAY/.3V%QM._,PC;O):;L1[6-0D5G(JUXO$'?;S>($Q$O$/DTIA0EMIB<M
M>O0P9[R!LK1@P!@TAM<?>4)1U$P[#%M[F$C>0!,,B1V#U+F_<1J'_+\+AOXC
MB/@=0,.=I$E?'F:G-W3;6I,^!OTH(4VR9-TS3!/*2SGN$H!W=-[!#6![*(Q>
M>&!5J3$C7RR4C$GL0[K>9%]6;BDD?#>YSQT&+P_SZ=M=# _#1N>GN"M,Z=;,
M"UZR6#_*3@YP"</HI8CZ"PLORM=$A =>XQ!&TC-:RPX]3.6W.X&UI-\S@;>7
M<-\B=>")MB5X(!E>XC0.O^"DL0B5'?0K00>N84MZQV!Y[%UR73Q#$J#<\9/7
M;9H+I,O5FW(WMN(5$YMB[-V-UV\$6;=>WA[8TZC4RS_?94)$67V4__'_ U!+
M P04    " "9@A)5O4\_OO.A  "D_@D %0   &-V86,M,C R,C V,S!?;&%B
M+GAM;.R]>Y/C-I8G^O^-V.^ ZQMWNQR1Z7*YYV7OS&XH7S49G57*R<RR=V_%
M1 =2A"2T*5(FJ:Q*?_J+ X OB2!!$B0/W?-'M[,DX+QTS@_O<_[U?WW=^>2%
M13$/@W_[YMUWWW]#6+ */1YL_NV;0WQ.XQ7GW_RO__G?_J]__;_/S__WQ<,=
M\<+58<>"A*PB1A/FD2\\V9*G<+^G ?G HHC[/KF(N+=AA/SXW3]]]R_O_NF?
MO_OAAW_^AW\@Y^>:T@6-1<\P()+D#]^]R[ZYU%3#X"?R+V_?_<O;'[[_X0?R
MSS_]\/U/__B/Y/Y#UO"#D'+-&UOZ//CU)_B_9\&2"'6#^*>O,?^W;[9)LO_I
M[=LO7[Y\]^7/WX711O3__MW;__WA[G&U93MZSH,XH<&*?4-$^Y]B^>%=N**)
MM%6A^]?GR$\)_/EMQLO8 OYUGC8[AX_.W_UP_N=WWWV-O6^TB/"U!9.T.7SK
M)5F'8N-_?*N^S)J>D-;JO_OQQQ_?RF^_$88CY%^CT&</;$WD9S\EKWOV;]_$
M?+?W@:W\;!NQ=;64?A2]A?YO [:!WQ/4_!'4?/=/H.;_HS^^H\_,_X9 RT\/
MMT:%?RS1TIVD.E8V>CN:/D\BE%@GI8H]46H6)M3OIEFA9VO-5/A"YSOQ5TE!
M]C5A@<>\5$7@64-:BI1[-] .5R6"/@1W&)V:+$Y#*F:K[S;ARUN/<4";=[_]
M _QYKOZ4UA+__.ME*!!U\1PG$5TE*36IP[]]4_5]2YN Y$!L$97%I]$J92;^
M;+"&;O%V%0J$VR?GOOY]9/=U%.ZJ157LPHHO_^H_=_A]4UU*BD0L#@_1BK7Z
M88ORFVR=R2A:P #'@O-/CRV$_I]7Z=A' X]<!PE/7LEML ZCG1P5R.>4TW_^
MJY)H:%=+!2H(\42?\[ O6**F*6(';%(P]453.Z1NV2AN;P\MN:6D/99/JKA8
M>)XP6,QB_<>3X+'XRN,*8S1V0.R?=LJF7EK?&JFO6@K=U6,UC&;TS](_"; 0
MD"J8C.6Z!=VNPAWE084YJMH@=E"C2JE/GC1 ZH9F.;MZ7MG/%-&Q/.WB$/-
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M8Z@LAQ6RU+VB,-B(J>_.%6IU(CHCX.IN-!-VM:<X$_CJH9B+.-2W, 7_<Q
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M8?62\.H0=:XL-884LP+AT7X6,TP/+L)L@'P\2[B!>J[E%0O53&!9H4:(3%Y
M9OC7!J2&YX:QEAN03 I^=H3^Z5:5)Z7'6I$+_Z]4'#5XL!>C!#G$,AF/W/([
M^K7@H\(O1A/U.Q"/)IU>1ECDP](WLO/L+S=A=+W;^^$K8ZG=6B3":D\.*4:[
M,E1EZJN6M+!OOKE0S>F+T$(6(;E7Q[0 .>ZQ7(0)LUI-:RS-O9"PB@C^)!6
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M^F+2Z!]8\+LKY&K)9?Z(UL6L+9&N#8L_!@)VTA@/,A8W>N&TC1Q2%6 G1.F
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M!^Q6F+ER)FO;$7,@ME+>:HV:]<(>J.V4Z#Q20@5Z#J1(E.[W$OVKE%]N49+
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M(B,8GK9#"A*-JI5'Z:-&J(=DDZR='XKH:>Q9?HUWT$W(,*%^_9#K6D/)$E?
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MU'L7KVH0>83G-[&8K;)(#P<G8U"5S0;@@1FNAS)IANRN&6 ?! ;3MVMX*H$
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MB%/,1^HE^Z_Y2%M#_>'F(['26Z%J0?._@_G(P#_YQ/,1K9V:CA1_V+^7^<C
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M\ <3$"$PU&@L:LBJW?A^^ :7J3>. [F&=V'T^<>9.0ES;R/F>N(Y2!9SM;V
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M7 (B\:E;SO;L3?68>34R@\TDB\^"Q6Z_4RR>!(NM8+' F]$SZ/V-_Z:"%/S
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M=>N:O?2\ OYFKSB)X@1G)Q1TS-[#^,=7+_+FV>)+6<(67^A%$]<>CF TC^\
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M'IZR0A8HGEN*XHD"BB>'@");R'+7?V03C)?DGU/\B%Y89]6<DG7ISHETQVY
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M"=_:L\L[QP\5.8UNTBV:' N=E%$J&I;6S-*N\D1"RD/9H><^964 \N)23^9
MAUW'.<:HRGHH>_9")7<8K+S7S EA'85*:BLO6=\Y/G61^U">75]Z,0V#0?]#
M;V*>R>8@$E&)6=P]YLB+V?5Y]6"(HF)JW#8HS6;#^<?2#32P%O^6QX'-B)MY
MP631/22U@\DK,8JWT'N"818OH/&46%2IKLW/0W2U4Q;O4 Z+"\5(TL,V0G0
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M.L%)BRMRY^@A,:EU/2'G<V%]2F[!*WPO7MR$Z&4]7S6\N3_K^.:>?&Y4?F_
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MK9$4'?C&1Y\B--F@1D\9@U8H4\8%*\]'@_WYL&M_LK;>96DO1I5T- ,V/(\
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M_8?R?K?0 7UX^+ @J-"CZZ (T_:(O2CV_"R"T23Z8P']Q1>$@GB*RX1V933
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MQ[Z)]7B2$^AL3N>YE%--1:&45$/J-]9O#^M(64>.#[Q'R- 95/OK ;ES'A@
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M5.XIT -D7M*>!VWET@F(R#N.!Z5U9NL:$#;+9HU%N3KB4SVVF^^G(@9L!WC
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MC##?XP%3W$ 11+0>(8RAJ-Z]Z'OVPX,(Q>Z?' #SOLT3!'UH YX<HA,8_C?
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M*/.:7!S-%FJ%RXD=5+,([];1U*5RFW<BWF&U6C]'X+\V1GF5P'MLO4K2[97
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MWN^I,O2"J?7K-;Y5+G='U&A!9>=?O>FL)1S+69MM6F\YR5USO2MEQW8'E9*
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M028ND D,>G#:8+%O(_@)[,@Z0DNY'OT%H>HG*XUX@_2TREATW&&Z-7N[V<5
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MMK4@2KT:X8HZDA14WBT6?'I4#S&$@H7FHF]*(M0?4#$3HDLTK34"E$/\Z0
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M09IKLT:E,!KQW:@ACDM-\423[PM"WZS7!XE&64NY+QCB^*0G<R,* $J>8V/
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M<0URQR]NT/P;[J%".M,@Z<QMT8A1*\]V/)&4X03]()@>':#K,3]*C?K.$+W
MGS'*\AW9@ U1B8\XGZ/R7!=%KBW(O?#VA&:.]5G_SV<E%7*AI$+N<GPX@<7K
MNY:DG6*:G-O$N]+VMZ-#=B,HN)#2#6??*<Z$?IO.6;O#L-T6SA.1J9?6]'#!
MQI31OG3\;2&5/8A!478!F8#P)8@]>+0$TR%+<)K3^+S" %?SLK6DOLQOA/1V
M_M=_:9J^BW :(1?HB$50V18VNC_+X#X>0OKQA-H;#Z%4JAP.-E3<?-GK.#US
MMQHD5V]PUO$IX'= 3R?6-FF](/U59->AK,!_<B(-\?FNYFZ:\T%>2[.*DRV#
M!;<?<]!S3T*O/9&Z/ "?,[#][&NI4]LE9,03^]DBM% A/WY"[=LSA].7![:R
M4_.T$)_094-+E85=>_YJ*@]YL#YQOXRDLVM57DZ8:H<W1&<KK[.UNICOHKCF
M9=8](&BDOI&F#Z3+OQ2V2^'N'N7:L?;KV-5FXPK24('M438A8P-KN*_3)0AP
M!%DYV"4\FA:/.F1^V21IJR*].\X_UP_01WK34;%X(;-IU63=E@1Q[NSH?=K*
M&OKVDZ+KK][Y,T_QW%5%ZOU;C\(.'.QWSL+.W662/S-.WYZ_^[AIL^Q=*O5S
M$K=P$HGT7>;G)#[P)%X++$:$TE>#3S[3Y_2"\*KH7O9%?Q# $I$6U]VBJPZB
MPSQX6S",GP&5].KD1ZBN9]14^EE-KO):/1EO++N'Y,KNO=6#(@0=3EF@BHP3
M,3_TFP;2U&AO-3H^W#8$M2+!^Z[RM84Q1T;H7_\ELIE8@J%C&>;2VG_?^+[G
M+)9/D 1X5RAKA0\2[( MJ<@#"1KA:B*)D9W@BE[! "_2_3>31?E4O7JKZ*!O
MB9>$?3'6YUAF.BDV^')_GASR<<>::HM"MT:OMF_D6$R5;4R4?$"3$5RJT@U^
ML3,]A?>4GC7,3K.YE#J?,HA+,]E8AOU(2-#;T-P#U+CH'0.8;^/&KU[$ES'H
M]T+\17S\ZWLS,K01<:=MU3RO',#P/@$M!Q]"#H?;\/_^%8]@]74]-Q=9>=_6
MQ%W)S@QF;;<]W,+7?IS5__Y6BOA#3'*BIGU[G'FE/?ZCKO\P>_O$\YUB?"&G
MU^V,MI?4Q+!53=2$Y/QZYK:2KRU+Y=F:TPI@K$SNI_LL&*$!J5<PM[]:&7)G
MJ<Z'24[,[ @/XT?5_T;^]6>:Y\G(5,EV:E;B(-[M:>W!3I(.]B(A%+BKIR31
M3,[Q0I"2>NT@M&MV<25HI4J+115-S.-)R6^ER8E+?>1;7&-PZ5ES*QN5%AQ3
MW#^*^CLHZF_.N(\P+6IS?\+-9DH<TQ0,;R\PTT6U*ZW2Y6H1519"CDW'HEI$
MO[M.?B8JAG@76=_O9-ZO7N6/;OX=6?QEH3.P 5QC(,P<NI\1ZNW!1"NRY3F9
MJ,CF8LE$E+']C93PA\3)_A!N_',C8%?@QP^+@.TKC=*@RU=V=#D[G62WK,O%
M\ULR,.X1CGUW!.S+-=1'!,7.6K?>'A/[\KVXA9D_MZ^^OR:4=A(>Y>6])N^:
MHZ9F;+>J5L@O>[3SUO#Y&T)I]&3':<66Z="C2@\LN_W^<IWGR& L%$I+IM.Q
M7.JYZ5BW,MEGY5[B![R8U*^.D_'2-R-=4U.:G2F962(YG678S#0I)N5I%LS$
M:5(!.38IIV<I5GG89V6T%_7B4"RV-&];!JMY9>O2>I<4)IQ?J4^F6GW?*P%!
M9+2&L0'\>%9$5R8?7KE.R(-!.9&H\&"PJP)WE*R5%EN21GW08Y8;9(M5L3G3
MO%3-,;>;^YG1X>"5%_><TNUNK2NVDC2SCBM]KYHTNZ-M5"^<PW$)L)A4TWQZ
MMN_L:AF]MLI']L(5EV5^$U=,H-57B>QL'2\(8,-%]<*5[9:R:PS3AA;/CWN%
M0<6:2@?NHA=NRHHSA693[%21P6R:3"FY:38+4M,,(V5H44PDLYGLPWNKU;Z7
MJ3 +21NE= [,.[O6O-.-ZAR4JJ79<I),M_E^;T+W^ZO.*)W@HLYJ=-])\?'X
M]EY;-YO:U@'YE>W.H\YJN>P?1OWD(B/TU7'2*^SFVY+8C3JKU&':KRW:L[8&
M:3_16(TZ6GT3>5:'Q*8KLX=BGA97FV5O:L1-DY]'G16]=YW<X%YITX6%G%]7
M#QNZNMU&G=50F3E=KYT7:&;L)JLK,=/-2]VHL[(.DZS)&,D9OR]/ASMWOLPT
ME<NS@E>N)&4Y&#MZD09;&32=^&J_+V^C^A83E:RA)>/*B$^[K<DP6\MUF'J7
M>#?G5^;D_4:<]" 7[3/CU;JNQNO%3;C#\?KH,;@WKT-:\[C3= ,GJDC=:6>$
MA5$4\II7UWMLCJO3RT7W$C F^KIO QB3NJ/Z$7V+MX84\Y:Q*">XZ5"K9[A)
M\T&KYM<"!'_XW$)_+!3JN[D@_L&I(]9!4S1X8Z5;>_#(#*F=9EK==KN1HM>)
MILCH7(U'7MM_;"R5NQQDJ.$CN#["[X</3_VX#=PO4EK7F->:PKJ_%N\9.M.8
M>P@J.<9$('1H,=07NT+C S< S>:[4E</<:I#,M/?@-/H*!3-]A?:!_9&E4"D
MZ,STBO,!?Y@O:2_'[O:I<8F;\%_4WQ,A+[%HR9)H]$F6K'"\_H%(^:KQ1[]Y
M&U+V0[J0,G?,D^."?SHNKM7[PMPE?_K!;N(D<G?I],])W,))_/#$K9P$@5?Z
M.8DOZ\Q[3E%?;]G9=T4]/U4>?'RCW9/Q^L>[\#ZDTY#HH2_,?V;/36X) ^^\
M8G\^L.ORSSKY,)C==SUYYGW5SS_R[AI4_QTVX3ES_,N)G1=ZA/NU[R+LOL.Q
M/V=QWNRQOTW2?77]1N^Y(? ?1M=?O=(/0TKP[;-;+C?YGND#'$1_F#G(/Y(Y
MJ)HCA*U8MBS9:=M!2#T8\%E4Y9;E=CVX6\J^9-F]$]PHYW". UQX@X#V.5,N
MGBC??X&+;,1 FC9ZVT3CGMDW^'+5RV[L<EVD,QQI]V0SE["!OPWO?$$5J&\+
M_\E<]CE9SIOGLORJ3.O*L \T<3S:* .M!%9C5/B1_.N_B%'WW\K7Z!-\6:AK
M26=E&&#Q>UJ0'ZQ6_QSN_CUT:!_H.CPDQ-PA*.TGN)OGQ>%L5EA/^?2RR?.5
M\60T+W;]IFKF*6B4[\057Z8P_QS^^3VTXZOY)SG/RO>55MW00#_7W,03*U-I
MH&)'J!W3']GS>!O^:1F8P/9'L8FRH9IHEW"JZ,=#?;V'>L--53_:]PW2P^<.
M*#VX,]YX0GYL9^G\*%^A=6V4.H#]/2\/QXDM 3K(Q#+,CQ=[%2_VAQ-_+SW^
M!D[D#_6T=-_,[7DP<TI,TLQ5ETL$.9)$Y<')Y.5L\6_EZCX91!]8+II:^&W3
M)L\GB3^Q&("%TD*V/%2;>GOBXD,Z'6]0J^<A@RMJ$+<ZJ^N^D"T1S-[*;U>V
M4Q048>35,ZJW.+09W/O%/%;*_HVYXP9Z@J-**7[XY@MT\#OY)EO3[P^-JBMJ
MZ6*!EWFFN.D;B&^2C_70/-$R?)LU@C=CZ7Y*0_7[>M=\L@EWH2'@LM-4P#@T
MOUP=M:(19$*'VHK.5;M^^M("R)[^2,^//X++&2 *',"GYG5+TH[M/N7NM).:
M;A2+5L5=OIQA5'<"NM?I?:0C>WG.FGC^^10"??CTJ':=8Q_,3Z_.G]NK0PCE
MCDX]U:3[TZ;P<S _G3S?XV!^..9&#^;/[?.YSL&\,?GVM9T 3V[24^ZJ;_1^
MEPC&<VO]Q*E;-]_K\\J3_[ZM/U<]]IMO]'G]L;^Y[^>Q/;IZSN+%FB#[&DUP
MVSSPNBWX0QI_7DG\W[X/Z"9._<O[?EY_ZM3W[P"Z7'1C4.U\YXJ/5Q[Q5XFW
M6VQL"&_,E3.U1^2PZ6"_ LXSF(/<3G6F*/@^;5CF? !LHVJBPX:.94<7S28>
M #QE376UW'#.@D]7:Z*16L5+"[;[KDJ2)^&\(K)7[9;32#:*ZPI=WFQUN6)5
M)^6LWS"4B;'L4_6:WX_U;HS1;K>#Z)J,]B"A]2F,IBLY;=B=.?3(7J?8;DH[
M<,/K,EIW7,XHK,G6M%$C[_02;)U?=?V>(39&9SYR;L37^R6]OO!MS,QOHH__
M*)GP0<H7#5SK =2U(+E QE.<T/OY4H'.2/<;&^@J#U1-&*]2&;U&OZ^D^K52
M@=6KT^(^[=1X4>7V?%;HI#))CO0:,:E/K'3^(S7M'\5"'Z16GV8A>5@8JU4F
M.Q+J2V.17.U&Y4SENHHUXW%R41QEMAIHK>1!3W2]<9XC[4;9J.*KW\H91G<9
M]MO?VB&^,5GQX_Y^H 8>JK;KB3H9Q>)GW:JJ+SW NM82AB5[R^_SM:&X:F?C
M&>&Z"IC+MOA.<:9H_)Y)<+E9SEJF'+_9B&78'^_W#_-^+S;FQ7/4OEA//\EH
M17.I90^-Y8+V>KM1MW$_[S;<][4L/<=H#^:QA3ANJ.X,O:K9?+NK30?B7&(;
M]QQI*LI>-AF\8Q;;U[O!'5NU[(_5SU^YG-\-2>-WT:=!E"O3KV9X4$[2ZU8O
MWQH.U/$B>5UU6EW6^))0F]6%0C%94U.M'3]3_)''+/U4C.L;L\6//_N-_-FG
M&&A6F(A+4=E7-&9PWU_4T^7Q8'I=;]9QJKK"<RXGI&M2O9R[[X['\RWI)DK\
M]MYLKR_@[AD-["D0#-WY,;D_W[6]^6;_,TF#-R:1_ A+Y(<ROCL,Q#?401'Q
M5*@=ZF!_'#3F*Z1))KT2:P./Y=?M[(2W<IM"(G5=BXXN:HX3+]VWZ'9%D40N
M55PF5VC@/51(R<CFUN_KKOVV@!"?[LK=?AO[B\_Y&R- O)'%YWI.X,K[>%VK
M9YU!<K%JMRUW.\W^=L@/+ZF?_@&"N'D.^GP\IE<K25/@MOOJKD:G[W5C7!]R
M_?$ <=#784"\#M7@(2OX+>5O&4EYBR -;9-J61ML4U&)-)XE3,>H@F>#H2A1
M<VBC05OLI63;7F%B7->5\:@DE1-"W\BN*YDT5[U?=A^C7$BZ:42N-*+=T&^?
M4>WFV.YTH+H(\*%JRNI&E3U1/WVUL%"!TI=4]#U%E=H*_ ^P_>^6&>F@3>=V
MGP:, +;C*F/U<F?,5&V57C5H%Q("O+&_,+)W3IGL>-5\:K5'/J-#PW;'ZTQ2
MW>GJ@&Y/*K6),1,DP'!__<>DT[%$*G7!9Y1%GDBY%L;DP(NG3JNG_.53OPK]
M]M]W5,FSX66V8=D@1D$:* +))YNOH!J&"#Q"-,=?OHIF\IZCFL!Q_"WC3!E_
M7+ ,R.J2*NKGI+1E$PTZGR]G!$-@4SVFR$S<\W#TUY(2,^YVBJ+09;5X>[>F
M6Y/)9 J/PB>E2VR[(RG]4DV*I5QX=VD!G+\#TI(L PK!_?_G^$06;%>(Q/+M
MOS%.++G@M'&A2PJ("CE=)_3E4%M@ \H094")+F5:\"F."VD,V@KXH2X\3SS3
M7*1,*$QU>,1Q]!FE!H=,H1'.U"_4-?$WM?)<^!?TD02HV1X3,SQ?JG4WO*/\
M':6V*GS\#% !< W\ AZLCI]S_@WS?#Y[#+XA_!5>AMXMV*^ 4P(6S+?_#UQF
M:!'HW<A"P0YM"!K<#E?K+N!_9-$%=]0 ?:_?#OW]$]DN%3(S4E,V\7EUR>^1
MU+D\/TV4*X; %YQV(0/DO,9J'RZI^6##W\!@^4&:J=HS,TFW-]6&<?"L:=*;
M__5?.L;2EY45B&H6JG.D&DAU37&/R>HNTK @S>NA'GU)!Z*-S.W%O^?V"XNL
M@.L.XWQ#'_[__!]G@ /'4!P"";+L?P(_(+1*'^B P2[!',0)GH&H0 'PCZAO
MQ;T3N!AA'^.?HR^!]H5*W66S_XLZ_1.MY&)K$?Y0: //\(7(M\X1AOS/G@%5
M.#NP\P=$?1.>/^)7U?0PGP8(54X[(RR,HI#7O+K>8W-<G5XNNE-T:>(SO*.W
MV9\U3]_[1D3BJD9$)A1V./[[NL(,_07+LO8*H+<RYP]$6:F_J,KQ.,.GV;VF
MM13H<QDW9'0>JKQ5E>I[B6XOI/2R))H%]QY9"G0,<N0+;4Y_[>CSD[9O1]F<
MG#>')/8EQ)(-$4OV:XCEI/GP,!Z A_$\H)?D% @3R4YH:6F1'A5;LY;KSF^'
M7FHF+Z?RCM+5F(PYK?+N<":+6U0!\0IZ"8TB"A%,\8WF(?KE"PQ$#G_TP$;\
M1/H]184^O:?L'>)ND^FUEX=D75BG,[M9?%,>ZLDGR3?N  F1,((J<H!Y%K**
M(MTA<$Z4FW\%Y98J'<,3%JS,E]7\=BR ?<8I0LI%9GVDQ?:4G=^.MO$W^.6P
M'[0 <&-CY&/3<@/S'@,EGCL EY[&[TY%+Y"#Z6&#65EV+L'OB]Z]M(A[U=GH
M2;UY-4(2Y$ZWL&8W23KN-H>#F=WO]8WY&PFI^'Y" CX=08$4W!(9KT?=JOKT
M)4+)%O9"X-XI0(6/(5(WF.@2AGOU5NA%%ZH![RANT+PT_!I0"@(;;MC=!R*4
MOML*;>))JHF AZYH6; AI_KX[R_@J(@LNS6^'RZG]3'+CP[E](3=\+WY](;,
MSW*]9X]Z"?M CZKI:FVM+SE-AD(YD8BEGC$G7GB@0:W5E-EU=MO>JE+5^OWM
M9F28(SN7^B..]"62,?R@R)/BLN6X/7!*<0TPG))=;'D]TX".@KNU+H_IK,CM
M3S'JA'YQVG0$W<Q;99MG&NS" "YMM*!Y?-M$%FG0!2'PD*U^KJ'-54^0969I
M\W6YWNJWC2[#9\YBX/37Z.?ZQBUWF.%LJ!F<<N"8<ED!YCL,/1S5_@ ]'1A\
MMZ0T,:4C&K^ZTDQ/(;&?#-'@ER\@?WX') ]])6_!Q9#O!,)VX#;%FE,R*T*\
MW(HGM>Y"DZ0;<L>G$[['K:M5ER^W4K76IKQT&Q4HE1,O],=!L'9JAA;_IXCJ
M[^TY/46P_3EH5>?;]4%+LZ+EY8KCE35Y,C-Y-;E<+@NR-]$S.:U0'<Z:C74;
M6/4WRN4'=/O[R>;! D1Z9*B%(+"L().0LAUT 9Z6]G ?9,]&3AOZW7EDRD3
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MJ!ZQB8>[]<O].@D?F28@1$5\,S/DK4$]$O2'0!L 24_;5YYHA ^*"CK4+P<
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M>3::P.:@F8>X(,"U+(U"C2NGFY(&&50Q;:,A;5 NB1+J^1?=Z,*_)-Z49PH
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M#-T5=2B3Y7W0EW(@&'!AF,P38D 8O%*,1LVXH_*B#:^M 7AUWX5GS^?^72V
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MQ+22>W8RL6H+EW2Y,-=O4$L#!!0    ( )F"$E6AYQLV-24  %@F   ;
M8W9A8RTR,#(R,#8S,'AE>#DY9#$P,#$N:G!GG7EG5%-=U.:E=T(+':*"@-)$
MBE)C P041) .$>E$>L= !*4WZ:\H1*E2([V#=!0ATB7T($U:0@T0R/!.^>:;
MM6;-FIE]S_/KG'ON?M;=Y]E[WTO^35X V'2U=+0 "DH H+BX /(T<!^@HJ3\
M=UP8]<6@H:>AH::F8:2CHZ5G9F1F9F)D8F)AY6!C865G96)BXV9CY^0"@\',
M(!Y>;BY>#BXPU[^;4%!=W$--PT!#P\#%PL3"]?]LY&\ .SW@0'&%BN(*0,E.
M0<5.0>X&(!=^TE#\5P/^NU%07OA(2T?/P,ATL:"6#:"DH**BI*;ZU^N+V9"+
M>8":G8;CLMQ=6DY#6[HK7EPWPY(_TXO<J^P /QW&B\J_\ YG8.3FX>7CORHF
M+G'MNH*BTJW;RBKW'VAJ:3_4T34R?F9B:F9N86?OX.CD[.+JX^OG'Q 8%/SF
M;41D5'1,;$IJ6GI&YC_OLW+S\@L*B[X4EU15U]36U3<T-G5V=??T]O5__S$R
M.C8^,?E["KN(6_JSO+*ZMOZ7L+NW?W!X1#P^^9<7!4!%\3_L?\N+_8(7)34U
M%37=O[PH* /^7<!.37-9CI;CKB&=K1?GE9MA]%SWDC]7=C"(R#_%@U]X#S-R
MBRHL7B7\2^V_,ON_(Q;^_\7L/XC]3UY8@)F*XN+E4;$#4.#,*#>V&/G%TJ5N
MQ,K:0*B&/0$C6@$V#DX)-FZ4**W,_[,9IQ"56+O8=NNL5$UQ<25E7COF8+J@
MGS5JX"WD*/H[B59]HZO%\%0K<+YGY!^W"C)0?<G_\O.OUF4^O^NED)22*P2K
M^^%=&F8#.=9Y:%R(/UV$C]0+H[0@D3F+4 &4TX:-^ A"E2Z[^"]WG9R=:H68
M,694/&L/R78^VD8_?/.=#:9$;\K-]C84+_:-5+J2S;DPF40*NM&HXC>_0T="
M_ 4M_PFQVH:^5ERW$3A+E'60%*LO[Z+CD[/0LE<F X%;YUHMZ"VK:;[S]:AE
MZV4R0-M_V%YY4XWN=%LV2R\?N6!]KCT2RCVY1(!&^6[92& E=I[K3-SJ-;Y!
M3954#E_-^HX?>@.*1$"+UI^H?F=)8Z"4/UMY!E"&$,M?^L#@!J@4-3( 3C\+
M1F4_6U[-%.\*\- /']8$5_YCJ,D%_#=<!:2Y#._07(!9G% AB9OL_@")L&$8
M4]SHK"#(#+Q"+&"NG99 W^\#69NSX==>> *8D7:5=E=D? K"F# UZKO^*(LV
M;8OFR_UDA?== SLI-]1?'RBN+Q-OQ96E$DW*CO5%AKB-WGC'G?VIB=W;V56&
M4#GGB!%G"0\U/8)N_LU*VU*?W4U1RQ^R3@3=40%]VD=_$3E+;[NT%IN01S(9
M8\\3C5YV289>O@PI\$=583H4B:8+!2UCGYEPTL92]31I[N$:Q:PAU:G;7K]-
M&\ ;@\&\FT,VDRD)C7:%W^=W-'RN++K"3)X1)@^KCVK<%$.SU$]1TLA.BE--
MHIUT$;&IRSQ!/GK%3ZKK'*M-FB84\^"<MN@6@Y3^SM'53-@^O:6>&_Y3[G=^
M%!FXB_ZR)G*E90?M@^3X"/LQG[R/^JV/.FT3RP\-@/DT[E%#ZM*R),MLI/#<
MZ-QZ+3\Z-((!#,T."!4Z*POE)\;3J*R-BMT^5J2WD'*"]H2WMH9(3KI+E6\O
M.A=%*N?:1NIPW4S>9O$,%3U#G4,"OS3#B#9=@UX_ZPC'LF0@1 P4'#K)8(1[
MDY37OM!S8+4!(JD0OC3K*I&,5%D@W5FFT6[GPX6N)EGQT/G:]PZ0K%0+NSWT
M>\6DWWGZ58WP';K (B/\\MIQJL]Q+*AP^?JW4+%*QX:SSZ&@C.26=L%U]CK]
M\;T9]"^W3.@_A5_32BYBL:3=*8\,7+'QB.\D VV+]IE[FL6RELXCQQ +3BWY
M0<3L G(:UF51WOD[L*1SI_-H8=/?[V:GP*\%=U@/DO^$2G-288=MG3#G$E!W
M=)@"/(4'44?/1U?H_G;]'>":7+]\E-,+DN]8820&QQS[V13_=374T?01_E)C
MJ EP72#HJ,<@#FO:.2OZ.. \]<LCT-2FX>L@T%%2;N+J[B#";PD2(RQ!1)=)
M!1@->HJFLIE94E7JK('IC/J,4LUA;"T.?DL8;E?^GK'X.1^4M,YI-*@_;TWN
MY&1RM+UJM4M26J"3$)BQPO7!J V3MGG3-IKC1EM$M"CJ$2.I*?"C-MN2,']:
MHXOL=[^0Z;50C '-VT4URE[3*/4 A[T0'ONFMB(P?O7P<<O8 ].VZXUP^H>S
MA[PW'#1^SD2<,*,*0E@6H9'"?/@'#Q42Q.A%#9/4,Q%%?U?%F@J@CPRG"T+:
M0!*=SY\>>AXUM\)(5'LON]3['!^?NB9H'YO$;6_L < ?T_=_H4(U":HX7:+<
MI@<_:5!0V+LD*,C/A&['B=<6VWKK$_H=25_GK/S7$FJ+R0:ZE?:,KT*FD%4A
M&UJKR+,VZ/V(11"Q<7WZ'D?*!+;4[&1?\+6SN@2L24*=Y574D+ 3I$]:V"!&
MO /VHI7_=5K7ZI:!Y&4FIXN]A=.'$?<(!ZBN)):!<EB'>D^+>[1=/2-,RE/E
M'=3BN/<G&>BUX9P\N]"O_?NFI>?C@B21%C* _@>Z+P>[IGT#K28F5I:U\B;%
MPM\" H==[S+J75C3U+"HC,MHM9SHY2$I@2)_._A:6R595R()OLBNYX$!YZ^#
M^\X(/&1 L!PT]1=S-W/1,6WRJ\N.IXU;K_V]^0T!/HSBNG11X+, ><OU.P&J
M=CU2"M6,^[:6&^Q6WU6]M_S^JEEYE\E<\=4HO?4#VZYTZ+_I94-]ED>27RIW
M4?BRU#SJ<57UA66-X0KDSK-$T"1X/:NNU"7799+G:+2@]B.]C;G5PO788Y[>
M)RZ<Y\-9]P)MI0?;L6YQ<8(O]ZC"B=-]^@U'1^C LSP&,A !+6?S2I*$'!%<
MOP8E!-D2.$I==#_XPQ]L5FA!KW=I@]]&,/4JIKGGE%O_7O$#89<ZZR8]P!6H
M$ION(DIGW)WR?>:%\Q>E9*#K.?$_$:^07 CHAD6UL>,MIN&5VF<EN\VZ6_8C
M*8W'H6Y%\?[H!U#!<\ZJL_Z[9."K'9( 7OWU4PY<W)M/\(QS/:P:'? 9[UXV
M>ZGN8AC)F#]FC0Y Y\S>OW^1%.7*72<FGIJY*C%Y74K:XF'B36!8,XL2!2&\
MC!"F9T4*L+?"(M8BYK\.WC]*9OC45)<HPOPC>.MJQVTU]J0527A'J HQ9.G,
M</^,?PZ+^WO[YT^TW5<P-:6WZ7C$K:6CC@V/N'/J#P:,R7\GWJ,,/A+J[F@L
M0F=M.T@@UU/F+-=\=-R7$LW6I8)V[E"?GAOE6G'F#M>>EH)#S>%(Z:>U$[V9
MG0;QP3R]UHPAVII[G^%!B.(M]_ 8.W7C=_GQ[+]6*_<KCM1#X'NR"^CN!+V%
M6]UDX.;)M<]U' +J3[]'#7Y5 D'FC/I/V.?:[R/T"%1:>$RXC)JIEV]2OO9+
M&1.S?@UG$0F>L<I+H/(082B 'W]:5.90?PQA?^=$^.F9DG'URU@1P7>T<:F]
MCJ<W><& G@QT*A;JT]:7739G1&4QV77=JG0W?N6N7MH#M4.'1_6&BFE(C7^:
MS5OWIG*ODAU0__;'[R]G>,AADL4>/%"1#&#UEMAIXFQ<4S,<EU,F*,A 5>YK
M]?/"]OLU RQT"YBN+PM/ZU3$DES-_X0V"%9#3%[H'(FUZNZ<JC)_'2,#,>J8
M]&\=!&$G-0QG 2.,\95+1?L'90A6?LD*2DL26K&H>0J?+!JH##M_+G>4;WLV
M#GE_*7CR,?X-+B2I!T5CME'WRBZ]+]//G?41)\6>[&B#>@=X%_4:H1IR:HYP
M'%,S*.^Z0C0R""EU_^F_"?G[F3H &A1]=, 5Z&34>I;<IFSE/+FK(_Y6\45[
MZ\LM=@Y_72CVWL.7?GR'%2X+UU[)VO*<CC6BCA%)^ADAL2?8WC&33IW=(NRT
MSK%2R/=?>U8!W<C84&'BLUP6@VX>QSEQ#QF)/.O='W.QK6>8NS.3IM3#,SV"
ME4TM^I_3T_ZP!;/!E^:)$NQB1]\V4FL*YK3=OTZFAW65Z5]^FH/9'SOYN7>C
M.--AKV=8IQ8.<[. %4^BIC$=[X]]I0,3^[Y'H4AQ.F2 975AYP2 SQ_]A9RK
MV@PLS -$U[[.ID=/G"V"M>HJGX>\!^%9=41$3[.FR<!;R3N0/>K1/3)@4WP.
M'OG[_ 7VT&"'#+P.JL$W_EG()QA.GJ+P!M>)MJ<F@1XX5-PG_#FJP+4NTTAK
MNVJVCS>)L2#ZV"KGS4AKO7KT5G_9-)1Y7<7M6T/-R)9T$1 F>N.*$LCFSJ#+
MT?I@T,&R_M-6B:F@9M3]\(+8(KU,'D5EF&]Y$5R0I]LCW(:-F.=R!1YL_-A_
MH%9VD5+U[<GMC7UEX?%=9$(H.^GN6>;.,@'R5O%5W"SUC9LM=MLR@9P]/Y*G
M PR.X-LS\0=_QGAN: 8Q:=Z4&KY]?>T;^'G@I3=CIB80H:=1C;+!0D:_=WVD
MHEB2SK:@L^.6NBJJQ],^G:&4Y^,6ICV<K$EE9<':,08_BIO99E GC@9:9,#^
MG'JR3:*/;S#4,W04PFRZL-K#+I;0-*G?0GDR\$.45R! HN@L@T_X=7E(Z:DZ
M0BL5%]4Y*VG2Y(:-I:UK5D.,%-$TK#>X>1#!?DOXM$7]VUD0ZB9_M43(D!S8
M"WRS!4EP.=C.W*A65XF50#.?+N3&2E#MM>.27KN?"Q';CO2RQ+E/!Z8?:H/X
MH-?HUCN.:-O"SS+;9,RMG2L#C9[^<S_$W7(S?I727C3[_3E>="$ HGNP$]W.
M4I,48R%IYNH%]LH(_WM#K=]RW*#HBQH_<14G^XT,<" 4&N$9,6B%L9=]7RRI
M:@($HHRA-NH,Z)^2SRN56:5Q^.&5PJ-=:]0QJG)Q3Q#"]=R$CD]&]\=$"/9O
M:S"ZX?3GWG2LY))'%*Q6IGG1+W+ .G[#7T(IAJ]NZ$W]( F&EPG96/.@(P7@
MD?$FBO7C(C7-H1H#@0\,4'<,Z/!B;5TTV0N$XJL:YO[!4*)XAZ.:ZC\.@XVC
M*TE[VL_V_K8YY?IKI.^"XAWU#+ =8MD9])IGQ?/7L V[N7S?T149FLEW39A!
M]T 6>Y!8&(4"+.8H>?ZQEU)V\95-^4XJ.L-?-W,:#J_$SS.8\NBRANL;IJ2C
M+'T;J@3]F%F"XSBP\8L2LY+8PXEYD3$.8_NG@FS:U/S\QHPZSX&=K.-AI(.Z
MHR(#)'&;G2?"T'T&='IZ]RQ=,9,&UA? '!5>.-L(.=K-VVB,.J-L)S'P(YT<
MD/N"[7@&P<1T+_#JEMM*QQ4=]K9W=$G)W5(@Z!/X!!EP#2,#W(EX,C#Z$W(B
M9$&TQ5,](+I\J2NLEW>UR&$L&Y5X%B_,.BYT:I\Z-JE#,%T\)F8N\M7<#99B
M3M$6__AB3ZYFE;?_W*_KOFQW%T5TD:%,<$)-*G8#GI,HJ=!I_!-?>^W6YKI$
MD5A]]?BTSRHZ EKM%M4-HIZ"&\%YE*KT1Z@$O4HEL,O!J *_>7R?BB&&9'P+
M=;2,[&T-6$2%&W1AZ,S7'/>V>F>SX^=L!J?_J7^4\_Z@HJ*^T]Y,\9XP%M7J
M$&)SN.NDH1I3N0,V7-S0T'<:R,6>N*./4$*!!H\;B"*$E4E-C^J_3ZST!/4\
M"2#Y@=37/_1UOXK3T7V$6!PAL1>M5@]J@O#K&'8BYUH4%TI[*S94_#>Q_M3*
M4KKZWKS#J09NSAPS-R.'*@@6CT:H.^!"N#=TQRYSFL]\3GPPQ*I^=_/N'XAK
MO)BU22*$,Z(V3^S8?2</AIRS@2I]CNZQE:M?^6ALM5E>$K +\X_"S%>O=K;3
M$C&+^Z9-A=DLV[EBR:(>ZN.OZ9;[37B7L*VJYWP[BSL0PN5XY'1W.\DZ:/\B
M&]W$6K=DR<9NUZRA2EI4/PA%+CN<&V.(#FX>D%V-&3*PH$H&"%A<EVWIDP)^
MHV^]^M<G6_SVQJWV*P/+-*[7;(S^+*#_/JLU.G*FX/_K ,.(D,$7A?OQM W7
M]&]6S,ES/JQ637D;KL47_9=NV3KH>U\!8H,,,)>7!Q .^LE ?0 96*K=OYK>
M6%,3SM%[+[K$ZB)JZ"Q.I*A+S#N-U;,LS0M1,X@,)T:K'Y[=32.OZK+@=6B?
M/TG3>@O(K'9\CO/$5+)GUD=#UKS<P:3OEN>4K_B/4Y\243@6NV\63F\JW ?6
M)CAKAK6'-G-B]8.>#;"INFO\/C-HJXHRKLX9^2N:@_5U_I/0^RPMGDW[,VW;
M,SQT$Z$@FWC+(@(G-<?V53+H145'_)#.%"?HD/Z[> 7/V-*^%*V=OH*5''\#
M'+(+9< )"W0;]Y9,A<;6-ZN^;*HC9;?M-9REAE[4A9TU>,\)10E$*])4,^7.
MTDI]5(GVIL&<!X)U?+F]%M8]J(<SB'-KXPN\*]J^N]R#NSL1U$>JQCPN#M=9
M1QW!-Y(X?L-<56BV"C,136[[P[R+S<XM'4S"M]SZOPLU;L3N>H0AJS4S.UG@
MAA,>BO=Q+#9K+Q.7%W9)Z>*R\=4</[U2<][,3&9K\X#@:L^<@D+25\D <"+H
M:&AMZ[Q\^_;N"%*P NU>,ETWM91#D73XFNBV6.I&]P#_.%[)T_UE5:^-EOC5
M]RUS!ON ?UE[K(T <8,0H%=7,TD"P^-TF"LQ+RM%2WOI659R0(+!8>LPGQ>1
M5HQP>2]4C?'2X-S04B9CIZ]&&4%14!IN;3'@)H5H/14BV66:C.;CN9LVLWHS
M>"V"^EA$=4.=,:</7R$#SK KR(5/HF?M%T*];4T&UIY,YA-W#BWX+PX1+\)K
M<9X=PN(*OZ*_5I?C75,ZWC?4,*.2Z(,IKMC!37:4"RS)1I7OS[KD)^*F6OIE
MW3S1G,F1WY1I##Q#Z+PLM,%1!7&)8@+JDX[CB3K+C8DB$J49STS37N:)C>>G
M/@Y6E73UTV!K#M_H/'GT#B-8J9BO:9_08;3+^M8$\T\4,7,/G<9Y"!DKBTHO
M0FBUU-1 _"\[SP3OIX%&LB^"V1!-!H:?M)*!;^90XH'/ .BMMYLI&?ANOF[T
MT\?Y[MT%&]1\S(&SGZAMF,;[ G&1#1L:_(=#I_%0?N+0M'4SH6>HD5FNQ7'H
MH1"5^U/Y5$G?H6!_=(B:3T[ZZD2$BG>MLH_,8>6^V75B[/Y' E?K1W3MZ&CK
M+[ODQ)J19T']@.FM)8/H<T%B4-&'=K:_AUA?IVVIA,QW)]=![Y-^F?;#P!=:
M#&,G634B&8E4CUMJJYO$Y$4OU<[^R*'O/.M9_<@1\I /W"9 8\FQG9XWWIIT
M2QYSX[V]VS4?XU>:KM/[:]ZPVJ/N:5@TBB.O:N2CE9DSX8-FNC*'KN5-L'JO
M9SM>\ A=1@8<Y@%KD@;Q?B$6EJ<9$H@)49"Y82>;4*+]@DLF9,_F0NM"^Z\M
M?F@V8 \<OM(TEB<I7?=/D:__IC++Y;6?MQ<\06B/DBA!QGT?YL>R#H)76>R$
MYGU6&UY=[U%[]FA>N-')R/E0?_JLWT^:R_1U:/2_7P/ @LFB_?UK%64W[C.'
M7]>]IAC2FUVG]J$/4HU\VV*[8@"N')']^&?0(>)IR"]2>P:H-1 6>^$G!.SL
MJ.,;\WGBN8VQUISQ6V13'R25_U0FM1*=T_/'3,IA6<)[H&GTG&*?*'SUIR>#
MEJ)R;I,>C B-P0NU1VM<(LG]<ZEA7.%U$>6UKB"G<\HNE_5UZXFP4^O (H/+
MBJJ2CQ_+3]**D_H@Q*V0 !\'FDUI+KRV@MNX_9.[)!;/K-5O,*J-9:P;+9,+
MK'0JE8&4%G9BFG06D]2);,19-ZNWP_I/( =)DGVRQ"<=I4<)Z!-H3[;!6S\R
M0-15DRW8$#:8PA[.*9/*I^O<GWCER,=/S&DZ!B(?U.-78NP*L-NGBOF2U);3
M/FZ&8:GS819FX,.:M+0K)1X.2*.]D@J9_(\: LW!OMP9L9)&-RZ*+B WUC:9
MHL.!;N/.!SVO?2/$V/G)N:\'; <TE!WQLSDQ]T,KL@6JHM9]OGON6R8XT/#7
M7<MYC_-TX'@\"%V^->I;S][=>G,;P"P]%OON$SN;H;R?EVR6F:.(/\]I;)RH
M.?7*;DQ9YT'I/[:=)\'QW!]QJDD\S@1E/F#N\A)>,=_%.&/8XX\/AB^RB# 6
M>^ BU"X6CN3?E=8[+"7:%8IPXHP;');<RCCZ#4:98O\<R$Z_^>;?R.V/K?A$
MO,T^74*)7'@$6K?LHXG)^87T6AW#W,3"P(&DBU,ILO9.HF\))HLYM2%&F3_/
M$2 ZE,Q[8#G,ZY>\U&\DHU:?(#L#3C4#6Z,./2*D2.I4OBF+8#,04NX[&>B#
M^V6.PP0,#YQQ",VWF7@1%=1B' G[\"0[FNH+Q&*5='<)PQJH*Q9B9UDYFJX-
M=6DPAB8K*^ZA2!))"39*% @# N\Z'@H22DL:/?O=>6UKKK9&]K==9]UNT,EV
M;0D\M5[FEI1$'WX N32NQQ)91+*HWXUMQ^W+!V4X19,!_\[;%7LNH8R;8X2H
MK=(%*"@C2>]6Z*6/S*"JGN4>U!&*;I>V9069@!30D*N?(@DM9OZJ.0[DB8-H
MJI/6;[0?]0^&\"S"PMIH\"_CQ#(7/] 7&8:I)1]7(><-4J",V^/<BHR?) 2?
M^Y:8?92&+(PV[X@C.YSM=V<F!<Z/8_XD[8Z:D&R*^N>XSF+]H&RP!%.<>$Q1
M6X,WOQ[<G%_;9VT4N@])"!%90$;F\!-]; \-0&N')\'OJ'[$O;<_"H#*AXHU
M5?ALZ-2KF4HC'%YJI69D9\1MJS]BU0L?F%?D?35K?^"Q0@;N=EZ$8/11>*S$
M)\K_ VB=PF():,'SG\&RB2W: >4S<.Q!]O(H)0Z[=>\U0,$%7M12,:U:4NQ%
M*!"+\A#/Z@G,3;+9RVO!XQ,1?JN%,S.67\T9=[T;U?@GLLU',A5O.7J]\$SS
M>O<$+6Q?>YQC,U\YE/:)OL4#U_ $R3A7"-UGO'\J-C/56UR(>$3P>R?=V&7#
M;4+B\= @C9.!Z8!>X4MX[<U!W-G]SN"W)TZQ5[GK@MT&B[M+U2;E'GP&O0A(
M1@4?AK#.;6.TOH:?+&T%#%OV9O+P]GVX](2O<EI<G%"!0K^ ?L##_@2A?BLC
M=?WWW4(?X<VA#NJNQO;(.(UKOK:1)MG](J-G#D91ATK)#A?%KP>[VG/2CZ3:
MZ,.KB5 1F&[8CM:=$C/2/2PLG Q<@8"61P)\+WI6#ST2)MOR\.9(?@AFR0.L
M? "O$2<#=W*AOY,Z5NY-J@PU^T>EI%AI?S\8^G'"@?.KC]0Q$THNMJOA\*0-
MI"I'S!:%3@5GQJ*OQG62 <HV\0WNXLL)LMN^7VJ(HI>6+F&N?PS1E$7C@A^G
M53'7EW.=N9,!)7?+T!XHZZ6^][0%GG>'; B1R)UWDNZ8P\=$6\?H=GSB\;+6
M+3T_><Z#XY*<@E--5QN6$:<)-0]\5X\PUZ_R%RX5!W<.,_%8K3QIT=PY)S]-
M/M&(V\#D5Y?@](K:0JPKMWS!>/K8-37.7N\JK1]\9I![](H@@9A78\B@&N]'
M=0*V2T<BL1=*C5 ;=;AY=V%+5)GW;+FJ'RK67U&DCX^,RLLMCTRR=2RYD<MD
M_PCTDK& (-!KB% F(G$&7(-.&GFL,456KK(N\"0EAU@E[YB<F_<6'$L1$L3L
M7(0],> 3<;2K^OU^B..XNZUT5V&@O>U4^IMKPB5PAF?%ZG_F?^X4O>D:.1>Z
MC7Z0/!$]K$U/]\OHJ[KD&V(C =T)I4*H<U?CMAZ7N16^ZZ&^8?G=QTL5,&]I
M>&'BS_BIFNU&"</MBLS.N6LC"+?%0:C-+_3"N$*(%DUC34M]R/"@ ',D'0E7
MI3*B9P?CJC&\T_D_3D,*%X<^L V7[&J[.J)F6<BB?7^LW ].)=)=;^)=5BF?
M!_;D\V;E9?.:,1'O?2BS'<H>B!-@L&!:5Y#\4Y^NS_C0;482]+FC##95VCFA
MP72&TA!T;O*U>59>%^80L6W^V<1?8_E]S)$"Q7HZ'7;Q5#MY57MU2<-DL5FX
M8</FU>E=8NDS?%+GH/Z.5M,Y9FS;J79T<8SO/I.\EY<@K3<(<NG=5PP?E>*N
MT]N6RY\W4,(5YY#!SW?J*C=4(I)(HJ8W%"P^Q+TRLS=?'$=@5/0ZI#YGJ;G]
MUOE&Q45QM P^=L,9$*\ANY.BA*^,(\1.W%$XNE_N!2-#%02EC26J?UKVZN/;
M!F>\]KPT@=#\X?_X6_6_@**+9$$L<,&_Z91&6SLWS4?'66G#:3\LGG(W-^>8
M]C\SY@6\!N2 @ NM_I84(RR!QW1[1(?2C9[SS+H$%Y:7#"S17R+0HCT<5[";
MEZ3 :B/3#@GC=9PU56_"X9NZ"VT2"*%?H9+W;<4^338Y5A>JZA7"F]0[ZMJ_
M^O/:<>55L_+Q@FW'^ $"&< R]:I4O%EHIYHEZ57]\E452((X#ZM:S-=,3.#+
M"@U%=P<$G]OF"GV]J5P1]80XNV00XZU/!F@4A 1@PV6[#@39Z J'^J_M?ALT
MF1D%!<H+@^?E!H])2^47#74'+W11:*S&0Q!^1 :XI#QFF2R))7-8,\,GR_>Z
MDZ^OJF5<2@T;:>7^\6/^<4WDQ C]EMOGNX)/[H5Q*%)1/-,&*'X_H7O7=?K8
M^1:J.B./\&*.\M+HYM6<';V,9QQ8:RU='3<YB&?9IU*.VU3^<C;J>,RW>7Z$
MQZD!EHBV)B1%2[>P?+:4:XZPEMXO=]Q^\*/'SKU1&LYK>WK,X,+G+3<]0X*>
MWD3<QD_&JKVJF H,EJTA+M^#3XPTZ\!];]P__Y,=U^XE'?9=N9!T_2RG!OV&
MQ[!G,8F=F"/+VID@*,S7-M8V631=/$1]3].%C1G_&7^#5NZ.<*4-N# PSF0$
M^?+LU9WFUO?[UDX=_ED)$7D/>T2RL-O.J]=;*:X$5B<V6!Q9]#3A"].#<' 0
MVZ"#P(:2TIZ%Y9S@3B*?KD+,-D,""#K["938 B7H8@XKB9E+H*AV+K]>8D"1
M"\^6,XKEZKLI:WC&0D+UC%4EK?/'U:,;"\]9>L+0GT-5B#AH!)+F(&RQ>.ME
MK6_L_(/ASTDT;ML5?&Y;6AU3YN.5,Y<K4#A(!X8*85Z;.-]KPS&B]C 96>*F
M-7PUD S,>-^27=#T[#I\0/2P%8_,O#]LVH5U3ZCHP2F-[G=5"6STY]F'K0[I
M11_1&N:42%!](E[#29(!(81L?37A>>Q2=U9@Y@,"M6JH=E/4D7?=_':_W*5-
M$TUT&M2^/19[:[/Q]!K)<+SECAB,D6C:V]26G6M9=#+=PTF32%\]5O,A\Q>B
M>U]Q_Z@'-+4]BI-I:IK[@+L('R*=:?I3@5,TXWR<W9<'[7Z.)EI/?]P$?V.E
MZ/5Z?6LKE"Z0 \(0Z-,EO5@JF<W9=60X[S)1?VU%RE3"K&P5&OSXYT_S*CTY
M\2S@F&H1LD7AE$O$/"68=@N)= NK$5=+'WQ6$UI\+&8Y3]146 <"R^J%*N]M
M%MB8.#)WOPXV07U#1[=)$,&$0C<F&-&KC*1.5%_:>GC1.JMSEWM1Y^F,Y]/D
ML'RMIK=M>%F5%S+9+\B9U""]Z;;Y)^>A]%*DSC2BG)_FII)<ADCQ-\$LF<V%
MMKB!ADCE)69!T2^\[G27%HZH[9_0E!!DXZ#L!QL[7/-$\4[^P]2%TP2HP9LG
M$VK/RCK%H@S,EYVW<(EB#MH96MI053> E?<K>*MV024])TYVR[PBT,ZRKJ;]
M*R$I?"%[__2WR<-MBZ&_#SSOVPM>_2'XRO&UVM%%PJR!)9ZS3R'<:XG))>OS
M;-(("@\G'R><D,SPR]!)Q1_9&4974F*N5,9=#6:@4,0$VB,08V3 ^91%?Z='
MXXH'(S'$H9'@D5W8!__T2*U\P*&@JV;0V_3V+>:9=Z#*DZ&-1=A;=Q+#ET!I
MDOKS'.ZVL*T*WR^V[%U7;G=1\@BB;%J5RW8BR #]E@;83-O6%B?+_A>+8*>7
MWO(K?SA;T&(G8,C$\OL)0!-S>^<.1#10_C"BB7BPJ$<&>$GW"<B(?23EWV3=
M-@&\4Z1[?FH/NXWD5MA1[^+Y\#ND?XFIS$T O*6"Z4%S!B(?#:N)E,$S0L&3
M"A>/T\9!P(%%3^IY&)Z_CD[L[Z ?40B_9T8J8?LH&'N  I'X\>(1:CH^."&>
MCBS6](J9#!<_2745B0K!^KFKXW=7V]4FF0ABUJJ=D!JZKC-',O!#J4VRNAD?
MTJG_.J\1XEIOE-,HI_^/>L O.IX%V3B50S2H^XP5R6N&T/^E,,_*8M/5@W7+
M]_SD8O=!*>4?G9C9!ZX+A:R3QY%>YEF3/<H"'?.@%BJ:[4H[Q?G7BP3J7T1?
MBE+78D'/7JDRLR5XY8NA'P'7P\(;I30R8;1KR8$O=KKJLAPJLG-G.JXV3_WN
M_JK%/E9J^P2XR?#'%(3#3*$6R4 "@FD1S>B*5<ODMA&(E/!]M;:='WO2-7 G
MEF"5QP#^FB<J[#4(!&5NII]JP,\A1"8<DI5D8+G10#(JGIV3"2MU]?BB5VCV
M@TOSY6B*3O*];:FBR$N)FK[>H4/"XBF_7<1Q-U38FD]=9X4H9S;T9&9SGK<.
MJ9$!J9=[)+2\T-Y@\&JXVB4$^R>Q-,5!&.SA3$V Q6Q_0\.SVYU\2N'?[,*G
MU'8?^Z91=*Y#:$B@SRY*%F[HB'U,M?FW#$+0Q(#(IB9C<W:5V0)SBG=PEF13
M[FM&B?\/+) T\7%Z!)Z>=CK2G0P<CL6NRZ2^SK./3]B*8%5":PK9_&<L/F"0
MZPE=D";7$PJ82NB,,*?P9:+#HMM3R>]2BB 0L4MS;$LLWCY&8^)=\IBGB6-N
M+' B\Y_*?A!YZK\ 4$L#!!0    ( )F"$E4B4J[[,WD  "R0 P 8    8W9A
M8RTR,#(R,#8S,'AE>#DY9#(N:'1M[+UI=QK7MC;Z5^IZ9Y_7&:/  M3:V1E#
MEIOHQ-VU'.>^'PM80,5%%;L:R>37W]FMIAH04F0CY#KC[%A -:N9:_;SF;_\
M/YW.RW@6Q",U]G[[]/:--TY&Q5S%N3=*59##MU=A/O,^)8M%$'MO59J&4>0]
M3\/Q5'G>2;>WW]WKGAQV.K_^ H\ZDWN2^*EW_*1W_*2_U^][>T=/^[VG_7WO
MPUOO\1^?SGZFJU^\/_OT?S^\Y+=^^./YF_,S[U'GR9,_!V=/GKSX]()_@,?W
MO$]I$&=A'B9Q$#UY\O+=(^_1+,\73Y\\N;JZZEX-NDDZ??+IXY-9/H_VGT1)
MDJGN.!\_^O47_ ;^JX+QK[_,51YXHUF09BK_SZ,_/KWJ',,5>9A'ZM=?GNA_
M^=IA,E[^^LLXO/2R?!FI_SR:!^DTC#MYLG@ZV%ODS^#.)_!SY9JOG:MPG,^>
M]O;V_OUL$8S'83SM1&J2/SWH'A_;K])P.C/?)3RUIZF*@CR\5/ALYZFC2 7I
MTV&2SYY57]!TYT+?-TGBO#,)YF&T?/I_/H5SE7GOU)7W,9D'\?_Q^1OX-U-I
M./D_S^CJ+/Q;P:-A>KGZFG>"*)S&3T= #"I]Q@OP5.8^++WE2M%\ADDTAA_?
MGKX[??WR[<MWG_[G7\?]WM&S"^_%^<79'Q<7Y^_?>:?O7L#_3M_\WXOS"^_]
MJU^>#&$E%]]CW![^K]?G/ZZ;Q*OS=Z?OSLY/WWAG[]^]./^DA_[QY<4?;S[A
MR+WW'UY^/,4?+K[%),)X#!-XVCN&+];,(2R]D?Y^&N:P B/X]=-,>9,DBI(K
M(#IO'&:C(LN 8+P@'L/_@FB9A9F73+RD2+U)& ,;"(/(&R7QF B+KDM55D0Y
M7[90:8 _9-XB32[#,4PKC"=).J=OO7P6Y-Z5\H8J"M6E\O($_H0'1.HR (X"
M'X&'!%FFLHQ8##Z^@'FF60Y_XAAE+,WOQ,N;1@D#@%<K#ZX,DW'FP;!&:3A4
MXZ[W:083=":>S9(B&O.H@C$,'A_S5Q&/Z$'$ZO#]11P4\'"%5P 1A7-ZFXHS
M^ ;^RI(H'!.CL\.!*>0*9\7CQ/'$20X+!+/&#TU7^M[5+!S-O"!5\*)15(SI
MC7 ]C/JC6B1ICDOP*DF!-F/O0QI>PJW>>985*@4FB[_,_^=?O<.]9X>=W[O>
M.:SNF!?%YX>XNR-S#Z(L6;L .%KW/K@@#\*8AX:K<QK'!<Q##] =1G^O\TKO
M!W^S!.[EJ1AG]D*-U'RH4OYAT/,]$ _PWTD8:3F#[[Y0HR*%22A>R9=?@6?'
M(&W.DOD\Y&V$_S]=@"22EQ[3D_J^)X10&J O2XODA3^6]B_@*YNWD>B/B$Z>
M>^U<]-:'J1>,1LD<9.82W\N48+88KH =C;N_/ GODF^L81-XY6I.T<3_DO0J
M2,>=-TGR!6=P8=;EER=X^9;XW:=;G0Q-PID'M^=)&HY@IUT2ETVF&4<R8X<2
MD#3I6"IOKH)8&!5R5_UBAV;?P#]3?NQ'A:_P3D<TV-[)R0%3.;"WA1KEFC4,
MBPR.5Y;Y-^3!\.FL2-7G8.2]ZW[NTH"NDA0X( K>_MXS8+KA*%S  'WZIO=,
M_R(<NOKU"#E$]4OU%0=;_9:Y2?7;113$U>^0A<;UIV9Y"*NO]-<X3?T0."TP
M\B#RW1^S$*@+S]_7!2Q'QA*!&&?.1Q)6,T0:"B?+-9O9]2X*8+G.[J9J$M%N
M(',HTA0ETV6HKF _0%85\X65/KP4*Y:_NK63(H>?/5AF+11PN%DQ_$LN2,/L
M2R9"<*12I%"DH*[W%MB&-PE&0*J91WOBC8(B4S1$^!I9EI"$CU*/"!D>@?PO
M&,UP9WEJU2&R0,9E3V%YHR6(QLE$T8PG:3+WZ+T\[(V>3P)_'BSQJ;(OJ/VG
M7CA? (&!H%W"A&&Y5^\',6U+]\ZI=!@W[,0\P5.'G!-O 2D4#,,HS)<XIV2(
M:P<C9R4"V35>X1R5&-AUE@4I78Z,.5)P:B=%B@\$A>%21<G"Z"1PP5RE.)[P
M;S[)HI> UC,N8/-&J*Z@!,E\$9=P5F700-8T8KAVFM*I-DO)S\YR1\T!B8(*
M /S@#H+N#>9,''BEIDMB5+Q!L-JC"%X\(JD%RR3RTGR9XQYGKO@K$?T4]D/+
M1!XS#LO.1*\$+I4L@7X-BD-ZN#"GB&0I#&@1P((GL,K AK[XCE+FC8$]PAM8
MW\'O'99&(^#G7:%U.53P6B#TRP ._#!29A6N72^_,AM]8YU6\)<Y'CC\ (M1
M1#SP8(&:+:H$0D2KMEP_$A^$HX8W(@_76PL" \@=U@,N&8$*'@P36IJ,"1 .
M>ERHU1."0QY>LCQAXPXW*EDQ($M7P*\2(%MCMH_PU$:1H6$XQ07R%:0?XJG%
M8@%<( !"%;H0,4=,B_9&I;"8I4.PX2ZHKWB$@&D!#\#/SV&16"+_3S!?///>
M@@B*QX'WFJ;P*H'#:UZ#@Q^GP17R.=1*])'7I\%=4#$RZWOLFPWV89@3138/
M\'#D,,C+X$$H.R)D_LA18?A K/ $^"-7(V-:R**#OJERY""\VGH$8'8WTH@V
M K(1/)4.#_)!^VA>I!25!UY'W />H_2+0@H8J47.7+?$?.KLSV57:B71AA,A
M;C4N/T&/U(A=?":,%CGFI$ IX9(-WCE.BRD*LHS&E\D$(E@*6)Y+!6<\@F]Q
M[5PF!0+,IR\K'(JW%8ZD!^)]"NPX@]\47VEFQG>7YC!5,?#WR -N$2?S< 0L
M%_3Z')^,&SY'8ES 6.CY6L>RBI6A]3]BLO1(PQ63HT!2@,%&!9*&N1J$4V1Y
MH]*&21JP=F_NJ^P/"D,Z7O3#-$VN<E1 \+;ILFDW%TJH @>+^XB7F!G(L%D,
MU&Y7<0JTZ8'2%]*!UA1<$PO$Q)C%\LU 9O^%<Q!.4'##2<B2.%:1(0_G':DB
MMLD4K2_T73;JL 5A3[14S6ONR\+)E(L8AHA2IL@S4.AP7/*[8\@%7U&-R1NU
M 2!#$B"DT,U SU'TZD62L4:"WY^]_WS^HM,[@84"Y1&H1ROC9LDGY54G(B5M
MX3( B59D\DG4-#3E%7T!ZB1J5"-6A,#R<[^YM7'O6UTK )5-:*+!7O"]*/QO
M$8[UR6XT';K>Y](D5FBB[NNT'HD7A:1 -#P7-6;K?O%(M.)$,['Q8?'U<VYB
M[I-N"E*=/$KXKZO4X&!*!G_7O&.<P$-Q!TB/5Z3>)L-(FV?PL&*!W!''D:EU
M1L-VK-T_XHA4"MRC*Q2E<!N<X9Q)2Z@5G^=<DBK8_90D4!19TLMN3WJX3F*9
MR<)JLTP&H7]D?T?5T+NJ69E N0U?94W?J>A2U7XH,F< VBQ$127C^>* *V;/
ME,\F$1T2# HO.",!,IJ[W-R[=,&\!SZ&=NA6'2Y_*K): V\:)4,X8L,P6<P"
ML-!&JB!1ZXF;2[-\/#@!V%M7('$"UH=S#-^(67>)+A0@8F2JWC @<S&&K\!P
MC*?$B89)7(#^@')[%(Z9[<V"K*ZB@%A%38!^0-V#WK50"0C;KO<>N.-E2-PC
MS%AF7291@><>E20]!F;K"Q73B /0>@O17)SI(.D$"V10P+]4#":)MILP3(0/
MGP=?%-%5<A63=H1&_,HYD<D[__CN%#26*%@"W_,P6(&Z#,AN14Y94$L+)&M8
M[RB9+K7<%,5.U&32)D/6310I7[ ..#:\O>O)WM%]<(<"8>FQV+:J'>PEBC>\
M"4=$W!MX KM30'LC.P#T'E9:Q;<-3!@#?>A85["%M"YS.(<C8INS FC0#!QU
MR66,#!;7'<>";TC)7N31\V:!6CR+^198E)P<9Z%#(@'(?- .R6F+*F" =B0(
M^P5:>[BC,'KR[>8I*LE,-\#YDC&J2NS?9B6?EXQ_#XDMA"CRD<CUT,+YO(C)
M/%O $\GO 8(L J(G2V)$=(R;&/+2F:<6F7$S*S1WR#3!50>5)LY0R\"S($KD
M''TIH,,N>06TC:^5=V33$]!H$^TXSJP2A]O@ZM:N,3A*$SAW<Y#.(1P%O4E:
M=FA=%BV:V3)"0W,$*LV(3B10)JP8;0(9R$"-(R)#/@+++<G!\Y7#O1+V-+Y$
M/0B-?EC(#"V"<8?M UYI) XQ3\':15<P&$=)"B1Q&::@!CV^./UXT3E+/G?Z
M/[.K#K1ZU$+()<+47V26X!WU VR"0L5_!QQ+,6:ACJ:\CH*OR<4<_OP]0H;S
MG,X%;EKF79P2*WA]\3LO;"VB7(K]4@ :_LZ3^=/^47=P &OC1(._?>RWOR];
ML]<LU9#?LAK^=!:.86/A CP">X-GK@SC6?)_9ZF^>1B,OH!I5,#&(06F3_^U
M1__WS%F#\@\SEI9 )L]P93OR>:^R5 ,KE]U0O'SC1N*K,?Y%,%6=(7"Z+YU@
M NOP-(BN@%W+HA\?=_O[_WX&NSU6J83E]RJQ^X>6$;!ID$953@)&'VN'TIA@
M<IQ=)L9'Y^)W[RK(M$^2#0HW[D?10SJMX5R$/+NF?"V^Q<]GW1<Q3J/*&30_
M$1&C67@"FQ*BT+#,@<QV=!_"$('!X[]@(>!"3,DN#"C"4%\ >*N*QYGC+$83
M/<UA'-DL7" ? VLC-8X[G#J\YG^+:&GFNJ?#Q9-D5" 32F*1I]8%!^P*%1GM
M*K+B<PU?Q),'"@I[7&Q @-?"NAM"%8U7L4-TV='0+#?$C</ >T16M^AODS#-
M<D<2\5*)(C>^=H DLU$I4+C>1>88U.7EGH!V KN=69U!] 21?ZZ2H]5(E-&!
MT;OHQ; EKH_,$=VX5" #4D7KR]X@"4.)+N#$J6B6J$64QF!T673 8HX&/13H
M"P,=],0@A9\JJ@C(]]S#B\>PKB:!@"+]-@Q&(7[T[:*AUT BI!M<!A%%N@SM
M)[):'BJ[8WAUML < 5QJYZ@RC;L'  R H781FZ=I(6OI"00M$+TFF2UI$F>?
M^W".A:OD=$JJU F*'K*1.&=K1?Q ?R4A"KKKF9AH&4S9-<Z&.P7641)W1C/T
M.M'NSY,Q.]W8)B"E5?,@&,NDX-05)L:_,>L$5/<.>K70C[@(ORA#=!)-:>)<
MI.B0 W9>1"9$ />\"6&[O7=!G"!'(M\MJ25OWGU W3SVW@;"A'H#G;*!>E<<
M)P4YM>A8RLKB_#!D@P>+M>H92#8O0@*4?(H\A/5S+1D*Q^!_+T/8$ECDO%BX
M!.:<":3ZSE@M%.UV_7#@HVJ1,;*>8+\R?1!A)X!! 5E*? O/!?.2_\7'\12'
MR]*#Z)Y% ;9?-N-KWQ&/(3]5$1O5&AW/,3EW*1191)$;3T '&"^4CF40T;D4
M5:>9L\\QW.&S&RQ2L-R1-<DX,DRN-6>SR2]/%J4(K.?!Y8<@[VF7S7/,A93#
M[#U^WNV!.MG[F9>/^!P,"!3M>8)19Z!/=.]JAB:4R6;>Z=G+/JP_QBJ2E#.0
M*!"8XG%!P8N^P$7N4 OF[A33(LN%I@XU3;':C9X9]=\"=U<6F!:=EQ?(*ROX
M&>^ 9]L$G-ZQ0YDZK"OG6(WK&QG&EYB ,.5=JO-82WQB=>=B]*G)!)XR(F^Y
M)OF8?2!IF+%34>^7YH'.OAAW--Z%;(!7$98+@_*B.A#-^MH3K<8K+(L7 6XK
MJ,RH[[Q]X7L?9MT771]'!ML[\\ZS-%"1]T(%\"3T([Y%IP>LP!EI];YDXF%*
MVS).P-:#34&;-/@O^D"8#&THL=>'E3[N/:.XJMC-EFDF3=I%C9*[.#!X-8<W
M3;0OC&,=!@O&P8+6N;8ER+(E]T!&Q,NOP^MLBWF3(,O)":\M=_A/[A,3P@&'
M&#'0;&B8F* YLQBX8@['-UUZS^G;3V3%NZ-E<0=[S8*V\0";Z?I""5WO-WZ]
MO'0).EJ!AS/\FYPUP2(8H9*!4TR ^M/*%+5)'WC#- G&UC+5TKB:XH:GVX>-
MCX#2<1YO@OEP'#@*Z@N.QEMJ--[X-9(CB(%(HSIE:)F*_'2"!IRDF0QYK^7P
MJ'%IY7AEK'ZJ)MJM0M:-CGOBD-A"%S4T*N(I;UD<9*1$9QF8:3"G4] M4HQ4
M.(?1'E(::> !(^$L3E?O;SZ+3'$BR[(9J%PDYTI;9S94Y-L<=)L"9VBS;DD"
MZ"43@M<K28.2LU0Z7S)H3+?Q!GOZ!\J2#5*6@GIUFF=$FX%$'RUE/7 F7>^5
M&1>'/*J,L2;9Q2ZA40.#04=2KQ)++%%!@NH"6&"2%[G'F9G,U_3M),051GDE
M,95EM-;K+=^#Y;:"/,R=\&'WHLN1J$QRLIBJ)/@)Z@-\Z/?VO)D*HGP&"O:8
M@E5X">B]A<1\O"R8J'R)+ 2C>"3SM+9/#,A^56+WI%+C'IB3:#8/WZLW;$LZ
M[I\V6Y&UUHIJ:BQ,WFRT%8SQDJSPQ&)<>H7"6G*Z)HXI@_34&:=PIM'ZCY1Q
M6Y/G7&6Y*QC^O"79!8WC6J.GEXY)B57O'>SU?*N>>*)3 /'R;QYF]H43>9<V
MCW&L[V$ *0D\8K".%-<)39L2-8?E_X"M.2U(?PL#FTKR80;Z_V+!]M4UQ-\[
M-L3OF\EW'-9]%R<"M#4XL!'&01(2NYHQR8(U'I6>>U8.S%GQ3B5S'3D1WB L
M=:B0GNQ-I"4,T6 W]YH,1)G(&/-$Q/R5'$2:5=,L2!L,<F&'SHM!5]&RJ9*N
MAHXW0Y.2$N>OH'!)GF0QK_7Y"?%U1]%=A)=);HP5^ID<VLK)YG-->$U4\V"L
MC'\F0:T7,SA2W GD28;QZN?SN9'5*GG5K"97?L# EV2U*;D.8K>60O)=;>I<
MD<\2CN3#D;&^/*V.!^.QMA],24C=L<"N&ZW)9,%<7>L6P@B !$^B)<<VK%3+
M4<^/IV3(NK[#GJX9$"N[;!_HC/_K7HTZ@F&>0&B![.%UNCL^^U4*K"H-1[/.
MFP34GTBEG7/@I&%>Y+Y68AJ-DWB\RB(!TS,1OPXE/6DG3]G+:1P,9 7"A4]@
MMJPM6HV2U"!8KN4ZHU!LMC]#Y-9H8O/76Q)\L,/O@6E9H["_PEVA=/85S&8,
M/#V3;!"==MBLUZ_V5_ME$YVRI70>*?R#T5:[[9S+1,64.@Y^"F\9+<GI\O+M
MJ:^#K.3GI;&L\C*M< &OH-H&/_N*F-7%[\PXS.*0+ARQS]3,!"/J%&X>+V/8
MW9%)YC4Y5<8,RQ/,K/&F5!^:@A*MN*H&C"UE?83,CC2=\A!0IE$R3C'4Z4!V
M*=^>LM$D1@L1J\/57JEA"NS,NM![I*&0V2M;9D*TY D*R>Z@YVMEF[,!]-+I
MP^:[(J62$$%)=/A3QKX0RLA!22^,GS(A(I/GR5Q3\LR!;"+C&W]#:P7S8"+6
M,^84>9AA(5'L$"0"%0E@JA/K3:G"S!'K1*1BO;&VNMB7!3P,+2>0!1/<!187
MISAH%G9T;'29AGCY:-N#- I)N(%1&E)^MB9V$OWT"AX0I>&)>&&BK NHYTOV
MX'->UY6R.HU#I^9<K?8RZ"/!QJ?.ON<E2)-B.FN4I2"ID$!)#D=+WPR?Z#VS
M+$&2T(*5]'AQ%6)5XQCS4.'O_&^51C!^0U]:.B[UH:"5TW*F0@6<FHWI/YG5
M*-)@023F) *OCXQQU@O004FS,_)B#>G:?6PFXB;:;4/8;0C[P82P3T'!KE77
MT#F_WMWG>[/@4H<6<JUP@)D*%A?:IBPXV$/406N-ID&R(=(Z.D=BPH6.M2W$
MVRKE9:CWR86@""9 5,@,NDKL1S9.^L,G ^_Q;R\_GKYY\;,-A#BYUF_0_>V=
MSA561'J/2]RD7."*X6>=&,-/']@GLITY0C4<ZWXDS>RUPJ*QY?6/!1&0D,"5
M&B9X#!6%4W:SZ..Z6+V+R:ISK,*@KT7?:)JO^ AP[=R@#:H4;U#*Y]ZY#62_
M,('L:F"A+R&O+:FTKTAC<(W-Y>JUQ>"5LZZ^N;,?V%L_J+2@C?P :SJO[OJ%
M6N35_?%7[7N)2+G>* &%;HC)YR$KE\]5- V+>>4M%4GU,Q&^+HRL'@PZ3$.E
M8N=$;70BNMX+H1&*+G(=OXMZ8$FG)_<Z2UNCG#]#///>%^0*>)J]/Q/X;PQ_
MPA[GM;#6GM"-=['>]U FX:#JY&K8,1Q9L8B20*+]E$1_\?&=C;M1"($2N?5Q
M\_1X6.J[\_K,^M-3[__#&S#CQ.MIQ]>[1F<WGT@);I'V4HTV:H_5T TSD@!"
M4Q)+XQQ74>QX5<G>EZ.++NP%^I6,$P8LIH]?08@T3%2K^EY_GP>_<J*9\5%[
M_0.9Z'8.]P?4SH#]8 *(L4XU&V0UUAX;<;*S@+'A'G/$*X3CL_5(*9%QE? P
M42 :DTN&G%KL3Z.=9!_=X8$%;\CPVE+L9@E#G3IW$W>81 5H/9U@/,?SD:>.
M:Y_2G&-)MRE-JIR8_SQ8PI^GKQTCC5Z;BTHF\1),A)!=1:Y-'D/CV^!< I[=
M(ED4D53E<K2?RR'5>$L;_LG,BP]'K"9ASBY%]I\Z<:*L;HN4(4(P\^"R\QSO
ME!-#9D62VB*G/V(LR<M$H[](0%T/YHL<UP-=S"9W2!RG9-9@'CG&B"L>!][F
M!@\"#*X\>C3<7V)VMB,>5HT8$P?"2SK@JOH8[W@?'2)'>\!OEIG#Y_&X$"N!
M)R[+:E:8BM]J60JYL</@*N&D*2> ?9;,PQ0N6N*;/@=?_T:3*V#'0VUU)3^O
M*FA[.CS;.Z[X\[G&[7=8UC'5UC/3&U.!&DJ\OG]\=-P@14LL4E8#4RLX;5![
MHHU)7!TH,\X52D]24\&VJM]@WKOV3CM:'$\$56+-\71ZH9P \CA\)<\$D,/^
MG@_65&DE?:D\<R!\K.@O<G1,9$Z4-C"IB=5KG?2GODDR,6'K@Q/@@G\5NBK+
MG)I1H#VU@79\-#W:$I)-@S'/[@WVUSU<J*R(T7FMQISH8NK!)I0G".P1EGM@
MO>NC,!T54D_NH)J83!#6[2SCY"A%WJQV2X3KSE1L[ST?#,/Y;"X5;GG-"8?C
MV#_^MU%%S +ID@=2_9;,TX )4GH2I2YQ8%S<ED9!4?%EF"8QNH78CF);0H=-
M5*YC!1((Q/7B6AIOE(:$J4$T:STL,K!LB5P7RY]&=I"5P1F@H=K=Z%+')0"K
MOD-7V^I5J;><:'0FG:R$^J^$?F3?'*^/D)\Y2SW@0P>],A_2_)KW 9T:G$H-
MU_9[)K!'%3'#A'_G]R$^CB2Q, $Q_H//[!/)KB>Z!7%UT0G+2H,F+SXWR 5]
MHK+]XV[?WMO5"EU]Q5:NL7[*O_4,-"M>O4R9HM-DTV$Z<4 U_R5F@VMST.\>
MR(.1<8,J!>MU3 [ WK/#/4>C6C/T-9M-HS_:ZQ[]VPP;7WMT)/,I^PS6O?T3
MXD^QG,B3Q)M@QGCMYL->20=,1:FZFB7:?^KR)!/Y#S1$TJ2(C/>81*Z>JD[9
M1EV3*6<[LD=.]U60E<-U0,!EIFKB'.C0S4;!0C+1!3@HTX7F\91CF\:'BM]+
MW62MWMP761_K/'+""2O(6"O1FY-S/6:5WP;*G>IV,00==#TTKE:76(!A2E[O
MD9L.:R%7D!/U4 -#-_U120X9\<.UENM)[70(TM8[V/LW/FFDBP7,N 11SE%<
M;#JKF3?>F6!=.NBM SAB:ZXC(0M41XR1"E"93\-E?_[VOMG#H5-/::2#VN.O
MPFC<R9>(ZV "3ZE":!'B9KU_.]=:@ #.LSN-@!=@Z.%*CEL2H_8J264F\:(F
MV!SCFE1 F> -#KE?REK0=>,VB*-?.0L<9"U^?>BD[Y]&BUG@>Z^#^5P246JY
MA 16%:LKF!B5PI 6D3+:&KIN,'7.$+F2,@H*G;!5QX_5,4"I5&_.LA-4G.KZ
MZ-?-T0$-;,@U(O22?BL> VK+X;7%4*Q;8HKAZ@/IJF.4YJF:4FKKQ3<VJXL3
M(9RZY97!72J)IDHD7:U3<F)?_+_GF+U<C<LV5(VX22TF;\-4GJXK<ZADC4FM
M0#W703;:8HA*VA6<]0E!T9CZ$CL9H0=*^2B'@,4+UM\LS7%%GF*L'7&.V7R+
M9$)<97R8)"ON5Y(5&_6Q<B;5P$TZ/#:)5*#D4J6IX5:TWFZ*@,:>,;5".67C
MK=HJ%WU/Q S7:(B(6Y6=X)= 0Y#NB"'0&V^Y^&MR_NS^-^1GO(H*[^(S34?*
M\\H5.4[BC).4>'W2:CV]#W;J#,AC#.SR8D'84SAY\8/[U^?MG1ROHX-_E*[W
MZLT?>A&NSV(]V#<$Q7D(L$=3U9R/5IV0'F%0XAF42"HDXVP-6_:,<L@C@;'1
MN.1D[)D\/Q%T;/<N, (0 5GF^J'.9&1ZMKP'E7O>,KG8T(UC5E>20=N(=AO1
M?C 1[>=JF4A4!CFQH7ID%1I)K4&[*"D0#+6%)=0V0;4)F,$1 )^/0-[Z-KG?
MFHX,#U>[63)@M-P/AIQ.2L\A7FU2,)W*YEI0OEPRS# @K//P$Z6H9!HM1XG4
M3OK>Q]/GGSNO:R623062.JQ7Y;S^2G%/X^>Z4UUZ)N;FJOQV@WRS*I.@'"G=
M)(.@%" E3>%_@[B<(4>JD?7G<38LNIIQG<O14CLOJJ\L[U0LI;4K"KJHKI,L
M S";^-Z.SJ_GS>DTV0!DFYAHU9])"D+C-Q*7WOMT&L0Z@RJ?P8MF230FVQYA
MY%(3?K*YL[X-)+C>)MH5&Y%&]PX;3;#:J"CU_N=?)P>'DHO>UQ]*N>-_BIJ#
M4W1SY^0);H+[X^;'(9'_S$:C'$]0=J@H,4\B<A&-#<*/37YF\]_D_06Y@=YU
MTLJIHINV:7MX+AIGALDM"BC_=EB$"%#O>I L" Z! U+^**PB,&<$_/)0TR!;
M&N$R>5DTP.+0,CSTY6A\4D%0;,23Z7HOK/6$. H&#<=-F<VHB0C<"<OPM]07
MB'8\EPI+QR\3:.3(*FA""9C7% ^0)X)\RJ&%991;.L8*DB+J#(O%9[*C\EU'
MGSPY<+9X4?**0:A-57-F>623V*GBFAYE7++%/$D[7QCJ5DHCT9<8?&&G% Y,
MPL>RWDV%1"(W,,&<&!2"+0#=;@)/$<9EJ=6XIF(%NZ:9AH  %17;R AT-[=Y
M"/];B'VD0:4D%:LAJYJBQS;*:240,ALWI7P!:Q2DV5,Z7#EY>U@A^<^CO4>T
M;J)@F,\95H#*9ZUZL0I#\G>1J:?ZCV=W@$^GM3#G&]2OZ!3C<#M1L$R*_.DD
M_*K&KCK+@])-8/(4_C?6 Y;+CJ4Y3CYV?_Q'@[Y4*:6GBOY+C ;&^PPLAUQU
M<.W4TSBY2H/%,V<0LL8R6%3FRT,J_UZ'Y[OM:!ULOY@RO4O8?O+5HU\_!]2#
M0I]Y%QO$8(]2M2]1IW.4#/H9DJE4*"/?X80*/*04!02;TNCW./$GN%M/:'M;
MHKPG1-F_;T3Y' 5PAST[ ?"QA2)/4HWYN?+08B9IJ80A4I"#N4WX(7T8=,RC
MP3.N(1+\.H%G0!Z*A,OU*/PF#6#<$O$])^+!?2-B74C*<2,TG9CRM!O(%C5K
MIAJ*T#= 5!JD!JL=,=8*:NKE>GZM#P8C2Y62[VHH$JM)NKGA'&K.MN'<-K+6
M!-R=E9TP<\#+M;[U=1$E*6?2&'>B16NURE4)N1D1M^C@D[5+"),,[0!K'M7T
M+<MH8I487D,Z+4D]I_F!_O6;V3='W>.#:Q.;(NRP53<AT"MRW!.O2" D^I7J
M]JB:NH.K2P6E%$#A4DU"AF)7*;H$*!]:8Y^.&8+V*P.AEK%5#*"9QNB1FC$^
M+9@$H] 8%G0N-!@36E;R,;I8IF"H$MX[0N(D"#^%L%/ZH=X1%2]^>O/QR&_Z
M^5C_?.P+*#GL8Z(A?LG,H'(HU/V]<[KXX_GKSCD-"-U[/_L.P&P@H[482+J)
M"-)!5Y875]?%>8/!I$68BX65,^2U-II$%FGLW$Q;_%3Q1''EO^15#(N;D7W#
M9*<I$:TS,@DX,X\U,7H8W"/VDO&[IQ(_CI;SQ0QV8ZRD69T+"X<$Q* *I3UE
M2\QX2^31QI,.MC1:::41R'1X&ABA#9$.AT4NT1C"\LW1M$2:,Y?Q(R(E5A,:
MN'D UV7LZ='+;/T/[.1S"O'7^+>HM$P !(*IKEEF-*5A*743E[CS 0P_UPVD
MK32"(M8V&L4$,5A/-A[U>1/5@GS>O6<=^7=4P&P5VHYS%05Q0N%M.-M).!XM
M,W0*C((4^ []D/VW"+#JF1FY^8%>\46'>-9<A#U%F;&IT1>B[M_>79R=H;LA
M#T+&17/J26U^FP8#<J(U;@P*G2,N^=LL"I/\"#O[\N+M>TFP.Z57.>FKI@??
MP;%M&4%/X*A4^=V>^^X 6^L-!B9SGWD7;^0HF2'T(#FT#IQ@C-E6N6#E[NJA
MFIH V*]D,O&8?S:]4JBQ.DQ^$<DILYKH3)#)FH"B;@EE_9,H5ZX29U7X2G);
M<!JN7#@:)=))*?$^OCP[O_CD];J]:C?&*X2RMT_#>%D:<E.(@+$B+&;5A,#^
M+':S25RD5:I/L;JN/DV1+D[5)*4.%4M#Z&;NY3'<=F+D_+CEO+8GGFL <GL&
MAHY9Y07H$ERGEWKG9+]H#07=WJ2:F'Z3%^>?SM#HE@R6$@B=08>@\FT\BM)S
M0J=_T049NLC=VB3QS57QQ\B>(E@MVS=5PID$#EE*H)1G9,#/E(6]YH-B>;R#
M=5?G_5*$3U$ \643=PHYC2"<ZSSAQE?6_*0L@QRG(N5KP;*A5HVI1B("S)=3
M3#S"5#6.B) XPA8$6:B+PC&UZ3(<%X'3\Z:4-VPSCT!?"",WR93DZ 2M!\>E
MJ;D+8?ITG)Q@JP=LL&I4TNCDP68E/-;9<H'DE(6BC44)=Z3\JZS/4*">:*\S
M3\:,LX*KDUC!Z4IH$OT&RY[WP 5AB 3-E4!OV3F<Y\'HBR$-0K:Q4XS'C7/;
MVJ$];T)TH,/F5!3-E'7T:D=:N7Z2&[!-PG1>2J'@L(J#]UN&>B3I EL5>(>8
MD&!C/KZ$CR)>).+.$FAR$7YUO-31B*HU6WS6[.@7DA13KU.T$4$6TYR%48$_
M,>5^88P)K+ Q^WL-P4%):^SMV?-SC4@?U"^]5K8CS@)8UVHFO,[&%?.5<S:X
M<":Y9#W649NNT:9K[$RZQK6)HP+C1XU,M0_!3=Q;&RP5'/B57EM642A_@+1<
MZZ!A)L09JR;4(/5!6=7DS6:!E!O:/,R*_W95- VT^0Y\W<EF*JK%U@1!CT/R
M9A0H+<%<2E);]^Q(?QZ:24RT:BXEFE"7NH#ALT61@Y<DFB^SZ"N[J0P8=-])
M9!Q1=ZVQ]RI%JX3U0*JG$' 63!; :A+R+NC62 S8SVULM!R ]4L(,XF!NA+3
M^!8?X;8RII')0G.'-@I:EGQ@7(!8VP,RA'DM:>!,V$Y6'++6,!/LW!GA>I$"
MGX<LQ,P@N/B3NZ9C['P>9E5'W$2:&JTF.B$M!"]*5R\@^UPX4R8HIH54?V5F
M#T[G6"8Z#KBDDC(P*XU\=1V4:=E)+_N0)L;WZ_K2Z.)28RDS:PG!P2:JB,^4
MG2\I;M-$YQD J6*O)*[+J#HH.;N1H^H$4L4J*:>$A%]4%,Z2A+HK..G;4J7F
M(.-6':(X N/*(KV2$&R;]?Z1V"RBY"&9NH>"G-JE,SG'FNUTJXGS+M5B NM*
MFF%6EG'J@H3A#=<L-=J@0G/.QNUP!%^?TOGRW<OW?AFI_&VPM"@!WA\$2\)U
M\M(Q5]:3GT'92>&\1$/&3><<E"(VD 99D4X"P3KF$-@*?LD^\;DU"7+=E:S+
MZAX-WX/EP/UL (LF@S%:(F4)[^%2"3%/W#%3;GY #CW=W<373OF(9(&#Y)\Q
MV7(-(C-AX3OGL 'I(A$H?)1',!CRX,Y5/DO&.O1B$RF,Q])$8 0^+Q3\?]N:
M@<#@2VG'3A,-%XO3#-/DPQ,8.#6  BM@K 1J6I=RDK@P[*"&([G-XR <(5O&
MN"GDI2S%L-8>$>J$0S0B 1N[<#9WRFGP2*AE=<T#\X-&>DMJ-%'1#[C[SI=2
M&H[9G.P;[ X[RJ@?#!5"FP 5=A(.<YDP@1(##\2<?]V!PLQTR&C>:4#5?)_$
M#/^0DE?B%[#BRTT<<3>/N@<-P=1D0;I[[V@?5'>X[U>_MKQ!067!9,>-L>13
ME=H546J8="VDF;]^^Z$S31'UM8SH*5Z@-.!(IVPYRUM--()G2,Q>1,/* T0=
M8.BI<O<D D6!H/XJ'8,Y.R7Q,I!HTD51E^B8GCG,OZW6H+NQ5=N8$QBD<2^1
MG-1->6F?T5\N\1PZY1C ZG"S:# %@2+RT'1G-PMKERPI\D5!O/0N-[4:9J)F
MDFXCR9*4Q:EKL2,ZFF'C6P--;4(A>)ZH&=(?C/ <_AN!83C7'4 4=P"FCD/:
M*ZG[Q+,>TM_K[5=JSXS$1$;__+PW..P=[Y]XCQ<6!.?L\PF\_&<F6[?Q_%"-
MD*M93:C>_^-(8PC@O9&:HM_&9*';R+&1QBLKS=@IV!!+]B:IAHFD^FMG,>)*
ME "]9D2=+,NP9X%1OX BWEV<O3GS&>N3#J_&JTF3'#:<.W$9SZI-_=)*J]0=
MV]JIW'0#</+$7/U!?-J8)HZ-$L29]*3J@,*9T.!H;*0JV)T*)%AM_#S:'TY0
M%M.$V._SBC*T(CD9(]>B=#"\=*'HX96><6C[5K+?3/*&41IH_IV$-5?T'KUY
M]T&.F+.,VSI>((^J731#,;]MDKT+/\WHRM*DQN.TBTD(NAQC-M ^_B\L3,P)
M^+\I(#W3(M9%(./C\$'CH+(R5'U>YF9-&!&,_+*@&B^Q4RB&B2\:+8'6J)=M
MH%N?>_OLNI>XYBOSD2P1=$E@6-G@A)-8^**6^FXS20PM#Q-8D;D)=]D5$API
M"N_BPNL&4 X6M8D7ZM(5QC>@C'&9&PD>@WZ-8Y5J0!M#=IM^8"$YBB2Z4*?K
M:U&K*.U[&E-# ")O,- I\9JG$\9_%=C9]5,)*&437/"/+Y^??_ST6^>C-#.4
M?CV<[VE[T%&_<YTL?:D,G#2-\(5"HT?;#J\#-#WI*<)('++!RU_&XV0$[%Z^
M86[Q&UI".!7=-^AB!%9JY-L?'@M8'K#L\URC#+N]U&JXZN7N6,23'&!;03^N
M:!=<O3.6;9 C4(KZ5ZB:+.XP36?X:5M-.-P((*I8E#C"]%PIJEE!!K#:2.:9
M]W()-*%I02/$WVGL]"Z[EO\.1_L5'>W,.V6!#3N-Z5 ?;0N%]PMM=VZ[N?E0
M1=A2RE;HS!%(RSG8PJ<0JD9/!C?-Z0>1F,EH3)VGWWAO3CAP<9OM,83$7,*J
M""^_(K&I[6X(DHD^_FA4N)W*I84Y07 /L3]+-3'>UIA@'9=X K61=ZF:+ Y=
MOIT[2$DBE\K;/2FH%9V4%CDO8 QQ&K?3E5S$$.>.5B^GU,CZ6(Q"4YT7Y5OR
M0+F"T@:W*4TFHP9P5YBB0PCP7V*PXJYF JRHS"1-+RMW56V?W*7!%2^709&)
MWS!>0@1/%2=QV>/"Y8UZGO [+!^">I# 0-=X@M5;J/00,!0);4)^9["T$0I<
M'02DJB#M> C+ZJ*X%3*@A$#@K_2+,PLQ!%*"JN08D1EQF<A:$0-?T1O<)D?2
MFS=:ZN8+<:6W>,-": PU5)5D;V_;6;T-7K;!RUT(7FZ GJY;@=3/"QJ%S- 0
MZ,'R168!5W)8092BX3BV01YS].F<CI W.'PG=06;RVU'(-#%$U/I"ZN;/Y:-
M8*[>U4H;J@4B[YL?KT1NFC&*?N8H$\60O.DZ\4)S-G,GMJUD^<(\,6.CR(5P
MT6%*RDMQTUN:(JN-; J;/BK=L])Z?"G-!6PT8JY:&-RZ_<V5LV_7KQ@M;MF&
M4E]'2NE&=,#!01+3SMC^P:L>FYGGNJW$L*4'/JJ>& .2DEYK'%@SIS4/]O0-
M,W>-=1\0MKJ9(FSG*]W_Q&G?XJ"7BK+(1A_?.DJFL0EK:<Q=/0$;G*0V C&0
MY; 0'RT;P#JC3>Z0Y>&$;K[7J@/6_(#7TMT5:B-SN]8\!!NQ$)C:6&><K?+G
M&52I%9$K'8FZ2?-LW=OU._3*;FIT:EU'RK;)?O<A\S5RUKI6X9O/TPUI14NM
M2#2GRQ.B724VB<? MMAT^CYN/H12_3WGJJYL LE04=^A$Z0EV3J?-]R#)!P?
M"BI,V:#_,.9E%HP->*4,*!51,@,78?\;C)5@MD6-E*T@,0 J3BL>LN39U<G'
M<1VSJD@-/*85Z<9^-]WTEIZ'&1%8IR$%)MB;@?&1"#J7&E<1NR 3]!JA)3S?
M6</ IC!NL)).HZ:;R,@,<1$$+RL#[F[8!\FL@""L@0)-3ZK<11>SR)G$YA0U
M,IR$F."(;7G1ID'[S342B##TKM"C==?"3%/8NH%;F8*^37ECXT9I7\]&RX!M
M>%'\!YB&XZ]][F;+BC0I/'WEQ<Y6XZH2B(^SP\*[U@"&^IZN_\+7;<CH'+6/
MVD8!-RG2C-*7KC0J)7E.#!4T,)[MN?!( ELU!,W"PB3S7[\OMH>B;D'&O>PQ
MT8:JZPP2!8:G26XE6""D\\<(7YD)$0%TP=[.$<P8"%I"G91TE.84F8V2  %!
M@*G'&AU^BD8WYZYC$N_(=#L7N!*G ?HB6,Y-NIXCZ2_7S!.3V\.1;HSDX%](
MODVE4N1*>1(F#4P>')+#B.2=DU$#(SC]<.K K;X\8R9C^MBY*K7.J]=4Z>BS
M^B6-^NQ*-9:&75,8:?RL-.IBCF^C+6KM3T+8NMVPCJ_RNV%]OK4#^!\X&<D=
M!L2"_YX96I(BO-[1,^_4^OAP\50Z"BE 3G=\$-O%MI"]3SY)H2 \%A3DMW[\
M!E.7 U69CF4&HER-FM9DE=]3$W'%2C7TWF1A4XDMM=9H(KP*]DZY7<5%SLR>
MJ9N5888UG@=_F=9_6PRKE#SV%B:EE/O<Z.I%3*B$HO.7TKE69[2.3<X*PRE)
M#,O)S-Q QQ&V0PK=,E31V-G&1GO\71*CCS:"2XBYC%"[STD[ IZ.;91"AJ]?
M:=/SR];L-+9B0:6;^F&/9O9[<L*0J%!CWSB)*:[)D&BQTF7E8/WA6,I920%W
MJ%P@?::48LC2@_P3\31@"$Y;VL94@W>";$M2YR#QTY;EXT2#M;JU+G)#,-&Y
M)%8+TS")8>5%DJ7A\R>YEB'[/18Y)WPO3=(&IPP9[*X$4T-T$1!U8NG@><'K
MEQ0(BG6O&>?(8LX#UH^:')5(P&KY[)C(O\[[Y 795A\B@495F#*%+:2=(K<P
MTP"]3O1>8B)&(%^[_B6]4;.]51QN5!(!0?T9U<W4P0VB5YW>M]#T58^L5) G
M"2<1"'V\E&U0#GB[25YI/?*M1_[!>.3_=/.PQ#'(8-PV[E<"=6+LT4ME6W0U
MB)=R^)$NQP<[KGL\8;G2-8OFE+/.ZSK P9*)Q2^D"Z/Y+0PQ6QX?:>C7EH(V
M]FK66A,[\&[JWG8:CVLU_2HHYW^RUTLNVN5VXXVMQO6\5O<;)\= >;W%"^[X
M=(9@)\:$?Z)K-[?0>)R[@_(UY5I?TW9/*_L<A2IUN2KW@!/P%O,83G8*>8DP
M/4G S%E$J@ZG6[(#33P@Y'56Y!Z;A:+PN,.R(J[)ERN!>RJ:J9B55MT@7:M$
M ,[VX'QMMW/4WL@Z:#"$B=*LPXT0D)TH2GD1G$)YUARHD4LFI6RBZ5*[6-Y\
M'*/5 <?.'I&Z*C03K)R1UA5M%WG]1K(+5#9*PZ%*M==#TG9AZ)A(&-375F _
M$+C7Z<WEML/$M]E,?%$L;">=LL+GG1K$X;*3(&_8N=6S++D+A/6:*D/'"8(^
MI698U7*IY5B-N-4\J7_,S RW,_V/I&&:R;34'ED+,9 GA#4\I:Q+L2(H E!N
M)6*6JY9RZA0,$!6@'!AA.-6\*R?=5,DG)WKC:+$D(*HBA7UV=3>,E!CY&GX(
MN\L&:?G\U(47$>'U'E#745X*^CK^V/K#44,NQ45-)J[F:5ABSQ#(8QO6)0]Z
M@YP58K!$T_5^ WJ^Q'ST!C_^9F,DG;P\REK<PN TAYNMEJ/R(U=!,-Z([#T;
MM@<%,#,1 '?DE/#CCJ <8QDBHH>&71<H$AO'.;7>1Y;GQ"7&Z&Q(KD@XN< $
M]<40&K+B@PN/T) J15'K3M)9N,C<]K<-051?,WC-WQ"KBV+"0HB.W]*Z6\G1
M3BUS$E8,L%=&C S;AF[A. 2IB9_R_N 596/?D8F5H+ ._?JTE"QZN>D3.V5U
MB<+J!TO7D[T]V!U0UI+8]FBUG:$%O*H4U=?+*^NH^=4KX,J7@>]]1+8^FD6P
MHL_#A%4F[^(E'_)W<.ZQQMD[?0U?S!'JFHP_KKRV*7%4XC)E!<!X>\M3B%6.
M/>]+V16&F<H*(9/7LS&0%VLXD02@*?_L)KP<M$3F7(XW76CK#&:D<5?_!+..
M,@-3Y;B5[[D[^<Q-/LAP?YDUO0E'E %Q:B>,<SP5I^D''5ZPOV_=F=R<.FS:
MW)LT*,/<U+P4U"1P&5\25,5U40CH,](EV5KN:FGQASV%R?.[ N.<*]4;!)WV
M1ZY)+BJQ'B=CMFFR% ?$A%1G!G+YZK"0=7BO;6J(8*5DL[&S5NKPS.+JU!O,
M#'$99"1DQ$O0F.=BTG(DR1M85P=.,_85<&-G\B3NF&G+G)(AK:#^%>$L(RPO
M(2BZI3R_]""]RED0-<7HKHW*=;W7UX0"L8:R$@FD'3,KA/FL'-9>:%<M3!Y-
M*X);)8--RR5BG)AA%UH]'%@K4%O9VG>?SQH>V,=Y9G9\S(7JK \[57B.EWG+
M\> 5 KURYG#^AJHJW+AT%*MGIUK:* D^>PTI63<-H]8#EG35RS--VB; JME#
M[?FB.8U*(<]O%%\]^Z[A5%?)H[ 2 CBC-&[JG,?ZAT ]N&@>MH.KD[Q>IPYD
MIBF1.1X;*D?7*23<TL1&%=VJ!JJ09J<Y(2Z'TI+:%,2;=((-:'%+Q^A,A G6
M .(VV!P(R=-Q/(8E1MPX"=]U,%"08>6)*.434!)R,<?TC+^-GK^=!?DE7*T-
M50IVWI- L<J,E#4BJL,O3\)MZ30,D]+K.[TU*ZFCZR?Q&+VB_;UG'_\GF"^>
MO:=/O6<_.Y/SWGTV5]$7^IJRF6-27]GBXUID34-D$QJI^9TA6@AJ:C23P#58
M'M,$X_ \.1JM*4G!TOIA2) >NFP2!:1O:N[%()GC\V)"=4QC'9,M TF52UL:
ML9RJ<S>1\%(/![ =1PB=;1H#E:OG760<V42705J#:ER-]6&N)*7]7264$C;G
M(M8@LH'<1ISG=17V!N>6="8'@Y%U&2?K;-6X)3("2EN$#@-1;T#]T@ JL57^
M0(/K4/LUMT6+8)4H(AJ@U<'A_K/>X-C? SO7XK"@PQA>$)IR8X[CLTFL[SKJ
M'AC3V"7@JMI7UR?I$GG,H/(8)X!;O[&-?+:1S_L=^6P21KH_REII^CH*OB87
M<Q LO^,V;4]H8NO%(K+!RR;UONSTH.-<<W<X+C@C_5(U8<U28BZ4*8X..L?+
MV2@V.9/"O!-XJJGM8#@$8CW^&H9>JGTTJ$12WH],.U6BI L.D"!UE)",')!_
MB]S2U/E<=ZO@&$9]FHSF,&?\;4Z*([00<O/7*EXNU")W["[^LA9E[M.#J/;"
M?K<ES1$GNPA""L^Z,DD8N2M\^M;!2F$.4[\[UJ*MH#[8)>?F*,#N2?F2MEZ
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M0EN7\:QP$;:F*W-L6DRYS+? @R_/#,X?KIG*<CM#4%KC;"*EN7!TRCDA3\B
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MYAK40@9M<.T6F1@RTX+?P-5DQ3!#]9I23_$A4^'"F5Y-CQ+)\.GD1G)A_]!
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M.)@Z90SEX9E[70<M-G575*.-8J;!)TMFG\\^=W%TQKHQI9% U@&*L0)CO_'
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M@X.&ZOZ=U&L>='O.5ITAB=?;\P\>1G?S'TBA\0:K,_=7;76_Y^\=#'90MWE
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M28$MJW0.5'()5@:/C(2MBND1159:A5I84SI:7L,/,<L!LQ/R$AE3*[0);M"
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M,#(R,#8S,%]D968N>&UL4$L! A0#%     @ F8(25;U//[[SH0  I/X) !4
M             ( !!($  &-V86,M,C R,C V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( )F"$E6DO!AB4&4  "PY!P 5              "  2HC 0!C=F%C+3(P
M,C(P-C,P7W!R92YX;6Q02P$"% ,4    " "9@A)5.F(<?<PK  !,S $ %
M            @ &MB $ 8W9A8RTR,#(R,#8S,'@V:RYH=&U02P$"% ,4
M" "9@A)5..=Q&A_]   (*PH &               @ &KM $ 8W9A8RTR,#(R
M,#8S,'AE>#DY9#$N:'1M4$L! A0#%     @ F8(25:'G&S8U)0  6"8  !L
M             ( ! +(" &-V86,M,C R,C V,S!X97@Y.60Q,# Q+FIP9U!+
M 0(4 Q0    ( )F"$E4B4J[[,WD  "R0 P 8              "  6[7 @!C
M=F%C+3(P,C(P-C,P>&5X.3ED,BYH=&U02P4&      D "0!B @  UU #

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
